Indoles

ABSTRACT

Herein are disclosed indoles of formula (I) 
     
       
         
         
             
             
         
       
     
     where the various groups are defined herein, and which are useful for treating cancer.

This application is a continuation of U.S. application Ser. No.14/603,660, filed 23 Jan. 2015, which is a continuation of U.S.application Ser. No. 13/961,044, now U.S. Pat. No. 8,975,291, filed 7Aug. 2013, which is a continuation of U.S. application Ser. No.13/696,362, now U.S. Pat. No. 8,536,179, filed 6 Nov. 2012, which is a371 Application of PCT/US2011/035336, filed 5 May 2011, which claims thepriority of U.S. Provisional Application No. 61/332,309, filed 7 May2010, which are incorporated herein in their entireties.

FIELD OF THE INVENTION

This invention relates to substituted indoles which inhibit EZH2 andthus are useful for inhibiting the proliferation of and/or inducingapoptosis in cancer cells.

BACKGROUND OF THE INVENTION

Epigenetic modifications play an important role in the regulation ofmany cellular processes including cell proliferation, differentiation,and cell survival. Global epigenetic modifications are common in cancer,and include global changes in DNA and/or histone methylation,dysregulation of non-coding RNAs and nucleosome remodeling leading toaberrant activation or inactivation of oncogenes, tumor suppressors andsignaling pathways. However, unlike genetic mutations which arise incancer, these epigenetic changes can be reversed through selectiveinhibition of the enzymes involved. Several methylases involved inhistone or DNA methylation are known to be dysregulated in cancer. Thus,selective inhibitors of particular methylases will be useful in thetreatment of proliferative diseases such as cancer.

EZH2 (enhancer of zeste homolog 2; human EZH2 gene: Cardoso, C, et al;European J of Human Genetics, Vol. 8, No. 3 Pages 174-180, 2000) is thecatalytic subunit of the Polycomb Repressor Complex 2 (PRC2) whichfunctions to silence target genes by tri-methylating lysine 27 ofhistone H3 (H3K27me3). Histone H3 is one of the five main histoneproteins involved in the structure of chromatin in eukaryotic cells.Featuring a main globular domain and a long N-terminal tail, Histonesare involved with the structure of the nucleosomes, a ‘beads on astring’ structure. Histone proteins are highly post-translationallymodified however Histone H3 is the most extensively modified of the fivehistones. The term “Histone H3” alone is purposely ambiguous in that itdoes not distinguish between sequence variants or modification state.Histone H3 is an important protein in the emerging field of epigenetics,where its sequence variants and variable modification states are thoughtto play a role in the dynamic and long term regulation of genes.

Increased EZH2 expression has been observed in numerous solid tumorsincluding those of the prostate, breast, skin, bladder, liver, pancreas,head and neck and correlates with cancer aggressiveness, metastasis andpoor outcome (Varambally et al., 2002; Kleer et al., 2003; Breuer etal., 2004; Bachmann et al., 2005; Weikert et al., 2005; Sudo et al.,2005; Bachmann et al., 2006). For instance, there is a greater risk ofrecurrence after prostatectomy in tumors expressing high levels of EZH2,increased metastasis, shorter disease-free survival and increased deathin breast cancer patients with high EZH2 levels (Varambally et al.,2002; Kleer et al., 2003). More recently, inactivating mutations in UTX(ubiquitously transcribed tetratricopeptixe repeats X), a H3K27demethylase which functions in opposition to EZH2, have been identifiedin multiple solid and hematological tumor types (including renal,glioblastoma, esophageal, breast, colon, non-small cell lung, small celllung, bladder, multiple myeloma, and chronic myeloid leukemia tumors),and low UTX levels correlate with poor survival in breast cancersuggesting that loss of UTX function leads to increased H3K27me3 andrepression of target genes (Wang et al., 2010). Together, these datasuggest that increased H3K27me3 levels contribute to canceraggressiveness in many tumor types and that inhibition of EZH2 activitymay provide therapeutic benefit.

Numerous studies have reported that direct knockdown of EZH2 via siRNAor shRNA or indirect loss of EZH2 via treatment with the SAH hydrolaseinhibitor 3-deazaneplanocin A (DZNep) decreases cancer cell lineproliferation and invasion in vitro and tumor growth in vivo (Gonzalezet al., 2008, GBM 2009). While the precise mechanism by which aberrantEZH2 activity leads to cancer progression is not known, many EZH2 targetgenes are tumor suppressors suggesting that loss of tumor suppressorfunction is a key mechanism. In addition, EZH2 overexpression inimmortalized or primary epithelial cells promotes anchorage independentgrowth and invasion and requires EZH2 catalytic activity (Kleer et al.,2003; Cao et al., 2008).

Thus, there is strong evidence to suggest that inhibition of EZH2activity decreases cellular proliferation and invasion. Accordingly,compounds that inhibit EZH2 activity would be useful for the treatmentof cancer. The indoles of this invention provide such treatment.

SUMMARY OF THE INVENTION

In a first instance, this invention relates to compounds of formula (I)

wherein

X and Z are selected independently from the group consisting ofhydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl,(C₆-C₁₀)bicycloalkyl, unsubstituted or substituted heterocycloalkyl,unsubstituted or substituted heterocycloalkyl-(C₁-C₈)alkyl or—(C₂-C₈)alkenyl, unsubstituted or substituted aryl, unsubstituted orsubstituted aryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, halo, cyano, —COR^(a),—CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a),—SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),—NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), and —OC(O)NR^(a)R^(b);

Y is H or halo;

R¹ is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₆-C₁₀)bicycloalkyl, unsubstituted or substitutedheterocycloalkyl or —(C₂-C₈)alkenyl, unsubstituted or substitutedheterocycloalkyl-(C₁-C₈)alkyl, unsubstituted or substituted aryl,unsubstituted or substituted aryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl,unsubstituted or substituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, —COR^(a), —CO₂R^(a),—CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b);

R² is hydrogen, (C₁-C₈)alkyl, trifluoromethyl, alkoxy, or halo, in whichsaid (C₁-C₈)alkyl maybe substituted with one to two groups selectedfrom: amino, and (C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy; R³ is hydrogen, (C₁-C₈)alkyl,cyano, trifluoromethyl, —NR^(a)R^(b), or halo;

R⁶ is selected from the group consisting of hydrogen, halo,(C₁-C₈)alkyl, (C₂-C₈)alkenyl, —B(OH)₂, substituted or unsubstituted(C₂-C₈)alkynyl, unsubstituted or substituted (C₃-C₈)cycloalkyl,unsubstituted or substituted (C₃-C₈)cycloalkyl-(C₁-C₈)alkyl,unsubstituted or substituted (C₅-C₈)cycloalkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl, (C₆-C₁₀)bicycloalkyl,unsubstituted or substituted heterocycloalkyl, unsubstituted orsubstituted heterocycloalkyl-(C₁-C₈)alkyl, unsubstituted or substitutedaryl, unsubstituted or substituted aryl-(C₁-C₈)alkyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl, cyano, —COR^(a), —CO₂R″, —CONR^(a)R^(b),—CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b),nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),—NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),—NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), —OC(O)NR^(a)R^(b);

-   -   wherein any (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl,        cycloalkyl, cycloalkenyl, bicycloalkyl, heterocycloalkyl, aryl,        or heteroaryl group is optionally substituted by 1, 2 or 3        groups independently selected from the group consisting of        —O(C₁-C₆)alkyl(R^(c))₁₋₂, —S(C₁-C₆)alkyl(R^(c))₁₋₂,        —(C₁-C₆)alkyl(R^(c))₁₋₂, (C₁-C₈)alkyl-heterocycloalkyl,        (C₃-C₈)cycloalkyl-heterocycloalkyl, halo, (C₁-C₆)alkyl,        (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano,        —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a),        —SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b),        —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a),        —OC(O)NR^(a)R^(b), heterocycloalkyl, aryl, heteroaryl,        aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;        -   wherein any aryl or heteroaryl moiety of said aryl,            heteroaryl, aryl(C₁-C₄)alkyl, or heteroaryl(C₁-C₄)alkyl is            optionally substituted by 1, 2 or 3 groups independently            selected from the group consisting of halo, (C₁-C₆)alkyl,            (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl,            cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a),            —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b),            —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a),            —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —OR^(a),            —OC(O)R^(a), and —OC(O)NR^(a)R^(b);

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, or —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

-   -   each R^(c) is independently (C₁-C₄)alkylamino, —NR^(a)SO₂R^(b),        —SOR^(a), —SO₂R^(a), —NR^(a)C(O)OR^(a), —NR^(a)R^(b), or        —CO₂R^(a);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring;

or a salt thereof.

In a further iteration of this invention it relates to a method ofinducing apoptosis in cancer cells of solid tumors; treating solid tumorcancers.

Another aspect of the invention are pharmaceutical preparationscomprising compounds of formula (I) and pharmaceutically acceptableexcipients.

In a fourth aspect, there is provided the use of a compound of formula(I) and/or a pharmaceutically acceptable salt or solvate thereof, in thepreparation of a medicament for use in the treatment of a disordermediated by inhibiting EZH2, such as inducing apoptosis in cancer cells.

In a fifth aspect there is provided methods of co-administering thepresently invented compounds of formula (I) with another activeingredients.

DETAILED DESCRIPTION OF THE INVENTION

For the avoidance of doubt, unless otherwise indicated, the term“substituted” means substituted by one or more defined groups. In thecase where groups may be selected from a number of alternative groupsthe selected groups may be the same or different.

The term “independently” means that where more than one substituent isselected from a number of possible substituents, those substituents maybe the same or different.

An “effective amount” means that amount of a drug or pharmaceuticalagent that will elicit the biological or medical response of a tissue,system, animal or human that is being sought, for instance, by aresearcher or clinician. Furthermore, the term “therapeuticallyeffective amount” means any amount which, as compared to a correspondingsubject who has not received such amount, results in improved treatment,healing, prevention, or amelioration of a disease, disorder, or sideeffect, or a decrease in the rate of advancement of a disease ordisorder. The term also includes within its scope amounts effective toenhance normal physiological function.

As used herein the term “alkyl” refers to a straight- or branched-chainhydrocarbon radical having the specified number of carbon atoms, so forexample, as used herein, the terms “C₁-C₈alkyl” refers to an alkyl grouphaving at least 1 and up to 8 carbon atoms respectively. Examples ofsuch branched or straight-chained alkyl groups useful in the presentinvention include, but are not limited to, methyl, ethyl, n-propyl,isopropyl, isobutyl, n-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl,n-heptyl, and n-octyl and branched analogs of the latter 5 normalalkanes.

The term “alkoxy” as used herein means —O(C₁-C₈alkyl) including —OCH₃,—OCH₂CH₃ and —OC(CH₃)₃ and the like per the definition of alkyl above.

The term “alkylthio” as used herein is meant —S(C₁-C₈alkyl) including—SCH₃, —SCH₂CH₃ and the like per the definition of alkyl above.

The term “acyloxy” means —OC(O)C₁-C₈alkyl and the like per thedefinition of alkyl above.

“Acylamino” means-N(H)C(O)C₁-C₈alkyl and the like per the definition ofalkyl above.

“Aryloxy” means —O(aryl), —O(substituted aryl), —O(heteroaryl) or—O(substituted heteroaryl).

“Arylamino” means —NH(aryl), —NH(substituted aryl), —NH(heteroaryl) or—NH(substituted heteroaryl), and the like.

When the term “alkenyl” (or “alkenylene”) is used it refers to straightor branched hydrocarbon chains containing the specified number of carbonatoms and at least 1 and up to 5 carbon-carbon double bonds. Examplesinclude ethenyl (or ethenylene) and propenyl (or propenylene).

When the term “alkynyl” (or “alkynylene”) is used it refers to straightor branched hydrocarbon chains containing the specified number of carbonatoms and at least 1 and up to 5 carbon-carbon triple bonds. Examplesinclude ethynyl (or ethynylene) and propynyl (or propynylene).

“Haloalkyl” refers to an alkyl group that is substituted with one ormore halo substituents, suitably from 1 to 6 substituents. Haloalkylincludes trifluoromethyl.

When “cycloalkyl” is used it refers to a non-aromatic, saturated, cyclichydrocarbon ring containing the specified number of carbon atoms. So,for example, the term “C₃-C₈cycloalkyl” refers to a non-aromatic cyclichydrocarbon ring having from three to eight carbon atoms. Exemplary“C₃-C₈cycloalkyl” groups useful in the present invention include, butare not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl and cyclooctyl.

The term “C₅-C₈cycloalkenyl” refers to a non-aromatic monocycliccarboxycyclic ring having the specified number of carbon atoms and up to3 carbon-carbon double bonds. “Cycloalkenyl” includes by way of examplecyclopentenyl and cyclohexenyl.

Where “C₃-C₈heterocycloalkyl” is used, it means a non-aromaticheterocyclic ring containing the specified number of ring atoms being,saturated or having one or more degrees of unsaturation and containingone or more heteroatom substitutions independently selected from O, Sand N. Such a ring may be optionally fused to one or more other“heterocyclic” ring(s) or cycloalkyl ring(s). Examples are given hereinbelow.

“Aryl” refers to optionally substituted monocyclic or polycarbocyclicunfused or fused groups having 6 to 14 carbon atoms and having at leastone aromatic ring that complies with Hückel's Rule. Examples of arylgroups are phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, andthe like, as further illustrated below.

“Heteroaryl” means an optionally substituted aromatic monocyclic ring orpolycarbocyclic fused ring system wherein at least one ring complieswith Hückel's Rule, has the specified number of ring atoms, and thatring contains at least one heteratom independently selected from N, Oand S. Examples of “heteroaryl” groups are given herein below.

The term “optionally” means that the subsequently described event(s) mayor may not occur, and includes both event(s), which occur, and eventsthat do not occur.

Herein, the term “pharmaceutically-acceptable salts” refers to saltsthat retain the desired biological activity of the subject compound andexhibit minimal undesired toxicological effects. Thesepharmaceutically-acceptable salts may be prepared in situ during thefinal isolation and purification of the compound, or by separatelyreacting the purified compound in its free acid or free base form with asuitable base or acid, respectively.

While the compounds encompassed by the general structure of formula (I)as defined herein are believed to be useful for inducing apoptosis incancer cells, some of these compounds are more active that others. Inthat vein, the following subgroups delineate certain compounds believedto have greater potency or other properties which suggest they may be abetter choice for use in therapy, versus other. Those subgroups arerepresented as follows:

Subgroup A

X and Z are selected from the group consisting of (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —NR^(a)R^(b), and—OR^(a);

Y is H or F;

R¹ is selected from the group consisting of (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;

R² is hydrogen, (C₁-C₈)alkyl, trifluoromethyl, alkoxy, or halo, in whichsaid (C₁-C₈)alkyl maybe substituted with one to two groups selectedfrom: amino, and (C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy; R³ is selected from the groupconsisting of hydrogen, (C₁-C₈)alkyl, cyano, trifluoromethyl,—NR^(a)R^(b), and halo;

R⁶ is selected from the group consisting of hydrogen, halo, cyano,trifluoromethyl, amino, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, aryl,heteroaryl, acylamino, (C₂-C₈)alkynyl, arylalkynyl, heteroarylalkynyl,—SO₂R^(a), —SO₂NR^(a)R^(b), and —NR^(a)SO₂R^(b);

wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, (C₂-C₈)alkynyl,arylalkynyl, heteroarylalkynyl group is optionally substituted by 1, 2or 3 groups independently selected from —O(C₁-C₆)alkyl(R^(c))₁₋₂,—S(C₁-C₆)alkyl(R^(c))₁₋₂, —(C₁-C₆)alkyl(R^(c))₁₋₂,(C₁-C₈)alkyl-heterocycloalkyl, (C₃-C₈)cycloalkyl-heterocycloalkyl, halo,(C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl,cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a),—SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),—NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b),heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, andheteroaryl(C₁-C₄)alkyl;

-   -   each R^(c) is independently (C₁-C₄)alkylamino, —NR^(a)SO₂R^(b),        —SOR^(a), —SO₂R^(a), —NR^(a)C(O)OR^(a), —NR^(a)R^(b), or        —CO₂R^(a);

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, and —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring. An aryl or heteroaryl group in this particular subgroupA is selected independently from the group consisting of furan,thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, oxadiazole,thiadiazole, triazole, tetrazole, benzofuran, benzothiophene,benzoxazole, benzothiazole, phenyl, pyridine, pyridazine, pyrimidine,pyrazine, triazine, tetrazine, quinoline, cinnoline, quinazoline,quinoxaline, and naphthyridine or another aryl or heteroaryl group asfollows:

wherein in (1),

A is O, NH, or S; B is CH or N, and C is hydrogen or C₁-C₈ alkyl; or

wherein in (2),

D is N or C optionally substituted by hydrogen or C₁-C₈ alkyl; or

wherein in (3),

E is NH or CH₂; F is O or CO; and G is NH or CH₂; or

wherein in (4),

J is O, S or CO; or

wherein in (5),

Q is CH or N;

M is CH or N; and

L/(5) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl,—COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b); wherein R^(a) and R^(b)        are defined as above; or

wherein in 6,

L/(6) is NH or CH₂; or

wherein in 7,

-   -   M/(7) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl,        (C₃-C₈)cycloalkyl, heterocycloalkyl, —COR^(a), —CO₂R^(a),        —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),        —SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b),        —NR^(a)NR^(a)C(O)R^(b), —

NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl        group is optionally substituted by 1, 2 or 3 groups        independently selected from (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl,        (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano, —COR^(a),        —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a),        —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),        —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b);        wherein R^(a) and R^(b) are defined as above; or

wherein in (8),

P is CH₂, NH, O, or S; Q/(8) is CH or N; and n is 0-2; or

wherein in (9),

S/(9) and T(9) is C, or S/(9) is C and T(9) is N, or S/(9) is N andT/(9) is C;

R is hydrogen, amino, methyl, trifluoromethyl, halo;

U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—OR^(a), 4-(1H-pyrazol-4-yl),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b); wherein R^(a) and R^(b)        are defined as above.

Subgroup B

X and Z are selected independently from the group consisting of(C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, heteroaryl,—NR^(a)R^(b), and —OR^(a);

Y is H;

R¹ is (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, or heterocycloalkyl;

R₂ is hydrogen, (C₁-C₃)alkyl, or halo, in which said (C₁-C₃)alkyl maybesubstituted with one to two groups selected from amino, and(C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy; R³ is hydrogen, (C₁-C₈)alkyl orhalo;

R⁶ is hydrogen, halo, cyano, trifluoromethyl, amino, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, aryl, heteroaryl, acylamino, (C₂-C₈)alkynyl,arylalkynyl, heteroarylalkynyl, —SO₂R^(a), —SO₂NR^(a)R^(b), or—NR^(a)SO₂R^(b);

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, (C₂-C₈)alkynyl,        arylalkynyl, heteroarylalkynyl group is optionally substituted        by 1, 2 or 3 groups independently selected from halo,        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b), heterocycloalkyl, aryl,        heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, and —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring. Aryl and heteroaryl in this definition are selectedfrom the group consisting of furan, thiophene, pyrrole, oxazole,thiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole,tetrazole, benzofuran, benzothiophene, benzoxazole, benzothiazole,phenyl, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine,quinoline, cinnoline, quinazoline, quinoxaline, and naphthyridine as ora compound of or another aryl or heteroaryl group as follows:

wherein in (1),

A is O, NH, or S; B is CH or N, and C is hydrogen or C₁-C₈ alkyl; or

wherein in (2),

D is N or C optionally substituted by hydrogen or C₁-C₈ alkyl; or

wherein in (3),

E is NH or CH₂; F is O or CO; and G is NH or CH₂; or

wherein in (4),

J is O, S or CO; or

wherein in (5),

Q is CH or N;

M is CH or N; and

L/(5) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl,—COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(b), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b),        wherein R^(a) and R^(b) are defined as above; or

wherein in 6,

L/(6) is NH or CH₂; or

wherein in 7,

-   -   M/(7) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl,        (C₃-C₈)cycloalkyl, heterocycloalkyl, —COR^(a), —CO₂R^(a),        —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(b),        —SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b),        —NR^(a)NR^(a)C(O)R^(b), —NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),    -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl        group is optionally substituted by 1, 2 or 3 groups        independently selected from (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl,        (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano, —COR^(a),        —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a),        —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),        —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b);        wherein R^(a) and R^(b) are defined as above; or

wherein in (8),

P is CH₂, NH, O, or S; Q/(8) is CH or N; and n is 0-2; or

wherein in (9),

S/(9) and T(9) is C, or S/(9) is C and T(9) is N, or S/(9) is N andT/(9) is C;

R is hydrogen, amino, methyl, trifluoromethyl, halo;

U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—OR^(a), 4-(1H-pyrazol-4-yl),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b), wherein R^(a) and R^(b)        are defined as above.

Subgroup C

X is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, phenyl, trifluoromethyl, tetrahydropyran,hydroxymethyl, methoxymethyl, or benzyl;

Y is H;

Z is methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, or benzyl;

R¹ is isopropyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl,(1-methylethyl)cyclopropyl, 1,1-dioxo-tetrahydrothiophene-3-yl,1-Me-piperidin-4-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl,N,N-dimethyl-1-propanaminyl, benzyl, or 4-pyridyl;

R₂ is hydrogen, (C₁-C₃)alkyl, or halo, in which said (C₁-C₃)alkyl maybesubstituted with one to two groups selected from amino, and(C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy; R³ is H, methyl, or Br; and

R⁶ is methyl, bis(1,1-dimethylethyl), bis(1-methylethyl), cyclopropyl,propyl, dimethylamino, ethylamino, (2-hydroxyethyl)amino,2-propen-1-ylamino, 1-piperazinyl, 1-piperidinyl, 4-morpholinyl,4-piperidinylamino, tetrahydro-2H-pyran-4-ylamino, phenylamino,(phenylmethyl)amino, (4-pyridinylmethyl)amino,[2-(2-pyridinylamino)ethyl]amino, 2-(dimethylamino)ethyl]amino,4-pyridinylamino, 4-(aminocarbonyl)phenyl]amino,3-hydroxy-3-methyl-1-butyn-1-yl, 4-pyridinylethynyl, phenylethynyl,2-furanyl, 3-thienyl; 1H-pyrazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl,3-methyl-1H-indazol-5-yl, 1H-1,2,3-benzotriazol-5-yl,2-oxo-2,3-dihydro-1H-benzimidazol-5-yl, 2-oxo-2,3-dihydro-1H-indol-5-yl,2-oxo-2,3-dihydro-1H-indol-6-yl, 2,1,3-benzoxadiazol-5-yl,2-amino-6-quinazolinyl, 2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl,2-amino-5-pyrimidinyl, 7-oxo-1,5,6,7-tetrahydro-1,8-naphthyridin-3-yl,phenyl, 2-methylphenyl, 2-nitrophenyl, 2-phenylethyl, 3-aminophenyl,4-aminophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-(methyloxy)phenyl,3-(acetylamino)phenyl, 4-(acetylamino)phenyl, 4-(aminocarbonyl)phenyl,4-(1H-pyrazol-4-yl)phenyl, 4-(aminosulfonyl)phenyl,4-(methylsulfonyl)phenyl, 4-[(dimethylamino)sulfonyl]phenyl,4-[(methylamino)carbonyl]phenyl, 4-[(methylamino)sulfonyl]phenyl,4-[(methylsulfonyl)amino]phenyl, 3-pyridinyl, 4-pyridinyl,2-(4-morpholinyl)-4-pyridinyl, 2-amino-4-pyridinyl,5-(methyloxy)-3-pyridinyl, 5-(methylsulfonyl)-3-pyridinyl,5-[(cyclopropylsulfonyl)amino]-6-(methyloxy)-3-pyridinyl,5-[(phenylsulfonyl)amino]-3-pyridinyl,6-(4-methyl-1-piperazinyl)-3-pyridinyl, 6-(4-morpholinyl)-3-pyridinyl,6-(acetylamino)-3-pyridinyl, 6-(dimethylamino)-3-pyridinyl,6-(methyloxy)-3-pyridinyl, 6-[(methylamino)carbonyl]-3-pyridinyl,6-[(methylamino)sulfonyl]-3-pyridinyl, 6-methyl-3-pyridinyl,4-pyridinyloxy.

Individual compounds can be found in the Examples set out below.

By the term “co-administering” and derivatives thereof as used herein ismeant either simultaneous administration or any manner of separatesequential administration of one or more additional pharmaceuticallyactive compounds, whether for treating cancer, the side effects ofcancer or cancer therapy, or some other disease. Preferably, if theadministration is not simultaneous, the compounds are administered in aclose time proximity to each other. Furthermore, it does not matter ifthe compounds are administered in the same dosage form, e.g. onecompound may be administered topically and another compound may beadministered orally.

In certain embodiments, compounds according to Formula I may contain anacidic functional group, one acidic enough to form salts. Representativesalts include pharmaceutically-acceptable metal salts such as sodium,potassium, lithium, calcium, magnesium, aluminum, and zinc salts;carbonates and bicarbonates of a pharmaceutically-acceptable metalcation such as sodium, potassium, lithium, calcium, magnesium, aluminum,and zinc; pharmaceutically-acceptable organic primary, secondary, andtertiary amines including aliphatic amines, aromatic amines, aliphaticdiamines, and hydroxy alkylamines such as methylamine, ethylamine,2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine,ethanolamine, diethanolamine, and cyclohexylamine.

In certain embodiments, compounds according to Formula (I) may contain abasic functional group and are therefore capable of formingpharmaceutically-acceptable acid addition salts by treatment with asuitable acid. Suitable acids include pharmaceutically-acceptableinorganic acids and pharmaceutically-acceptable organic acids.Representative pharmaceutically-acceptable acid addition salts includehydrochloride, hydrobromide, nitrate, methylnitrate, sulfate, bisulfate,sulfamate, phosphate acetate, hydroxyacetate, phenylacetate, propionate,butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate,fumarate, malate, tartrate, citrate, salicylate, p-aminosalicyclate,glycollate, lactate, heptanoate, phthalate, oxalate, succinate,benzoate, o-acetoxybenzoate, chlorobenzoate, methylbenzoate,dinitrobenzoate, hydroxybenzoate, methoxybenzoate, mandelate, tannate,formate, stearate, ascorbate, palmitate, oleate, pyruvate, pamoate,malonate, laurate, glutarate, glutamate, estolate, methanesulfonate(mesylate), ethanesulfonate (esylate), 2-hydroxyethanesulfonate,benzenesulfonate (besylate), p-aminobenzenesulfonate, p-toluenesulfonate(tosylate) and napthalene-2-sulfonate.

All tautomeric forms of the compounds described herein, includingmixtures thereof, are intended to be encompassed within the scope of theinvention. Generally, the compounds exemplified herein have beenassigned names based on the structure of the tautomer of formula (IA).It should be understood that any reference to named compounds of thisinvention is intended to encompass all tautomers of the named compoundsand any mixtures of tautomers of the named compounds.

The compounds of formula (I) may be prepared in crystalline ornon-crystalline form, and, if crystalline, may optionally be solvated,e.g. as the hydrate. This invention includes within its scopestoichiometric solvates (e.g. hydrates) as well as compounds containingvariable amounts of solvent (e.g. water).

Certain of the compounds described herein may contain one or more chiralatoms, or may otherwise be capable of existing as two enantiomers. Thecompounds claimed below include mixtures of enantiomers as well aspurified enantiomers or enantiomerically enriched mixtures. Alsoincluded within the scope of the invention are the individual isomers ofthe compounds represented by formula (I), or claimed below, as well asany wholly or partially equilibrated mixtures thereof. The presentinvention also covers the individual isomers of the claimed compounds asmixtures with isomers thereof in which one or more chiral centers areinverted.

Where there are different isomeric forms they may be separated orresolved one from the other by conventional methods, or any given isomermay be obtained by conventional synthetic methods or by stereospecificor asymmetric syntheses.

While it is possible that, for use in therapy, a compound of formula(I), as well as salts, solvates and the like, may be administered as aneat preparation, i.e. no additional carrier, the more usual practice isto present the active ingredient confected with a carrier or diluent.Accordingly, the invention further provides pharmaceutical compositions,which includes a compound of formula (I) and salts, solvates and thelike, and one or more pharmaceutically acceptable carriers, diluents, orexcipients. The compounds of formula (I) and salts, solvates, etc, areas described above. The carrier(s), diluent(s) or excipient(s) must beacceptable in the sense of being compatible with the other ingredientsof the formulation and not deleterious to the recipient thereof. Inaccordance with another aspect of the invention there is also provided aprocess for the preparation of a pharmaceutical formulation includingadmixing a compound of the formula (I), or salts, solvates etc, with oneor more pharmaceutically acceptable carriers, diluents or excipients.

It will be appreciated by those skilled in the art that certainprotected derivatives of compounds of formula (I), which may be madeprior to a final deprotection stage, may not possess pharmacologicalactivity as such, but may, in certain instances, be administered orallyor parenterally and thereafter metabolised in the body to form compoundsof the invention which are pharmacologically active. Such derivativesmay therefore be described as “prodrugs”. Further, certain compounds ofthe invention may act as prodrugs of other compounds of the invention.All protected derivatives and prodrugs of compounds of the invention areincluded within the scope of the invention. It will further beappreciated by those skilled in the art, that certain moieties, known tothose skilled in the art as “pro-moieties” may be placed on appropriatefunctionalities when such functionalities are present within compoundsof the invention. Preferred prodrugs for compounds of the inventioninclude: esters, carbonate esters, hemi-esters, phosphate esters, nitroesters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds,phosphamides, glycosides, ethers, acetals and ketals.

Treatments

The compounds and compositions of the invention are used to treatcellular proliferation diseases. Disease states which can be treated bythe methods and compositions provided herein include, but are notlimited to, cancer (further discussed below), autoimmune disease, fungaldisorders, arthritis, graft rejection, inflammatory bowel disease,proliferation induced after medical procedures, including, but notlimited to, surgery, angioplasty, and the like. It is appreciated thatin some cases the cells may not be in a hyper or hypo proliferationstate (abnormal state) and still requires treatment. For example, duringwound healing, the cells may be proliferating “normally”, butproliferation enhancement may be desired. Thus, in one embodiment, theinvention herein includes application to cells or individuals afflictedor impending affliction with any one of these disorders or states.

The compositions and methods provided herein are particularly deemeduseful for the treatment of cancer including tumors such as prostate,breast, brain, skin, cervical carcinomas, testicular carcinomas, etc.They are particularly useful in treating metastatic or malignant tumors.More particularly, cancers that may be treated by the compositions andmethods of the invention include, but are not limited to tumor typessuch as astrocytic, breast, cervical, colorectal, endometrial,esophageal, gastric, head and neck, hepatocellular, laryngeal, lung,oral, ovarian, prostate and thyroid carcinomas and sarcomas. Morespecifically, these compounds can be used to treat: Cardiac: sarcoma(angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma,rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma(squamous cell, undifferentiated small cell, undifferentiated largecell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchialadenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma,leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma,leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma,glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel(adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma,leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel(adenocarcinoma, tubular adenoma, villous adenoma, hamartoma,leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor(nephroblastoma), lymphoma, leukemia), bladder and urethra (squamouscell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonalcarcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cellcarcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver:hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma,angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gallbladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone:osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibroushistiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma(reticulum cell sarcoma), multiple myeloma, malignant giant cell tumorchordoma, osteochronfroma (osteocartilaginous exostoses), benignchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma andgiant cell tumors; Nervous system: skull (osteoma, hemangioma,granuloma, xanthoma, osteitis deformans), meninges (meningioma,meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform,oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological:uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumorcervical dysplasia), ovaries (ovarian carcinoma (serouscystadenocarcinoma, mucinous cystadenocarcinoma, unclassifiedcarcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors,dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma,intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma),vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma(embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic:blood (myeloid leukemia (acute and chronic), acute lymphoblasticleukemia, chronic lymphocytic leukemia, myeloproliferative diseases,multiple myeloma, myelodysplastic syndrome), Hodgkin's disease,non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma,basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, molesdysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis;and Adrenal glands: neuroblastoma. Thus, the term “cancerous cell” asprovided herein, includes a cell afflicted by any one or related of theabove identified conditions.

The instant compounds can be combined with or co-administered with othertherapeutic agents, particularly agents that may enhance the activity ortime of disposition of the compounds. Combination therapies according tothe invention comprise the administration of at least one compound ofthe invention and the use of at least one other treatment method. In oneembodiment, combination therapies according to the invention comprisethe administration of at least one compound of the invention andsurgical therapy. In one embodiment, combination therapies according tothe invention comprise the administration of at least one compound ofthe invention and radiotherapy. In one embodiment, combination therapiesaccording to the invention comprise the administration of at least onecompound of the invention and at least one supportive care agent (e.g.,at least one anti-emetic agent). In one embodiment, combinationtherapies according to the present invention comprise the administrationof at least one compound of the invention and at least one otherchemotherapeutic agent. In one particular embodiment, the inventioncomprises the administration of at least one compound of the inventionand at least one anti-neoplastic agent. In yet another embodiment, theinvention comprises a therapeutic regimen where the EZH2 inhibitors ofthis disclosure are not in and of themselves active or significantlyactive, but when combined with another therapy, which may or may not beactive as a standalone therapy, the combination provides a usefultherapeutic outcome.

By the term “co-administering” and derivatives thereof as used herein ismeant either simultaneous administration or any manner of separatesequential administration of an EZH2 inhibiting compound, as describedherein, and a further active ingredient or ingredients, known to beuseful in the treatment of cancer, including chemotherapy and radiationtreatment. The term further active ingredient or ingredients, as usedherein, includes any compound or therapeutic agent known to or thatdemonstrates advantageous properties when administered to a patient inneed of treatment for cancer. Preferably, if the administration is notsimultaneous, the compounds are administered in a close time proximityto each other. Furthermore, it does not matter if the compounds areadministered in the same dosage form, e.g. one compound may beadministered topically and another compound may be administered orally.

Typically, any anti-neoplastic agent that has activity versus asusceptible tumor being treated may be co-administered in the treatmentof specified cancers in the present invention. Examples of such agentscan be found in Cancer Principles and Practice of Oncology by V. T.Devita and S. Hellman (editors), 6^(th) edition (Feb. 15, 2001),Lippincott Williams & Wilkins Publishers. A person of ordinary skill inthe art would be able to discern which combinations of agents would beuseful based on the particular characteristics of the drugs and thecancer involved. Typical anti-neoplastic agents useful in the presentinvention include, but are not limited to, anti-microtubule agents suchas diterpenoids and vinca alkaloids; platinum coordination complexes;alkylating agents such as nitrogen mustards, oxazaphosphorines,alkylsulfonates, nitrosoureas, and triazenes; antibiotic agents such asanthracyclins, actinomycins and bleomycins; topoisomerase II inhibitorssuch as epipodophyllotoxins; antimetabolites such as purine andpyrimidine analogues and anti-folate compounds; topoisomerase Iinhibitors such as camptothecins; hormones and hormonal analogues; DNAmethyltransferase inhibitors such as azacitidine and decitabine; signaltransduction pathway inhibitors; non-receptor tyrosine kinaseangiogenesis inhibitors; immunotherapeutic agents; proapoptotic agents;and cell cycle signaling inhibitors.

Typically, any chemotherapeutic agent that has activity against asusceptible neoplasm being treated may be utilized in combination withthe compounds the invention, provided that the particular agent isclinically compatible with therapy employing a compound of theinvention. Typical anti-neoplastic agents useful in the presentinvention include, but are not limited to: alkylating agents,anti-metabolites, antitumor antibiotics, antimitotic agents, nucleosideanalogues, topoisomerase I and II inhibitors, hormones and hormonalanalogues; retinoids, histone deacetylase inhibitors; signaltransduction pathway inhibitors including inhibitors of cell growth orgrowth factor function, angiogenesis inhibitors, and serine/threonine orother kinase inhibitors; cyclin dependent kinase inhibitors; antisensetherapies and immunotherapeutic agents, including monoclonals, vaccinesor other biological agents.

Nucleoside analogues are those compounds which are converted todeoxynucleotide triphosphates and incorporated into replicating DNA inplace of cytosine. DNA methyltransferases become covalently bound to themodified bases resulting in an inactive enzyme and reduced DNAmethylation. Examples of nucleoside analogues include azacitidine anddecitabine which are used for the treatment of myelodysplastic disorder.Histone deacetylase (HDAC) inhibitors include vorinostat, for thetreatment of cutaneous T-cell lymphoma. HDACs modify chromatin throughthe deactylation of histones. In addition, they have a variety ofsubstrates including numerous transcription factors and signalingmolecules. Other HDAC inhibitors are in development.

Signal transduction pathway inhibitors are those inhibitors which blockor inhibit a chemical process which evokes an intracellular change. Asused herein this change is cell proliferation or differentiation orsurvival. Signal transduction pathway inhibitors useful in the presentinvention include, but are not limited to, inhibitors of receptortyrosine kinases, non-receptor tyrosine kinases, SH2/SH3 domainblockers, serine/threonine kinases, phosphatidyl inositol-3-OH kinases,myoinositol signaling, and Ras oncogenes. Signal transduction pathwayinhibitors may be employed in combination with the compounds of theinvention in the compositions and methods described above.

Receptor kinase angiogenesis inhibitors may also find use in the presentinvention. Inhibitors of angiogenesis related to VEGFR and TIE-2 arediscussed above in regard to signal transduction inhibitors (both arereceptor tyrosine kinases). Other inhibitors may be used in combinationwith the compounds of the invention. For example, anti-VEGF antibodies,which do not recognize VEGFR (the receptor tyrosine kinase), but bind tothe ligand; small molecule inhibitors of integrin (alpha_(v) beta₃) thatinhibit angiogenesis; endostatin and angiostatin (non-RTK) may alsoprove useful in combination with the compounds of the invention. Oneexample of a VEGFR antibody is bevacizumab (AVASTIN®).

Several inhibitors of growth factor receptors are under development andinclude ligand antagonists, antibodies, tyrosine kinase inhibitors,anti-sense oligonucleotides and aptamers. Any of these growth factorreceptor inhibitors may be employed in combination with the compounds ofthe invention in any of the compositions and methods/uses describedherein. Trastuzumab (Herceptin®) is an example of an anti-erbB2 antibodyinhibitor of growth factor function. One example of an anti-erbB1antibody inhibitor of growth factor function is cetuximab (Erbitux™C225). Bevacizumab (Avastin®) is an example of a monoclonal antibodydirected against VEGFR. Examples of small molecule inhibitors ofepidermal growth factor receptors include but are not limited tolapatinib (Tykerb™) and erlotinib (TARCEVA®). Imatinib mesylate(GLEEVEC®) is one example of a PDGFR inhibitor. Examples of VEGFRinhibitors include pazopanib, ZD6474, AZD2171, PTK787, sunitinib andsorafenib.

Anti-microtubule or anti-mitotic agents are phase specific agents activeagainst the microtubules of tumor cells during M or the mitosis phase ofthe cell cycle. Examples of anti-microtubule agents include, but are notlimited to, diterpenoids and vinca alkaloids.

Diterpenoids, which are derived from natural sources, are phase specificanti-cancer agents that operate at the G₂/M phases of the cell cycle. Itis believed that the diterpenoids stabilize the β-tubulin subunit of themicrotubules, by binding with this protein. Disassembly of the proteinappears then to be inhibited with mitosis being arrested and cell deathfollowing. Examples of diterpenoids include, but are not limited to,paclitaxel and its analog docetaxel.

Paclitaxel, 5β,20-epoxy-1,2α,4,7β,10β,13α-hexa-hydroxytax-11-en-9-one4,10-diacetate 2-benzoate 13-ester with(2R,3S)—N-benzoyl-3-phenylisoserine; is a natural diterpene productisolated from the Pacific yew tree Taxus brevifolia and is commerciallyavailable as an injectable solution TAXOL®. It is a member of the taxanefamily of terpenes. It was first isolated in 1971 by Wani et al. J. Am.Chem, Soc., 93:2325. 1971), who characterized its structure by chemicaland X-ray crystallographic methods. One mechanism for its activityrelates to paclitaxel's capacity to bind tubulin, thereby inhibitingcancer cell growth. Schiff et al., Proc. Natl, Acad, Sci. USA,77:1561-1565 (1980); Schiff et al., Nature, 277:665-667 (1979); Kumar,J. Biol, Chem, 256: 10435-10441 (1981). For a review of synthesis andanticancer activity of some paclitaxel derivatives see: D. G. I.Kingston et al., Studies in Organic Chemistry vol. 26, entitled “Newtrends in Natural Products Chemistry 1986”, Attaur-Rahman, P. W. LeQuesne, Eds. (Elsevier, Amsterdam, 1986) pp 219-235.

Paclitaxel has been approved for clinical use in the treatment ofrefractory ovarian cancer in the United States (Markman et al., YaleJournal of Biology and Medicine, 64:583, 1991; McGuire et al., Ann.lntem, Med., 111:273, 1989) and for the treatment of breast cancer(Holmes et al., J. Nat. Cancer Inst., 83:1797, 1991.) It is a potentialcandidate for treatment of neoplasms in the skin (Einzig et. al., Proc.Am. Soc. Clin. Oncol., 20:46) and head and neck carcinomas (Forastireet. al., Sem. Oncol., 20:56, 1990). The compound also shows potentialfor the treatment of polycystic kidney disease (Woo et. al., Nature,368:750. 1994), lung cancer and malaria. Treatment of patients withpaclitaxel results in bone marrow suppression (multiple cell lineages,Ignoff, R. J. et. al, Cancer Chemotherapy Pocket Guide, 1998) related tothe duration of dosing above a threshold concentration (50 nM) (Kearns,C. M. et. al., Seminars in Oncology, 3(6) p. 16-23, 1995).

Docetaxel, (2R,3S)— N-carboxy-3-phenylisoserine,N-tert-butyl ester,13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one4-acetate 2-benzoate, trihydrate; is commercially available as aninjectable solution as TAXOTERE®. Docetaxel is indicated for thetreatment of breast cancer. Docetaxel is a semisynthetic derivative ofpaclitaxel q.v., prepared using a natural precursor,10-deacetyl-baccatin III, extracted from the needle of the European Yewtree. The dose limiting toxicity of docetaxel is neutropenia.

Vinca alkaloids are phase specific anti-neoplastic agents derived fromthe periwinkle plant. Vinca alkaloids act at the M phase (mitosis) ofthe cell cycle by binding specifically to tubulin. Consequently, thebound tubulin molecule is unable to polymerize into microtubules.Mitosis is believed to be arrested in metaphase with cell deathfollowing. Examples of vinca alkaloids include, but are not limited to,vinblastine, vincristine, and vinorelbine.

Vinblastine, vincaleukoblastine sulfate, is commercially available asVELBAN® as an injectable solution. Although, it has possible indicationas a second line therapy of various solid tumors, it is primarilyindicated in the treatment of testicular cancer and various lymphomasincluding Hodgkin's Disease; and lymphocytic and histiocytic lymphomas.Myelosuppression is the dose limiting side effect of vinblastine.

Vincristine, vincaleukoblastine, 22-oxo-, sulfate, is commerciallyavailable as ONCOVIN® as an injectable solution. Vincristine isindicated for the treatment of acute leukemias and has also found use intreatment regimens for Hodgkin's and non-Hodgkin's malignant lymphomas.Alopecia and neurologic effects are the most common side effect ofvincristine and to a lesser extent myelosupression and gastrointestinalmucositis effects occur.

Vinorelbine,3′,4′-didehydro-4′-deoxy-C′-norvincaleukoblastine[R—(R*,R*)-2,3-dihydroxybutanedioate(1:2)(salt)], commercially available as an injectable solution ofvinorelbine tartrate (NAVELBINE®), is a semisynthetic vinca alkaloid.Vinorelbine is indicated as a single agent or in combination with otherchemotherapeutic agents, such as cisplatin, in the treatment of varioussolid tumors, particularly non-small cell lung, advanced breast, andhormone refractory prostate cancers. Myelosuppression is the most commondose limiting side effect of vinorelbine.

Platinum coordination complexes are non-phase specific anti-canceragents, which are interactive with DNA. The platinum complexes entertumor cells, undergo, aquation and form intra- and interstrandcrosslinks with DNA causing adverse biological effects to the tumor.Examples of platinum coordination complexes include, but are not limitedto, cisplatin and carboplatin.

Cisplatin, cis-diamminedichloroplatinum, is commercially available asPLATINOL® as an injectable solution. Cisplatin is primarily indicated inthe treatment of metastatic testicular and ovarian cancer and advancedbladder cancer. The primary dose limiting side effects of cisplatin arenephrotoxicity, which may be controlled by hydration and diuresis, andototoxicity.

Carboplatin, platinum, diammine[1,1-cyclobutane-dicarboxylate(2-)-O,O′],is commercially available as PARAPLATIN® as an injectable solution.Carboplatin is primarily indicated in the first and second linetreatment of advanced ovarian carcinoma. Bone marrow suppression is thedose limiting toxicity of carboplatin.

Alkylating agents are non-phase anti-cancer specific agents and strongelectrophiles. Typically, alkylating agents form covalent linkages, byalkylation, to DNA through nucleophilic moieties of the DNA moleculesuch as phosphate, amino, sulfhydryl, hydroxyl, carboxyl, and imidazolegroups. Such alkylation disrupts nucleic acid function leading to celldeath. Examples of alkylating agents include, but are not limited to,nitrogen mustards such as cyclophosphamide, melphalan, and chlorambucil;alkyl sulfonates such as busulfan; nitrosoureas such as carmustine; andtriazenes such as dacarbazine.

Cyclophosphamide,2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxidemonohydrate, is commercially available as an injectable solution ortablets as CYTOXAN®. Cyclophosphamide is indicated as a single agent orin combination with other chemotherapeutic agents, in the treatment ofmalignant lymphomas, multiple myeloma, and leukemias. Alopecia, nausea,vomiting and leukopenia are the most common dose limiting side effectsof cyclophosphamide.

Melphalan, 4-[bis(2-chloroethyl)amino]-L-phenylalanine, is commerciallyavailable as an injectable solution or tablets as ALKERAN®. Melphalan isindicated for the palliative treatment of multiple myeloma andnon-resectable epithelial carcinoma of the ovary. Bone marrowsuppression is the most common dose limiting side effect of melphalan.

Chlorambucil, 4-[bis(2-chloroethyl)amino]benzenebutanoic acid, iscommercially available as LEUKERAN® tablets. Chlorambucil is indicatedfor the palliative treatment of chronic lymphatic leukemia, andmalignant lymphomas such as lymphosarcoma, giant follicular lymphoma,and Hodgkin's disease. Bone marrow suppression is the most common doselimiting side effect of chlorambucil.

Busulfan, 1,4-butanediol dimethanesulfonate, is commercially availableas MYLERAN® TABLETS. Busulfan is indicated for the palliative treatmentof chronic myelogenous leukemia. Bone marrow suppression is the mostcommon dose limiting side effects of busulfan.

Carmustine, 1,3-[bis(2-chloroethyl)-1-nitrosourea, is commerciallyavailable as single vials of lyophilized material as BiCNU®. Carmustineis indicated for the palliative treatment as a single agent or incombination with other agents for brain tumors, multiple myeloma,Hodgkin's disease, and non-Hodgkin's lymphomas. Delayed myelosuppressionis the most common dose limiting side effects of carmustine.

Dacarbazine, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, iscommercially available as single vials of material as DTIC-Dome®.Dacarbazine is indicated for the treatment of metastatic malignantmelanoma and in combination with other agents for the second linetreatment of Hodgkin's Disease. Nausea, vomiting, and anorexia are themost common dose limiting side effects of dacarbazine.

Antibiotic anti-neoplastics are non-phase specific agents, which bind orintercalate with DNA. Typically, such action results in stable DNAcomplexes or strand breakage, which disrupts ordinary function of thenucleic acids leading to cell death. Examples of antibioticanti-neoplastic agents include, but are not limited to, actinomycinssuch as dactinomycin, anthrocyclins such as daunorubicin anddoxorubicin; and bleomycins.

Dactinomycin, also know as Actinomycin D, is commercially available ininjectable form as COSMEGEN®. Dactinomycin is indicated for thetreatment of Wilm's tumor and rhabdomyosarcoma. Nausea, vomiting, andanorexia are the most common dose limiting side effects of dactinomycin.

Daunorubicin,(8S-cis-)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12naphthacenedione hydrochloride, is commercially available as a liposomalinjectable form as DAUNOXOME® or as an injectable as CERUBIDINE®.Daunorubicin is indicated for remission induction in the treatment ofacute nonlymphocytic leukemia and advanced HIV associated Kaposi'ssarcoma. Myelosuppression is the most common dose limiting side effectof daunorubicin.

Doxorubicin,(8S,10S)-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl,7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12 naphthacenedionehydrochloride, is commercially available as an injectable form as RUBEX®or ADRIAMYCIN RDF®. Doxorubicin is primarily indicated for the treatmentof acute lymphoblastic leukemia and acute myeloblastic leukemia, but isalso a useful component in the treatment of some solid tumors andlymphomas. Myelosuppression is the most common dose limiting side effectof doxorubicin.

Bleomycin, a mixture of cytotoxic glycopeptide antibiotics isolated froma strain of Streptomyces verticillus, is commercially available asBLENOXANE®. Bleomycin is indicated as a palliative treatment, as asingle agent or in combination with other agents, of squamous cellcarcinoma, lymphomas, and testicular carcinomas Pulmonary and cutaneoustoxicities are the most common dose limiting side effects of bleomycin.

Topoisomerase II inhibitors include, but are not limited to,epipodophyllotoxins.

Epipodophyllotoxins are phase specific anti-neoplastic agents derivedfrom the mandrake plant. Epipodophyllotoxins typically affect cells inthe S and G₂ phases of the cell cycle by forming a ternary complex withtopoisomerase II and DNA causing DNA strand breaks. The strand breaksaccumulate and cell death follows. Examples of epipodophyllotoxinsinclude, but are not limited to, etoposide and teniposide.

Etoposide, 4′-demethyl-epipodophyllotoxin9[4,6-0-(R)-ethylidene-β-D-glucopyranoside], is commercially availableas an injectable solution or capsules as VePESID® and is commonly knownas VP-16. Etoposide is indicated as a single agent or in combinationwith other chemotherapy agents in the treatment of testicular andnon-small cell lung cancers. Myelosuppression is the most common sideeffect of etoposide. The incidence of leucopenia tends to be more severethan thrombocytopenia.

Teniposide, 4′-demethyl-epipodophyllotoxin9[4,6-0-(R)-thenylidene-β-D-glucopyranoside], is commercially availableas an injectable solution as VUMON® and is commonly known as VM-26.Teniposide is indicated as a single agent or in combination with otherchemotherapy agents in the treatment of acute leukemia in children.Myelosuppression is the most common dose limiting side effect ofteniposide. Teniposide can induce both leucopenia and thrombocytopenia.

Antimetabolite neoplastic agents are phase specific anti-neoplasticagents that act at S phase (DNA synthesis) of the cell cycle byinhibiting DNA synthesis or by inhibiting purine or pyrimidine basesynthesis and thereby limiting DNA synthesis. Consequently, S phase doesnot proceed and cell death follows. Examples of antimetaboliteanti-neoplastic agents include, but are not limited to, fluorouracil,methotrexate, cytarabine, mecaptopurine, thioguanine, and gemcitabine.

5-fluorouracil, 5-fluoro-2,4-(1H,3H) pyrimidinedione, is commerciallyavailable as fluorouracil. Administration of 5-fluorouracil leads toinhibition of thymidylate synthesis and is also incorporated into bothRNA and DNA. The result typically is cell death. 5-fluorouracil isindicated as a single agent or in combination with other chemotherapyagents in the treatment of carcinomas of the breast, colon, rectum,stomach and pancreas. Myelosuppression and mucositis are dose limitingside effects of 5-fluorouracil. Other fluoropyrimidine analogs include5-fluoro deoxyuridine (floxuridine) and 5-fluorodeoxyuridinemonophosphate.

Cytarabine, 4-amino-1-β-D-arabinofuranosyl-2 (1H)-pyrimidinone, iscommercially available as CYTOSAR-U® and is commonly known as Ara-C. Itis believed that cytarabine exhibits cell phase specificity at S-phaseby inhibiting DNA chain elongation by terminal incorporation ofcytarabine into the growing DNA chain. Cytarabine is indicated as asingle agent or in combination with other chemotherapy agents in thetreatment of acute leukemia. Other cytidine analogs include5-azacytidine and 2′,2′-difluorodeoxycytidine (gemcitabine). Cytarabineinduces leucopenia, thrombocytopenia, and mucositis.

Mercaptopurine, 1,7-dihydro-6H-purine-6-thione monohydrate, iscommercially available as PURINETHOL®. Mercaptopurine exhibits cellphase specificity at S-phase by inhibiting DNA synthesis by an as of yetunspecified mechanism. Mercaptopurine is indicated as a single agent orin combination with other chemotherapy agents in the treatment of acuteleukemia. Myelosuppression and gastrointestinal mucositis are expectedside effects of mercaptopurine at high doses. A useful mercaptopurineanalog is azathioprine.

Thioguanine, 2-amino-1,7-dihydro-6H-purine-6-thione, is commerciallyavailable as TABLOID®. Thioguanine exhibits cell phase specificity atS-phase by inhibiting DNA synthesis by an as of yet unspecifiedmechanism. Thioguanine is indicated as a single agent or in combinationwith other chemotherapy agents in the treatment of acute leukemia.Myelosuppression, including leucopenia, thrombocytopenia, and anemia, isthe most common dose limiting side effect of thioguanine administration.However, gastrointestinal side effects occur and can be dose limiting.Other purine analogs include pentostatin, erythrohydroxynonyladenine,fludarabine phosphate, and cladribine.

Gemcitabine, 2′-deoxy-2′,2′-difluorocytidine monohydrochloride(β-isomer), is commercially available as GEMZAR®. Gemcitabine exhibitscell phase specificity at S-phase and by blocking progression of cellsthrough the G1/S boundary. Gemcitabine is indicated in combination withcisplatin in the treatment of locally advanced non-small cell lungcancer and alone in the treatment of locally advanced pancreatic cancer.Myelosuppression, including leucopenia, thrombocytopenia, and anemia, isthe most common dose limiting side effect of gemcitabine administration.

Methotrexate,N-[4[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamicacid, is commercially available as methotrexate sodium. Methotrexateexhibits cell phase effects specifically at S-phase by inhibiting DNAsynthesis, repair and/or replication through the inhibition ofdyhydrofolic acid reductase which is required for synthesis of purinenucleotides and thymidylate. Methotrexate is indicated as a single agentor in combination with other chemotherapy agents in the treatment ofchoriocarcinoma, meningeal leukemia, non-Hodgkin's lymphoma, andcarcinomas of the breast, head, neck, ovary and bladder.Myelosuppression (leucopenia, thrombocytopenia, and anemia) andmucositis are expected side effect of methotrexate administration.

Camptothecins, including, camptothecin and camptothecin derivatives areavailable or under development as Topoisomerase I inhibitors.Camptothecins cytotoxic activity is believed to be related to itsTopoisomerase I inhibitory activity. Examples of camptothecins include,but are not limited to irinotecan, topotecan, and the various opticalforms of7-(4-methylpiperazino-methylene)-10,11-ethylenedioxy-20-camptothecindescribed below.

Irinotecan HCl,(4S)-4,11-diethyl-4-hydroxy-9[(4-piperidinopiperidino)carbonyloxy]-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dionehydrochloride, is commercially available as the injectable solutionCAMPTOSAR®.

Irinotecan is a derivative of camptothecin which binds, along with itsactive metabolite SN-38, to the topoisomerase I-DNA complex. It isbelieved that cytotoxicity occurs as a result of irreparable doublestrand breaks caused by interaction of the topoisomerase I:DNA:irintecanor SN-38 ternary complex with replication enzymes. Irinotecan isindicated for treatment of metastatic cancer of the colon or rectum. Thedose limiting side effects of irinotecan HCl are myelosuppression,including neutropenia, and GI effects, including diarrhea.

Topotecan HCl,(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′,6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dionemonohydrochloride, is commercially available as the injectable solutionHYCAMTIN®. Topotecan is a derivative of camptothecin which binds to thetopoisomerase I-DNA complex and prevents religation of singles strandbreaks caused by Topoisomerase I in response to torsional strain of theDNA molecule. Topotecan is indicated for second line treatment ofmetastatic carcinoma of the ovary and small cell lung cancer. The doselimiting side effect of topotecan HCl is myelosuppression, primarilyneutropenia.

Pharmaceutical compositions may be presented in unit dose formscontaining a predetermined amount of active ingredient per unit dose.Such a unit may contain, for example, 0.5 mg to 1 g, preferably 1 mg to700 mg, more preferably 5 mg to 100 mg of a compound of the formula (I),depending on the condition being treated, the route of administrationand the age, weight and condition of the patient, or pharmaceuticalcompositions may be presented in unit dose forms containing apredetermined amount of active ingredient per unit dose. Preferred unitdosage compositions are those containing a daily dose or sub-dose, asherein above recited, or an appropriate fraction thereof, of an activeingredient. Furthermore, such pharmaceutical compositions may beprepared by any of the methods well known in the pharmacy art.

Pharmaceutical compositions may be adapted for administration by anyappropriate route, for example by the oral (including buccal orsublingual), rectal, nasal, topical (including buccal, sublingual ortransdermal), vaginal or parenteral (including subcutaneous,intramuscular, intravenous or intradermal) route. Such compositions maybe prepared by any method known in the art of pharmacy, for example bybringing into association a compound of formal (I) with the carrier(s)or excipient(s).

Pharmaceutical compositions adapted for oral administration may bepresented as discrete units such as capsules or tablets; powders orgranules; solutions or suspensions in aqueous or non-aqueous liquids;edible foams or whips; or oil-in-water liquid emulsions or water-in-oilliquid emulsions.

Capsules are made by preparing a powder mixture, as described above, andfilling formed gelatin sheaths. Glidants and lubricants such ascolloidal silica, talc, magnesium stearate, calcium stearate or solidpolyethylene glycol can be added to the powder mixture before thefilling operation. A disintegrating or solubilizing agent such asagar-agar, calcium carbonate or sodium carbonate can also be added toimprove the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants,disintegrating agents and coloring agents can also be incorporated intothe mixture. Suitable binders include starch, gelatin, natural sugarssuch as glucose or beta-lactose, corn sweeteners, natural and syntheticgums such as acacia, tragacanth or sodium alginate,carboxymethylcellulose, polyethylene glycol, waxes and the like.Lubricants used in these dosage forms include sodium oleate, sodiumstearate, magnesium stearate, sodium benzoate, sodium acetate, sodiumchloride and the like. Disintegrators include, without limitation,starch, methyl cellulose, agar, bentonite, xanthan gum and the like.Tablets are formulated, for example, by preparing a powder mixture,granulating or slugging, adding a lubricant and disintegrant andpressing into tablets. A powder mixture is prepared by mixing thecompound, suitably comminuted, with a diluent or base as describedabove, and optionally, with a binder such as carboxymethylcellulose, analiginate, gelatin, or polyvinyl pyrrolidone, a solution retardant suchas paraffin, a resorption accelerator such as a quaternary salt and/oran absorption agent such as bentonite, kaolin or dicalcium phosphate.The powder mixture can be granulated by tablet forming dies by means ofthe addition of stearic acid, a stearate salt, talc or mineral oil. Thelubricated mixture is then compressed into tablets. The compounds of thepresent invention can also be combined with a free flowing inert carrierand compressed into tablets directly without going through thegranulating or slugging steps. A clear or opaque protective coatingconsisting of a sealing coat of shellac, a coating of sugar or polymericmaterial and a polish coating of wax can be provided. Dyestuffs can beadded to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared indosage unit form so that a given quantity contains a predeterminedamount of a compound of formula (I). Syrups can be prepared bydissolving the compound in a suitably flavored aqueous solution, whileelixirs are prepared through the use of a non-toxic alcoholic vehicle.Suspensions can be formulated by dispersing the compound in a non-toxicvehicle. Solubilizers and emulsifiers such as ethoxylated isostearylalcohols and polyoxy ethylene sorbitol ethers, preservatives, flavoradditive such as peppermint oil or natural sweeteners or saccharin orother artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit pharmaceutical compositions for oraladministration can be microencapsulated. The formulation can also beprepared to prolong or sustain the release as for example by coating orembedding particulate material in polymers, wax or the like.

Pharmaceutical compositions adapted for rectal administration may bepresented as suppositories or as enemas.

Pharmaceutical compositions adapted for vaginal administration may bepresented as pessaries, tampons, creams, gels, pastes, foams or sprayformulations.

Pharmaceutical formulations adapted for parenteral administrationinclude aqueous and non-aqueous sterile injection solutions which maycontain anti-oxidants, buffers, bacteriostats and solutes which renderthe composition isotonic with the blood of the intended recipient; andaqueous and non-aqueous sterile suspensions which may include suspendingagents and thickening agents. The pharmaceutical compositions may bepresented in unit-dose or multi-dose containers, for example sealedampoules and vials, and may be stored in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample water for injections, immediately prior to use. Extemporaneousinjection solutions and suspensions may be prepared from sterilepowders, granules and tablets.

It should be understood that in addition to the ingredients particularlymentioned above, the pharmaceutical compositions may include otheragents conventional in the art having regard to the type of formulationin question, for example those suitable for oral administration mayinclude flavouring agents.

A therapeutically effective amount of a compound of the presentinvention will depend upon a number of factors including, for example,the age and weight of the intended recipient, the precise conditionrequiring treatment and its severity, the nature of the formulation, andthe route of administration, and will ultimately be at the discretion ofthe attendant prescribing the medication. However, an effective amountof a compound of formula (I) for the treatment of anemia will generallybe in the range of 0.001 to 100 mg/kg body weight of recipient per day,suitably in the range of 0.01 to 10 mg/kg body weight per day. For a 70kg adult mammal, the actual amount per day would suitably be from 7 to700 mg and this amount may be given in a single dose per day or in anumber (such as two, three, four, five or six) of sub-doses per day suchthat the total daily dose is the same. An effective amount of a salt orsolvate, etc., may be determined as a proportion of the effective amountof the compound of formula (I) per se. It is envisaged that similardosages would be appropriate for treatment of the other conditionsreferred to above.

Chemical Background

The present compounds are automatically named by computer software, eg.ISISdraw, ChemDraw, or eLNB. A person skilled in the art understandsthat there might be slight differences in the chemical names generatedby different software. The compounds of this invention may be made by avariety of methods, including standard chemistry. Any previously definedvariable will continue to have the previously defined meaning unlessotherwise indicated. Illustrative general synthetic methods are set outbelow and then specific compounds of the invention as prepared are givenin the examples.

Compounds of general formula (I) may be prepared by methods known in theart of organic synthesis as set forth in part by the following synthesisschemes. In all of the schemes described below, it is well understoodthat protecting groups for sensitive or reactive groups are employedwhere necessary in accordance with general principles of chemistry.Protecting groups are manipulated according to standard methods oforganic synthesis (T. W. Green and P. G. M. Wuts (1991) ProtectingGroups in Organic Synthesis, John Wiley & Sons). These groups areremoved at a convenient stage of the compound synthesis using methodsthat are readily apparent to those skilled in the art. The selection ofprocesses as well as the reaction conditions and order of theirexecution shall be consistent with the preparation of compounds offormula (I). Those skilled in the art will recognize if a stereocenterexists in compounds of formula (I). Accordingly, the present inventionincludes both possible stereoisomers and includes not only racemiccompounds but the individual enantiomers as well. Also included in thepresent invention are fully or partially deuterated forms of the presentcompounds. When a compound is desired as a single enantiomer, it may beobtained by stereospecific synthesis or by resolution of the finalproduct or any convenient intermediate. Resolution of the final product,an intermediate, or a starting material may be effected by any suitablemethod known in the art. See, for example, Stereochemistry of OrganicCompounds by E. L. Eliel, S. H. Wilen, and L. N. Mander(Wiley-Interscience, 1994).

EXAMPLES General Experimental Methods

The following abbreviations are used throughout the experimental andhave the following meaning:

aq aqueousBINAP 2,2′-bis(diphenylphosphino)-1,1′-binapthylca. circaCDCl₃-d chloroform-dCD₃OD-d₄ methanol-d₄Cs₂CO₃ cesium carbonateCHCl₃ chloroformACN acetonitrileCH₃CN acetonitrileCelite registered trademark of Celite Corp. brand of diatomaceous earthDBU 1,8-diazabicyclo[5.4.0]undeca-7-eneDCE dichloroethaneDCM methylene chlorideDME 1,2 dimethoxyethane

DMF N,N-dimethylformamide

DIEA diisopropyl ethylamineDMSO-d₆ dimethylsulfoxide-d₆EtOAc ethyl acetateEDC 1-(3-dimethylaminopropyl)-3-ethylcarbodimmide hydrochlorideh hour(s)¹H NMR proton nuclear magnetic resonanceHCl hydrochloric acidHOAT 1-hydroxy-7-azabenzotriazoleHPLC high performance liquid chromatographyIPA 2-propanolK₂CO₃ potassium carbonateKOH potassium hydroxideLC/MS liquid chromatography/mass spectroscopyMgSO₄ magnesium sulfateMeOH methanolmin minute(s)MTBE methyl tert-butyl etherMS mass spectrometryNaOH sodium hydroxideNa₂SO₄ sodium sulfateNH₄OH ammonium hydroxideNMM 4-methylmorpholineNMP N-Methyl-2-pyrrolidonePd/C Palladium (10% by wt) on carbonPdCl₂(dppf)-CH₂Cl₂1,1′-Bis(diphenylphosphino)ferrocene-palladium(II)dichloridedichloromethane complexPd(Ph₃P)₄ tetrakis(triphenylphosphine)palladium(0)SOCl₂ thionyl chlorideSPhos 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenylTFA trifluoroacetic acdTHF tetrahydrofuranTLC thin layer chromatography

The following guidelines apply to all experimental procedures describedherein. All reactions were conducted under a positive pressure ofnitrogen using oven-dried glassware, unless otherwise indicated.Temperatures designated are external (i.e. bath temperatures), and areapproximate. Air and moisture-sensitive liquids were transferred viasyringe. Reagents were used as received. Solvents utilized were thoselisted as “anhydrous” by vendors. Molarities listed for reagents insolutions are approximate, and were used without prior titration againsta corresponding standard. All reactions were agitated by stir bar,unless otherwise indicated. Heating was conducted using heating bathscontaining silicon oil, unless otherwise indicated. Reactions conductedby microwave irradiation (0-400 W at 2.45 GHz) were done so using aBiotage Initiator™ 2.0 instrument with Biotage microwave EXP vials(0.2-20 mL) and septa and caps. Irradiation levels utilized (i.e. high,normal, low) based on solvent and ionic charge were based on vendorspecifications. Cooling to temperatures below −70° C. was conductedusing dry ice/acetone or dry ice/2-propanol. Magnesium sulfate andsodium sulfate used as drying agents were of anhydrous grade, and wereused interchangeably. Solvents described as being removed “in vacuo” or“under reduced pressure” were done so by rotary evaporation.

Preparative normal phase silica gel chromatography was carried out usingeither a Teledyne ISCO CombiFlash Companion instrument with RediSep orISCO Gold silica gel cartridges (4 g-330 g), or an Analogix IF280instrument with SF25 silica gel cartridges (4 g-3-00 g), or a BiotageSP1 instrument with HP silica gel cartridges (10 g-100 g). Purificationby reverse phase HPLC was conducted using a YMC-pack column (ODS-A 75×30mm) as solid phase, unless otherwise noted. A mobile phase of 25 mL/minA (acetonitrile-0.1% TFA):B (water-0.1% TFA), 10-80% gradient A (10 min)was utilized with UV detection at 214 nM, unless otherwise noted.

A PE Sciex API 150 single quadrupole mass spectrometer (PE Sciex,Thornhill, Ontario, Canada) was operated using electrospray ionizationin the positive ion detection mode. The nebulizing gas was generatedfrom a zero air generator (Balston Inc., Haverhill, Mass., USA) anddelivered at 65 psi and the curtain gas was high purity nitrogendelivered from a Dewar liquid nitrogen vessel at 50 psi. The voltageapplied to the electrospray needle was 4.8 kV. The orifice was set at 25V and mass spectrometer was scanned at a rate of 0.5 scan/sec using astep mass of 0.2 amu and collecting profile data.

Method A LCMS. Samples were introduced into the mass spectrometer usinga CTC PAL autosampler (LEAP Technologies, Carrboro, N.C.) equipped witha hamilton 10 uL syringe which performed the injection into a Valco10-port injection valve. The HPLC pump was a Shimadzu LC-10ADvp(Shimadzu Scientific Instruments, Columbia, Md.) operated at 0 3 mL/minand a linear gradient 4.5% A to 90% B in 3.2 min. with a 0.4 min. hold.The mobile phase was composed of 100% (H₂O 0.02% TFA) in vessel A and100% (CH₃CN 0.018% TFA) in vessel B. The stationary phase is Aquasil (C,18) and the column dimensions were 1 mm×40 mm. Detection was by UV at214 nm, evaporative light-scattering (ELSD) and MS.

Method B, LCMS. Alternatively, an Agilent 1100 analytical HPLC systemwith an LC/MS was used and operated at 1 mL/min and a linear gradient 5%A to 100% B in 2.2 min with a 0.4 min hold. The mobile phase wascomposed of 100% (H₂O 0.02% TFA) in vessel A and 100% (CH₃CN 0.018% TFA)in vessel B. The stationary phase was Zobax (C₈) with a 3.5 um particalsize and the column dimensions were 2.1 mm×50 mm. Detection was by UV at214 nm, evaporative light-scattering (ELSD) and MS.

Method C, LCMS. Alternatively, an MDSSCIEX API 2000 equipped with acapillary column of (50×4.6 mm, 5 μm) was used. HPLC was done onAgilent-1200 series UPLC system equipped with column Zorbax SB-C₁₈(50×4.6 mm, 1.8 μm) eluting with CH₃CN: ammonium acetate buffer. Thereactions were performed in the microwave (CEM, Discover).

¹H-NMR spectra were recorded at 400 MHz using a Bruker AVANCE 400 MHzinstrument, with ACD Spect manager v. 10 used for reprocessing.Multiplicities indicated are: s=singlet, d=doublet, t=triplet,q=quartet, quint=quintet, sxt=sextet, m=multiplet, dd=doublet ofdoublets, dt=doublet of triplets etc. and br indicates a broad signal.All NMRs in DMSO unless otherwise noted.

Analytical HPLC: Products were analyzed by Agilent 1100 AnalyticalChromatography system, with 4.5×75 mm Zorbax XDB-C₁₈ column (3.5 um) at2 mL/min with a 4 min gradient from 5% CH₃CN (0.1% formic acid) to 95%CH₃CN (0.1% formic acid) in H₂O (0.1% formic acid) and a 1 min hold.

The compounds of formula (I) can be made according to Scheme 1 or byanalogous methods. Methyl 6-bromo-1H-indole-4-carboxylate (I) isalkylated with an alkyl halide in the presence of base (e.g. sodiumhydride) or with an alcohol in the presence of(cyanomethyl)trimethylphosphonium chloride and base (e.g. sodiumhydride) to give compounds of Formula II. Saponification of the esterwith aqueous base provides compounds of Formula III, which are coupledto various aminomethylpyridones IV utilizing standard peptide couplingreagents (e.g. EDC, HOAT, NMM) to furnish compounds of Formula V.Palladium-mediated cross-coupling of various boronic acids (orboronates) with V provides compounds of Formula VI.

The following examples are for illustrative purposes only and are notintended to limit the scope of the present invention. The compounds werenamed using ACD Name software [Advanced Chemistry Development, Inc.,(ACD/Labs), Toronto, Canada.(http://www.acdlabs.com/products/name_lab/)].

Example 16-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

1a) Methyl 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate

To a cooled (0° C.) solution of methyl 6-bromo-1H-indole-4-carboxylate(1.0 g, 3.94 mmol) solid in N,N-dimethylformamide (25 mL) was addedsodium hydride (0.173 g, 4.33 mmol). The reaction was stirred for 15min, at which time 2-bromopropane (0.554 mL, 5.90 mmol) was added. Thereaction was then allowed to warm to RT and was maintained overnight.LCMS showed about 25% starting material remaining. The reaction washeated at 45° C. for 4 h, but no further conversion was noted. Thereaction vessel was put back into an ice bath and stirred for 15 min.Then excess NaH (60%) was added, stirred for 10 min, and then2-bromopropane (excess) was added. The ice bath was removed and thereaction stirred for 1 h. Approximately half of the reaction volume wasremoved in vacuo and poured into saturated NH₄Cl (200 mL). This wasextracted with ether (2×) and the combined organics were washed withbrine, dried (MgSO₄), and concentrated. Purification by columnchromatography (80 g Isco silica column; Gradient B: 5-25%, A: hexane,B: ethyl acetate) gave methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.53 g, 1.718 mmol,43.7% yield).

1b) 6-Bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.52 g, 1.756 mmol)in methanol (15 mL) and tetrahydrofuran (3 mL) was added 3 M NaOH (1.756mL, 5.27 mmol) via syringe drop wise (over 2 min) The solution wasmaintained at RT for 2 h, at which time LCMS showed only 12% conversionto product. Then 1.5 mL 3 M NaOH was added and the solution wasmaintained at RT overnight. LCMS showed complete conversion to product.Removed volatiles in vacuo and dissolved the residue in water and slowlyacidified with 1 M HCl (solids precipitated). Extracted with EtOAc (2×),combined organics and dried over MgSO₄. Filtered and concentrated invacuo to give 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.50 g, 1.737 mmol, 99% yield) as a white solid.

1c)6-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

To a mixture of 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.71 g, 2.52 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone(0.575 g, 3.77 mmol), 1-hydroxy-7-azabenzotriazole (0.514 g, 3.77 mmol),and EDC (0.724 g, 3.77 mmol) in dimethylsulfoxide (20 mL) was addedquickly N-methylmorpholine (1.107 mL, 10.07 mmol) via syringe. Thesolids slowly dissolved and the reaction was maintained at RT overnight.The reaction was slowly poured into ice-water (300 mL), stirred for 10min, then allowed to sit for 10 min. The solids were filtered and washedwith water (100 mL), airdried for 15 min, then dried in vacuum oven at45° C. for 4 h to give6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.82 g, 1.871 mmol, 74.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.39-1.46 (m, 6H) 2.09-2.15 (m, 3H) 2.21 (s, 3H) 4.32 (d, J=5.05 Hz, 2H)4.82 (quin, J=6.63 Hz, 1H) 5.88 (s, 1H) 6.86 (d, J=3.28 Hz, 1H) 7.51 (d,J=1.77 Hz, 1H) 7.62 (d, J=3.28 Hz, 1H) 7.92 (s, 1H) 8.31 (t, J=4.93 Hz,1H) 11.55 (br. s., 1H). MS(ES) [M+H]⁺ 416.0.

Example 2N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

A mixture of6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.10 g, 0.240 mmol),1-methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(0.087 g, 0.288 mmol) and potassium phosphate (tribasic) (0.153 g, 0.721mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was degassed with N₂ for10 min, at which time PdCl₂(dppf)-CH₂Cl₂ (0.029 g, 0.036 mmol) wasadded. The reaction was sealed and heated at 100° C. for 2 h. Thereaction was then allowed to cool to RT and sat overnight, at which timeit was diluted with EtOAc, filtered through Celite, washed with EtOAc,and concentrated in vacuo. Purification of the residue by columnchromatography (12 g Isco GOLD silica column; Gradient B: 5-90%; A:dichloromethane, B: 10% chloroform containing 2 M ammonia in methanol)gaveN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide(94 mg, 0.180 mmol, 74.8% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.46(d, J=6.57 Hz, 6H) 2.12 (s, 3H) 2.17-2.28 (m, 6H) 2.38-2.46 (m, 4H)3.49-3.57 (m, 4H) 4.37 (d, J=5.05 Hz, 2H) 4.86-4.98 (m, 1H) 5.88 (s, 1H)6.87 (d, J=3.03 Hz, 1H) 6.93 (d, J=8.84 Hz, 1H) 7.58 (d, J=3.28 Hz, 1H)7.65 (d, J=1.26 Hz, 1H) 7.87 (s, 1H) 7.98 (dd, J=8.97, 2.65 Hz, 1H) 8.28(t, J=5.05 Hz, 1H) 8.57 (d, J=2.27 Hz, 1H) 11.55 (s, 1H). MS(ES) [M+H]⁺513.3.

Examples 3-263 were prepared by the methods described above for Examples1 and 2 or routine variations thereof, starting from the requisite4-aminomethylpyridones and 6-substituted-4-indolecarboxylates. Routinevariations include, but are not limited to, reversing the bromide andboronate coupling partners for the Suzuki type couplings or using a onepot procedure in which the boroate is formed in situ.

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 3

N-[(4,6-Dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-phenyl- 1H-indole-4-carboxamide 1.45-1.51 (m, 6 H) 2.12(s, 3 H) 2.23 (s, 3 H) 4.37 (d, J = 5.05 Hz, 2 H) 4.89- 5.02 (m, 1 H)5.88 (s, 1 H) 6.88 (d, J = 3.28 Hz, 1 H) 7.30-7.37 (m, 1 H) 7.47 (t, J =7.71 Hz, 2 H) 7.62 (d, J = 3.28 Hz, 1 H) 7.71 (d, J = 1.52 Hz, 1 H)7.76- 7.84 (m, 2 H) 7.92 (s, 1 H) 8.32 (t, J = 5.05 Hz, 1 H) 11.55 (s, 1H) 414.1 4

N-[(4,6-Dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-(2-oxo- 2,3-dihydro-1H- benzimidazol-5-yl)-1H-indole-4-carboxamide 1.47 (d, J = 6.57 Hz, 6 H) 2.12 (s, 3 H) 2.23(s, 3 H) 4.38 (d, J = 5.05 Hz, 2 H) 4.86-5.01 (m, 1 H) 5.89 (s, 1 H)6.86 (d, J = 3.03 Hz, 1 H) 7.00 (d, J = 8.08 Hz, 1 H) 7.30 (s, 1 H) 7.36(dd, J = 8.08, 1.77 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H) 7.65 (d, J =1.26 Hz, 1 H) 7.83 (s, 1 H) 8.30 (t, J = 5.18 Hz, 1 H) 10.70 (s, 1 H)10.66 (s, 1 H) 11.55 (s, 1 H) 469.2 5

1-(1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl- 1-piperazinyl)-4- pyridinyl]-1H-indole-4-carboxamide 0.91 (t, J = 7.33 Hz, 3 H) 1.48 (d, J = 6.57 Hz, 6 H)1.51-1.59 (m, 2 H) 2.13 (s, 3 H) 2.23 (s, 3 H) 2.43 (t, J = 4.93 Hz, 4H) 2.52-2.59 (m, 2 H) 3.50-3.65 (m, 4 H) 4.41 (d, J = 5.05 Hz, 2 H)4.91-5.09 (m, 1 H) 5.91 (s, 1 H) 6.89 (d, J = 3.03 Hz, 1 H) 7.05-7.21(m, 2 H) 7.66-7.78 (m, 2 H) 8.05 (s, 1 H) 8.16 (d, J = 5.31 Hz, 1 H)8.32 (t, J = 5.05 Hz, 1 H) 11.56 (s, 1 H) 541.3 6

1-(1-Methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(2-oxo-2,3- dihydro-1H- benzimidazol-5-yl)-1H-indole-4-carboxamide 0.91 (t, J = 7.33 Hz, 3 H) 1.47 (d, J = 6.57 Hz, 6H) 1.50-1.60 (m, 2 H) 2.13 (s, 3 H) 2.55 (d, J7.07 Hz, 2 H) 4.41 (d, J =5.05 Hz, 2 H) 4.94 (quin, J = 6.63 Hz, 1 H) 5.91 (s, 1 H) 6.85 (d, J =3.28 Hz, 1 H) 7.00 (d, J = 7.83 Hz, 1 H) 7.29 (s, 1 H) 7.35 (dd, J =8.08, 1.77 Hz, 1 H) 7.57- 7.69 (m, 2 H) 7.83 (s, 1 H) 8.30 (t, J = 5.05Hz, 1 H) 10.70 (s, 1 H) 10.66 (s, 1 H) 11.56 (s, 1 H) 498.3 7

6-Bromo-1-cyclopentyl- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4- carboxamide 1.64-1.87 (m, 6 H) 2.08-2.18 (m, 5 H)2.21 (s, 3 H) 4.32 (d, J = 5.05 Hz, 2 H) 4.86-5.02 (m, 1 H) 5.88 (s, 1H) 6.86 (d, J = 3.03 Hz, 1 H) 7.52 (d, J = 1.77 Hz, 1 H) 7.58 (d, J =3.28 Hz, 1 H) 7.92 (s, 1 H) 8.24-8.38 (m, 1 H) 11.54 (s, 1 H) 442.0,444.2 8

1-(1-Methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)- 1H-indole-4-carboxamide 0.90 (t, J = 7.33 Hz, 3H) 1.44-1.59 (m, 8 H) 2.13 (s, 3 H) 2.54 (dd, J = 8.59, 6.82 Hz, 2 H)4.41 (d, J = 5.05 Hz, 2 H) 4.98 (quin, J = 6.63 Hz, 1 H) 5.91 (s, 1 H)6.92 (d, J = 3.28 Hz, 1 H) 7.49 (dd, J = 7.33, 4.80 Hz, 1 H) 7.66 (d, J= 3.03 Hz, 1 H) 7.75 (d, J = 1.26 Hz, 1 H) 8.04 (s, 1 H) 8.20 (dt, J =8.27, 1.80 Hz, 1 H) 8.34 (t, J = 5.05 Hz, 1 H) 8.54 (dd, J = 4.67, 1.64Hz, 1 H) 9.04 (d, J = 1.77 Hz, 1 H) 11.56 (s, 1 H) 443.2 9

6-Bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 0.90 (t, J = 7.33 Hz, 3 H)1.43 (d, J = 6.57 Hz, 6 H) 1.47-1.62 (m, 2 H) 2.13 (s, 3 H) 2.53 (d, J =7.83 Hz, 2 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.76-4.88 (m, 1 H) 5.91 (s, 1H) 6.86 (d, J = 3.03 Hz, 1 H) 7.51 (d, J = 1.52 Hz, 1 H) 7.63 (d, J =3.28 Hz, 1 H) 7.92 (s, 1 H) 8.29 (t, J = 5.05 Hz, 1 H) 11.56 (br.s., 1H) 444.2, 446.0 10

1-(1-Methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-phenyl-1H- indole-4-carboxamide 0.91 (t, J = 7.33 Hz, 3 H)1.48 (d, J = 6.57 Hz, 6 H) 1.50-1.60 (m, 2 H) 2.13 (s, 3 H) 2.54 (dd, J= 8.59, 6.82 Hz, 2 H) 4.41 (d, J = 5.05 Hz, 2 H) 4.88-5.02 (m, 1 H) 5.91(s, 1 H) 6.88 (d, J = 3.03 Hz, 1 H) 7.28-7.38 (m, 1 H) 7.43-7.51 (m, 2H) 7.63 (d, J = 3.28 Hz, 1 H) 7.71 (d, J = 1.26 Hz, 1 H) 7.75-7.83 (m, 2H) 7.93 (s, 1 H) 8.32 (t, J = 5.05 Hz, 1 H) 11.57 (s, 1 H) 442.1 11

6-Bromo-N-[(4- cyclopropyl-6-methyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.48 (s,1 H) 8.36 (t, J = 4.93 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H)7.52 (d, J = 1.52 Hz, 1 H) 6.84 (d, J = 3.28 Hz, 1 H) 5.52 (s, 1 H)4.80-4.86 (m, 1 H) 4.52 (d, J = 5.05 Hz, 2 H) 2.14-2.19 (m, 1 H) 2.10(s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 0.91-0.98 (m, 2 H) 0.70-0.77 (m, 2H) 442.0, 444.1 12

6-Bromo-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl] methyl}-1H-indole-4- carboxamide 11.54 (s, 1 H)8.31 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.51(d, J = 1.52 Hz, 1 H) 6.86 (d, J = 3.28 Hz, 1 H) 6.02 (s, 1 H) 4.78-4.87(m, 1 H) 4.40 (d, J = 4.80 Hz, 2 H) 3.36-3.40 (m, 1 H) 3.24-3.28 (m, 1H) 2.16 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 1.09-1.15 (m, 6 H) 444.1,446.0 13

6-Bromo-N-[(4- cyclobutyl-6-methyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.60 (s,1 H) 8.26 (t, J = 4.80 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H)7.50 (d, J = 1.52 Hz, 1 H) 6.87 (d, J = 3.28 Hz, 1 H) 6.12 (s, 1 H)4.78-4.86 (m, 1 H) 4.31 (d, J = 4.80 Hz, 2 H) 3.80 (m, 1 H) 2.21-2.26(m, 2 H) 2.18 (s, 3 H) 2.05-2.13 (m, 2 H) 1.93-2.03 (m, 1 H) 1.78 (m, 1H) 1.43 (d, J = 6.57 Hz, 6 H) 455.9, 458.1 14

6-Bromo-1-(1- methylethyl)-N-[(4- methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4- carboxamide 8.33 (br.s.,1H), 7.92 (s, 1H), 7.63 (d, J = 3.28 Hz, 1H), 7.52 (d, J = 1.52 Hz, 1H),6.87 (d, J = 3.28 Hz, 1H), 5.90 (s, 1H), 4.78-4.87 (m, 1H), 4.33 (d, J =5.05 Hz, 2H), 2.37 (t, J = 7.58 Hz, 2H), 2.23 (s, 3H), 1.58 (sxt, J =7.43 Hz, 2H), 1.43 (d, J = 6.57 Hz, 6H), 0.88 (t, J = 7.33 Hz, 3H)444.2, 446.0 15

6-Bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-phenyl-1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4- carboxamide 11.88 (s, 1 H)8.35 (t, J = 4.42 Hz, 1 H) 7.93 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H)7.40-7.50 (m, 6 H) 6.86 (d, J = 3.03 Hz, 1 H) 6.00 (s, 1 H) 4.78-4.87(m, 1 H) 4.19 (d, J = 4.29 Hz, 2 H) 2.22 (s, 3 H) 1.44 (d, J = 6.57 Hz,6 H) 447.9, 479.7 16

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-6-(6-(2-oxopyrrolidin-1-yl) pyridin-3-yl)-1H-indole- 4-carboxamide 1.49(d, J = 4.00 Hz 6 H), 2.03-2.15 (m, 5 H), 2.24 (s, 3 H), 2.61 (t, J =8.08 Hz, 2 H), 4.06 (t, J = 7.20 Hz, 2 H), 4.38 (d, J = 5.05 Hz, 2 H),4.96 (quin, J = 6.69 Hz, 1 H), 5.89 (s, 1 H), 6.91 (d, J = 3.28 Hz, 1H), 7.65 (d, J = 3.28 Hz, 1 H), 7.75 (d, J = 1.26 Hz, 1 H), 8.01 (s, 1H), 8.25 (dd, J = 8.59, 2.53 Hz, 1 H), 8.32 (t, J = 5.05 Hz, 1 H), 8.39(d, J = 8.84 Hz, 1 H), 8.85 (d, J = 2.02 Hz, 1 H), 11.55 (s, 1 H) 498.317

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(2- methylpyridin-3-yl)-1H- indole-4-carboxamide 0.86-0.94(m, 3 H), 1.46 (d, J = 6.57 Hz, 6 H), 1.50-1.59 (m, 2 H) 2.12 (s, 3 H),4.38 (d, J = 5.31 Hz, 2 H), 4.80-4.94 (m, 1 H), 5.90 (s, 1 H), 6.92 (d,J = 3.03 Hz, 1 H), 7.31 (dd, J = 7.71, 4.93 Hz, 1 H), 7.42 (d, J = 1.26Hz, 1 H), 7.66 (d, J = 3.28 Hz, 1 H), 7.67-7.72 (m, 3 H), 8.17 (s, 1 H),8.24 (t, J = 5.18 Hz, 1 H), 8.46 (dd, J = 4.80, 1.77 Hz, 1 H) 457.1 18

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(2- methylpyrimidin- 5-yl)-1H-indole-4- carboxamide 0.85-0.95(m, 3 H), 1.44-1.60 (m, 8 H), 2.13 (s, 3 H), 3.33 (br.s., 2 H), 2.67 (s,3H), 4.41 (d, J = 5.31 Hz, 2 H), 4.97 (quin, J = 6.63 Hz, 1 H), 5.92 (s,1 H), 6.90 (d, J = 3.03 Hz, 1 H), 7.65 (d, J = 3.28 Hz, 1 H), 7.78 (d, J= 1.26 Hz, 2 H), 8.11 (s, 1 H), 8.32 (m, 1 H) 458.2 19

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(6- methylpyridin-3-yl)- 1H-indole-4-carboxamide 0.85-0.96 (m,3 H), 1.48 (d, J = 8.00 Hz, 6 H), 1.55 (m, 2 H), 2.13 (s, 3 H), 3.33(br.s., 1 H), 4.41 (d, J = 5.31 Hz, 2 H), 4.97 (quin, J = 6.63 Hz, 1 H),5.92 (s, 1 H), 6.90 (d, J = 3.03 Hz, 1 H), 7.35 (d, J = 8.08 Hz, 1 H),7.65 (d, J = 3.28 Hz, 1 H), 7.72 (d, J = 1.26 Hz, 1 H), 7.99 (s, 1 H),8.09 (dd, J = 8.08, 2.53 Hz, 1 H), 8.15 (s, 1 H), 8.33 (t, J = 5.05 Hz,1 H), 8.89 (d, J = 2.02 Hz, 1 H) 457.1 20

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-6-(4-((dimethylamino)methyl) phenyl)-1-isopropyl-3- methyl-1H-indole-4-carboxamide 1.44 (m, 6 H), 1.73-1.80 (m, 2 H), 2.11 (s, 3 H), 2.17 (s, 3H), 2.22-2.26 (m, 9 H), 3.58-3.65 (m, 2 H), 4.36 (d, J = 5.05 Hz, 2 H),4.87 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 7.25 (d, J = 1.26 Hz, 1H), 7.32 (d, J = 1.01 Hz, 1 H), 7.38 (d, J = 8.08 Hz, 2 H), 7.71 (d, J =8.34 Hz, 2 H), 7.78 (d, J = 1.26 Hz, 1 H), 8.12-8.23 (m, 1 H) 485.3 21

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-6-(6-methoxypyridin-3- yl)-3-methyl-1H-indole- 4-carboxamide 1.38-1.47 (m,6 H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 3.90 (s, 3 H), 4.35(d, J = 5.05 Hz, 2 H), 4.86 (quin, J = 6.57 Hz, 1 H), 5.87 (s, 1 H),6.88- 6.96 (m, 1 H), 7.22 (d, J = 1.26 Hz, 1 H), 7.33 (d, J = 1.01 Hz, 1H), 7.79 (d, J = 1.52 Hz, 1 H), 8.09 (dd, J = 8.59, 2.53 Hz, 1 H), 8.17(t, J = 5.05 Hz, 1 H), 8.54 (d, J = 2.02 Hz, 1 H) 459.3 22

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(6- morpholinopyridin-3-yl)- 1H-indole-4- carboxamide 1.43 (m,6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 3.45-3.54 (m, 4 H),3.70-3.79 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.85 (quin, J = 6.63 Hz,1 H), 5.87 (s, 1 H), 6.93 (d, J = 8.84 Hz, 1 H), 7.20 (d, J = 1.26 Hz, 1H), 7.29 (s, 1 H), 7.69- 7.77 (m, 1 H), 7.96 (dd, J = 8.97, 2.65 Hz, 1H), 8.15 (t, J = 5.05 Hz, 1 H), 8.54 (d, J = 2.27 Hz, 1 H), 11.48 (s, 1H) 514.3 23

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(4-(4- methylpiperazin-1-yl) phenyl)-1H-indole-4- carboxamide1.43 (m, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.29 (s, 3H), 2.53- 2.58 (m, 4 H), 3.15-3.28 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H),4.84 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 7.02 (d, J = 8.84 Hz, 2H), 7.19 (d, J = 1.26 Hz, 1 H), 7.27 (s, 1 H), 7.60 (d, J = 8.84 Hz, 2H), 7.67 (d, J = 1.26 Hz, 1 H), 8.09-8.21 (m, 2 H) 526.3 24

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(3- ((methylsulfonyl)methyl) phenyl) 1.45 (m, 6 H), 2.11 (s, 3H), 2.17 (s, 3 H), 2.24 (s, 3 H), 2.95 (s, 3 H), 4.36 (d, J = 5.05 Hz, 2H), 4.57 (s, 2 H), 4.85 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.25(d, J = 1.52 Hz, 1 H), 7.33-7.40 (m, 2 H), 7.49 (t, J = 7.71 Hz, 1 H),7.72- 7.82 (m, 3 H), 8.19 (t, J = 5.05 Hz, 1 H), 11.47 (s, 1 H) 520.0 25

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(2- methylpyrimidin-5-yl)- 1H-indole-4- carboxamide 1.44 (m, 6H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.25 (s, 3 H), 2.67 (s, 3 H), 4.36 (d,J = 5.05 Hz, 2 H), 4.90 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.33(d, J = 1.52 Hz, 1 H), 7.39 (d, J = 1.01 Hz, 1 H), 7.96 (d, J = 1.26 Hz,1 H), 8.20 (t, J = 5.05 Hz, 1 H), 9.09 (s, 2 H), 11.49 (s, 1 H) 444.2 26

6-(2-aminopyrimidin-5- yl)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl- 3-methyl-1H-indole-4- carboxamide 1.43 (d, 6H), 2.11 (s, 3 H), 2.15-2.20 (m, 3 H), 2.24 (s, 3 H), 4.35 (d, J = 5.05Hz, 2 H), 4.85 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 6.70 (s, 2 H),7.18 (d, J = 1.26 Hz, 1 H), 7.30 (s, 1 H), 7.75 (d, J = 1.26 Hz, 1 H),8.10-8.19 (m, 1 H), 8.61-8.68 (m, 2H), 11.49 (br.s., 1 H) 445.2 27

6-(6-aminopyridin-3-yl)- N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3- methyl-1H-indole-4-carboxamide 1.42 (d, J = 8.00 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.83 (quin, J = 6.63 Hz, 1H), 5.87 (s, 1 H), 6.02 (s, 2 H), 6.54 (d, J = 8.59 Hz, 1 H), 7.14 (d, J= 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.66 (d, J = 1.26 Hz, 1 H), 7.78 (dd, J= 8.59, 2.53 Hz, 1 H), 8.11-8.18 (m, 1 H), 8.30 (d, J = 2.02 Hz, 1 H)444.2 28

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-6-(6-(dimethylamino)pyridin- 3-yl)-1-isopropyl-3- methyl-1H-indole-4-carboxamide 1.43 (d, J = 8.00 Hz , 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 3.07 (s, 6 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.84 (quin, J= 6.57 Hz, 1 H), 5.87 (s, 1 H), 6.73 (d, J = 8.59 Hz, 1 H), 7.17 (d, J =1.52 Hz, 1 H), 7.28 (d, J = 1.01 Hz, 1 H), 7.68-7.74 (m, 1 H), 7.90 (dd,J = 8.84, 2.53 Hz, 1 H), 8.11-8.18 (m, 1 H), 8.48 (d, J = 2.02 Hz, 1 H)472.5 29

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin- 1-yl)pyridin-3-yl)-1H- indole-4-carboxamide1.39-1.47 (d, J = 8.00 Hz , 6 H), 1.,3- 2.01 (m, 4 H), 2.11 (s, 3 H),2.16 (s, 3 H), 2.24 (s, 3 H), 3.41-3.48 (m, 4 H), 4.35 (d, J = 5.05 Hz,2 H), 4.84 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 6.56 (d, J = 8.59Hz, 1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.27 (d, J = 1.01 Hz, 1 H), 7.69(d, J = 1.26 Hz, 1 H), 7.91 (dd, J = 8.72, 2.15 Hz, 1 H), 8.10-8.17 (m,1 H), 8.45 (d, J = 2.27 Hz, 1 H) 498.4 30

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-6-(4-fluorophenyl)-1- isopropyl-3-methyl-1H- indole-4-carboxamide 1.43 (m, 6H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 4.31-4.41 (m, 2 H),4.80-4.93 (m, 1 H), 5.87 (s, 1 H), 7.17- 7.36 (m, 4 H), 7.74-7.84 (m, 3H), 8.16-8.24 (m, 1 H), 11.43-11.55 (m, 1 H) 446.0 31

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-6-(4-(4-isopropylpiperazin- 1-yl)phenyl)-3-methyl- 1H-indole-4-carboxamide 1.01-1.11 (m, 6 H), 1.43 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.68 (br.s., 4 H), 2.74-2.84 (m, 1 H),3.15-3.26 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.83 (quin, J = 6.57 Hz,1 H), 5.87 (s, 1 H), 7.02 (d, J = 8.84 Hz, 2 H), 7.19 (d, J = 1.52 Hz, 1H), 7.27 (s, 1 H), 7.60 (d, J = 8.84 Hz, 2 H), 7.67 (d, J = 1.26 Hz, 1H), 8.11-8.21 (m, 2 H) 554.2 32

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-6-(1H-indazol-6-yl)-1-isopropyl-3- methyl-1H-indole-4- carboxamide 1.40-1.51 (m, 6 H),2.11 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.33-4.46 (m, 2 H), 4.90(quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.33 (dd, J = 12.76, 1.14 Hz, 2H), 7.54 (dd, J = 8.46, 1.39 Hz, 1 H), 7.76- 7.89 (m, 3 H), 8.09 (s, 1H), 8.24 (t, J = 5.05 Hz, 1 H), 11.48 (br.s., 1 H), 13.07 (br.s., 1 H)468.3 33

6-bromo-N-[(4-ethyl-6- methyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.49 (s, 1H) 8.23 (t, J = 5.05 Hz, 1 H) 7.77 (d, J = 1.77 Hz, 1 H) 7.33 (s, 1 H)7.00 (d, J = 1.77 Hz, 1 H) 5.91 (s, 1 H) 4.74 (quin, J = 6.63 Hz, 1 H)4.33 (s, 1 H) 4.32 (s, 1 H) 2.56 (q, J = 7.58 Hz, 2 H) 2.13 (s, 6 H)1.40 (s, 3 H) 1.38 (s, 3 H) 1.13 (t, J = 7.58 Hz, 3 H) 444.1/ 446.0 34

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 11.46 (br.s., 1 H) 8.50 (d, J = 2.27Hz, 1 H) 8.10-8.18 (m, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 7.72 (d, J= 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.52 Hz, 1 H) 6.92 (d, J =8.84 Hz, 1 H) 5.92 (s, 1 H) 4.84 (quin, J = 6.57 Hz, 1 H) 4.37 (d, J =4.80 Hz, 2 H) 3.49-3.55 (m, 4 H) 2.59 (q, J = 7.41 Hz, 2 H) 2.40-2.44(m, 4 H) 2.23 (s, 3 H) 2.17 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.42(s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 541.5 35

6-{3- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (br.s., 1 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.76(d, J = 1.26 Hz, 1 H) 7.59-7.65 (m, 2 H) 7.40 (t, J = 7.58 Hz, 1 H) 7.33(s, 1 H) 7.22-7.26 (m, 2 H) 5.92 (s, 1 H) 4.88 (dt, J = 13.33, 6.60 Hz,1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 3.46 (s, 2 H) 2.59 (q, J = 7.58 Hz, 2H) 2.18 (s, 9 H) 2.13 (s, 3 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 1.15 (t, J =7.58 Hz, 3 H) 499.3 36

6-{4- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (br.s., 1 H) 8.16 (t, J = 4.93 Hz, 1 H) 7.77(s, 1 H) 7.70 (s, 1 H) 7.68 (s, 1 H) 7.37 (s, 1 H) 7.35 (s, 1 H) 7.32(s, 1 H) 7.25 (s, 1 H) 5.92 (s, 1 H) 4.87 (dt, J = 13.14, 6.57 Hz, 1 H)4.38 (br.s., 1 H) 4.37 (br.s., 1 H) 3.42 (s, 2 H) 2.59 (q, J = 7.58 Hz,2 H) 2.17 (s, 9 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 1.15 (t, J= 7.45 Hz, 3 H) 499.4 37

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4-carboxamide 11.49 (s, 1 H) 8.53 (d, J = 2.02 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 8.09 (dd, J = 8.59, 2.53 Hz, 1 H) 7.79 (d, J = 1.26 Hz, 1H) 7.33 (s, 1 H) 7.22 (d, J = 1.26 Hz, 1 H) 6.91 (d, J = 8.59 Hz, 1 H)5.92 (s, 1 H) 4.86 (quin, J = 6.63 Hz, 1 H) 4.38 (s, 1 H) 4.36 (s, 1 H)3.90 (s, 3 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.17 (s, 3 H) 2.13 (s, 3 H)1.44 (s, 3 H) 1.43 (s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 473.1 38

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-(2- methyl-5-pyrimidinyl)- 1H-indole-4-carboxamide 11.50 (s, 1 H) 9.09 (s, 2 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.96(d, J = 1.26 Hz, 1 H) 7.39 (s, 1 H) 7.32 (d, J = 1.52 Hz, 1 H) 5.92 (s,1 H) 4.90 (quin, J = 6.69 Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.65-2.68(m, 3 H) 2.60 (q, J = 7.58 Hz, 2 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.45 (s,3 H) 1.43 (s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 458.3 39

6-(6-amino-3-pyridinyl)- N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide11.50 (s, 1 H) 8.30 (d, J = 2.02 Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H)7.76 (dd, J = 8.59, 2.53 Hz, 1 H) 7.66 (d, J = 1.26 Hz, 1 H) 7.27 (s, 1H) 7.14 (d, J = 1.52 Hz, 1 H) 6.53 (d, J = 8.59 Hz, 1 H) 5.98 (s, 2 H)5.92 (s, 1 H) 4.83 (quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36 (s, 1 H)2.59 (q, J = 7.58 Hz, 2 H) 2.16 (s, 3 H) 2.13 (s, 3 H) 1.43 (s, 3 H)1.41 (s, 3 H) 1.14 (t, J = 7.45 Hz, 3 H) 458.2 40

6-[6-(dimethylamino)-3- pyridinyl]-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.47 (br.s., 1 H) 8.48 (d, J = 2.27 Hz, 1 H) 8.14 (t, J =4.67 Hz, 1 H) 7.89 (dd, J = 8.72, 2.65 Hz, 1 H) 7.70 (d, J = 1.26 Hz, 1H) 7.28 (s, 1 H) 7.17 (d, J = 1.52 Hz, 1 H) 6.73 (d, J = 8.84 Hz, 1 H)5.92 (s, 1 H) 4.84 (quin, J = 6.57 Hz, 1 H) 4.37 (s, 1 H) 4.36 (s, 1 H)3.07 (s, 6 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.16 (s, 3 H) 2.13 (s, 3 H)1.44 (s, 3 H) 1.42 (s, 3 H) 1.15 (t, J = 7.58 Hz, 3 H) 486.3 41

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-(6- methyl-3-pyridinyl)- 1H-indole-4-carboxamide 11.44 (br.s., 1 H) 8.83 (d, J = 2.02 Hz, 1 H) 8.20 (t, J =4.93 Hz, 1 H) 8.03 (dd, J = 8.08, 2.53 Hz, 1 H) 7.84 (d, J = 1.52 Hz, 1H) 7.31-7.36 (m, 2 H) 7.26 (d, J = 1.52 Hz, 1 H) 5.92 (s, 1 H) 4.88(quin, J = 6.63 Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.59 (q, J = 7.58Hz, 2 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 1.14(t, J = 7.58 Hz, 3 H) 457.2 42

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(1H- pyrazol-3-yl)-1H-indole- 4-carboxamide 12.77 (br.s.,1 H) 11.48 (br.s., 1 H) 8.10 (br.s., 1 H) 7.89 (s, 1 H) 7.76 (br.s., 1H) 7.46 (br.s., 1 H) 7.29 (br.s., 1 H) 6.75 (br.s., 1 H) 5.87 (s, 1 H)4.79 (br.s., 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 2.25 (s, 3 H) 2.15 (s, 3H) 2.11 (s, 3 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 418.2 43

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(1- methyl-1H-pyrazol-4-yl)- 1H-indole-4-carboxamide11.47 (s, 1 H) 8.14 (s, 1 H) 8.05 (t, J = 5.18 Hz, 1 H) 7.89 (s, 1 H)7.69 (d, J = 1.26 Hz, 1 H) 7.23 (s, 1 H) 7.15 (d, J = 1.52 Hz, 1 H) 5.87(s, 1 H) 4.77 (quin, J = 6.69 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s, 1 H) 3.86(s, 3 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.43 (s, 3 H) 1.41(s, 3 H) 432.2 44

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(1H- pyrazol-4-yl)-1H-indole- 4-carboxamide 11.50 (br.s.,1 H) 7.95-8.17 (m, 3 H) 7.72 (d, J = 1.01 Hz, 1 H) 7.23 (s, 1 H) 7.20(d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.79 (quin, J = 6.63 Hz, 1 H) 4.35(s, 1 H) 4.34 (s, 1 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.43(s, 3 H) 1.42 (s, 3 H) 418.2 45

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2- pyridinylmethyl)-1H- pyrazol-4-yl]-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.56 (d, J = 4.04 Hz, 1 H) 8.33 (s, 1 H)8.07 (t, J = 5.05 Hz, 1 H) 7.99 (s, 1 H) 7.76-7.81 (m, 1 H) 7.73 (s, 1H) 7.33 (dd, J = 6.69, 4.93 Hz, 1 H) 7.24 (s, 1 H) 7.18 (d, J = 1.26 Hz,1 H) 7.10 (d, J = 7.83 Hz, 1 H) 5.87 (s, 1 H) 5.45 (s, 2 H) 4.79 (dt, J= 13.14, 6.57 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s, 1 H) 2.24 (s, 3 H) 2.13(s, 3 H) 2.11 (s, 3 H) 1.43 (s, 3 H) 1.41 (s, 3 H) 509.0 46

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(1H- pyrrolo[2,3-b]pyridin- 5-yl)-1H-indole-4-carboxamide 11.67 (br.s., 1 H) 11.48 (s, 1 H) 8.60 (d, J = 2.27 Hz, 1 H)8.27 (d, J = 2.02 Hz, 1 H) 8.20 (t, J = 5.05 Hz, 1 H) 7.82 (d, J = 1.26Hz, 1 H) 7.49-7.52 (m, 1 H) 7.32 (s, 1 H) 7.29 (d, J = 1.52 Hz, 1 H)6.51 (dd, J = 3.28, 1.77 Hz, 1 H) 5.87 (s, 1 H) 4.89 (dt, J = 13.33,6.60 Hz, 1 H) 4.38 (s, 1 H) 4.36 (s, 1 H) 2.25 (s, 3 H) 2.19 (s, 3 H)2.11 (s, 3 H) 1.45 (s, 3 H) 1.44 (s, 3 H) 468.0 47

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2- thienylmethyl)-1H- pyrazol-4-yl]-1H-indole-4-carboxamide 11.38 (br.s., 1 H) 8.26 (s, 1 H) 8.08 (t, J = 4.93 Hz, 1H) 7.96 (s, 1 H) 7.70 (d, J = 1.26 Hz, 1 H) 7.48 (dd, J = 5.05, 1.26 Hz,1 H) 7.23 (s, 1 H) 7.16 (s, 2 H) 7.01 (dd, J = 5.05, 3.28 Hz, 1 H) 5.87(s, 1 H) 5.53 (s, 2 H) 4.78 (quin, J = 6.63 Hz, 1 H) 4.35 (s, 1 H) 4.33(s, 1 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.42 (s, 3 H) 1.41(s, 3 H) 514.2 48

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(3-(methyl- sulfonamidomethyl) phenyl)-1H-indole-4- carboxamide11.47 (s, 1 H) 8.18 (t, J = 4.93 Hz, 1 H) 7.70-7.78 (m, 2 H) 7.61-7.68(m, 2 H) 7.44 (t, J = 7.71 Hz, 1 H) 7.30-7.35 (m, 2 H) 7.26 (d, J = 1.52Hz, 1 H) 5.87 (s, 1 H) 4.86 (quin, J = 6.69 Hz, 1 H) 4.37 (br.s., 1 H)4.35 (br.s., 1 H) 4.26 (s, 1 H) 4.24 (s, 1 H) 2.87-2.90 (m, 3 H) 2.22-2.26 (m, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (s, 3 H) 1.41-1.45 (m, 3H) 534.9 49

N-((4-benzyl-6-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-bromo-1- isopropyl-3-methyl- 1H-indole-4- carboxamide 11.56(s, 1 H) 8.34 (t, J = 5.05 Hz, 1 H) 7.76 (d, J = 1.52 Hz, 1 H) 7.29-7.34(m, 3 H) 7.20-7.26 (m, 3 H) 6.97 (d, J = 1.77 Hz, 1 H) 5.78 (s, 1 H)4.74 (quin, J = 6.63 Hz, 1 H) 4.40 (s, 1 H) 4.39 (s, 1 H) 3.97 (s, 2 H)2.13 (s, 3 H) 2.09 (s, 3 H) 1.40 (s, 3 H) 1.38 (s, 3 H) 505.8/ 507.9 50

6-(6-acetamidopyridin-3- yl)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1- isopropyl-3-methyl-1H- indole-4-carboxamide 11.48(br.s., 1 H) 10.58 (s, 1 H) 8.71 (t, J = 1.64 Hz, 1 H) 8.12-8.21 (m, 3H) 7.85 (d, J = 1.26 Hz, 1 H) 7.34 (s, 1 H) 7.27 (d, J = 1.52 Hz, 1 H)5.87 (s, 1 H) 4.89 (quin, J = 6.57 Hz, 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H)2.25 (s, 3 H) 2.17 (s, 3 H) 2.12 (s, 3 H) 2.11 (s, 3 H) 1.45 (s, 3 H)1.43 (s, 3 H) 486.2 51

6-(6-acetamidopyridin-3- yl)-1-isopropyl-3-methyl- N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3- yl)methyl)-1H- indole-4-carboxamide 11.49(s, 1 H) 10.58 (s, 1 H) 8.70 (s, 1 H) 8.13-8.18 (m, 3 H) 7.83-7.87 (m, 1H) 7.35 (s, 1 H) 7.26 (d, J = 1.26 Hz, 1 H 5.90 (s, 1 H) 4.89 (dt, J =13.20, 6.66 Hz, 1 H) 4.38 (br.s., 1 H) 4.36 (br.s., 1 H) 2.53-2.58 (m, 2H) 2.18 (s, 3 H) 2.12 (s, 5 H) 1.54-1.62 (m, 2 H) 1.45 (s, 3 H) 1.43 (s,3 H) 0.94 (t, J = 7.33 Hz, 3 H) 514.2 52

1-isopropyl-3-methyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3-yl) methyl)-6-(1- (2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-indole- 4-carboxamide 11.47 (br.s., 1 H) 8.18 (s, 1 H)8.03 (t, J = 5.05 Hz, 1 H) 7.89 (s, 1 H) 7.69 (d, J = 1.01 Hz, 1 H) 7.24(d, J = 1.01 Hz, 1 H) 7.15 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.78(quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.35 (s, 1 H) 4.24 (t, J = 6.69Hz, 2 H) 3.52-3.58 (m, 4 H) 2.75 (t, J = 6.69 Hz, 2 H) 2.52-2.58 (m, 2H) 2.39-2.47 (m, 4 H) 2.13 (s, 3 H) 2.12 (s, 3 H) 1.53- 1.62 (m, 2 H)1.43 (s, 3 H) 1.42 (s, 3 H) 0.95 (t, J = 7.33 Hz, 3 H) 559.0 53

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole-4- carboxamide 1.44 (d, J = 6.57Hz, 6 H), 2.10 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 4.36 (d, J = 5.05Hz, 2 H), 4.89 (dt, J = 13.14, 6.57 Hz, 1 H), 5.87 (s, 1 H), 7.35 (s, 1H), 7.40 (s, 1 H), 7.73 (dd, J = 7.83, 5.31 Hz, 1 H), 7.98 (s, 1 H),8.21 (t, J = 5.05 Hz, 1 H), 8.49 (d, J = 8.08 Hz, 1 H), 8.65 (d, J =4.55 Hz, 1 H), 9.13 (s, 1 H), 11.48 (br.s., 1 H) 429.0 54

6-bromo-3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4- carboxamide 0.93 (t, 3 H),1.38 (d, J = 6.57 Hz, 6 H), 1.44-1.67 (m, 2 H), 2.12 (d, J = 5.31 Hz, 6H), 4.31 (d, J = 5.05 Hz, 2 H), 4.73 (dt, J = 13.14, 6.57 Hz, 1 H), 5.89(s, 1 H), 6.99 (d, J = 1.52 Hz, 1 H), 7.33 (s, 1 H), 7.76 (d, J = 1.52Hz, 1 H), 8.20 (t, J = 4.80 Hz, 1 H), 11.48 (s, 1 H) 458.2/ 460.1 55

6-(1H-benzo[d]imidazol- 2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin- 3-yl)methyl)-1- isopropyl-3-methyl-1H-indole-4-carboxamide 1.50 (d, J = 6.82 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s,3 H), 2.26 (s, 3 H), 4.39 (d, J = 5.05 Hz, 2 H), 4.82 (spt, J = 6.44 Hz,1 H), 5.88 (s, 1 H), 7.12-7.24 (m, 2 H), 7.44 (s, 1 H), 7.51 (d, J =6.82 Hz, 1 H), 7.64 (d, J = 7.07 Hz, 1 H), 7.82 (d, J = 1.52 Hz, 1 H),8.22 (t, J = 5.05 Hz, 1 H), 8.33 (d, J = 1.26 Hz, 1 H), 11.49 (br.s., 1H), 12.83 (s, 1 H) 468.4 56

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(2-methyl-3- pyridinyl)-1H-indole-4-carboxamide 0.87-0.97 (m, 3 H), 1.41 (d, J = 6.57 Hz, 6 H), 1.55 (m, J =15.16, 7.52, 7.36, 7.36 Hz, 2 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.48 (s,3 H), 3.17 (d, J = 5.31 Hz, 5 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (dt,J = 13.20, 6.66 Hz, 1 H), 5.88 (s, 1 H), 6.91 (d, J = 1.52 Hz, 1 H),7.29 (dd, J = 7.58, 4.80 Hz, 2 H), 7.35 (s, 1 H), 7.54 (d, J = 1.26 Hz,1 H), 7.65 (dd, J = 7.58, 1.52 Hz, 1 H), 8.11 (t, J = 5.05 Hz, 1 H),8.44 (dd, J = 4.80, 1.52 Hz, 1 H), 11.47 (br.s., 1 H) 471.4 57

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-[6-(4-methyl- 1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.42 (d,J = 6.57 Hz, 5 H), 1.56 (m, J = 7.60, 7.60, 7.60, 7.39, 7.20 Hz, 2 H),2.12 (s, 3 H), 2.16 (s, 3 H), 2.23 (s, 3 H), 2.43 (t, J = 4.93 Hz, 4 H),3.44-3.61 (m, 5 H), 4.36 (d, J = 5.05 Hz, 2 H), 4.84 (ddd, J = 13.26,6.57, 6.44 Hz, 1 H), 5.89 (s, 1 H), 6.92 (d, J = 8.84 Hz, 1 H), 7.17 (d,J = 1.52 Hz, 1 H), 7.28 (s, 1 H), 7.72 (d, J = 1.26 Hz, 1 H), 7.91 (dd,J = 8.84, 2.53 Hz, 1 H), 8.11 (t, J = 4.93 Hz, 1 H), 8.17 (s, 1 H), 8.49(d, J = 2.53 Hz, 1 H), 11.49 (br.s., 1 H) 555.1 58

3-methyl-1-(1- methylethyl))-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-[5-(4-methyl- 1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.43 (d,J = 6.57 Hz, 6 H), 1.57 (m, J = 7.54, 7.54, 7.54, 7.33, 7.20 Hz, 2 H),2.12 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 2.44 (t, J = 4.80 Hz, 4 H),2.52-2.58 (m, 2 H), 3.52- 3.61 (m, 4 H), 4.36 (d, J = 4.80 Hz, 2 H),4.92 (dt, J = 13.14, 6.57 Hz, 1 H), 5.90 (s, 1 H), 7.03 (d, J = 5.31 Hz,1 H), 7.11 (s, 1 H), 7.30 (d, J = 1.26 Hz, 1 H), 7.38 (s, 1 H), 7.90 (d,J = 1.26 Hz, 1 H), 8.09- 8.31 (m, 3 H) 555.1 59

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(6-methyl-3- pyridinyl)-1H-indole-4-carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.45 (d, J = 6.57 Hz, 6H), 1.57 (m, J = 15.16, 7.52, 7.36, 7.36 Hz, 2 H), 2.12 (s, 3 H), 2.17(s, 3 H), 2.53-2.59 (m, 2 H), 2.68 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H),4.90 (dt, J = 13.33, 6.60 Hz, 1 H), 5.91 (s, 1 H), 7.11 (s, 1 H), 7.37(d, J = 1.26 Hz, 1 H), 7.43 (s, 6 H), 7.81 (d, J = 8.34 Hz, 6 H), 8.02(d, J = 1.26 Hz, 6 H), 8.17 (t, J = 5.05 Hz, 6 H), 8.66 (br.s., 6 H),9.09 (d, J = 1.77 Hz, 1 H), 11.50 (br.s., 1 H) 471.4 60

6-{4- [(dimethylamino)methyl] phenyl}-3-methyl-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4-carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.43 (d, J = 6.82 Hz, 6 H), 1.57(dq, J = 15.06, 7.44 Hz, 2H), 2.12 (s, 3 H), 2.15-2.20 (m, 9 H), 2.53(1H),3.41 (s, 2 H), 4.36 (d, J = 5.05 Hz, 2 H), 4.86 (quin, J = 6.63 Hz, 1H), 5.89 (s, 1 H), 7.24 (d, J = 1.26 Hz, 1 H), 7.32 (s, 1 H), 7.35 (d, J= 8.34 Hz, 2 H), 7.68 (d, J = 8.08 Hz, 2 H), 7.76 (d, J = 1.26 Hz, 1 H),8.15 (t, J = 4.93 Hz, 1 H), 11.47 (br.s., 1 H) 513.4 61

6-methyl-3-({2-[3- methyl-1-(1- methylethyl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)- 1H-indol-4-yl]-2- oxoethyl}amino)-4-propyl-2(1H)- pyridinone 0.93 (t, J = 7.33 Hz, 3 H), 1.40 (d, J = 6.57Hz, 6 H), 1.50-1.65 (m, 2 H), 2.12 (d, J = 6.06 Hz, 6 H), 3.08 (br.s., 2H), 3.52 (br.s., 2 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (dt, J = 13.20,6.66 Hz, 1 H), 5.89 (s, 1 H), 6.18 (br.s., 1 H), 7.05 (d, J = 1.26 Hz, 1H), 7.27 (s, 1 H), 7.50 (s, 3 H), 8.03 (t, J = 5.05 Hz, 1 H), 11.49(br.s., 1 H) 461.2 62

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole- 4-carboxamide 11.55 (br.s., 1H), 9.11 (d, J = 1.8 Hz, 1 H), 8.60 (dd, J = 5.1, 1.5 Hz, 1 H), 8.36 (m,2 H), 8.08 (s, 1 H), 7.78 (d, J = 1.5 Hz, 1 H), 7.68 (d, J = 3.3 Hz, 1H), 7.61 (dd, J = 8.0, 4.9 Hz, 1 H), 6.93 (d, J = 3.3 Hz, 1 H), 5.89 (s,1 H), 4.98 (quin, J = 6.6 Hz, 1 H), 4.38 (d, J = 5.1 Hz, 2 H), 2.23 (s,3 H), 2.12 (s, 3 H), 1.49 (d, J = 6.8 Hz, 6 H) 415.0 63

6-bromo-1-cyclopentyl- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.30 (t, J =5.2 Hz, 1 H), 7.93 (s, 1 H), 7.59 (d, J = 3.3 Hz, 1 H), 7.52 (d, J = 1.5Hz, 1 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.94 (m, 1 H), 4.35(d, J = 5.1 Hz, 2 H), 2.53 (d, J = 7.8 Hz, 2 H), 2.12 (m, 5 H), 1.80 (m,4 H), 1.71 (m, 2 H), 1.52 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 470.1 64

1-(1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1H-indole-4-carboxamide 11.56 (s, 1 H), 8.56 (d, J = 2.5 Hz, 1 H), 8.27 (t, J = 5.2Hz, 1 H), 7.97 (dd, J = 9.0, 2.7 Hz, 1 H), 7.87 (s, 1 H), 7.65 (d, J =1.3 Hz, 1 H), 7.58 (d, J = 3.3 Hz, 1 H), 6.93 (d, J = 9.1 Hz, 1 H), 6.86(d, J = 3.0 Hz, 1 H), 5.91 (s, 1 H), 4.92 (m, 1 H), 4.39 (d, J = 5.1 Hz,2 H), 3.52 (m, 4 H), 2.54 (m, 2 H), 2.41 (m, 4 H), 2.22 (m, 3 H), 2.13(s, 3 H), 1.53 (m, 2 H), 1.47 (d, J = 6.6 Hz, 6 H), 0.90 (t, J = 7.3 Hz,3 H) 541.5 65

6-bromo-1-cyclobutyl-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.31 (t, J =5.1 Hz, 1 H), 7.87 (s, 1 H), 7.73 (d, J = 3.3 Hz, 1 H), 7.53 (d, J = 1.5Hz, 1 H), 6.88 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 5.04 (t, J = 8.3 Hz,1 H), 4.35 (d, J = 5.1 Hz, 2 H), 2.54 (s, 1 H), 2.41 (m, 4 H), 2.13 (s,3 H), 1.83 (m, 2 H), 1.52 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 445.9 66

1-cyclobutyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(6-methyl-2-oxo-4-propyl-1,2- dihydro-3-pyridinyl) methyl]-1H-indole-4- carboxamide11.55 (s, 1 H), 8.32 (t, J = 5.1 Hz, 1 H), 7.89 (s, 1 H), 7.73 (m, 4 H),7.37 (d, J = 8.1 Hz, 2 H), 6.90 (d, J = 3.0 Hz, 1 H), 5.91 (s, 1 H),5.16 (t, J = 8.5 Hz, 1 H), 4.40 (d, J = 5.1 Hz, 2 H), 3.42 (s, 2 H),2.55 (m, 3 H), 2.43 (m, 2 H), 2.15 (m, 9 H), 1.85 (dt, J = 9.8, 4.8 Hz,2 H), 1.54 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 511.3 67

1-cyclopropyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-3-methyl-1H-indole-4-carboxamide 11.46 (s, 1 H), 8.19 (t, J = 5.1 Hz, 1 H), 7.76 (d,J = 1.5 Hz, 1 H), 7.67 (m, J = 8.1 Hz, 2 H), 7.37 (m, J = 8.1 Hz, 2 H),7.28 (d, J = 1.5 Hz, 1 H), 7.14 (d, J = 1.0 Hz, 1 H), 5.86 (s, 1 H),4.34 (d, J = 5.1 Hz, 2 H), 3.43 (m, 3 H), 2.23 (s, 3 H), 2.14 (m, 12 H),1.06 (m, 2 H), 0.92 (m, 2 H) 483.1 68

1-cyclopropyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4-carboxamide 11.46 (br.s., 1 H), 8.52 (d, J = 2.3 Hz, 1 H), 8.19 (t, J =4.9 Hz, 1 H), 8.07 (dd, J = 8.6, 2.5 Hz, 1 H), 7.76 (d, J = 1.5 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1 H), 7.15 (d, J = 1.0 Hz, 1 H), 6.92 (d, J =8.6 Hz, 1 H), 5.86 (s, 1 H), 4.34 (d, J = 5.1 Hz, 2 H), 3.90 (s, 3 H),3.42 (m, 1 H), 2.22 (m, 3 H), 2.10 (s, 3 H), 2.13 (s, 3 H), 1.06 (m, 2H), 0.92 (m, 2 H) 457.1 69

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[3- (methylsulfonyl)phenyl]- 1H-indole-4- carboxamide11.47 (s, 1 H), 8.23 (m, 2 H), 8.12 (d, J = 7.8 Hz, 1 H), 7.89 (m, 2 H),7.73 (m, 1 H), 7.39 (s, 1 H), 7.32 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H),4.92 (m, 1 H), 4.36 (d, J = 4.8 Hz, 2 H), 3.31 (s, 3 H), 2.23 (m, 3 H),2.18 (m, 3 H), 2.11 (s, 3 H), 1.42 (m, 6 H) 505.9 70

6-bromo-1-cyclopentyl- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H- indole-4-carboxamide 11.48 (s, 1 H), 8.24 (t, J =4.9 Hz, 1 H), 7.77 (d, J = 1.8 Hz, 1 H), 7.29 (s, 1 H), 7.00 (d, J = 1.8Hz, 1 H), 5.86 (s, 1 H), 4.86 (t, J = 7.1 Hz, 1 H), 4.30 (d, J = 4.8 Hz,2 H), 2.21 (s, 3 H), 2.08 (m, 8 H), 1.74 (m, 6 H) 455.9 71

1-cyclopentyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-3-methyl-1H-indole-4-carboxamide 11.47 (s, 1 H), 8.18 (t, J = 5.1 Hz, 1 H), 7.78 (d,J = 1.5 Hz, 1 H), 7.69 (m, J = 8.1 Hz, 2 H), 7.36 (m, J = 8.3 Hz, 2 H),7.26 (m, 2 H), 5.86 (s, 1 H), 5.00 (d, J = 7.1 Hz, 1 H), 4.35 (d, J =5.1 Hz, 2 H), 3.41 (s, 2 H), 2.23 (s, 3 H), 2.14 (m, 14 H), 1.78 (m, 6H) 511.3 72

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(1-methyl-1H- pyrazol-4-yl)-1H-indole-4-carboxamide 11.49 (s, 1 H), 8.12 (s, 1 H), 8.01 (t, J = 5.1 Hz,1 H), 7.87 (s, 1 H), 7.69 (d, J = 1.3 Hz, 1 H), 7.23 (s, 1 H), 7.14 (d,J = 1.5 Hz, 1 H), 5.90 (s, 1 H), 4.77 (quin, J = 6.6 Hz, 1 H), 4.35 (d,J = 5.1 Hz, 2 H), 3.86 (s, 3 H), 2.54 (m, 2 H), 2.11 (m, 6 H), 1.57(sxt, J = 7.5 Hz, 2 H), 1.42 (d, J = 6.6 Hz, 6 H), 0.94 (t, J = 7.3 Hz,3 H) 460.1 73

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(2-(4- methylpiperazin-1-yl) pyrimidin-5-yl)-1H-indole-4-carboxamide 11.48 (s, 1 H), 8.76 (s, 2 H), 8.13 (t, J = 5.2 Hz,1 H), 7.77 (d, J = 1.5 Hz, 1 H), 7.30 (s, 1 H), 7.19 (d, J = 1.3 Hz, 1H), 5.87 (s, 1 H), 4.83 (quin, J = 6.6 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2H), 3.77 (m, 4 H), 2.38 (t, J = 5.1 Hz, 4 H), 2.23 (d, J = 6.3 Hz, 6 H),2.16 (s, 3 H), 2.11 (s, 3 H), 1.42 (d, J = 6.6 Hz, 6 H) 528.0 74

6-bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-1,2-dihydro-4,4′-bipyridin-3- yl)methyl]-1H-indole-4- carboxamide 11.99(br.s., 1 H) 8.66 (d, J = 6.06 Hz, 2 H) 8.33 (t, J = 4.42 Hz, 1 H) 7.93(s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.42-7.48 (m, 3 H) 6.84 (d, J = 3.03Hz, 1 H) 6.00 (s, 1 H) 4.76-4.88 (m, 1 H) 4.16 (d, J = 4.29 Hz, 2 H)2.23 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 480.7 75

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-(2-(dimethylamino)propyl)- 3-methyl-6-(6-(4- methylpiperazin-1-yl)pyridin-3-yl)-1H-indole- 4-carboxamide 0.82 (d, J = 6.57 Hz, 3 H), 2.10(s, 3 H), 2.14 (s, 3 H), 2.20 (s, 6 H), 2.23 (d, J = 5.05 Hz, 6 H),2.37-2.46 (m, 4 H), 2.98 (q, J = 6.82 Hz, 1 H), 3.48-3.58 (m, 4 H),3.95-4.27 (m, 1 H), 4.34 (d, J = 5.05 Hz, 2 H), 5.86 (s, 1 H), 6.92 (d,J = 9.09 Hz, 1 H), 7.14 (s, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.68 (d, J= 1.26 Hz, 1 H), 7.90 (dd, J = 8.84, 2.78 Hz, 1 H), 8.17 (t, J = 5.05Hz, 1 H), 8.50 (d, J = 2.27 Hz, 1 H), 11.47 (br.s., 1 H) 570.6 76

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(2- methylpyrimidin-4-yl)- 1H-indole-4- carboxamide 1.46 (d, J= 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.18 (s, 3 H), 2.25 (s, 3 H), 2.68 (s, 3H), 4.37 (d, J = 4.80 Hz, 2 H), 4.92 (spt, J = 6.57 Hz, 1 H), 5.88 (s, 1H), 7.48 (s, 1 H), 7.84 (d, J = 1.26 Hz, 1 H), 7.98 (d, J = 5.56 Hz, 1H), 8.22 (t, J = 4.93 Hz, 1 H), 8.37 (d, J = 1.26 Hz, 1 H), 8.68 (d, J =5.56 Hz, 1 H), 11.48 (s, 1 H) 444.4 77

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl-1- (tetrahydro-2H-pyran- 4-yl)-1H-indole-4-carboxamide 1.76-1.86 (m, 2 H), 1.93 (dd, J = 12.00, 4.17 Hz, 2 H), 2.12(d, J = 5.81 Hz, 6 H), 2.22 (s, 3 H), 3.49-3.62 (m, 2 H), 3.97 (dd, J =11.12, 3.79 Hz, 2 H), 4.31 (d, J = 5.05 Hz, 2 H), 4.64 (br.s., 1 H),5.86 (s, 1 H), 7.02 (d, J = 1.52 Hz, 1 H), 7.36 (s, 1 H), 7.88 (d, J =1.52 Hz, 1 H), 8.24 (t, J = 4.93 Hz, 1 H), 11.47 (br.s., 1 H) 472, 47478

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-(2-(dimethylamino) propyl)-3-methyl-1H- indole-4- carboxamide(CHLOROFORM-d) 0.90 (d, J = 6.57 Hz, 3 H), 2.15 (s, 3 H), 2.22 (s, 3 H),2.34 (s, 6 H), 2.39 (s, 3 H), 2.88-3.11 (m, 1 H), 3.81 (dd, J = 14.27,8.46 Hz, 1 H), 4.19 (dd, J = 14.02, 4.42 Hz, 1 H), 4.57 (d, J = 5.56 Hz,2 H), 5.93 (s, 1 H), 6.86 (s, 1 H), 7.20 (d, J = 1.52 Hz, 1 H), 7.45 (d,J = 1.52 Hz, 1 H), 12.52 (br.s., 1 H) 473.2, 475.2 79

6-bromo-N-[(4-ethyl-6- methyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.56 (s, 1 H) 8.31(t, J = 5.18 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.03 Hz, 1 H) 7.52 (d,J = 1.52 Hz, 1 H) 6.86 (d, J = 3.28 Hz, 1 H) 5.93 (s, 1 H) 4.75-4.90 (m,1 H) 4.35 (d, J = 5.05 Hz, 2 H) 2.54-2.60 (m, 2 H) 2.14 (s, 3 H) 1.43(d, J = 6.57 Hz, 6 H) 1.11 (t, J = 7.33 Hz, 3 H) 80

6-{4- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide11.56 (s, 1 H) 8.33 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.70-7.78 (m, 3H) 7.62 (d, J = 3.28 Hz, 1 H) 7.37 (d, J = 8.34 Hz, 2 H) 6.88 (d, J =3.28 Hz, 1 H) 5.93 (s, 1 H) 4.87-5.04 (m, 1 H) 4.41 (d, J = 5.31 Hz, 2H) 3.42 (s, 2 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.17 (s, 6 H) 2.14 (s, 3 H)1.48 (d, J = 6.82 Hz, 6 H) 1.12 (t, J = 7.33 Hz, 3 H) 485.3 81

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.57 (br.s., 1 H) 8.57 (d, J = 2.27Hz, 1 H) 8.30 (t, J = 5.05 Hz, 1 H) 7.98 (dd, J = 8.97, 2.65 Hz, 1 H)7.88 (s, 1 H) 7.66 (d, J = 1.26 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H) 6.93(d, J = 9.09 Hz, 1 H) 6.87 (d, J = 3.03 Hz, 1 H) 5.93 (s, 1 H) 4.88-4.98 (m, 1 H) 4.40 (d, J = 5.05 Hz, 2 H) 3.49-3.59 (m, 4 H) 2.58 (q, J =7.58 Hz, 2 H) 2.37-2.45 (m, 4 H) 2.23 (s, 3 H) 2.14 (s, 3 H) 1.47 (d, J= 6.82 Hz, 6 H) 1.12 (t, J = 7.33 Hz, 3 H) 527.2 82

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4- carboxamide11.57 (br.s., 1 H) 8.60 (br.s., 1 H) 8.31 (br.s., 1 H) 8.11-8.19 (m, 1H) 7.94 (s, 1 H) 7.58-7.73 (m, 2 H) 6.85-6.99 (m, 2 H) 5.93 (s, 1 H)4.87-5.02 (m, 1 H) 4.40 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3 H) 2.55-2.64(m, 2 H) 2.14 (s, 3 H) 1.48 (d, J = 6.57 Hz, 6 H) 1.12 (t, J = 7.33 Hz,3 H) 459.2 83

6-[6-(acetylamino)-3- pyridinyl]-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.56 (s, 1 H) 10.58 (s, 1 H) 8.76 (d, J = 2.02 Hz,1 H) 8.32 (t, J = 4.93 Hz, 1 H) 8.14-8.23 (m, 2 H) 8.00 (s, 1 H) 7.73(d, J = 1.26 Hz, 1 H) 7.65 (d, J = 3.03 Hz, 1 H) 6.90 (d, J = 3.28 Hz, 1H) 5.92 (s, 1 H) 4.92-5.03 (m, 1 H) 4.41 (d, J = 5.05 Hz, 2 H) 2.53-2.58(m, 2 H) 2.13 (d, J = 4.04 Hz, 6 H) 1.51-1.61 (m, 2 H) 1.48 (d, J = 6.57Hz, 6 H) 0.91 (t, J = 7.33, 3 H) 500.1 84

6-(4-fluorophenyl)-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H)8.31 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.80-7.86 (m, 2 H) 7.68 (d, J =1.52 Hz, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.27-7.34 (m, 2 H) 6.88 (d, J =3.03 Hz, 1 H) 5.92 (s, 1 H) 4.91- 5.00 (m, 1 H) 4.41 (d, J = 5.05 Hz, 2H) 2.53-2.58 (m, 2 H) 2.13 (s, 3 H) 1.51- 1.59 (m, 2 H) 1.48 (d, J =6.82 Hz, 6 H) 0.91 (t, J = 7.33 Hz, 3 H) 460.1 85

6-[4-(acetylamino) phenyl]-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4-carboxamide 11.56 (br.s., 1 H) 10.02 (s, 1 H) 8.29 (t, J = 5.05 Hz, 1 H)7.89 (s, 1 H) 7.57- 7.75 (m, 6 H) 6.86 (d, J = 3.28 Hz, 1 H) 5.92 (s, 1H) 4.94 (quin, J = 6.57 Hz, 1 H) 4.41 (d, J = 5.05 Hz, 2 H) 2.57-2.53(m, 2 H) 2.13 (s, 3 H) 2.07 (s, 3 H) 1.51-1.60 (m, 2 H) 1.48 (d, J =6.57 Hz, 6 H) 0.91 (t, J = 7.33 Hz , 3 H) 499.4 86

methyl 4-[4-({[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]amino}carbonyl)- 3-methyl-1-(1- methylethyl)-1H-indol-6-yl]benzoate 11.48 (s, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.01-8.07 (m, 2H) 7.90-7.96 (m, 3 H) 7.39 (s, 1 H) 7.33 (d, J = 1.26 Hz, 1 H) 5.87 (s,1 H) 4.91 (t, J = 6.69 Hz, 1 H) 4.36 (d, J = 4.80 Hz, 2 H) 3.88(s, 3 H)2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H)486.1 87

methyl 5-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl] amino}carbonyl)- 1H-indol-6-yl]-2-pyridinecarboxylate 11.50 (s, 1 H) 9.13 (d, J = 1.77 Hz, 1 H) 8.36 (dd,J = 8.34, 2.27 Hz, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.13 (d, J = 8.34 Hz,1 H) 8.02 (d, J = 1.52 Hz, 1 H) 7.43 (s, 1 H) 7.37 (d, J = 1.52 Hz, 1 H)5.91 (s, 1 H) 4.88-4.99 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 3.91 (s, 3H) 2.53-2.59 (m, 2 H) 2.19 (s, 3 H) 2.13 (s, 3 H) 1.52-1.64 (m, 2 H)1.45 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H) 515.1 88

methyl 3-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl] amino}carbonyl)- 1H-indol-6-yl]benzoate11.49 (br.s., 1 H) 8.19-8.31 (m, 2 H) 8.01-8.08 (m, 1 H) 7.95-7.90 (m, 1H) 7.85 (s, 1 H) 7.59-7.65 (m, 1 H) 7.37 (s, 1 H) 7.26 (s, 1 H) 5.91(br.s., 1 H) 4.87- 4.97 (m, 1 H) 4.38 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3H) 2.55-2.62 (m, 2 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.55-1.65 (m, 2 H)1.44 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.2 Hz, 3 H) 514.2 89

6-bromo-N-((6-ethyl-4- methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide 8.36 (br.s., 1H), 7.92(s, 1H), 7.63 (d, J = 3.28 Hz, 1H), 7.53 (d, J = 1.77 Hz, 1H), 6.88 (d,J = 3.28 Hz, 1H), 5.91 (s, 1H), 4.82 (dt, J = 6.60, 13.33 Hz, 1H), 4.33(d, J = 5.05 Hz, 2H), 2.42 (q, J = 7.58 Hz, 2H), 2.23 (s, 3H), 1.43 (d,J = 6.57 Hz, 6H), 1.14 (t, J = 7.58 Hz, 3H) 432.2 90

N-((6-benzyl-4-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-bromo-1- isopropyl-1H-indole- 4-carboxamide 7.62 (d, J =3.28 Hz, 1H), 7.51 (d, J = 1.52 Hz, 1H), 7.32 (s, 4H), 7.23 (td, J =2.78, 5.56 Hz, 1H), 6.87 (d, J = 3.28 Hz, 1H), 5.89 (s, 1H), 4.82 (ddd,J = 6.44, 6.57, 13.26 Hz, 1H), 4.31 (d, J = 5.05 Hz, 2H), 3.74 (s, 2H),2.19 (s, 3H), 1.43 (d, J = 6.82 Hz, 6H) 494.2 91

6-bromo-N-((6- cyclobutyl-4-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide 8.40 (br.s., 1H), 7.92 (s,1H), 7.63 (d, J = 3.28 Hz, 1H), 7.53 (d, J = 1.77 Hz, 1H), 6.88 (d, J =3.28 Hz, 1H), 5.96 (s, 1H), 4.82 (quin, J = 6.63 Hz, 1H), 4.33 (d, J =4.80 Hz, 2H), 3.25-3.38 (m, 2H), 2.25 (s, 3H), 2.06-2.22 (m, 4H),1.84-1.99 (m, 1H), 1.70-1.82 (m, 1H), 1.43 (d, J = 6.57 Hz, 6H) 455.9 92

6-bromo-1-(1- methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-1H- indole-4-carboxamide 11.70(s, 1H), 8.32 (t, J = 5.05 Hz, 1H), 7.93 (s, 1H), 7.63 (d, J = 3.28 Hz,1H), 7.51 (d, J = 1.52 Hz, 1H), 6.87 (d, J = 3.03 Hz, 1H), 6.09 (s, 1H),4.82 (quin, J = 6.63 Hz, 1H), 4.49 (s, 2H), 4.30 (d, J = 5.05 Hz, 2H),3.32 (s, 3H), 2.17 (s, 3H), 1.43 (d, J = 6.57 Hz, 6H) 447.8 93

1-(1-methylethyl)-N-({6- methyl-4-[(methyloxy) methyl]-2-oxo-1,2-dihydro-3-pyridinyl} methyl)-6-[6-(4-methyl- 1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 8.58 (d, J = 2.53 Hz, 1H), 8.31 (t,J = 5.05 Hz, 1H), 8.17 (s, 1H), 7.99 (dd, J = 2.53, 8.84 Hz, 1H), 7.88(s, 1H), 7.66 (d, J = 1.26 Hz, 1H), 7.59 (d, J = 3.28 Hz, 1H), 6.94 (d,J = 8.84 Hz, 1H), 6.87 (d, J = 3.28 Hz, 1H), 6.10 (s, 1H), 4.93 (dq, J =6.65, 6.82 Hz, 1H), 4.52 (s, 2H), 4.35 (d, J = 5.05 Hz, 2H), 3.50- 3.58(m, 4H), 3.32 (s, 3H), 2.45 (t, J = 4.93 Hz, 4H), 2.25 (s, 3H), 2.17 (s,3H), 1.47 (d, J = 6.57 Hz, 6H) 543.1 94

1-(1-methylethyl)-N-({6- methyl-4-[(methyloxy) methyl]-2-oxo-1,2-dihydro-3-pyridinyl} methyl)-6-[2-(4-methyl- 1-piperazinyl)-4-pyridinyl]-1H-indole-4- carboxamide 8.35 (t, J = 5.18 Hz, 1H), 8.18 (s,1H), 8.16 (s, 2H), 8.05 (s, 1H), 7.74 (d, J = 1.26 Hz, 1H), 7.69 (d, J =3.28 Hz, 1H), 7.17 (s, 1H), 7.11 (dd, J = 1.01, 5.31 Hz, 1H), 6.90 (d, J= 3.28 Hz, 1H), 6.10 (s, 1H), 5.01 (quin, J = 6.57 Hz, 1H), 4.53 (s,2H), 4.35 (d, J = 5.31 Hz, 2H), 3.54-3.68 (m, 4H), 3.32 (s, 3H), 2.51-2.54 (m, 4H), 2.30 (s, 3H), 2.17 (s, 3H), 1.48 (d, J = 6.57 Hz, 6H)543.2 95

1-(1-methylethyl)-N-({6- methyl-4-[(methyloxy) methyl]-2-oxo-1,2-dihydro-3-pyridinyl} methyl)-6-(3-pyridinyl)- 1H-indole-4- carboxamide11.75 (s, 1H), 9.05 (d, J = 2.02 Hz, 1H), 8.55 (dd, J = 1.52, 4.80 Hz,1H), 8.39 (t, J = 5.18 Hz, 1H), 8.21 (dddd, J = 1.17, 1.52, 8.02 Hz,1H), 8.15 (s, 1H), 8.05 (s, 1H), 7.76 (d, J = 1.52 Hz, 1H), 7.66 (d, J =3.28 Hz, 1H), 7.49 (qd, 1H), 6.93 (d, J = 3.28 Hz, 1H), 6.10 (s, 1H),4.98 (quin, J = 6.63 Hz, 1H), 4.52 (s, 2H), 4.36 (d, J = 5.05 Hz, 2H),3.32 (s, 3H), 2.17 (s, 3H), 1.48 (d, J = 6.57 Hz, 6H) 445.2 96

1-(1-methylethyl)-N-({6- methyl-4-[(methyloxy) methyl]-2-oxo-1,2-dihydro-3-pyridinyl} methyl)-6-[6-(4- morpholinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.71 (br.s., 1H), 8.60 (d, J = 2.53Hz, 1H), 8.31 (t, J = 5.05 Hz, 1H), 8.15 (s, 1H), 8.02 (dd, J = 2.53,8.84 Hz, 1H), 7.89 (s, 1H), 7.67 (d, J = 1.26 Hz, 1H), 7.59 (d, J = 3.28Hz, 1H), 6.95 (d, J = 8.59 Hz, 1H), 6.88 (d, J = 3.28 Hz, 1H), 6.10 (s,1H), 4.93 (quin, J = 6.63 Hz, 1H), 4.52 (s, 2H), 4.35 (d, J = 5.05 Hz,2H), 3.70-3.77 (m, 4H), 3.46-3.52 (m, 4H), 3.32 (s, 3H), 2.17 (s, 3H),1.47 (d, J = 6.57 Hz, 6H) 530.9 97

6-bromo-1-cyclopropyl- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.32 (t, J =4.9 Hz, 1 H), 7.85 (s, 1 H), 7.56 (d, J = 1.8 Hz, 1 H), 7.45 (d, J = 3.3Hz, 1 H), 6.78 (d, J = 3.0 Hz, 1 H), 5.90 (s, 1 H), 4.34 (d, J = 5.1 Hz,2 H), 3.47 (dt, J = 7.0, 3.4 Hz, 1 H), 2.53 (br.s., 1 H), 2.13 (s, 3 H),1.52 (m, 2 H), 1.07 (m, 2 H), 0.92 (m, 5 H) 442.0 98

1-cyclopropyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1-piperazinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.56 (s, 1 H), 8.54 (d, J = 2.5 Hz, 1 H), 8.30 (t,J = 5.1 Hz, 1 H), 7.95 (dd, J = 9.0, 2.7 Hz, 1 H), 7.85 (s, 1 H), 7.68(d, J = 1.5 Hz, 1 H), 7.41 (d, J = 3.0 Hz, 1 H), 6.94 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.39 (d, J = 5.1 Hz, 2 H),3.51 (m, 5 H), 2.54 (m, 2 H), 2.41 (m, 4 H), 2.21 (m, 3 H), 2.13 (s, 3H), 1.53 (m, 2 H), 1.09 (m, 2 H), 0.98 (m, 2 H), 0.89 (t, J = 7.3 Hz, 3H) 539.4 99

1-cyclopropyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(3- pyridinyl)-1H-indole-4- carboxamide 11.56 (s, 1H), 9.02 (d, J = 1.8 Hz, 1 H), 8.56 (dd, J = 4.8, 1.5 Hz, 1 H), 8.37 (t,J = 5.1 Hz, 1 H), 8.18 (dt, J = 8.3, 1.9 Hz, 1 H), 7.99 (s, 1 H), 7.78(d, J = 1.5 Hz, 1 H), 7.50 (m, 2 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.91 (s,1 H), 4.40 (d, J = 5.1 Hz, 2 H), 3.55 (tt, J = 7.0, 3.6 Hz, 1 H), 2.54(m, 2 H), 2.13 (s, 3 H), 1.53 (m, 2 H), 1.11 (m, 2 H), 1.00 (m, 2 H),0.89 (t, J = 7.3 Hz, 3 H) 441.0 100

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(4- (piperazin-1-yl)phenyl)- 1H-indole-4- carboxamide 1.43 (d,J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H),2.82-2.90 (m, 4 H), 3.04-3.12 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.84(quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.00 (d, J = 8.84 Hz, 2 H),7.19 (d, J = 1.52 Hz, 1 H), 7.25- 7.31 (m, 1 H), 7.59 (d, J = 8.84 Hz, 2H), 7.67 (d, J = 1.26 Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1 H) 512.4 101

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.50 (br.s., 1 H) 8.50 (d, J = 2.53Hz, 1 H) 8.13 (t, J = 4.80 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H)7.69-7.76 (m, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 6.88 (d, J =8.84 Hz, 1 H) 5.92 (s, 1 H) 4.80-4.89 (m, 1 H) 4.38 (br.s., 1 H) 4.36(br.s., 1 H) 3.39-3.51 (m, 4 H) 2.71-2.85 (m, 4 H) 2.53-2.63 (m, 3 H)2.16 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.14 (t, J =7.58 Hz, 3 H) 527.2 102

1-isopropyl-3-methyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3-yl) methyl)-6-(2-(piperazin- 1-yl)pyridin-4-yl)1H-indole-4- carboxamide 11.51 (br.s., 1 H) 8.18 (t, J = 5.05 Hz, 1 H)8.11-8.16 (m, 1 H) 7.90 (d, J = 1.52 Hz, 1 H) 7.39 (s, 1 H) 7.30 (d, J =1.52 Hz, 1 H) 6.99-7.12 (m, 2 H) 5.90 (s, 1 H) 4.93 (quin, J = 6.63 Hz,1 H) 4.38 (br.s., 1 H) 4.36 (br.s., 1 H) 3.42-3.61 (m, 4 H) 2.79-2.83(m, 3 H) 2.53-2.58 (m, 2 H) 2.17 (s, 3 H) 2.12 (s, 3 H) 1.53- 1.62 (m, 2H) 1.45 (s, 3 H) 1.43 (s, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 541.4 103

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(2-(piperazin- 1-yl)pyridin-4-yl)-1H- indole-4-carboxamide11.51 (br.s., 1 H) 8.21 (t, J = 4.93 Hz, 1 H) 8.14 (d, J = 5.05 Hz, 1 H)7.90 (d, J = 1.52 Hz, 1 H) 7.38 (s, 1 H) 7.31 (d, J = 1.52 Hz, 1 H) 7.08(s, 1 H) 7.02 (d, J = 4.80 Hz, 1 H) 5.87 (s, 1 H) 4.93 (quin, J = 6.57Hz, 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 3.43-3.52 (m, 4 H) 3.35 (br.s., 2H) 2.79-2.84 (m, 3 H) 2.25 (s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.44 (s,3 H) 1.43 (s, 3 H) 513.3 104

1-cyclopropyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-6-[6- (1-piperazinyl)-3- pyridinyl]-1H-indole-4-carboxamide 11.46 (br.s., 1 H), 8.48 (d, J = 2.3 Hz, 1 H), 8.16 (t, J =5.1 Hz, 1 H), 7.89 (dd, J = 9.0, 2.7 Hz, 1 H), 7.70 (d, J = 1.5 Hz, 1H), 7.22 (d, J = 1.5 Hz, 1 H), 7.11 (d, J = 1.0 Hz, 1 H), 6.89 (d, J =8.8 Hz, 1 H), 5.86 (s, 1 H), 4.34 (d, J = 5.1 Hz, 2 H), 3.42 (m, 5 H),2.80 (m, 4 H), 2.23 (s, 3 H), 2.12 (d, J = 7.1 Hz, 6 H), 1.05 (m, 2 H),0.91 (m, 2 H) 511.3 105

methyl 4-[4-({[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]amino}carbonyl)- 3-methyl-1-(1- methylethyl)-1H-indol-6-yl]benzoate 11.48 (s, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.01-8.07 (m, 2 H)7.90-7.96 (m, 3 H) 7.39 (s, 1 H) 7.33 (d, J = 1.26 Hz, 1 H) 5.87 (s, 1H) 4.91 (t, J = 6.69 Hz, 1 H) 4.36 (d, J = 4.80 Hz, 2 H) 3.88(s, 3 H)2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H)486.1 106

methyl 3-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]amino}carbonyl)- 1H-indol-6-yl]benzoate11.49 (br.s., 1 H) 8.19-8.31 (m, 2 H) 8.01-8.08 (m, 1 H) 7.95-7.90 (m, 1H) 7.85 (s, 1 H) 7.59-7.65 (m, 1 H) 7.37 (s, 1 H) 7.26 (s, 1 H) 5.91(br.s., 1 H) 4.87- 4.97 (m, 1 H) 4.38 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3H) 2.55-2.62 (m, 2 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.55-1.65 (m, 2 H)1.44 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.2 Hz, 3 H) 514.2 107

methyl 5-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]amino}carbonyl)- 1H-indol-6-yl]-2-pyridinecarboxylate 11.50 (s, 1 H) 9.13 (d, J = 1.77 Hz, 1 H) 8.36 (dd,J = 8.34, 2.27 Hz, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.13 (d, J = 8.34 Hz,1 H) 8.02 (d, J = 1.52 Hz, 1 H) 7.43 (s, 1 H) 7.37 (d, J = 1.52 Hz, 1 H)5.91 (s, 1 H) 4.88-4.99 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 3.91 (s, 3H) 2.53-2.59 (m, 2 H) 2.19 (s, 3 H) 2.13 (s, 3 H) 1.52-1.64 (m, 2 H)1.45 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H) 515.1 108

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6- (methylsulfonyl)-1H- indole-4-carboxamide 0.91 (t, J =8.00 Hz, 3 H), 1.45-1.60 (m, H), 2.14 (s, 3 H), 3.23 (s, 3 H), 4.40 (d,J = 4.80 Hz, 2 H), 4.92-5.04 (m, 1 H), 5.92 (s, 1 H), 6.99 (d, J = 3.03Hz, 1 H), 7.86 (d, J = 1.26 Hz, 1 H), 7.94 (d, J = 3.28 Hz, 1 H), 8.20(s, 1 H), 8.44 (t, J = 4.80 Hz, 1 H), 11.58 (s, 1 H) 444.2 109

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide 1.42-1.51 (d, J =8.00 Hz , 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.24 (s, 3 H), 3.20 (s, 3H), 4.35 (d, J = 5.05 Hz, 2 H), 4.89 (quin, J = 6.69 Hz, 1 H), 5.88 (s,1 H), 7.41 (s, 1 H) 7.66 (s, 1 H), 8.07 (d, J = 1.52 Hz, 1 H), 8.37 (t,J = 4.93 Hz, 1 H), 11.50 (s, 1 H) 430.0 110

N-((4-ethyl-6-methyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide 1.14 (m,3 H), 1.45 (d, J = 6.57 Hz, 6 H), 2.13 (s, 3 H), 2.19 (s, 3 H),2.54-2.65 (m, 3 H), 3.20 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.89(quin, J = 6.69 Hz, 1 H), 5.93 (s, 1 H), 7.40 (d, J = 1.52 Hz, 1 H),7.66 (s, 1 H), 8.07 (d, J = 1.52 Hz, 1 H), 8.36 (t, J = 5.05 Hz, 1 H),11.51 (s, 1 H) 444.2 111

N-((4-benzyl-6-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3- methyl-6- (methylsulfonyl)-1H-indole-4-carboxamide 1.45 (m, 6 H), 2.09 (s, 3 H), 2.18 (s, 3 H), 3.20(s, 3 H), 3.99 (s, 2 H), 4.44 (d, J = 5.05 Hz, 2 H), 4.89 (quin, J =6.69 Hz, 1 H), 5.79 (s, 1 H), 7.16-7.28 (m, 3 H) 7.30-7.36 (m, 2 H),7.42 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.08 (d, J = 1.52 Hz, 1 H),8.50 (t, J = 5.05 Hz, 1 H), 11.58 (s, 1 H) 505.9 112

1-isopropyl-3-methyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3-yl) methyl)-6- (methylsulfonyl)-1H-indole-4-carboxamide 0.94 (m, 3 H), 1.45 (d, J = 6.57 Hz, 6 H), 1.56(sxt, J = 7.53 Hz, 2 H), 2.13 (s, 3 H), 2.19 (s, 3 H), 3.19 (s, 3 H),4.37 (d, J = 4.80 Hz, 2 H), 4.89 (dt, J = 13.33, 6.60 Hz, 1 H), 5.91 (s,1 H), 7.40 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.08 (d, J = 1.26 Hz, 1H), 8.35 (t, J = 4.67 Hz, 1 H), 11.51 (s, 1 H) 458.2 113

3-({2-[6-(cyclopropyl- sulfonyl)-1-(1- methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)- 4,6-dimethyl-2(1H)- pyridinone 0.93-1.06 (m, 2H), 1.11-1.25 (m, 2 H), 1.49 (d, J = 6.57 Hz, 61 H), 2.13 (s, 3 H), 2.24(s, 3 H), 2.81-2.98 (m, 1 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.99 (dt, J =13.33, 6.60 Hz, 1 H), 5.90 (s, 1 H), 6.99 (d, J = 3.28 Hz, 1 H), 7.85(d, J = 1.52 Hz, 1 H), 7.93 (d, J = 3.28 Hz, 1 H), 8.16 (s, 1 H), 8.49(t, J = 4.93 Hz, 1 H), 11.57 (br.s., 1 H) 442.0 114

3-({2[6-(cyclopropyl- sulfonyl)-3-methyl-1-(1- methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)- 4,6-dimethyl-2(1H)- pyridinone 1.00 (dd, J =7.71, 2.65 Hz, 2 H), 1.13 (dd, J = 4.67, 2.40 Hz, 2 H), 1.45 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.23 (s, 3 H), 2.76-2.95(m, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.91 (quin, J = 6.63 Hz, 1 H),5.88 (s, 1 H), 7.36 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.03 (d, J =1.52 Hz, 1 H), 8.40 (t, J = 4.93 Hz, 1 H), 11.51 (s, 1 H) 455.9 115

3-methyl-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4- (phenylmethyl)-1,2-dihydro-3-pyridinyl] methyl}-6-(methyloxy)- 1H-indole-4- carboxamide11.54 (br.s., 1 H) 8.13 (t, J = 5.18 Hz, 1 H) 7.29-7.33 (m, 2 H)7.19-7.26 (m, 3 H) 7.12 (d, J = 1.01 Hz, 1 H) 7.03 (d, J = 2.27 Hz, 1 H)6.58 (d, J = 2.27 Hz, 1 H) 5.78 (s, 1 H) 4.67 (quin, J = 6.63 Hz, 1 H)4.40 (s, 1 H) 4.39 (s, 1 H) 3.98 (s, 2 H) 3.78-3.81 (m, 3 H) 2.10 (s, 3H) 2.08 (s, 3 H) 1.40 (s, 3 H) 1.38 (s, 3 H) 458.2 116

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.47(br.s., 1 H) 8.00 (t, J = 4.93 Hz, 1 H) 7.12 (s, 1 H) 7.02 (d, J = 2.02Hz, 1 H) 6.57 (d, J = 2.27 Hz, 1 H) 5.91 (s, 1 H) 4.67 (quin, J = 6.63Hz, 1 H) 4.33 (s, 1 H) 4.32 (s, 1 H) 3.79 (s, 3 H) 2.53-2.60 (m, 2 H)2.13 (s, 3 H) 2.10 (s, 3 H) 1.39 (s, 3 H) 1.38 (s, 3 H) 1.13 (t, J =7.45 Hz, 3 H) 395.8 117

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(methyloxy)- 1H-indole-4- carboxamide11.48 (br.s., 1 H) 7.98 (t, J = 5.05 Hz, 1 H) 7.10-7.13 (m, 1 H) 7.02(d, J = 2.02 Hz, 1 H) 6.57 (d, J = 2.02 Hz, 1 H) 5.90 (s, 1 H) 4.66(quin, J = 6.63 Hz, 1 H) 4.33 (s, 1 H) 4.32 (s, 1 H) 3.79 (s, 3 H) 2.55(m, 2 H) 2.12 (s, 3 H) 2.10 (s, 3 H) 1.51- 1.59 (m, 2 H) 1.39 (s, 3 H)1.38 (s, 3 H) 0.93 (t, J = 7.33 Hz, 3 H) 410.3 118

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.48(br.s., 1H), 8.24 (t, J = 4.93 Hz, 1H), 7.76 (d, J = 1.52 Hz, 1H), 7.33(d, J = 0.76 Hz, 1H), 7.00 (d, J = 1.77 Hz, 1H), 5.86 (s, 1H), 4.74(quin, J = 6.63 Hz, 1H), 4.31 (d, J = 4.80 Hz, 2H), 2.22 (s, 3H), 2.12(d, J = 7.07 Hz, 6H), 1.39 (d, J = 6.57 Hz, 6H) 429.9 119

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.55 (s, 1H), 8.12(t, J = 5.18 Hz, 1H), 7.43 (d, J = 3.28 Hz, 1H), 7.19 (d, J = 2.02 Hz,1H), 7.06 (d, J = 2.27 Hz, 1H), 6.74 (d, J = 3.28 Hz, 1H), 5.89 (s, 1H),4.75 (quin, J = 6.63 Hz, 1H), 4.34 (d, J = 5.31 Hz, 2H), 3.82 (s, 3H),2.23 (s, 3H), 2.12 (s, 3H), 1.43 (d, J = 6.57 Hz, 6H) 368.1 120

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.47 (s, 1H), 8.02(t, J = 5.05 Hz, 1H), 7.11 (s, 1H), 7.02 (d, J = 2.02 Hz, 1H), 6.57 (d,J = 2.02 Hz, 1H), 5.86 (s, 1H), 4.66 (quin, J = 6.63 Hz, 1H), 4.31 (d, J= 5.05 Hz, 2H), 3.79 (s, 3H), 2.22 (s, 3H), 2.10 (d, J = 4.80 Hz, 6H),1.38 (d, J = 6.57 Hz, 6H) 382.2 121

6-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H-indole- 4-carboxamide 11.48(br.s., 1H), 8.23 (t, J = 4.93 Hz, 1H), 7.63 (d, J = 1.77 Hz, 1H), 7.34(d, J = 0.76 Hz, 1H), 6.90 (d, J = 2.02 Hz, 1H), 5.87 (s, 1H), 4.73(quin, J = 6.63 Hz, 1H), 4.31 (d, J = 5.05 Hz, 2H), 2.22 (s, 3H), 2.12(d, J = 7.07 Hz, 6H), 1.39 (d, J = 6.82 Hz, 6H) 386.0 122

6-{3- [(dimethylamino)methyl] phenyl}-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (s, 1H), 8.19 (t, J = 4.93 Hz, 1H), 7.77 (d,J = 1.26 Hz, 1H), 7.62-7.72 (m, 2H), 7.43 (t, J = 7.58 Hz, 1H), 7.33 (d,J = 0.76 Hz, 1H), 7.28 (d, J = 7.58 Hz, 1H), 7.24 (d, J = 1.52 Hz, 1H),5.87 (s, 1H), 4.88 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H),3.62 (br.s., 2H), 2.28 (br.s., 6H), 2.24 (s, 3H), 2.17 (d, J = 1.01 Hz,3H), 2.11 (s, 3H), 1.44 (d, J = 6.82 Hz, 6H) 485.3 123

6-bromo-3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(4-morpholinylmethyl)-2- oxo-1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 11.64 (br.s., 1 H), 8.43 (br.s., 1 H), 7.78 (d, J =1.3 Hz, 1 H), 7.33 (s, 1 H), 7.02 (d, J = 1.5 Hz, 1 H), 6.04 (s, 1 H),4.75 (dt, J = 6.6, 13.0 Hz, 1 H), 4.41 (d, J = 4.8 Hz, 2 H), 3.40 (s, 2H), 2.33 (br.s., 4 H), 2.25 (br.s., 4 H), 2.15 (s, 3 H), 2.11 (s, 3 H),1.39 (d, J = 6.6 Hz, 6 H) 515.2 124

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-iodo-1-(1-methylethyl)-1H-indole- 4-carboxamide 11.54 (s, 1 H), 8.27 (t, J = 5.1Hz, 1 H), 8.05 (s, 1 H), 7.65 (d, J = 1.3 Hz, 1 H), 7.57 (d, J = 3.3 Hz,1 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.89 (s, 1 H), 4.81 (quin, J = 6.6 Hz,1 H), 4.32 (d, J = 5.1 Hz, 2 H), 2.22 (s, 3 H), 2.12 (s, 3 H), 1.43 (d,J = 6.6 Hz, 6 H) 464.0 125

6-iodo-1-(1-methylethyl)- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.27 (t, J =5.1 Hz, 1 H), 8.05 (s, 1 H), 7.65 (d, J = 1.3 Hz, 1 H), 7.58 (d, J = 3.3Hz, 1 H), 6.84 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.82 (dt, J = 6.6,13.3 Hz, 1 H), 4.35 (d, J = 5.3 Hz, 2 H), 2.52 (2 H under DMSO), 2.13(s, 3 H), 1.53 (dq, J = 7.4, 15.1 Hz, 2 H), 0.91 (t, J = 7.3 Hz, 3 H)491.9 126

6-bromo-1-ethyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 0.92-0.88 (t, 3H), 1.34-1.31(t, 3H), 1.53-1.49 (m, 2H), 2.13 (s, 3H), 2.54- 2.49 (m, 2H), 4.25-4.20(m, 2H), 4.35 (d, J = 4.8 Hz, 2H), 5.90 (s, 1H), 6.83 (d, J = 3.2 Hz,1H), 7.51 (d, J = 3.2 Hz, 2H), 7.89 (s, 1H), 8.29-8.27 (t, 1H), 11.54(s, 1H) 432.15 127

6-bromo-N-[(6-methyl- 2-oxo-4-propyl-1,2- dihydro-3-pyridinyl)methyl]-1-propyl-1H- indole-4-carboxamide 0.83-0.79 δ (t, 3H), 0.92-0.88(t, 3H), 1.55-1.51 (m, 2H), 1.74-1.71 (m, 2H),1.76 (s, 3H), 2.54-2.45(m, 2H), 4.17-4.14 (t, 2H), 4.35-4.34 (d, J = 5.2 Hz, 2H), 5.75 (s, 1H),5.90 (s, 1H), 6.82 (d, J = 2.8 Hz), 7.51-7.49 (m, 2H), 7.90 (s, 1H),8.28 (s, 1H), 11.54 (s, 1H) 446.04 128

3-({2-[6-chloro-1-(1- methylethyl)-1H-indol-4- yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)- pyridinone 1.43 (d, 6 H), 2.12 (s, 3 H), 2.21 (s, 3H), 4.32 (d, J = 4.80 Hz, 2 H), 4.81 (dt, J = 13.33, 6.60 Hz, 1 H), 5.88(s, 1 H), 6.86 (d, J = 3.03 Hz, 1 H), 7.40 (d, J = 1.52 Hz, 1 H), 7.63(d, J = 3.28 Hz, 1 H), 7.79 (s, 1 H), 8.29 (t, J = 4.80 Hz, 1 H), 11.53(br.s., 1 H) 371.9 129

3-({2-[6-chloro-1-(1- methylethyl)-1H-indol-4- yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)- pyridinone 0.90 (t, J = 7.20 Hz, 3 H), 1.43 (d, J= 6.57 Hz, 6 H), 1.48-1.57 (m, 3 H), 2.13 (s, 3 H), 4.35 (d, J = 4.80Hz, 2 H), 4.69-4.93 (m, 1 H), 5.90 (s, 1 H), 6.86 (d, J = 2.78 Hz, 1 H),7.40 (s, 1 H), 7.64 (d, J = 3.28 Hz, 1 H), 7.79 (s, 1 H), 8.28 (br.s., 1H), 11.55 (br.s., 1 H) 399.8 130

3-({2-[6-chloro-3- methyl-1-(1- methylethyl)-1H- indol-4-yl]-2-oxoethyl}amino)-6-methyl-4- propyl-2(1H)- pyridinone 0.93 (t, J = 7.33 Hz, 3 H),1.39 (d, J = 6.57 Hz, 6 H), 1.47-1.67 (m, 2 H), 2.12 (d, J = 4.80 Hz, 6H), 4.32 (d, J = 4.55 Hz, 2 H), 4.54-4.90 (m, 1 H), 5.89 (s, 1 H), 6.88(s, 1 H), 7.34 (s, 1 H), 7.63 (s, 1 H), 8.20 (br.s., 1 H), 11.48 (br.s.,1 H) 414.0 131

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-fluoro-1-(1-methylethyl)-1H- indole-4-carboxamide 1.42 (d, 6 H), 2.12 (s, 3 H), 2.22(s, 3 H), 4.33 (d, J = 5.05 Hz, 2 H), 4.74 (dt, J = 13.14, 6.57 Hz, 1H), 5.88 (s, 1 H), 6.85 (d, J = 3.03 Hz, 2 H), 7.25 (dd, J = 10.36, 1.77Hz, 2 H), 7.51-7.67 (m, 4 H), 8.24 (t, J = 4.55 Hz, 2 H), 11.55 (br.s.,1 H) 356.2 132

3-({2-[6-fluoro-1-(1- methylethyl)-1H-indol-4- yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)- pyridinone 0.90 (t, J = 7.20 Hz, 3 H), 1.43 (d, 6H), 1.47-1.61 (m, 2 H), 2.13 (s, 3 H), 4.36 (d, J = 5.05 Hz, 2 H), 2.53(2H), 4.75 (ddd, J = 13.20, 6.51, 6.32 Hz, 1 H), 5.91 (s, 1 H), 6.84 (d,J = 3.03 Hz, 1 H), 7.25 (dd, J = 10.36, 2.02 Hz, 1 H), 7.49-7.69 (m, 2H), 8.23 (t, J = 4.93 Hz, 1 H), 11.57 (br.s., 1 H) 384.0 133

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(1H-tetrazol-5- yl)-1H-indole-4- carboxamide 11.50 (br.s., 1H), 8.29 (t, J = 4.9 Hz, 1 H), 8.21 (s, 1 H), 7.62 (d, J = 1.3 Hz, 1 H),7.51 (s, 1 H), 5.88 (s, 1 H), 4.80 (dt, J = 6.6,13.1 Hz, 1 H), 4.37 (d,J = 5.1 Hz, 2 H), 2.25 (s, 3 H), 2.19 (s, 3 H), 2.12 (s, 3 H), 1.48 (d,J = 6.6 Hz, 6 H) 419.9 134

1-isopropyl-3-methyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3-yl) methyl)-6-(2H-tetrazol- 5-yl)-1H-indole-4-carboxamide 11.50 (br.s., 1H), 8.25 (t, J = 4.93 Hz, 1H), 8.21 (d, J =1.26 Hz, 1H), 7.63 (d, J = 0.76 Hz, 1H), 7.52 (s, 1H), 5.91 (s, 1H),4.80 (qd, J = 6.19, 6.44 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 2.19 (s,3H), 2.13 (s, 3H), 1.51-1.63 (m, 2H), 1.48 (d, J = 6.57 Hz, 6H), 1.10(t, J = 6.95 Hz, 2H), 0.95 (t, J = 7.33 Hz, 3H) 447.8 135

6-cyano-3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.50 (br.s.,1H) 8.31 (t, J = 4.80 Hz, 1 H) 8.16 (d, J = 1.26 Hz, 1H) 7.65 (s, 1H)7.19 (d, J = 1.26 Hz, 1H) 5.90 (s, 1H) 4.79-4.93 (m, 1H) 4.33 (d, J =5.05 Hz, 2H) 2.55 (d, J = 1.52 Hz, 1H) 2.17 (s, 3 H) 2.13 (s, 3H)1.51-1.61 (m, 2H) 1.43 (d, J = 6.57 Hz, 6H) 0.94 (t, J = 7.33 Hz, 3H)405.1 136

6-bromo-3-chloro-1- isopropyl-N-((6-methyl- 2-oxo-4-propyl-1,2-dihydropyridin-3-yl) methyl)-1H-indole-4- carboxamide 11.48 (s, 1H),8.23 (t, J = 5.05 Hz, 1H), 7.93 (d, J = 1.52 Hz, 1H), 7.78 (s, 1H), 7.06(d, J = 1.52 Hz, 1H), 5.89 (s, 1H), 4.84 (quin, J = 6.63 Hz, 1H), 4.33(d, J = 5.05 Hz, 2H), 2.52-2.57 (m, 2H), 2.12 (s, 3H), 1.49-1.61 (m, J =7.33, 7.52, 7.52, 7.52, 7.52 Hz, 2H), 1.41 (d, J = 6.82 Hz, 6H), 0.94(t, J = 7.33 Hz, 3H) 479.7 137

6-bromo-3-chloro-1-(1- methylethyl)-N-({6- methyl-4-[(methyloxy)methyl]-2-oxo-1,2- dihydro-3-pyridinyl} methyl)-1H-indole-4- carboxamide8.32 (t, J = 4.80 Hz, 1H), 7.93 (s, 1H), 7.78 (s, 1H), 7.08 (s, 1H),6.07 (s, 1H), 4.84 (q, J = 6.19, 6.38, 12.95 Hz, 1H), 4.48 (s, 2H), 4.29(d, J = 5.05 Hz, 2H), 3.33 (br.s., 3H), 2.16 (s, 3H), 1.41 (d, J = 6.57Hz, 6H) 481.8 138

6-bromo-3-chloro-N- [(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide 8.27 (t, J= 4.93 Hz, 1H), 7.93 (d, J = 1.52 Hz, 1H), 7.78 (s, 1H), 7.07 (d, J =1.77 Hz, 1H), 5.86 (s, 1H), 4.84 (quin, J = 6.63 Hz, 1H), 4.32 (d, J =5.05 Hz, 2H), 2.21 (s, 3H), 2.11 (s, 3H), 1.41 (d, J = 6.57 Hz, 6H)451.8 139

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(4-(morpholinomethyl) phenyl)-1H-indole-4-carboxamide 8.17 (t, J = 5.05 Hz, 1H), 8.15 (s, 1H), 7.90 (d, J = 1.26Hz, 1H), 7.75 (s, 1H), 7.71 (d, J = 8.08 Hz, 2H), 7.40 (d, J = 8.34 Hz,2H), 7.30 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 4.96 (quin, J = 6.63 Hz,1H), 4.37 (d, J = 5.05 Hz, 2H), 3.59 (t, J = 4.55 Hz, 4H), 3.51 (s, 2H),2.39 (br.s., 4H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H)547.0 140

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(3-fluoro- 4-(morpholinomethyl) phenyl)-1-isopropyl-1H-indole-4- carboxamide 8.18 (t, J = 5.05 Hz, 1H), 8.14 (s, 1H), 7.98(d, J = 1.26 Hz, 1H), 7.78 (s, 1H), 7.57-7.66 (m, 2H), 7.45-7.51 (m,1H), 7.33 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 4.99 (quin, J = 6.63 Hz,1H), 4.37 (d, J = 5.05 Hz, 2H), 3.58 (dd, J = 4.04, 8.84 Hz, 6H), 2.42(br.s., 4H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 565.3141

6-(4-((1H-pyrazol-1- yl)methyl)phenyl)-3- chloro-N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl) methyl)-1-isopropyl-1H-indole-4-carboxamide 8.15 (s, 1H), 7.97 (s, 1H), 7.77 (s, 1H), 7.44 (s,1H), 7.24-7.40 (m, 6H), 6.17 (br.s., 1H), 5.39 (s, 2H), 4.78-4.89 (m,1H), 4.57 (br.s., 2H), 2.45 (s, 3H), 2.26 (br.s., 3H), 1.51 (d, J = 6.57Hz, 6H) 528.0 142

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(2-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.49 (br.s., 1H),8.19 (t, J = 5.05 Hz, 1H), 7.76-7.83 (m, 2H), 7.56-7.68 (m, 1H),7.38-7.46 (m, 1H), 7.29-7.36 (m, 2H), 7.17 (t, J = 1.39 Hz, 1H), 5.87(s, 1H), 4.90 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.23(s, 3H), 2.11 (s, 3H), 1.45 (d, J = 6.82 Hz, 6H) 465.9 143

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-1H-indole- 4-carboxamide 8.19 (s, 1H), 8.14-8.18 (m, 1H),7.91 (d, J = 1.26 Hz, 1H), 7.75 (s, 1H), 7.73 (s, 1H), 7.71 (s, 1H),7.39 (d, J = 8.08 Hz, 2H), 7.30 (d, J = 1.52 Hz, 1H), 5.87 (s, 1H), 4.97(quin, J = 6.57 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H), 3.49 (s, 2H), 2.24(s, 3H), 2.21 (s, 6H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 506.0 144

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole- 4-carboxamide11.46 (s, 1H), 8.56 (d, J = 2.02 Hz, 1H), 8.16 (t, J = 5.05 Hz, 1H),8.11 (dd, J = 2.78, 8.59 Hz, 1H), 7.92 (d, J = 1.26 Hz, 1H), 7.75 (s,1H), 7.28 (d, J = 1.26 Hz, 1H), 6.92 (d, J = 8.59 Hz, 1H), 5.87 (s, 1H),4.96 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 3.91 (s, 3H),2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 478.9 145

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole- 4-carboxamide 11.47 (br.s.,1H), 8.99 (d, J = 2.27 Hz, 1H), 8.56 (dd, J = 1.64, 4.67 Hz, 1H),8.14-8.22 (m, 2H), 8.03 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.49 (dd, J= 4.67, 7.96 Hz, 1H), 7.35 (d, J = 1.52 Hz, 1H), 5.87 (s, 1H), 4.94-5.05(m, 1H), 4.37 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d,J = 6.82 Hz, 6H) 450.9 146

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.48 (br.s., 1H), 8.14 (t, J = 4.80 Hz, 1H), 7.91(d, J = 1.01 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.39 (s,1H), 7.37 (s, 1H), 7.29 (d, J = 1.01 Hz, 1H), 5.90 (s, 1H), 4.97 (qd, J= 6.44, 6.61 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 3.44 (s, 2H), 2.55 (dd,J = 6.95, 8.72 Hz, 2H), 2.18 (s, 6H), 2.12 (s, 3H), 1.57 (dq, J = 7.48,15.19 Hz, 2H), 1.46 (d, J = 6.57 Hz, 6H), 0.95 (t, J = 7.33 Hz, 3H)534.4 147

3-chloro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-[6- (methyloxy)-3-pyridinyl]-1H-indole-4- carboxamide 11.48 (s, 1H), 8.55 (d, J = 2.02 Hz,1H), 8.13 (t, J = 5.05 Hz, 1H), 8.10 (dd, J = 2.53, 8.59 Hz, 1H), 7.93(d, J = 1.52 Hz, 1H), 7.76 (s, 1H), 7.27 (d, J = 1.52 Hz, 1H), 6.93 (d,J = 8.59 Hz, 1H), 5.90 (s, 1H), 4.96 (quin, J = 6.63 Hz, 1H), 4.38 (d, J= 5.05 Hz, 2H), 3.91 (s, 3H), 2.55 (dd, J = 6.82, 8.84 Hz, 2H), 2.12 (s,3H), 1.51-1.63 (m, 2H), 1.46 (d, J = 6.82 Hz, 6H), 0.94 (t, J = 7.33 Hz,3H) 509.0 148

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-1-(1- methylethyl)-N-({6-methyl-4-[(methyloxy) methyl]-2-oxo-1,2- dihydro-3-pyridinyl}methyl)-1H-indole-4- carboxamide 11.62 (br.s., 1H), 8.22 (t, J = 5.05Hz, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.74 (s, 1H), 7.72 (s, 1H), 7.70(s, 1H), 7.39 (d, J = 8.34 Hz, 2H), 7.30 (s, 1H), 6.07 (s, 1H), 4.97(dt, J = 6.69, 13.39 Hz, 1H), 4.51 (s, 2H), 4.33 (d, J = 5.05 Hz, 2H),3.48 (s, 2H), 3.33 (s, 3H), 2.21 (s, 6H), 2.15 (s, 3H), 1.45 (d, J =6.57 Hz, 6H) 534.9 149

3-chloro-1-(1- methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6- [6-(methyloxy)-3-pyridinyl]-1H-indole- 4-carboxamide 11.63 (br.s., 1H), 8.56 (d, J = 2.02Hz, 1H), 8.22 (t, J = 5.05 Hz, 1H), 8.11 (dd, J = 2.65, 8.72 Hz, 1H),7.93 (d, J = 1.26 Hz, 1H), 7.75 (s, 1H), 7.29 (d, J = 1.52 Hz, 1H), 6.93(d, J = 8.08 Hz, 1H), 6.08 (s, 1H), 4.96 (quin, J = 6.57 Hz, 1H), 4.52(s, 2H), 4.34 (d, J = 5.31 Hz, 2H), 3.91 (s, 3H), 3.33 (br.s., 3H), 2.16(s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 510.0 150

3-chloro-1-isopropyl-N- ((4-(methoxymethyl)-6- methyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-6-(pyridin-3- yl)-1H-indole-4- carboxamide11.63 (br.s., 1H), 9.00 (d, J = 1.77 Hz, 1H), 8.56 (dd, J = 1.52, 4.80Hz, 1H), 8.26 (t, J = 5.18 Hz, 1H), 8.17 (ddd, J = 1.77, 2.02, 8.34 Hz,1H), 8.04 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.49 (ddd, J = 0.76, 4.74,7.89 Hz, 1H), 7.36 (d, J = 1.26 Hz, 1H), 6.08 (s, 1H), 5.00 (quin, J =6.63 Hz, 1H), 4.53 (s, 2H), 4.34 (d, J = 5.05 Hz, 2H), 3.33 (s, 3H),2.16 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 479.0 151

3-chloro-1-isopropyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3-yl) methyl)-6-(6-(4- methylpiperazin-1-yl)pyridin-3-yl)-1H- indole-4-carboxamide 8.51 (d, J = 2.53 Hz, 1H),8.13 (t, J = 4.55 Hz, 1H), 7.93 (dd, J = 2.53, 8.84 Hz, 1H), 7.86 (d, J= 1.26 Hz, 1H), 7.71 (s, 1H), 7.24 (d, J = 1.26 Hz, 1H), 6.93 (d, J =9.09 Hz, 1H), 5.89 (s, 1H), 4.95 (quin, J = 6.63 Hz, 1H), 4.37 (d, J =4.80 Hz, 2H), 3.51-3.57 (m, 4H), 2.52- 2.58 (m, 2H), 2.37-2.45 (m, 4H),2.23 (s, 3H), 2.12 (s, 3H), 1.57 (dddd, J = 7.20, 7.33, 7.48, 15.13 Hz,2H), 1.45 (d, J = 6.57 Hz, 6H), 0.94 (t, J = 7.33 Hz, 3H) 575.3 152

3-chloro-N-((4-ethyl-6- methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6-(4-methylpiperazin- 1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 8.52 (d, J = 2.53 Hz, 1H), 8.13 (t, J = 5.05 Hz,1H), 7.94 (dd, J = 2.65, 8.97 Hz, 1H), 7.86 (d, J = 1.52 Hz, 1H), 7.71(s, 1H), 7.24 (d, J = 1.52 Hz, 1H), 6.93 (d, J = 8.84 Hz, 1H), 5.91 (s,1H), 4.94 (quin, J = 6.57 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 3.50-3.57(m, 4H), 2.59 (q, J = 7.58 Hz, 2H), 2.39-2.45 (m, 4H), 2.23 (s, 3H),2.13 (s, 3H), 1.45 (d, J = 6.82 Hz, 6H), 1.14 (t, J = 7.58 Hz, 3H) 561.1153

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6-(4-methylpiperazin- 1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 8.52 (d, J = 2.27 Hz, 1H), 8.15 (t, J = 4.55 Hz,1H), 7.94 (dd, J = 2.53, 8.84 Hz, 1H), 7.85 (d, J = 1.26 Hz, 1H), 7.71(s, 1H), 7.25 (d, J = 1.26 Hz, 1H), 6.93 (d, J = 8.84 Hz, 1H), 5.86 (s,1H), 4.94 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 3.50-3.57(m, 4H), 2.38- 2.45 (m, 4H), 2.23 (d, J = 3.03 Hz, 6H), 2.11 (s, 3H),1.45 (d, J = 6.57 Hz, 6H) 547.0 154

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-6- (4-(trifluoromethyl) phenyl)-1H-indole-4-carboxamide 11.47 (s, 1H), 8.23 (t, J = 4.93 Hz, 1H), 7.98-8.05 (m, 3H),7.79-7.86 (m, 3H), 7.37 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 5.00 (qd, J= 6.44, 6.61 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H), 2.24 (s, 3H), 2.11 (s,3H), 1.47 (d, J = 6.57 Hz, 6H) 516.0 155

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6-(trifluoromethyl) pyridin-3-yl)-1H-indole-4-carboxamide 11.49 (br.s., 1H), 9.20 (d, J = 2.02 Hz, 1H), 8.47(dd, J = 2.02, 8.08 Hz, 1H), 8.24 (t, J = 5.05 Hz, 1H), 8.16 (d, J =1.26 Hz, 1H), 7.99 (d, J = 8.34 Hz, 1H), 7.86 (s, 1H), 7.45 (d, J = 1.52Hz, 1H), 5.88 (s, 1H), 5.01 (quin, J = 6.63 Hz, 1H), 4.38 (d, J = 4.80Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.47 (d, J = 6.57 Hz, 6H) 517.0 156

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(3-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (br.s., 1H),8.19 (t, J = 4.93 Hz, 1H), 7.99 (s, 1H), 7.79 (s, 1H), 7.44- 7.69 (m,4H), 7.34 (s, 1H), 7.18 (t, J = 7.33 Hz, 1H), 5.87 (s, 1H), 5.00 (dt, J= 6.66, 13.20 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H), 2.25 (s, 3H), 2.11 (s,3H), 1.46 (d, J = 6.57 Hz, 6H) 466.0 157

3-chloro-6-(3,5- difluorophenyl)-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-1H- indole-4-carboxamide 11.47(s, 1H), 8.19 (t, J = 5.05 Hz, 1H), 8.06 (d, J = 1.52 Hz, 1H), 7.81 (s,1H), 7.52-7.63 (m, 2H), 7.38 (d, J = 1.26 Hz, 1H), 7.20 (tt, J = 2.27,9.35 Hz, 1H) 5.87 (s, 1H), 5.02 (quin, J = 6.63 Hz, 1H), 4.37 (d, J =5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H)484.0 158

3-chloro-6-(3,4- difluorophenyl)-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-1H- indole-4-carboxamide 11.46(s, 1H), 8.17 (t, J = 5.05 Hz, 1H), 7.98 (d, J = 1.52 Hz, 1H), 7.90(ddd, J = 2.27, 7.83, 12.63 Hz, 1H), 7.78 (s, 1H), 7.59-7.69 (m, 1H),7.52 (dt, J = 8.59, 10.61 Hz, 1H), 7.32 (d, J = 1.52 Hz, 1H), 5.87 (s,1H), 4.99 (qd, J = 6.44, 6.61 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H), 2.24(s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 484.0 159

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(4-fluoro-3- hydroxyphenyl)-1- isopropyl-1H-indole-4-carboxamide 11.46 (br.s., 1H), 9.94 (br.s., 1H), 8.18 (t, J = 5.05 Hz,1H), 7.82 (d, J = 1.26 Hz, 1H), 7.74 (s, 1H), 7.29 (dd, J = 2.27, 8.59Hz, 1H), 7.13-7.25 (m, 3H), 5.87 (s, 1H), 4.95 (quin, J = 6.63 Hz, 1H),4.36 (d, J = 5.05 Hz, 2H), 2.24 (s, 3H), 2.11 (s, 3H), 1.45 (d, J = 6.82Hz, 6H) 481.8 160

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(4-fluoro-3- methoxyphenyl)-1- isopropyl-1H-indole-4-carboxamide 11.46 (br.s., 1H), 8.16 (t, J = 5.05 Hz, 1H), 7.90 (s, 1H),7.76 (s, 1H), 7.46 (d, J = 8.59 Hz, 1H), 7.24-7.34 (m, 3H), 5.87 (s,1H), 4.98 (ddd, J = 6.44, 6.57, 13.26 Hz, 1H), 4.37 (d, J = 5.05 Hz,2H), 3.97 (s, 3H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H)496.1 161

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-6- (4-methoxyphenyl)-1H- indole-4-carboxamide 11.48(br.s., 1H), 8.16 (t, J = 5.05 Hz, 1H), 7.84 (d, J = 1.01 Hz, 1H), 7.64-7.75 (m, 3H), 7.26 (d, J = 1.01 Hz, 1H), 7.03 (d, J = 8.59 Hz, 2H), 5.87(s, 1H), 4.95 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 3.81(s, 3H), 2.24 (s, 3H), 2.11 (s, 3H),61.45 (d, J = 6.57 Hz, 477.9 162

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(3-methoxyphenyl)- 1H-indole-4- carboxamide11.47 (br.s., 1H), 8.18 (t, J = 5.05 Hz, 1H), 7.91 (d, J = 1.01 Hz, 1H),7.76 (s, 1H), 7.35-7.42 (m, 1H), 7.25-7.34 (m, 3H), 6.93 (dd, J = 1.77,8.08 Hz, 1H), 5.87 (s, 1H), 4.99 (dt, J = 6.60, 13.33 Hz, 1H), 4.37 (d,J = 5.05 Hz, 2H), 3.85 (s, 3H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J =6.57 Hz, 6H) 477.9 163

3-chloro-6-(3-cyano-4- fluorophenyl)-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide 11.47(s, 1H), 8.40 (dd, J = 2.40, 6.19 Hz, 1H), 8.15-8.24 (m, 2H), 8.06 (d, J= 1.52 Hz, 1H), 7.81 (s, 1H), 7.63 (t, J = 9.09 Hz, 1H), 7.38 (d, J =1.52 Hz, 1H)' 5.87 (s, 1H), 4.99 (quin, J = 6.63 Hz, 1H), 4.37 (d, J =5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.47 (d, J = 6.57 Hz, 6H)491.0 164

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-phenyl-1H-indole-4- carboxamide 11.48 (br.s.,1H), 8.19 (t, J = 5.05 Hz, 1H), 7.91 (s, 1H), 7.72-7.80 (m, 3H), 7.47(t, J = 7.58 Hz, 2H), 7.33-7.39 (m, 1H), 7.30 (d, J = 1.26 Hz, 1H), 5.87(s, 1H), 4.97 (dt, J = 6.60, 13.33 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H),2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H) 447.8 165

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(4-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (s, 1H), 8.18(t, J = 5.05 Hz, 1H), 7.90 (d, J = 1.26 Hz, 1H), 7.80 (dd, J = 5.31,8.84 Hz, 2H), 7.76 (s, 1H), 7.26- 7.34 (m, 3H), 5.87 (s, 1H), 4.97(quin, J = 6.57 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.24 (s, 3H), 2.11(s, 3H), 1.45 (d, J = 6.57 Hz, 6H) 466.0 166

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(3-fluoro- 4-morpholinophenyl)-1- isopropyl-1H-indole-4-carboxamide 11.48 (br.s., 1H), 8.16 (t, J = 4.93 Hz, 1H), 7.91 (d, J =1.26 Hz, 1H), 7.74 (s, 1H), 7.63 (dd, J = 2.02, 14.65 Hz, 1H), 7.54 (dd,J = 1.77, 8.34 Hz, 1H), 7.30 (d, J = 1.01 Hz, 1H), 7.11 (t, J = 8.84 Hz,1H), 5.87 (s, 1H), 4.98 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz,2H), 3.70-3.82 (m, 4H), 2.99-3.12 (m, 4H), 2.24 (s, 3H), 2.11 (s, 3H),1.45 (d, J = 6.57 Hz, 6H) 551.2 167

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(6-fluoropyridin-3-yl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (s, 1H),8.64 (d, J = 2.53 Hz, 1H), 8.39 (td, J = 2.53, 8.21 Hz, 1H), 8.19 (t, J= 4.93 Hz, 1H), 8.03 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.34 (d, J =1.52 Hz, 1H), 7.30 (dd, J = 2.78, 8.59 Hz, 1H), 5.87 (s, 1H), 4.98 (ddd,J = 6.69, 6.82, 13.26 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H),2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H) 467.3 168

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-(1H- pyrrolo[2,3-b]pyridin- 5-yl)-1H-indole-4-carboxamide 11.70 (br.s., 1 H) 11.42 (br.s., 1 H) 8.61 (d, J = 2.02 Hz,1 H) 8.30 (d, J = 2.27 Hz, 1 H) 8.20 (t, J = 5.05 Hz, 1 H) 7.96 (d, J =1.26 Hz, 1 H) 7.74 (s, 1 H) 7.52 (d, J = 3.54 Hz, 1 H) 7.35 (d, J = 1.26Hz, 1 H) 6.51 (d, J = 3.54 Hz, 1 H) 5.87 (s, 1 H) 5.00 (quin, J = 6.63Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.25 (s, 3 H) 2.11 (s, 3 H) 1.48(s, 3 H) 1.46 (s, 3 H) 488.0 169

3-chloro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(1-methyl- 1H-pyrazol-4-yl)-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.19 (s, 1 H) 8.02 (t, J = 5.05 Hz,1 H) 7.92 (s, 1 H) 7.81- 7.84 (m, 1 H) 7.66 (s, 1 H) 7.21 (d, J = 1.26Hz, 1 H) 5.90 (s, 1 H) 4.87 (quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36(s, 1 H) 3.87 (s, 3 H) 2.53-2.58 (m, 2 H) 2.12 (s, 3 H) 1.53-1.61 (m, 2H) 1.45 (s, 3 H) 1.44 (s, 3 H) 0.95 (t, J = 7.33 Hz, 3 H) 479.8/4 170

6-bromo-1-cyclopropyl- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H- indole-4-carboxamide 11.48 (s, 1 H) 8.27 (t, J =4.93 Hz, 1 H) 7.71 (d, J = 1.77 Hz, 1 H) 7.15 (s, 1 H) 7.06 (d, J = 1.52Hz, 1 H) 5.86 (s, 1 H) 4.31 (s, 1 H) 4.29 (s, 1 H) 3.36-3.41 (m, 1 H)2.21 (s, 3 H) 2.11 (s, 3 H) 2.10 (s, 3 H) 1.01-1.07 (m, 2 H) 0.86-0.91(m, 2 H) 427.7/ 429.9 171

6-bromo-3-chloro-1- cyclopentyl-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1H-indole-4- carboxamide 1.62-1.90 (m, 6H), 2.08-2.15 (m, 5 H), 2.22 (s, 3 H), 2.22 (s, 3 H), 4.32 (d, J = 4.80Hz, 2 H), 4.87-5.04 (m, 1 H), 5.86 (s, 1 H), 7.08 (m, 1 H), 7.72 (m, 1H), 7.93 (d, J = 1.52 Hz, 1 H), 8.25 (t, J = 4.93 Hz, 1 H), 11.47(br.s., 1 H) 475.7 172

6-cyano-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 1H-indole-4- carboxamide 1.39-1.47 (m, 6 H), 2.12(s, 3 H), 2.16 (s, 3 H), 2.22-2.26 (m, 3 H), 4.32 (d, J = 5.05 Hz, 2 H),4.85 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.21 (d, J = 1.26 Hz, 1H), 7.64 (s, 1 H), 8.16 (d, J = 1.26 Hz, 1 H), 8.33 (t, J = 5.05 Hz, 1H), 11.48 (br.s., 1 H) 377.2 173

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (4-methyl-1-piperazinyl)-3-pyridinyl]-1H- indole-4-carboxamide 11.44 (br.s., 1 H) 8.50 (d, J =2.27 Hz, 1 H) 8.18 (t, J = 4.80 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1H) 7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H)6.92 (d, J = 9.09 Hz, 1 H) 6.01 (s, 1 H) 4.84 (quin, J = 6.63 Hz, 1 H)4.41 (br.s., 1 H) 4.40 (br.s., 1 H) 3.48-3.56 (m, 4 H) 3.24-3.31 (m, 1H) 2.39-2.44 (m, 4 H) 2.23 (s, 3 H) 2.17 (s, 3 H) 2.14 (s, 3 H) 1.44 (s,3 H) 1.42 (s, 3 H) 1.15 (s, 3 H) 1.13 (s, 3 H) 555.4 174

6-(4-{[2- (dimethylamino)ethyl] oxy}phenyl)-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.43 (br.s., 1 H) 8.09-8.27 (m, 1 H) 7.70 (d, J =1.52 Hz, 1 H) 7.66-7.68 (m, 1 H) 7.63-7.66 (m, 1 H) 7.29 (d, J = 1.01Hz, 1 H) 7.19 (d, J = 1.52 Hz, 1 H) 7.02-7.04 (m, 1 H) 7.00-7.02 (m, 1H) 5.87 (s, 1 H) 4.85 (dt, J = 13.39, 6.69 Hz, 1 H) 4.36 (s, 1 H) 4.34(s, 1 H) 4.09 (t, J = 5.81 Hz, 2 H) 2.61-2.67 (m, 2 H) 2.23 (s, 9 H)2.17 (s, 3 H) 2.11 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 515.1 175

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-fluoro-1-(1- methylethyl)-1H-indole- 4-carboxamide 1H NMR (400MHz, METHANOL- d4) δ 7.81 (t, J = 1.77 Hz, 1H), 7.40 (d, J = 1.52 Hz,1H), 7.38 (d, J = 2.27 Hz, 1H), 6.13 (s, 1H), 4.71-4.81 (m, J = 1.52,6.63, 6.63, 13.26 Hz, 1H), 4.54 (s, 2H), 2.40 (s, 3H), 2.26 (s, 3H),1.47 (d, J = 6.82 Hz, 6H) 434.1 176

6-bromo-3-fluoro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-1H-indole-4- carboxamide 11.49 (s, 1H),8.20-8.28 (m, 1H), 7.94 (t, J = 1.77 Hz, 1H), 7.66 (d, J = 2.27 Hz, 1H),7.24 (d, J = 1.52 Hz, 1H), 5.90 (s, 1H), 4.82 (dd, J = 1.52, 6.82 Hz,1H), 4.33 (d, J = 5.05 Hz, 2H), 2.13 (s, 3H), 1.48-1.59 (m, 2H), 1.39(d, J = 6.57 Hz, 6H), 0.92 (t, 3H) 462.2 177

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-fluoro-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)-3- pyridinyl]-1H-indole-4-carboxamide 11.48 (d, J = 11.87 Hz, 1H), 8.54 (d, J = 2.53 Hz, 1H), 8.19(t, J = 5.05 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, J = 2.53, 8.84 Hz, 1H),7.86 (s, 1H), 7.58 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.01 Hz, 1H), 6.94(d, J = 8.84 Hz, 1H), 5.88 (s, 1H), 4.86- 5.03 (m, J = 7.07 Hz, 1H),4.36 (d, J = 4.80 Hz, 2H), 3.48-3.59 (m, 4H), 2.44 (t, J = 4.93 Hz, 4H),2.23 (d, J = 10.36 Hz, 6H), 2.12 (s, 3H), 1.42 (d, 6H) 531.4 178

3-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 1H NMR (400 MHz, METHANOL- d4) δ 8.49 (d, J = 2.27Hz, 1H), 7.97 (dd, J = 2.53, 8.84 Hz, 1H), 7.77 (d, J = 1.26 Hz, 1H),7.55 (s, 1H), 7.37 (d, J = 1.26 Hz, 1H), 6.99 (d, J = 8.84 Hz, 1H), 6.14(s, 1H), 4.60 (s, 2H), 3.74 (br.s., 4H), 2.96 (t, J = 4.55 Hz, 4H), 2.65(s, 3H), 2.47 (s, 3H), 2.26 (s, 3H), 1.54 (d, J = 6.57 Hz, 6H) 592.2 179

3-fluoro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-[6-(4-methyl- 1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.50 (br.s., 1H), 8.53 (d, J = 2.53Hz, 1H), 8.12-8.21 (m, 1H), 7.95 (dd, J = 2.53, 8.84 Hz, 1H), 7.86 (s,1H), 7.59 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.26 Hz, 1H), 6.94 (d, J =8.84 Hz, 1H), 5.90 (s, 1H), 4.86-5.03 (m, 1H), 4.37 (d, J = 5.05 Hz,2H), 3.49-3.58 (m, 4H), 2.37- 2.47 (m, 4H), 2.24 (s, 3H), 2.13 (s, 3H),1.55 (sxt, J = 7.53 Hz, 2H), 1.42 (d, J = 6.57 Hz, 6H), 0.92 (t, J =7.33 Hz, 3H) 559.7 180

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(4- pyridazinyl)-1H-indole-4-carboxamide 11.00-11.70 (bs, 1H), 9.70-9.79 (m, 1H), 9.16-9.27 (m,1H), 8.25 (t, J = 4.80 Hz, 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.08 (dd, J =2.53, 5.56 Hz, 1H), 7.48 (s, 2H), 5.91 (s, 1H), 4.96 (quin, J = 6.63 Hz,1H), 4.38 (d, J = 4.80 Hz, 2H), 2.53-2.59 (m, 2H), 2.19 (s, 3H), 2.12(s, 3H), 1.58 (sxt, J = 7.43 Hz, 2H), 1.46 (d, J = 6.82 Hz, 6H), 0.94(t, J = 7.45 Hz, 3H) 458.3 181

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(6- phenyl-3-pyridinyl)-1H- indole-4-carboxamide 11.52(br.s., 1 H) 9.10 (d, J = 2.27 Hz, 1 H) 8.31 (dd, J = 8.21, 2.15 Hz, 1H) 8.25 (t, J = 5.05 Hz, 1 H) 8.16 (d, J = 7.33 Hz, 2 H) 8.09 (d, J =8.34 Hz, 1 H) 7.98 (d, J = 1.26 Hz, 1 H) 7.51-7.56 (m, 2 H) 7.45-7.49(m, 1 H) 7.37-7.40 (m, 2 H) 5.89 (s, 1 H) 4.89-4.96 (m, 1 H) 4.37 (d, J= 5.05 Hz, 2 H) 2.26 (s, 3 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.46 (d, J =6.57 Hz, 6 H) 182

6-[3-(aminomethyl) phenyl]-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 8.17 (br.s., 1 H) 7.78 (br.s., 2 H) 7.65 (br.s., 1 H) 7.43(t, J = 7.83 Hz, 1 H) 7.33 (br.s., 2 H) 7.20-7.31 (m, 1 H) 5.87 (s, 1 H)4.85 (d, J = 6.57 Hz, 1 H) 4.36 (br.s., 1 H) 4.35 (br.s., 1 H) 3.92 (s,1 H) 2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (br.s., 3 H) 1.44(br.s., 3 H) 457.3 183

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[5- (4-morpholinylcarbonyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.48 (s, 1 H) 9.07 (d, J = 2.27 Hz, 1 H) 8.56 (d, J = 1.77Hz, 1 H) 8.18-8.25 (m, 2 H) 7.96 (d, J = 1.26 Hz, 1 H) 7.39 (s, 1 H)7.34 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.92 (quip, J = 6.63 Hz, 1 H)4.36 (d, J = 5.05 Hz, 2 H) 3.69 (br.s., 4 H) 3.54- 3.62 (m, 2 H) 3.43(br.s., 2 H) 2.25 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57Hz, 6 H) 542.4 184

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (1-piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 11.49 (br.s., 1 H) 8.49 (d, J = 2.27Hz, 1 H) 8.18 (t, J = 4.67 Hz, 1 H) 7.90 (dd, J = 8.84, 2.27 Hz, 1 H)7.72 (s, 1 H) 7.29 (s, 1 H) 7.18 (s, 1 H) 6.88 (d, J = 8.84 Hz, 1 H)6.01 (s, 1 H) 4.79-4.90 (m, 1 H) 4.41 (br.s., 1 H) 4.40 (br.s., 1 H)3.41-3.57 (m, 4 H) 3.22-3.30 (m, 1 H) 2.62-2.90 (m, 4 H) 2.55 (s, 1 H)2.17 (s, 3 H) 2.14 (s, 3 H) 1.43 (s, 3 H) 1.42 (s, 3 H) 1.15 (s, 3 H)1.13 (s, 3 H) 541.3 185

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-(6-formyl-3-pyridinyl)-3-methyl- 1-(1-methylethyl)-1H- indole-4-carboxamide 11.50(br.s., 1 H) 10.04 (s, 1 H) 9.27 (d, J = 1.52 Hz, 1 H) 8.44 (dd, J =8.08, 1.77 Hz, 1 H) 8.27 (t, J = 5.05 Hz, 1 H) 8.07 (d, J = 1.26 Hz, 1H) 8.01 (d, J = 8.08 Hz, 1 H) 7.42-7.45 (m, 2 H) 5.88 (s, 1 H) 4.89-4.99(m, 1 H) 4.37 (d, J = 5.05 Hz, 2 H) 2.25 (s, 3 H) 2.18 (s, 3 H) 2.11 (s,3 H) 1.45 (d, J = 6.57 Hz, 6 H) 457.2 186

N-[(4-cyclopropyl-6- methyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide 11.42 (br.s., 1 H) 8.50 (d, J = 2.02 Hz, 1 H)8.23 (t, J = 4.93 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H) 7.72 (s, 1H) 7.29 (s, 1 H) 7.20 (s, 1 H) 6.88 (d, J = 9.09 Hz, 1 H) 5.49 (s, 1 H)4.79-4.89 (m, 1 H) 4.54 (br.s., 1 H) 4.53 (br.s., 1 H) 3.42-3.50 (m, 4H) 2.74-2.88 (m, 4 H) 2.15-2.23 (m, 4 H) 2.09 (s, 3 H) 1.44 (s, 3 H)1.42 (s, 3 H) 0.94-1.01 (m, 2 H) 0.76 (d, J = 3.54 Hz, 2 H) 539.3 187

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)- 3-pyridinyl]-1-(1- methylpropyl)-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.50 (d, J = 2.53 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 7.73 (d, J = 1.26 Hz, 1H) 7.26 (s, 1 H) 7.17 (d, J = 1.52 Hz, 1 H) 6.92 (d, J = 9.09 Hz, 1 H)5.87 (s, 1 H) 4.56-4.65 (m, 1 H) 4.36 (s, 1 H) 4.34 (s, 1 H) 3.49-3.55(m, 4 H) 2.40-2.44 (m, 4 H) 2.24 (s, 3 H) 2.23 (s, 3 H) 2.16 (s, 3 H)2.11 (s, 3 H) 1.76- 1.87 (m, 2 H) 1.41 (d, J = 6.57 Hz, 3 H) 0.73 (t, J= 7.33 Hz, 3 H) 541.6 188

6-(4-(2- (dimethylamino)ethyl) phenyl)-1-isopropyl-3-methyl-N-((6-methyl- 2-oxo-4-propyl-1,2- dihydropyridin-3-yl)methyl)-1H- indole-4-carboxamide 11.50 (br.s., 1 H) 8.15 (t, J = 4.93Hz, 1 H) 7.73-7.76 (m, 1 H) 7.61-7.66 (m, 2 H) 7.31 (d, J = 2.78 Hz, 2H) 7.29 (s, 1 H) 7.22 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.86 (quin, J= 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36 (br.s., 1 H) 2.72-2.78 (m, 2 H) 2.55(d, J = 7.33 Hz, 2 H) 2.47 (d, J = 7.07 Hz, 2 H) 2.14-2.23 (m, 9 H) 2.12(s, 3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 0.94 (t, J =7.45 Hz, 3 H) 527.1 189

3,6-dibromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H-indole- 4-carboxamide 1H NMR (400 MHz,METHANOL- d4) δ 7.81 (d, J = 1.52 Hz, 1H), 7.54 (s, 1H), 7.23 (d, J =1.52 Hz, 1H), 6.12 (s, 1H), 4.77 (quin, J = 6.69 Hz, 1H), 4.55 (s, 2H),2.44 (s, 3H), 2.25 (s, 3H), 1.50 (d, J = 6.57 Hz, 6H) 495.8 190

N-{[(1,1- dimethylethypoxy] carbonyl}-4-[4-({[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-3-methyl-1-(1-methylethyl)- 1H-indol-6-yl]-L- phenylalanine 12.61 (br.s., 1 H) 11.49(br.s., 1 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.75 (s, 1 H) 7.65 (d, J = 8.34Hz, 2 H) 7.34 (s, 1 H) 7.32 (s, 2 H) 7.23 (s, 1 H) 7.15 (s, 1 H) 5.87(s, 1 H) 4.82-4.90 (m, 1 H) 4.35 (d, J = 5.31 Hz, 2 H) 4.12-4.08 (m, 1H) 3.08-2.88 (m, 2 H) 2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.43 (d,J = 6.57 Hz, 6 H 615.4 191

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-[6-(1H-imidazol-1-ylmethyl)-3- pyridinyl]-3-methyl-1- (1-methylethyly 1H-indole-4-carboxamide 9.31 (br.s., 1 H) 9.04 (br.s., 1 H) 8.39 (d, J =2.53 Hz, 1 H) 7.97 (br.s., 1 H) 7.70-7.86 (m, 3 H) 7.39 (br.s., 2 H)6.25 (br.s., 1 H) 5.68 (br.s., 2 H) 4.80- 4.95 (m, 1 H) 4.42 (br.s., 2H) 2.34 (br.s., 3 H) 2.22 (br.s., 3 H) 2.15 (br.s., 3 H) 1.44 (br.s., 6H); spiked with d-TFA 509.6 192

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(5,6,7,8- tetrahydro-1,6- naphthyridin-3-yl)-1H-indole-4-carboxamide 11.49 (br.s., 1 H) 8.71 (d, J = 2.02 Hz, 1 H) 8.19(t, J = 5.05 Hz, 1 H) 7.82 (dd, J = 11.49, 1.64 Hz, 2 H) 7.34 (s, 1 H)7.26 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.88 (quin, J = 6.63 Hz, 1 H)4.36 (d, J = 5.05 Hz, 2 H) 3.94 (s, 2 H) 3.05 (t, J = 5.81 Hz, 2 H)2.75-2.86 (m, 2 H) 2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.43 (d, J= 6.57 Hz, 6 H) 484.3 193

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4- methyl-1-piperazinyl)- 1,3-thiazol-5-yl]-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 7.57 (s,1 H) 7.56 (d, J = 1.26 Hz, 1 H) 7.28 (d, J = 1.01 Hz, 1 H) 7.05 (d, J =1.26 Hz, 1 H) 5.87 (s, 1 H) 4.77 (quin, J = 6.63 Hz, 1 H) 4.34 (s, 1 H)4.33 (s, 1 H) 3.41 -3.47 (m, 4 H) 2.41-2.47 (m, 4 H) 2.23 (s, 6 H) 2.13(s, 3 H) 2.11 (s, 3 H) 1.42 (s, 3 H) 1.40 (s, 3 H) 533.6 194

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-{6-[(9aS)-hexahydropyrazino[2,1- c][1,4]oxazin-8(1H)-yl]- 3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 11.44 (br.s., 1 H) 8.50 (d, J= 2.53 Hz, 1 H) 8.16 (t, J = 5.05 Hz, 1 H) 7.94 (dd, J = 8.84, 2.53 Hz,1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.52 Hz, 1 H)6.93 (d, J = 8.84 Hz, 1 H) 5.87 (s, 1 H) 4.84 (quin, J = 6.63 Hz, 1 H)4.35 (s, 1 H) 4.34 (s, 1 H) 4.24 (d, J = 12.63 Hz, 1 H) 4.14 (d, J =11.62 Hz, 1 H) 3.78- 3.82 (m, 1 H) 3.77 (br.s., 1 H) 3.56 (td, J =11.37, 2.27 Hz, 1 H) 3.19 (t, J = 10.48 Hz, 1 H) 2.80-2.95 (m, 2 H) 2.69(d, J = 11.87 Hz, 1 H) 2.39-2.46 (m, 1 H) 2.14-2.27 (m, 9 H) 2.11 (s, 3H) 1.43 (s, 3 H) 1.42 (s, 3 H) 569.5 195

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(5,6,7,8- tetrahydro-1,8-naphthyridin-3-yl)- 1H-indole-4- carboxamide 11.49 (s, 1 H) 8.14 (d, J =2.27 Hz, 1 H) 8.09 (t, J = 5.05 Hz, 1 H) 7.64 (d, J = 1.26 Hz, 1 H) 7.56(d, J = 1.77 Hz, 1 H) 7.26 (s, 1 H) 7.14 (d, J = 1.26 Hz, 1 H) 6.51 (s,1 H) 5.90 (s, 1 H) 4.83 (quin, J = 6.57 Hz, 1 H) 4.37 (br.s., 1 H) 4.35(br.s., 1 H) 3.30 (br.s., 2 H) 2.76 (t, J = 6.06 Hz, 2 H) 2.56 (d, J =7.33 Hz, 2 H) 2.16 (s, 3 H) 2.12 (s, 3 H) 1.78-1.85 (m, 2 H) 1.53-1.62(m, 2 H) 1.43 (s, 3 H) 1.41 (s, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 512.4196

6-[6-(4-ethyl-1- piperazinyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.49 (s, 1 H) 8.50 (d, J =2.53 Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H) 7.91 (dd, Hz, 2.53 Hz, 1 H)7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.52 Hz, 1 H) 6.92(d, J = 8.84 Hz, 1 H) 5.90 (s, 1 H) 4.84 (quin, J = 6.63 Hz, 1 H) 4.37(s, 1 H) 4.36 (s, 1 H) 3.48-3.56 (m, 4 H) 2.55 (dd, J = 8.72, 6.95 Hz, 2H) 2.44- 2.49 (m, 4 H) 2.38 (q, J = 7.24 Hz, 2 H) 2.17 (s, 3 H) 2.12 (s,3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.05 (t, J = 7.07Hz, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 569.8 197

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)- 3-pyridinyl]-1-(1- methylpropyl)-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.50 (d, J = 2.53 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 7.72-7.75 (m, 1 H) 7.26(s, 1 H) 7.17 (d, J = 1.26 Hz, 1 H) 6.92 (d, J = 8.84 Hz, 1 H) 5.87 (s,1 H) 4.56-4.65 (m, 1 H) 4.36 (s, 1 H) 4.34 (s, 1 H) 3.50-3.55 (m, 4 H)2.40-2.44 (m, 4 H) 2.24 (s, 3 H) 2.23 (s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3H) 1.81 (dq, J = 9.85, 7.16 Hz, 2 H) 1.41 (d, J = 6.57 Hz, 3 H) 0.73 (t,J = 7.33 Hz, 3 H) 541.8 198

3-methyl-1-(1- methylethyl)-6-{6- [4-(1-methylethyl)-1- piperazinyl]-3-pyridinyl}-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4- carboxamide 11.49 (br.s., 1 H) 8.50 (d, J = 2.53Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H)7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 5.90(s, 1 H) 4.84 (quin, J = 6.69 Hz, 1 H) 4.37 (br.s., 1 H) 4.36 (br.s., 1H) 3.46-3.55 (m, 4 H) 2.66-2.73 (m, 1 H) 2.52-2.57 (m, 6 H) 2.17 (s, 3H) 2.12 (s, 3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.02 (s,3 H) 1.01 (s, 3 H) 0.99 (d, J = 6.57 Hz, 1 H) 0.94 (t, J = 7.33 Hz, 3 H)583.6 199

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4- morpholinylmethyl)-2- pyridinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H),2.25 (s, 3 H), 3.57-3.66 (m, 4 H), 3.69 (s, 2 H), 4.37 (d, J = 5.05 Hz,2 H), 4.87 (spt, J = 6.40 Hz, 1 H), 5.87 (s, 1 H), 7.33-7.41 (m, 2 H),7.74 (d, J = 1.52 Hz, 1 H), 7.83 (t, J = 7.71 Hz, 1 H), 7.93 (d, J =7.83 Hz, 1 H), 8.15 (t, J = 5.05 Hz, 1 H), 8.19 (d, J = 1.26 Hz, 1 H),11.47 (s, 1 H) 528.4 200

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4- morpholinyl)-2- pyridinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.17 (s, 3 H),2.25 (s, 3 H), 3.48-3.61 (m, 4 H), 3.70-3.83 (m, 4 H), 4.36 (d, J = 5.05Hz, 2 H), 4.86 (spt, J = 6.57 Hz, 1 H), 5.88 (s, 1 H), 6.75 (d, J = 8.59Hz, 1 H), 7.30-7.43 (m, 2 H), 7.63 (t, J = 7.95 Hz, 1 H), 7.71 (d, J =1.52 Hz, 1 H), 8.09-8.21 (m, 2 H), 11.46 (s, 1 H) 514 201

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(6- methyl-2-pyridinyl)-1H- indole-4-carboxamide 1.45 (d,J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2.25 (s, 3 H), 2.55 (s,3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.87 (spt, J = 6.57 Hz, 1 H), 5.87 (s,1 H), 7.16 (d, J = 7.33 Hz, 1 H), 7.37 (d, J = 1.01 Hz, 1 H), 7.70-7.78(m, 2 H), 7.85 (d, J = 8.08 Hz, 1 H), 8.15 (t, J = 4.93 Hz, 1 H), 8.19(d, J = 1.52 Hz, 1 H), 11.48 (s, 1 H) 443 202

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4- morpholinyl)-4- pyrimidinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.17 (s, 3 H),2.25 (s, 3 H), 3.68-3.76 (m, 4 H), 3.76-3.86 (m, 4 H), 4.36 (d, J = 5.05Hz, 2 H), 4.92 (spt, J = 6.48 Hz, 1 H), 5.88 (s, 1 H), 7.38 (d, J = 5.31Hz, 1 H), 7.45 (s, 1 H), 7.79 (d, J = 1.26 Hz, 1 H), 8.20 (t, J = 5.05Hz, 1 H), 8.29 (d, J = 1.26 Hz, 1 H), 8.41 (d, J = 5.31 Hz, 1 H), 11.46(s, 1 H) 515 203

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(2- pyrimidinyl)-1H-indole- 4-carboxamide 1.47 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.37 (d, J =5.05 Hz, 2 H), 4.84 (spt, J = 6.61 Hz, 1 H), 5.88 (s, 1 H), 7.38 (t, J =4.80 Hz, 1 H), 7.46 (s, 1 H), 8.06 (d, J = 1.26 Hz, 1 H), 8.18 (t, J =5.05 Hz, 1 H), 8.52 (d, J = 1.26 Hz, 1 H), 8.87 (d, J = 4.80 Hz, 2 H),11.48 (s, 1 H) 204

6-{6-[(dimethylamino) methyl]-2-pyridinyl}-N- [(4,6-dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H-indole- 4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11(s, 3 H), 2.17 (s, 3 H), 2.25 (s, 9 H), 3.62 (s, 2 H), 4.37 (d, J = 4.80Hz, 2 H), 4.87 (spt, J = 6.36 Hz, 1 H), 5.87 (s, 1 H), 7.33 (d, J = 7.58Hz, 1 H), 7.37 (s, 1 H), 7.75 (d, J = 1.26 Hz, 1 H), 7.83 (t, J = 7.71Hz, 1 H), 7.92 (d, J = 7.83 Hz, 1 H), 8.15 (t, J = 4.93 Hz, 1 H), 8.19(d, J = 1.26 Hz, 1 H), 11.47 (s, 1 H) 205

6-(6-amino-2-pyridinyl)- N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.44 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.74-4.87 (m, 1 H), 5.87 (s,1 H), 5.96 (s, 2 H), 6.37 (d, J = 7.83 Hz, 1 H), 7.14 (d, J = 7.33 Hz, 1H), 7.65 (d, J = 1.26 Hz, 1 H), 8.04-8.13 (m, 2 H), 11.47 (s, 1 H). 444206

6-[2-amino-6-(4- morpholinyl)-4- pyrimidinyl]-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-1H-indole- 4-carboxamide 1.44 (d, 6 H), 2.11 (s, 3 H), 2.15(s, 3 H), 2.24 (s, 3 H), 3.53-3.79 (m, 8 H), 4.35 (d, J = 4.29 Hz, 2 H),4.80-4.95 (m, 1 H), 5.87 (s, 1 H), 6.10 (br.s., 2 H), 6.68 (s, 1 H),7.38 (s, 1 H), 7.76 (s, 1 H), 8.06 (br.s., 1 H), 8.18 (s, 1 H), 11.46(br.s., 1 H). 530 207

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-6-[2-(methylamino)-4- pyrimidinyl]-1-(1- methylethyl)-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.17 (s,3 H), 2.25 (s, 3 H), 2.88 (br.s., 3 H), 4.36 (d, J = 5.05 Hz, 2 H),4.81- 4.94 (spt, J = 6.57 Hz, 1 H), 5.87 (s, 1 H), 7.07 (br.s., 1 H),7.25 (d, J = 5.31 Hz, 1 H), 7.44 (s, 1 H), 7.78 (s, 1 H), 8.16 (t, J =4.93 Hz, 1 H), 8.26 (s, 1 H), 8.31 (d, J = 4.80 Hz, 1 H), 11.47 (s, 1 H)459.1 208

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(4- pyrimidinyl)-1H-indole- 4-carboxamide 1.46 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.37 (d, J =5.05 Hz, 2 H), 4.92 (spt, J = 6.65 Hz, 1 H), 5.88 (s, 1 H), 7.49 (s, 1H), 7.85 (d, J = 1.26 Hz, 1 H), 8.17-8.27 (m, 2 H), 8.42 (d, J = 1.52Hz, 1 H), 8.80 (d, J = 5.31 Hz, 1 H), 9.19 (d, J = 1.01 Hz, 1 H), 11.48(s, 1 H) 430.0 209

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-[2-(ethylamino)-4- pyrimidinyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.17 (t, J = 7.07 Hz, 3 H), 1.45 (d, J = 6.57 Hz, 6H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 3.34-3.45 (m, 2 H),4.36 (d, J = 5.05 Hz, 2 H), 4.86 (spt, J = 6.61 Hz, 1 H), 5.87 (s, 1 H),7.12 (br.s., 1 H), 7.23 (d, J = 5.31 Hz, 1 H), 7.43 (s, 1 H), 7.76 (d, J= 1.26 Hz, 1 H), 8.16 (t, J = 4.93 Hz, 1 H), 8.25 (s, 1 H), 8.30 (d, J =5.05 Hz, 1 H), 11.47 (s, 1 H) 473.0 210

6-(2-amino-4- pyrimidinyl)-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.45 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.17 (s,3 H), 2.24 (s, 3 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.80-4.92 (m, 1 H),5.87 (s, 1 H), 6.61 (s, 2 H), 7.25 (d, J = 5.31 Hz, 1 H), 7.44 (s, 1 H),7.75 (d, J = 1.26 Hz, 1 H), 8.15 (t, J = 5.05 Hz, 1 H), 8.23 (d, J =1.01 Hz, 1 H), 8.27 (d, J = 5.31 Hz, 1 H), 11.47 (s, 1 H) 445 211

6-(1H-benzimidazol-5- yl)-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.45 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H),4.37 (d, J = 5.05 Hz, 2 H), 4.82-4.95 (m, 1 H), 5.87 (s, 1 H), 7.24-7.30(m, 1 H), 7.30 (s, 1 H), 7.53-7.64 and 7.66-7.75 (m, 2 H), 7.79 (s, 1H), 7.80-7.84 and 7.98- 8.06 (m, 1 H), 8.20 (t, J = 5.05 Hz, 1 H), 8.23(s, 1 H), 11.47 (br.s., 1 H), 12.45 (br.s., 1 H) 212

6-(3-amino-1H-indazol- 6-yl)-N-[(4,6-dimethyl- 2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.44 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2.24 (s, 3 H),4.37 (d, J = 4.80 Hz, 2 H), 4.89 (spt, J = 6.48 Hz, 1 H), 5.35 (s, 2 H),5.87 (s, 1 H), 7.25- 7.35 (m, 3 H), 7.50 (s, 1 H), 7.74 (d, J = 8.34 Hz,1 H), 7.80 (d, J = 1.26 Hz, 1 H), 8.21 (t, J = 5.05 Hz, 1 H), 11.37(br.s., 1 H), 11.47 (br.s., 1 H) 483 213

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(1- methyl-1H-indazol-6-yl)- 1H-indole-4-carboxamide 1.46(d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2.26 (s, 3 H), 4.13(s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.91 (spt, J = 6.57 Hz, 1 H), 5.87(s, 1 H), 7.35 (s, 1 H), 7.39 (d, J = 1.26 Hz, 1 H), 7.57 (dd, J = 8.46,1.39 Hz, 1 H), 7.81 (d, J = 8.59 Hz, 1 H), 7.90 (d, J = 1.52 Hz, 1 H),7.96 (s, 1 H), 8.04 (s, 1 H), 8.18 (t, J = 5.05 Hz, 1 H), 11.47 (s, 1 H)214

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-(5- methyl-1H-indazol-6-yl)- 1H-indole-4-carboxamide 1.42(d, J = 6.57 Hz, 6 H), 2.09 (s, 3 H), 2.20 (s, 3 H), 2.22 (s, 3 H), 2.31(s, 3 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (spt, J = 6.53 Hz, 1 H), 5.85(s, 1 H), 6.93 (d, J = 1.52 Hz, 1 H), 7.33 (s, 1 H), 7.37 (s, 1 H), 7.50(d, J = 1.26 Hz, 1 H), 7.65 (s, 1 H), 8.01 (s, 1 H), 8.13 (t, J = 5.05Hz, 1 H), 11.45 (br.s., 1 H), 12.92 (br.s., 1 H) 215

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-ethyl-1- piperazinyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.05 (t, J = 7.20 Hz, 3 H) 1.43(d, J = 6.57 Hz, 6 H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.24 (s, 3 H) 2.37 (q,J = 7.07 Hz, 2 H) 2.45- 2.49 (m, 4 H) 3.49-3.55 (m, 4 H) 4.35 (d, J =5.05 Hz, 2 H) 4.78-4.90 (m, 1 H) 5.87 (s, 1 H) 6.92 (d, J = 8.84 Hz, 1H) 7.18 (d, J = 1.52 Hz, 1 H) 7.29 (s, 1 H) 7.72 (d, J = 1.26 Hz, 1 H)7.92 (dd, J = 8.84, 2.78 Hz, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 8.51 (d, J= 2.53 Hz, 1 H) 11.48 (br.s., 1 H) 541.6 216

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-{6- [4-(1-methylethyl)-1- piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide 1.01 (d, J = 6.57 Hz, 6 H) 1.43 (d, J = 6.57 Hz,6 H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.24 (s, 3 H) 2.53-2.57 (m, 4 H)2.67-2.73 (m, 1 H) 3.47-3.54 (m, 4 H) 4.35 (d, J = 5.31 Hz, 2 H) 4.84(s, 1 H) 5.87 (s, 1 H) 6.91 (d, J = 8.84 Hz, 1 H) 7.18 (d, J = 1.26 Hz,1 H) 7.29 (s, 1 H) 7.72 (d, J = 1.52 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53Hz, 1 H) 8.14 (s, 1 H) 8.50 (d, J = 2.27 Hz, 1 H) 11.48 (s, 1 H) 555.8217

6-chloro-3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1-methylpropyl)-2-oxo-1,2- dihydro-3-pyridinyl] methyl}-1H-indole-4-carboxamide 0.79 (t, J = 7.33 Hz, 3 H) 1.11 (d, J = 6.82 Hz, 3 H) 1.39(d, J = 6.57 Hz, 6 H) 1.50 (quin, J = 7.33 Hz, 2 H) 2.14 (s, 6 H) 2.98(q, J = 6.91 Hz, 1 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.73 (quin, J = 6.63Hz, 1 H) 5.95 (s, 1 H) 6.88 (d, J = 1.77 Hz, 1 H) 7.34 (s, 1 H) 7.64 (d,J = 1.77 Hz, 1 H) 8.23 (t, J = 4.93 Hz, 1 H) 11.48 (s, 1 H) 428.2 218

6-bromo-3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1-methylpropyl)-2-oxo-1,2- dihydro-3-pyridinyl] methyl}-1H-indole-4-carboxamide 0.79 (t, J = 7.33 Hz, 3 H) 1.11 (d, J = 6.82 Hz, 3 H)1.33-1.44 (m, 6 H) 1.50 (quin, J = 7.33 Hz, 2 H) 2.07-2.20 (m, 6 H)2.91-3.05 (m, 1 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.74 (dt, J = 13.33, 6.60Hz, 1 H) 5.95 (s, 1 H) 6.99 (d, J = 1.52 Hz, 1 H) 7.34 (s, 1 H) 7.76 (d,J = 1.52 Hz, 1 H) 8.24 (t, J = 4.80 Hz, 1 H) 11.48 (br.s., 1 H) 474.2219

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylpropyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (4-methyl-1-piperazinyl)-3-pyridinyl]-1H- indole-4-carboxamide 0.80 (t, J = 7.33 Hz, 3 H)1.10-1.15 (m, 3 H) 1.34-1.47 (m, 6 H) 1.51 (quin, J = 7.33 Hz, 2 H)2.10-2.28 (m, 9 H) 2.35-2.44 (m, 4 H) 3.01 (sxt, J = 6.92 Hz, 1 H)3.45-3.58 (m, 4 H) 4.33-4.50 (m, 2 H) 4.84 (quin, J = 6.63 Hz, 1 H) 5.96(s, 1 H) 6.92 (d, J = 8.84 Hz, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 7.29 (s,1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.90 (dd, J = 8.84, 2.53 Hz, 1 H) 8.16(t, J = 4.93 Hz, 1 H) 8.49 (d, J = 2.53 Hz, 1 H) 11.48 (br.s., 1 H)569.4 220

6-(6-chloro-3-pyridinyl)- N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.36-1.52 (m, 6 H) 2.11 (s, 3 H) 2.16- 2.20 (m, 3 H)2.21-2.28 (m, 3 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.89 (quin, J = 6.63 Hz, 1H) 5.87 (s, 1 H) 7.30 (d, J = 1.26 Hz, 1 H) 7.39 (s, 1 H) 7.59 (d, J =8.34 Hz, 1 H) 7.92 (d, J = 1.52 Hz, 1 H) 8.18-8.29 (m, 2 H) 8.83 (d, J =2.27 Hz, 1 H) 11.49 (s, 1 H) 463.2 221

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-[6-(1H-imidazol-1-yl)-3- pyridinyl]-3-methyl-1- (1-methylethyl)-1H-indole-4-carboxamide 1.42-1.48 (m, 6 H) 2.11 (s, 3 H) 2.18 (s, 3 H)2.22-2.30 (m, 3 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.84-4.97 (m, 1 H) 5.87(s, 1 H) 7.16 (s, 1 H) 7.33-7.41 (m, 2 H) 7.91 (d, J = 8.34 Hz, 1 H)7.95 (d, J = 1.26 Hz, 1 H) 8.02 (s, 1 H) 8.22 (t, J = 5.05 Hz, 1 H) 8.39(dd, J = 8.59, 2.53 Hz, 1 H) 8.60 (s, 1 H) 8.90 (d, J = 2.27 Hz, 1 H)11.49 (s, 1 H) 495.2 222

6-[6-(4-cyclopropyl-1- piperazinyl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 0.34-0.49 (m, 4 H) 1.42 (d, J =6.57 Hz, 6 H) 1.65 (tt, J = 6.57, 3.41 Hz, 1 H) 2.11 (s, 3 H) 2.16 (s, 3H) 2.24 (s, 3 H) 2.59-2.69 (m, 4 H) 3.42-3.56 (m, 4 H) 4.34 (d, J = 5.05Hz, 2 H) 4.84 (quin, J = 6.63 Hz, 1 H) 5.87 (s, 1 H) 6.91 (d, J = 8.84Hz, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 7.28 (s, 1 H) 7.71 (d, J = 1.26 Hz,1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 8.50(d, J = 2.27 Hz, 1 H) 11.48 (s, 1 H) 553.8 223

6-{6-[2-(dimethylamino) ethyl]-3-pyridinyl}-N- [(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.43 (d, J = 6.57 Hz, 6 H) 2.11 (s, 3 H) 2.14-2.22 (m, 9H) 2.24 (s, 3 H) 2.61 (t, J = 7.58 Hz, 2 H) 2.89 (t, J = 7.45 Hz, 2 H)4.35 (d, J = 5.05 Hz, 2 H) 4.81-4.94 (m, 1 H) 5.87 (s, 1 H) 7.25 (d, J =1.26 Hz, 1 H) 7.32-7.40 (m, 2 H) 7.84 (d, J = 1.26 Hz, 1 H) 8.03 (dd, J= 8.08, 2.53 Hz, 1 H) 8.19 (t, J = 5.05 Hz, 1 H) 8.84 (d, J = 2.02 Hz, 1H) 11.48 (s, 1 H) 500.3 224

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)- 3-pyridinyl]-1-(1- methylpropyl)-1H-indole-4-carboxamide 0.72 (t, J = 7.33 Hz, 3 H) 1.40 (d, J = 6.82 Hz, 3 H) 1.80(td, J = 7.26, 2.91 Hz, 2 H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.23 (d, J =5.31 Hz, 6 H) 2.37-2.46 (m, 4 H) 3.46-3.56 (m, 4 H) 4.35 (d, J = 5.05Hz, 2 H) 4.60 (d, J = 7.07 Hz, 1 H) 5.86 (s, 1 H) 6.91 (d, J = 8.84 Hz,1 H) 7.17 (d, J = 1.26 Hz, 1 H) 7.26 (s, 1 H) 7.73 (d, J = 1.26 Hz, 1 H)7.91 (dd, J = 8.84, 2.53 Hz, 1 H) 8.16 (t, J = 4.93 Hz, 1 H) 8.50 (d, J= 2.53 Hz, 1 H) 11.48 (s, 1 H) 541.7 225

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-6-{6-[(3R,5S)-3,5-dimethyl-1- piperazinyl]-3-pyridinyl}- 3-methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.00-1.07 (m, 6 H) 1.39-1.46 (m, 6H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.21-2.34 (m, 6 H) 2.70-2.82 (m, 2 H)4.17 (dd, J = 12.25, 2.15 Hz, 2 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.83(quin, J = 6.57 Hz, 1 H) 5.87 (s, 1 H) 6.89 (d, J = 9.09 Hz, 1 H) 7.17(d, J = 1.26 Hz, 1 H) 7.28 (s, 1 H) 7.70 (d, J = 1.52 Hz, 1 H) 7.89 (dd,J = 8.84, 2.53 Hz, 1 H) 8.15 (t, J = 5.18 Hz, 1 H) 8.47 (d, J = 2.27 Hz,1 H) 11.48 (br.s., 1 H) 541.4 226

6-{6-[3-(dimethylamino)- 1-pyrrolidinyl]-3- pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-1H-indole- 4-carboxamide 1.35-1.49 (m, 6 H) 1.75-1.88 (m, 1H) 2.11 (s, 3 H) 2.13-2.19 (m, 4 H) 2.20- 2.27 (m, 9 H) 2.72-2.84 (m, 1H) 3.14 (dd, J = 9.85, 8.34 Hz, 1 H) 3.34-3.41 (m, 1 H) 3.61 (t, J =8.59 Hz, 1 H) 3.71 (dd, J = 10.11, 7.07 Hz, 1 H) 4.35 (d, J = 5.05 Hz, 2H) 4.83 (quin, J = 6.63 Hz, 1 H) 5.87 (s, 1 H) 6.54 (d, J = 8.84 Hz, 1H) 7.16 (d, J = 1.52 Hz, 1 H) 7.27 (s, 1 H) 7.68 (d, J = 1.26 Hz, 1 H)7.88 (dd, J = 8.59, 2.53 Hz, 1 H) 8.14 (t, J = 5.05 Hz, 1 H) 8.45 (d, J= 2.27 Hz, 1 H) 11.48 (s, 1 H) 541.7 227

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4- methylhexahydro-1H- 1,4-diazepin-1-yl)-3-pyridinyl]-1H-indole-4- carboxamide 1.42 (d, J = 6.57 Hz, 6 H) 1.87-1.97(m, 2 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 2.20- 2.32 (m, 6 H) 2.59-2.72 (m, 2H) 3.63 (t, J = 6.19 Hz, 2 H) 3.78 (br.s., 2 H) 4.34 (d, J = 5.05 Hz, 2H) 4.76- 4.89 (m, 1 H) 5.87 (s, 1 H) 6.70 (d, J = 8.84 Hz, 1 H) 7.16 (d,J = 1.52 Hz, 1 H) 7.27 (s, 1 H) 7.69 (d, J = 1.26 Hz, 1 H) 7.87 (dd, J =8.84, 2.53 Hz, 1 H) 8.14 (t, J = 5.05 Hz, 1 H) 8.45 (d, J = 2.27 Hz, 1H) 11.48 (s, 1 H) 541.3 228

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4- piperidinyl)-3-pyridinyl]- 1H-indole-4-carboxamide1H NMR (400 MHz, MeOH-d4) 1.55 (d, J = 6.82 Hz, 6 H) 2.14-2.29 (m, 5 H)2.35 (br.s., 2 H) 2.47 (s, 3 H) 2.60 (s, 3 H) 3.23-3.31 (m, 1 H)3.47-3.59 (m, 1 H) 3.64 (br.s., 2 H) 4.68 (s, 2 H) 6.77 (br.s., 1 H)7.45 (s, 1 H) 7.65 (s, 1 H) 8.08-8.17 (m, 2 H) 9.03 (d, J = 8.34 Hz, 1H) 9.22 (d, J = 1.77 Hz, 1 H) 585 229

6-bromo-1-isopropyl-N- ((6-methyl-2-oxo-4-((6- (trifluoromethyl)pyridin-2-yl)methyl)-1,2- dihydropyridin-3- yl)methyl)-1H-indole- 4-carboxamide1.42 (s, 3 H), 1.44 (s, 3 H), 2.11 (s, 3 H), 4.27 (s, 2 H), 4.44 (d, J =5.05 Hz, 2 H), 4.74-4.88 (m, 1 H), 5.88 (s, 1 H), 6.84 (d, J = 3.03 Hz,1 H), 7.45 (d, J = 1.77 Hz, 1 H), 7.54-7.64 (m, 2 H), 7.71 (d, J = 7.58Hz, 1 H), 7.91 (s, 1 H), 7.93-8.00 (m, 1 H), 8.35 (t, J = 5.05 Hz, 1 H),11.68 (s, 1 H) 461, 463 230

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(pyridazin- 4-yl)-1H-indole-4- carboxamide 11.10-11.70 (br.s,1H), 9.77 (dd, J = 1.26, 2.53 Hz, 1H), 9.22 (dd, J = 1.14, 5.43 Hz, 1H),8.30 (br.s., 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.09 (dd, J = 2.53, 5.56Hz, 1H), 7.42-7.54 (m, 2H), 5.87 (s, 1H), 4.96 (quin, J = 6.63 Hz, 1H),4.36 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.11 (s, 3H),1.45 (d, 6H) 430.3 231

N-[(6-amino-4-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-chloro-3-methyl-1-(1- methylethyl)-1H-indole- 4-carboxamide 10.62(br.s., 1 H), 8.14 (t, J = 4.4 Hz, 1 H), 7.63 (d, J = 1.8 Hz, 1 H), 7.34(s, 1 H), 6.89 (d, J = 1.8 Hz, 1 H), 5.85 (br.s., 2 H), 5.20 (s, 1 H),4.73 (dt, J = 6.7, 13.2 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3H), 2.12 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H) 387.2 232

N-[(6-amino-4-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1-(1- methylethyl)-1H-indole- 4-carboxamide 10.59(br.s., 1 H), 8.13 (t, J = 4.4 Hz, 1 H), 7.76 (d, J = 1.5 Hz, 1 H), 7.33(s, 1 H), 6.99 (d, J = 1.5 Hz, 1 H), 5.83 (br.s., 2 H), 5.19 (s, 1 H),4.74 (dt, J = 6.6, 13.3 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3H), 2.11 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H) 431.1 233

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1- [(3R)-tetrahydro-3- furanyl]-1H-indole-4-carboxamide 1.94-2.07 (m, 1 H), 2.11, (s, 3 H), 2.12 (s, 3 H), 2.22(s, 3 H), 2.40-2.48 (m, 1 H), 3.75-3.87 (m, 2 H), 3.88-3.96 (m, 1 H),3.98-4.11 (m, 1 H), 4.31 (d, J = 5.05 Hz, 2 H), 5.17-5.32 (m, 1 H), 5.86(s, 1 H), 7.04 (d, J = 1.52 Hz, 1 H), 7.23 (s, 1 H), 7.84 (d, J = 1.77Hz, 1 H), 8.25 (t, J = 4.93 Hz, 1 H), 11.47 (s, 1 H) 458, 460 234

6-bromo-3-methyl-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)- (1,2-dihydro-3-pyridinyl] methyl}-1H-indole-4-carboxamide 1.39 (d, J = 6.8 Hz, 6 H), 2.06 (s, 3 H), 2.11 (s, 3 H),4.44 (d, J = 5.3 Hz, 2 H), 4.75 (dt, J = 13.3, 6.6 Hz, 1 H), 5.41 (s, 1H), 5.44 (s, 2 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.33 (s, 1 H), 7.47 (d, J= 1.3 Hz, 1 H), 7.78 (d, J = 1.5 Hz, 1 H), 7.84 (d, J = 1.8 Hz, 1 H),8.52 (t, J = 5.2 Hz, 1 H), 11.67 (br.s., 1 H) 496.3 235

6-bromo-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)-1,2- dihydro-3-pyridinyl] methyl}-1H-indole-4-carboxamide 1.44 (d, J = 6.6 Hz, 6 H), 2.06 (s, 3 H), 4.46 (d, J = 5.3Hz, 2 H), 4.83 (dt, J = 13.2, 6.7 Hz, 1 H), 5.45 (s, 3 H), 6.31 (t, J =2.0 Hz, 1 H), 6.90 (d, J = 3.0 Hz, 1 H), 7.51 (d, J = 1.8 Hz, 1 H), 7.57(d, J = 1.5 Hz, 1 H), 7.64 (d, J = 3.3 Hz, 1 H), 7.87 (d, J = 2.3 Hz, 1H), 7.94 (s, 1 H), 8.56 (t, J = 5.1 Hz, 1 H), 11.73 (br.s., 1 H) 484.2236

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide 0.94 (t, J = 7.3 Hz, 3 H), 1.44 (d, J = 6.6 Hz,6 H), 1.51-1.67 (m, 2 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.52-2.59 (m, 2H), 4.38 (d, J = 4.0 Hz, 2 H), 4.81-4.98 (m, 1 H), 5.90 (s, 1 H), 7.28(s, 1 H), 7.37 8.18 (br.s., 1 H), 8.53 (dd, J = 4.8, 1.3 (s, 1 H), 7.47(dd, J = 7.8, 4.5 Hz, 1 H), 7.89 (s, 1 H), 8.14 (d, J = 8.1 Hz, 1 H),Hz, 1 H), 8.97 (d, J = 1.8 Hz, 1 H), 11.49 (s, 1 H) 457.3 237

6-[(aminocarbonyl) amino]-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.39 (m, 6 H), 2.08-2.12 (m, 6 H), 2.22 (s, 3 H), 4.32 (d,J = 5.05 Hz, 2 H), 4.44-4.59 (m, 1 H), 5.76 (s, 2 H), 5.87 (s, 1 H),6.79 (d, J = 1.77 Hz, 1 H), 7.11 (s, 1 H), 7.71 (d, J = 1.52 Hz, 1 H),7.98 (t, J = 5.05 Hz, 1 H), 8.47 (s, 1 H), 11.46 (s, 1 H) 410.3 238

1-cyclopentyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-6-[6- (4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 1.66-1.89 (m, 6 H), 2.05-2.20 (m,8 H), 2.25 (d, J = 7.07 Hz, 6 H), 3.49-3.58 (m, 4 H), 2.47 (m, 4 H),4.35 (d, J = 5.05 Hz, 2 H), 4.97 (quin, J = 6.88 Hz, 1 H), 5.87 (s, 1H), 6.93 (d, J = 8.84 Hz, 1 H), 7.19 (d, J = 1.26 Hz, 1 H), 7.25 (s, 1H), 7.74 (d, J = 1.26 Hz, 1 H), 7.93 (dd, J = 8.84, 2.53 Hz, 1 H),8.14-8.21 (m, 1 H), 8.51 (d, J = 2.53 Hz, 1 H) 553.8 239

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-(1-(dimethylamino)propan- 2-yl)-3-methyl-1H- indole-4-carboxamide (600 MHz,CHLOROFORM-d) 1.44 (d, J = 6.42 Hz, 3 H) 2.14 (s, 3 H) 2.22 (br.s., 9 H)2.38 (s, 3 H) 2.55-2.60 (m, 1 H) 2.65-2.74 (m, 1 H) 4.45-4.54 (m, 1 H)4.57 (d, J = 5.29 Hz, 2 H) 5.92 (s, 1 H) 6.93 (s, 1 H) 7.19 (s, 1 H)7.23 (br.s., 1 H) 7.48 (s, 1 H) 12.53 (br.s., 1 H) 473.2, 475.2 240

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo [3,4-b]pyridin-5-yl)-1H- indole-4-carboxamide 1.45(d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.37(d, J = 5.05 Hz, 2 H), 4.84-4.96 (m, J = 13.29, 6.59, 6.59, 6.59, 6.59Hz, 1 H), 5.87 (s, 1 H), 7.32 (d, J = 1.52 Hz, 1 H), 7.35 (s, 1 H), 7.90(d, J = 1.26 Hz, 1 H), 8.16- 8.25 (m, 2 H), 8.53 (d, J = 2.02 Hz, 1 H),8.94 (d, J = 2.02 Hz, 1 H), 11.47 (s, 1 H), 13.67 (s, 1 H) 469 241

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-(2-(dimethylamino)propyl)- 3-methyl-6-(6-(piperazin- 1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 0.82 (d, 3 H), 2.10 (s, 3 H), 2.14 (s, 3 H), 2.20(s, 6 H), 2.23 (s, 3 H), 2.75- 2.84 (m, 4 H), 2.91-3.04 (m, 1 H), 3.39-3.50 (m, 4 H), 4.03 (dd, J = 14.40, 7.07 Hz, 1 H), 4.20 (dd, J = 14.15,7.07 Hz, 1 H), 4.34 (d, J = 5.05 Hz, 2 H), 5.86 (s, 1 H), 6.88 (d, J =8.84 Hz, 1 H), 7.14 (s, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.67 (d, J =1.26 Hz, 1 H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.17 (t, J = 4.93 Hz,1 H), 8.49 (d, J = 2.27 Hz, 1 H), 11.48 (br.s., 1 H) 556.7 242

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl-1- (pentan-2-yl)-1H-indole- 4-carboxamide 0.76-0.86(m, 3 H), 0.92-1.20 (m, 2 H), 1.36 (d, J = 6.82 Hz, 3 H), 1.63-1.86 (m,2 H), 2.08-2.15 (m, 6 H), 2.19- 2.26 (m, 3 H), 4.30 (d, J = 5.05 Hz, 2H), 4.51-4.68 (m, 1 H), 5.86 (s, 1 H), 6.99 (d, J = 1.52 Hz, 1 H), 7.31(s, 1 H), 7.78 (d, J = 1.77 Hz, 1 H), 8.25 (t, J = 4.93 Hz, 1 H), 11.48(s, 1 H) 243

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-6-(2-methoxypyrimidin-4- yl)-3-methyl-1H-indole- 4-carboxamide 1.46 (d, J= 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.18 (s, 3 H), 2.25 (s, 3 H), 4.00 (s, 3H), 4.37 (d, J = 4.80 Hz, 2 H), 4.92 (spt, J = 6.61 Hz, 1 H), 5.87 (s, 1H), 7.49 (s, 1 H), 7.79-7.86 (m, 2 H), 8.22 (t, J = 5.05 Hz, 1 H), 8.38(d, J = 1.26 Hz, 1 H), 8.60 (d, J = 5.30 Hz, 1 H), 11.48 (s, 1 H) 460.4244

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo [4,3-c]pyridin-6-yl)-1H- indole-4-carboxamide 1.46(d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.26 (s, 3 H), 4.38(d, J = 5.05 Hz, 2 H), 4.90 (spt, J = 6.61 Hz, 1 H), 5.88 (s, 1 H), 7.37(s, 1 H), 7.79 (d, J = 1.26 Hz, 1 H), 8.08 (s, 1 H), 8.19 (t, J = 4.93Hz, 1 H), 8.27-8.35 (m, 2 H), 9.18 (d, J = 1.01 Hz, 1 H), 11.48 (br.s.,1 H), 13.45 (br.s., 1 H) 469.4 245

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1- [(1R)-1-methyl-2- (methyloxy)ethyl]-1H-indole-4-carboxamide 1.33-1.40 (m, 3 H), 2.12 (d, J = 4.80 Hz, 6 H),2.22 (s, 3 H), 3.15-3.21 (m, 3 H), 3.49-3.65 (m, 2 H), 4.31 (d, J = 5.05Hz, 2 H), 4.73-4.90 (m, 1 H), 5.87 (s, 1 H), 6.97-7.06 (m, 1 H), 7.31(s, 1 H), 7.78 (d, J = 1.52 Hz, 1 H), 8.26 (t, J = 4.93 Hz, 1 H), 11.48(s, 1 H) 460.2 246

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-[(1S)-1-methyl-2- (methyloxy)ethyl]-6-[6- (1-piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 1.41 (m, 3 H), 2.11 (s, 3 H), 2.15(s, 3 H), 2.24 (s, 3 H), 2.77-2.83 (m, 3 H), 3.13-3.26 (m, 3 H),3.41-3.48 (m, 3 H), 3.53-3.69 (m, 2 H), 4.35 (d, J = 5.05 Hz, 2 H),4.85-4.99 (m, 1 H), 5.87 (s, 1 H), 6.85-6.93 (m, 1 H), 7.18 (d, J = 1.26Hz, 1 H), 7.27 (s, 1 H), 7.74 (d, J = 1.26 Hz, 1 H), 7.88-7.96 (m, 1 H),8.17 (t, J = 4.93 Hz, 1 H), 8.45-8.54 (m, 1 H) 543.7 247

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-[(1S)-1-methyl-2- (methyloxy)ethyl]-6-[6- (4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 1.41 (d, J = 6.82 Hz, 3 H), 2.11(s, 3 H), 2.16 (s, 3 H), 2.23 (d, J = 4.04 Hz, 5 H), 2.39-2.45 (m, 4 H),3.31-3.38 (m, 1 H), 3.47-3.70 (m, 6 H), 4.35 (d, J = 5.05 Hz, 2 H),4.84-4.99 (m, 1 H), 5.87 (s, 1 H), 6.92 (d, J = 8.84 Hz, 1 H), 7.19 (d,J = 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.75 (d, J = 1.26 Hz, 1 H), 7.92 (dd,J = 8.84, 2.78 Hz, 1 H), 8.19 (t, J = 4.93 Hz, 1 H), 8.51 (d, J = 2.53Hz, 1 H) 557.8 248

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1- [(1S)-1-methyl-2- (methyloxy)ethyl]- 1H-indole-4-carboxamide 1.37 (m, 3 H), 2.12 (d, J = 4.55 Hz, 6 H), 2.22 (s, 3 H),3.18 (s, 3 H), 3.50-3.66 (m, 2 H), 4.30 (d, J = 5.05 Hz, 2 H), 4.72-4.87 (m, 1 H), 5.80-5.92 (m, 1 H), 7.00 (d, J = 1.52 Hz, 1 H), 7.31 (s,1 H), 7.78 (d, J = 1.52 Hz, 1 H), 8.26 (t, J = 4.80 Hz, 1 H), 11.48 (s,1 H) 460.2 249

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-6-{6-[(methylamino)methyl]- 3-pyridinyl}-1-(1- methylethyl)-1H-indole-4-carboxamide 11.52 (s, 1H) 8.87 (d, J = 2.27 Hz, 1 H) 8.21 (t, J= 5.05 Hz, 1 H) 8.08-8.14 (m, 1 H) 7.86 (d, J = 1.26 Hz, 1 H) 7.49 (d, J= 8.08 Hz, 1 H) 7.36 (s, 1 H) 7.28 (d, J = 1.26 Hz, 1 H) 5.87 (s, 1 H)4.89 (dt, J = 13.33, 6.60 Hz, 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 3.78 (s,2 H) 2.29-2.38 (m, 3 H) 2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.45(s, 3 H) 1.43 (s, 3 H) 472.3 250

6-[6-(2,6-dimethyl-4- morpholinyl)-3- pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 11.47 (s, 1 H) 8.51 (d, J = 2.27Hz, 1 H) 8.15 (t, J = 4.93 Hz, 1 H) 7.94 (dd, J = 8.84, 2.53 Hz, 1 H)7.72 (d, J = 1.26 Hz, 1 H) 7.27-7.31 (m, 1 H) 7.19 (d, J = 1.26 Hz, 1 H)6.94 (d, J = 8.84 Hz, 1 H) 5.87 (s, 1 H) 4.85 (quin, J = 6.63 Hz, 1 H)4.36 (s, 1 H) 4.34 (s, 1 H) 4.19-4.22 (m, 1 H) 4.17 (s, 1 H) 3.60-3.68(m, 2 H) 2.42 (dd, J = 12.63, 10.61 Hz, 2 H) 2.24 (s, 3 H) 2.16 (s, 3 H)2.11 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.19 (s, 3 H) 1.18 (s, 3 H)542.5 251

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl) methyl]-3-methyl-1-(1-methylethyl)-6-[6-(2- methyl-4-morpholinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.48 (s, 1 H) 8.52 (d, J = 2.53 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 7.95 (dd, J = 8.84, 2.53 Hz, 1 H) 7.73 (d, J = 1.26 Hz, 1H) 7.29 (s, 1 H) 7.19 (d, J = 1.26 Hz, 1 H) 6.93 (d, J = 8.84 Hz, 1 H)5.87 (s, 1 H) 4.85 (dt, J = 13.20, 6.66 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s,1 H) 4.18 (d, J = 12.38 Hz, 1 H) 4.07 (s, 1 H) 3.93 (dd, J = 11.37, 2.27Hz, 1 H) 3.54-3.64 (m, 2 H) 2.82 (td, J = 12.25, 3.54 Hz, 1 H) 2.52-2.56 (m, 1 H) 2.22-2.26 (m, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.44 (s, 3H) 1.42 (s, 3 H) 1.18 (d, J = 6.32 Hz, 3 H) 528.3 252

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-(7-oxo-5,6,7,8- tetrahydro-1,8-naphthyridin-3-yl)-1H- indole-4-carboxamide 11.44 (br.s., 1 H) 10.53(br.s., 1 H) 8.48 (d, J = 2.27 Hz, 1 H) 8.11-8.22 (m, 1 H) 8.01 (d, J =2.27 Hz, 1 H) 7.82 (d, J = 1.26 Hz, 1 H) 7.34 (s, 1 H) 7.25 (d, J = 1.26Hz, 1 H) 5.90 (s, 1 H) 4.88 (quin, J = 6.69 Hz, 1 H) 4.37 (br.s., 1 H)4.36 (br.s., 1 H) 2.98 (t, J = 7.58 Hz, 2 H) 2.53-2.57 (m, 4 H) 2.17 (s,3 H) 2.12 (s, 3 H) 1.53-1.62 (m, 2 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 0.94(t, J = 7.45 Hz, 3 H) 526.2 253

N-[(6-amino-4-methyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4-carboxamide 10.47 (br.s., 1 H) 8.50 (d, J =2.53 Hz, 1 H) 7.98 (br.s., 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.71-7.74 (m, 1 H) 7.26 (s, 1 H) 7.16 (d, J = 1.26 Hz, 1 H) 6.92 (d, J =9.09 Hz, 1 H) 5.76 (s, 2 H) 5.16 (br.s., 1 H) 4.57-4.65 (m, 1 H) 4.26(br.s., 1 H) 4.25 (br.s., 1 H) 3.52 (br.s., 4 H) 2.42 (br.s., 4 H) 2.23(s, 3 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.81 (td, J = 7.20, 3.03 Hz, 2 H)1.41 (d, J = 6.82 Hz, 3 H) 0.73 (t, J = 7.20 Hz, 3 H) 542.6 254

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-1-isopropyl-3-methyl-6-(pyridazin- 4-yl)-1H-indole-4- carboxamide 11.10-11.70 (br.s,1H), 9.77 (dd, J = 1.26, 2.53 Hz, 1H), 9.22 (dd, J = 1.14, 5.43 Hz, 1H),8.30 (br.s., 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.09 (dd, J = 2.53, 5.56Hz, 1H), 7.42-7.54 (m, 2H), 5.87 (s, 1H), 4.96 (quin, J = 6.63 Hz, 1H),4.36 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.11 (s, 3H),1.45 (d, 6H) 430.3 255

N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3-yl) methyl)-3-fluoro-1-isopropyl-6-(6-(4- methylpiperazin-1-yl) pyridin-3-yl)-1H-indole-4-carboxamide 11.48 (d, J = 11.87 Hz, 1H), 8.54 (d, J = 2.53 Hz,1H), 8.19 (t, J = 5.05 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, J = 2.53, 8.84Hz, 1H), 7.86 (s, 1H), 7.58 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.01 Hz,1H), 6.94 (d, J = 8.84 Hz, 1H), 5.88 (s, 1H), 4.86- 5.03 (m, J = 7.07Hz, 1H), 4.36 (d, J = 4.80 Hz, 2H), 3.48-3.59 (m, 4H), 2.44 (t, J = 4.93Hz, 4H), 2.23 (d, J = 10.36 Hz, 6H), 2.12 (s, 3H), 1.42 (d, 6H) 531.4256

(R)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-3-methyl-6-(6-(4-methylpiperazin- 1-yl)pyridin-3-yl)-1- (tetrahydrofuran-3-yl)-1H-indole-4- carboxamide 2.02-2.13 (m, 4 H), 2.15 (s, 3 H), 2.19- 2.28(m, 6 H), 2.37-2.49 (m, 5 H), 3.45-3.59 (m, 4 H), 3.77-3.89 (m, 2 H),3.94-4.01 (m, 1 H), 4.01-4.11 (m, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 5.33(dd, J = 7.96, 5.68 Hz, 1 H), 5.87 (s, 1 H), 6.93 (d, J = 8.84 Hz, 1 H),7.15-7.26 (m, 2 H), 7.81 (d, J = 1.26 Hz, 1 H), 7.93 (dd, J = 8.84, 2.53Hz, 1 H), 8.16 (t, J = 5.05 Hz, 1 H), 8.52 (d, J = 2.53 Hz, 1 H), 11.47(s, 1 H) 555.6 257

(S)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-(1-methoxypropan-2-yl)-3- methyl-6-(6-(piperazin- 1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 1.34-1.48 (m, 3 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 2.76-2.86 (m, 4 H), 3.34 (s, 3 H), 3.40-3.48 (m, 4 H),3.53-3.69 (m, 2 H), 4.35 (d, J = 5.05 Hz, 2 H) 4.84-4.98 (m, 1 H), 5.87(s, 1 H), 6.88 (d, J = 8.84 Hz, 1 H), 7.18 (d, J = 1.26 Hz, 1 H), 7.27(d, J = 1.01 Hz, 1 H), 7.74 (d, J = 1.26 Hz, 1 H), 7.87-7.96 (m, 1 H),8.17 (t, J = 5.05 Hz, 1 H), 8.44- 8.54 (m, 1 H) 543.5 258

6-bromo-1-(1- ethylpropyl)-3-methyl- N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.48(br.s., 1 H) 8.24 (br.s., 1 H) 7.79 (s, 1 H) 7.28 (s, 1 H) 6.98 (s, 1 H)5.89 (s, 1 H) 4.33 (d, J = 4.29 Hz, 2 H) 4.21- 4.29 (m, 1 H) 2.58-2.55(m, 2 H) 2.14 (d, J = 9.85 Hz, 6 H) 1.74-1.82 (m, 4 H) 1.55 (br.s., 2 H)0.94 (t, J = 7.07 Hz, 3 H) 0.64 (t, J = 7.07 Hz, 6 H) 486.3 259

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl) methyl]-1-(1-ethylpropyl)-3-methyl- 1H-indole-4- carboxamide 11.47 (br.s., 1 H) 8.26(t, J = 4.80 Hz, 1 H) 7.79 (d, J = 1.26 Hz, 1 H) 7.27 (s, 1 H) 6.99 (d,J = 1.52 Hz, 1 H) 5.86 (s, 1 H) 4.31 (d, J = 4.80 Hz, 2 H) 4.23-4.29 (m,1 H) 2.22 (s, 3 H) 2.13 (d, J = 11.62 Hz, 6 H) 1.73-1.83 (m, 4 H) 0.64(t, J = 7.33 Hz, 6 H) 458.2 260

1-(1-ethylpropyl)-3- methyl-N-[(6-methyl- 2-oxo-4-propyl-1,2-dihydro-3-pyridinyl) methyl]-6-[6-(4- methyl-1-piperazinyl)-3-pyridinyl]-1H- indole-4-carboxamide 11.49 (br.s., 1 H) 8.49 (br.s., 1H) 8.15 (br.s., 1 H) 7.90 (br.s., 1 H) 7.75 (br.s., 1 H) 7.11-7.26 (m, 2H) 6.93 (br.s., 1 H) 5.90 (br.s., 1 H) 4.37 (br.s., 3 H) 3.47-3.57 (m, 4H) 2.36-2.45 (m, 6 H) 2.10-2.25 (m, 9 H) 1.81 (br.s., 4 H) 1.58 (br.s.,2 H) 0.94 (br.s., 3 H) 0.67 (br.s., 6 H) 583.8 261

6-{3- [(dimethylamino) methyl]phenyl}-1-(1- ethylpropyl)-3-methyl-N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.37 (br.s., 1 H) 7.39-7.58 (m, 7 H) 6.95 (br.s.,1 H) 5.89 (br.s., 1 H) 4.66 (d, J = 5.31 Hz, 2 H) 4.16 (br.s., 1 H) 3.53(br.s., 2 H) 2.68-2.18 (m, 2 H) 2.31 (br.s., 9 H) 2.09 (br.s., 3 H)1.80- 1.96 (m, 4 H) 1.60-1.72 (m, 2 H) 0.98- 1.09 (m, 3 H) 0.79 (d, J =6.06 Hz, 6 H) 541.2 262

6-{3- [(dimethylamino)methyl] phenyl}N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-1- (1-ethylpropyl)-3-methyl-1H-indole-4-carboxamide 11.47 (br.s., 1 H) 8.23 (br.s., 1 H) 7.78(br.s., 1 H) 7.61 (br.s., 2 H) 7.40 (br.s., 1 H) 7.19-7.29 (m, 3 H) 5.87(br.s., 1 H) 4.33-4.45 (m, 3 H) 3.47 (br.s., 2 H) 2.24 (br.s., 3 H) 2.18(br.s., 9 H) 2.11 (br.s., 3 H) 1.75-1.90 (m, 4 H) 0.68 (br.s., 6 H)513.4 263

6-bromo-1-(1- ethylpropyl)-3-methyl- N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.48(br.s., 1 H) 8.24 (br.s., 1 H) 7.79 (s, 1 H) 7.28 (s, 1 H) 6.98 (s, 1 H)5.89 (s, 1 H) 4.33 (d, J = 4.29 Hz, 2 H) 4.21- 4.29 (m, 1 H) 2.58-2.55(m, 2 H) 2.14 (d, J = 9.85 Hz, 6 H) 1.74-1.82 (m, 4 H) 1.55 (br.s., 2 H)0.94 (t, J = 7.07 Hz, 3 H) 0.64 (t, J = 7.07 Hz, 6 H) 486.3

Example 264N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a stirred solution of6-bromo-N-((1,2-dihydro-4,6-dimethyl-2-oxopyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(2 g, 4.65 mmol) in DMF (100 mL) was added1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(1.55 g, 5.12 mmol) followed by a solution of sodium carbonate (1.23 g,11.62 mmol) in water (10 mL) and the contents were degassed with argonfor 30 min. After that PdCl₂(PPh₃)₂ (326 mg, 0.464 mmol) was added andthe contents again degassed with argon for 10 min. The reaction mixturewas stirred at reflux for 3 h. The reaction mixture was diluted withwater (100 mL) and extracted with ethyl acetate (3×150 mL). The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated to afford the crude product (2.8 g). The crude compound waspurified by column chromatography over silica gel (100-200 mesh, eluent:0-10% MeOH: DCM), and the obtained product was further triturated withdiethyl ether (100 mL) to afford the title compound as an off whitesolid (1.2 g, 50%). ¹H NMR (DMSO-d₆, 400 MHz): δ 1.493 (d, J=6.4 Hz,6H), 2.092 (s, 3H), 2.286 (s, 3H), 2.409 (s, 3H), 2.424 (s, 3H), 2.632(s, 4H), 3.621 (s, 4H), 4.603-4.685 (m, 3H), 5.880 (s, 1H), 6.606 (d,J=8.8 Hz, 1H), 7.016 (s, 1H), 7.261 (s, 1H), 7.433 (s, 1H), 7.675-7.704(dd, J=9 Hz, 2.4 Hz, 1H), 8.425 (d, J=2.0 Hz, 1H), 11.699 (brs, 1H);LCMS (ES+): 525.23 [M−H].

Example 265N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

6-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(1.9 g, 4.42 mmol),1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(1.277 g, 4.42 mmol) and potassium phosphate (tribasic) (2.81 g, 13.25mmol) were placed in a 150 mL pressure vessel followed by addition of1,4-dioxane (40 mL) and water (10.00 mL). The suspension was stirred anddegassed under N₂ for 15 min. (emulsion). Next added inPdCl₂(dppf)-CH₂Cl₂ adduct (0.361 g, 0.442 mmol) and degassed for 2 min.The reaction flask was sealed and the contents heated at reflux for 2 h.The suspension was filtered, and dioxane was removed in vacuo. Theresultant oil was partitioned between 300 mL of ethyl acetate and 100 mLof water, and the layers were separated. Decolorizing carbon was added,and after 10 min, the organic layer was filtered through short pad ofsilica. 300 mL of 1 M HCl was added and neutralized with NaOH (to pH˜9). The contents were extracted with ethyl acetate. The organic layerwas separated, washed with brine, dried over MgSO₄, filtered andconcentrated in vacuo. The product was suspended in diethyl ether andfiltered. The title compound was isolated as a yellow solid (950 mg, 41%yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.49 (br. s., 1H), 8.52 (d, J=2.27Hz, 1H), 8.15 (t, J=5.05 Hz, 1H), 7.95 (dd, J=2.53, 8.84 Hz, 1H), 7.73(d, J=1.26 Hz, 1H), 7.29 (s, 1H), 7.19 (d, J=1.52 Hz, 1H), 6.93 (d,J=9.09 Hz, 1H), 5.87 (s, 1H), 4.85 (quin, J=6.63 Hz, 1H), 4.35 (d,J=5.05 Hz, 2H), 3.49-3.63 (m, 4H), 2.81-3.02 (m, 4H), 2.24 (s, 3H), 2.16(s, 3H), 2.11 (s, 3H), 1.43 (d, J=6.57 Hz, 6H); LCMS=513.3 (MH+).

Example 2666-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide

Added sequentially to a reaction flask were6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylic acid (1.33 g, 4.29mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (1.213 g, 6.43mmol), 1-hydroxy-7-azabenzotriazole (0.875 g, 6.43 mmol), EDC (1.233 g,6.43 mmol), followed by DMSO (30 mL, via syringe) and thenN-methylmorpholine (1.886 mL, 17.15 mmol, via syringe). The contentswere sealed and stirred at room temperature and the solids graduallydissolved. The contents were stirred at room temperature for 32 h, andthen slowly diluted into 220 mL of ice-water with stirring. The contentswere stirred for 10 min, and then allowed to stand for an additional 10min. The contents were filtered and the filtered solid was washed withadditional water (50 mL). The solid was then air dried for 10 min, andthen in a vacuum oven at 50° C. for 23 h total. The product wascollected as 1.75 g (87%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.69 (t,J=7.33 Hz, 3H), 1.36 (d, J=6.57 Hz, 3H), 1.77 (dq, J=10.29, 7.09 Hz,2H), 2.12 (d, J=9.09 Hz, 6H), 2.21 (s, 3H), 4.30 (d, J=5.05 Hz, 2H),4.43-4.56 (m, 1H), 5.86 (s, 1H), 6.99 (d, J=1.52 Hz, 1H), 7.30 (s, 1H),7.77 (d, J=1.77 Hz, 1H), 8.25 (t, J=4.93 Hz, 1H), 11.49 (br. s., 1H);LCMS=444.1 (MH+).

Examples 267 and 268(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(Ex 267) and(R)-6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(Ex 268)

6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(racemic mixture, 1.9 g) was resolved by chiral HPLC (column: ChiralpakAD-H, 5 microns, 50 mm×250 mm, UV detection: 240 nM, flow rate: 100mL/min, T=20 deg C, eluent: 60:40:0.1 n-heptane:ethanol:isopropylamine(isocratic)). For each run, 100 mg of the racemic compound was dissolvedin 30 volumes (3.0 mL) of warm ethanol with a few drops ofisopropylamine added. A total of 19 runs were performed. Baselineresolution was observed for each run. The isomer that eluted at 8.3-10.1min was collected (following concentration) as a white solid, which wasdried at 50° C. (<5 mm Hg) to afford 901 mg, and was determined to bethe S isomer* (Ex. 267; chiral HPLC: >99.5% ee (no R isomer detected).The isomer that eluted at 10.8-13.0 min was collected as a white solid,which was dried at 50° C. (<5 mm Hg) to afford 865 mg, and wasdetermined to be the R isomer* (Ex. 268; chiral HPLC: 99.2% ee; 0.4% Sisomer detected). ¹H NMR and LCMS were consistent with the parentracemate.

* The absolute configuration was determined by an independent synthesisof each enantiomer from the corresponding commercially availablehomochiral alcohols via Mitsunobu reaction. The sterochemicalassignments were also consistent by vibrational circular dichroism (VCD)analysis.

Example 2691-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

Added sequentially to a reaction vial were6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(0.15 g, 0.338 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(0.127 g, 0.439 mmol), and potassium phosphate (tribasic) (0.287 g,1.350 mmol), followed by 1,4-Dioxane (3 mL) and water (0.75 mL). Thesuspension was stirred under N₂ degassing for 10 min., and then addedPdCl₂(dppf)-CH₂Cl₂ adduct (0.028 g, 0.034 mmol). The reaction vial wassealed, placed into a heat block at 95° C., and stirred for 1.5 h. Thecontents were removed from heating and allowed to cool to roomtemperature. The aq layer was removed from bottom of the reaction vialvia pipette. The reaction mixture was diluted into EtOAc (20 mL)followed by addition of 0.2 g each of Thiol-3 silicycle resin and silicagel. The volatiles were removed in vacuo and the residue dried on hi-vacfor 1 h. The contents were purified by silica gel chromatography (dryloaded, eluent: A: Dichloromethane, B: 10% (2M Ammonia in Methanol) inChloroform, Gradient B: 8-95%). The obtained solid was concentrated fromTBME and dried in vacuum oven at 45° C. for 18 h. The product wascollected as 129 mg (70%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.73 (t,J=7.33 Hz, 3H), 1.40 (d, J=6.57 Hz, 3H), 1.80 (dq, J=10.07, 7.08 Hz,2H), 2.11 (s, 3H), 2.14-2.19 (m, 3H), 2.24 (s, 3H), 2.76-2.85 (m, 4H),3.41-3.49 (m, 4H), 4.35 (d, J=5.05 Hz, 2H), 4.54-4.67 (m, 1H), 5.87 (s,1H), 6.88 (d, J=8.84 Hz, 1H), 7.17 (d, J=1.26 Hz, 1H), 7.26 (s, 1H),7.73 (d, J=1.26 Hz, 1H), 7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05Hz, 1H), 8.50 (d, J=2.53 Hz, 1H), 11.48 (br. s., 1H); LCMS MH+=527.3.

Example 270N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 30 mL microwave vial were added(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.225 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(85 mg, 0.293 mmol), 1,2-Dimethoxyethane (DME) (3 mL), water (1.000 mL)and sodium carbonate (0.338 mL, 0.675 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(14.70 mg, 0.018 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 91 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.70-0.78 (m, 3H),1.37-1.44 (m, 3H), 1.75-1.87 (m, 2H), 2.11 (s, 3H), 2.16 (s, 3H),2.22-2.27 (m, 3H), 2.77-2.85 (m, 4H), 3.41-3.49 (m, 4H), 4.35 (d, J=5.31Hz, 2H), 4.56-4.68 (m, 1H), 5.87 (s, 1H), 6.88 (d, J=8.84 Hz, 1H), 7.17(d, J=1.52 Hz, 1H), 7.26 (s, 1H), 7.73 (d, J=1.26 Hz, 1H), 7.91 (dd,J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05 Hz, 1H), 8.50 (d, J=2.53 Hz, 1H);LCMS: 527.8 (MH+).

Example 271N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 30 mL microwave vial were added(R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.225 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(85 mg, 0.293 mmol), 1,2-Dimethoxyethane (DME) (3 mL), water (1.000 mL)and sodium carbonate (0.338 mL, 0.675 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(14.70 mg, 0.018 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 90 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.73 (m, 3H), 1.41 (d,J=6.57 Hz, 3H), 1.81 (td, J=7.14, 2.91 Hz, 2H), 2.11 (s, 3H), 2.15-2.20(m, 3H), 2.24 (s, 3H), 2.77-2.83 (m, 4H), 3.41-3.49 (m, 4H), 4.35 (d,J=5.05 Hz, 2H), 4.54-4.68 (m, 1H), 5.87 (s, 1H), 6.88 (d, J=8.84 Hz,1H), 7.17 (d, J=1.52 Hz, 1H), 7.26 (s, 1H), 7.73 (d, J=1.26 Hz, 1H),7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05 Hz, 1H), 8.50 (d, J=2.27Hz, 1H); LCMS: 527.7 (MH+).

Example 2721-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-((dimethylamino)methyl)phenyl)-3-methyl-1H-indole-4-carboxamide

Added sequentially to a reaction vial were6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(0.15 g, 0.338 mmol),N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine-hydrochloride(0.131 g, 0.439 mmol) and potassium phosphate (tribasic) (0.287 g, 1.350mmol), followed by 1,4-Dioxane (4 mL) and water (0.75 mL). Thesuspension was stirred under N₂ degassing for 10 min., and then addedPdCl₂(dppf)-CH₂Cl₂ adduct (0.028 g, 0.034 mmol). The reaction vial wassealed, placed into a heat block at 95° C., and stirred for 1.5 h. Thecontents were removed from heating and allowed to cool to roomtemperature. The aq layer was removed from bottom of the reaction vialvia pipette. The reaction mixture was diluted into EtOAc (20 mL)followed by addition of 0.2 g each of Thiol-3 silicycle resin and silicagel. The volatiles were removed in vacuo and the residue dried on hi-vacfor 1 h. The contents were purified by silica gel chromatography (dryloaded, eluent:A:Dichloromethane, B: 10% (2M Ammonia in Methanol) inChloroform; Gradient B: 8-95%). The obtained solid was concentrated fromTBME to afford a foam, and was dried in vacuum oven at 45° C. for 18 h.The product was collected as 116 mg (65%). ¹H NMR (400 MHz, DMSO-d6) δppm 0.73 (t, J=7.33 Hz, 3H), 1.41 (d, J=6.57 Hz, 3H), 1.82 (dq, J=9.85,7.16 Hz, 2H), 2.08-2.12 (m, 3H), 2.15-2.21 (m, 9H), 2.24 (s, 3H),3.44-3.49 (m, 2H), 4.35 (d, J=5.05 Hz, 2H), 4.57-4.70 (m, 1H), 5.86 (s,1H), 7.19-7.26 (m, 2H), 7.30 (s, 1H), 7.36-7.44 (m, 1H), 7.58-7.65 (m,2H), 7.76 (d, J=1.26 Hz, H), 8.21 (t, J=5.05 Hz, 1H), 11.47 (s, 1H);LCMS M+H=499.3.

Example 2736-{3-[(Dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-1H-indole-4-carboxamide

(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.23 mmol),N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine,HCl (100 mg, 0.34 mmol) and Palladium Tetrakis (26 mg, 0.023 mmol) inDMF/water (3 ml:1 ml) were stirred for 10 min under nitrogen. Cesiumcarbonate (220 mg, 0.68 mmol) was added and the insoluble mixture wasirradiated (microwave) at 150° C. for 15 min. The contents wereevaporated, dissolved in DCM/MeOH (1:1), and pre-absorbed on silica geland purified using silica gel chromatography (eluent: DCM/MeOH/NH₄OH,gradient 0 to 80:20:2 in DCM). The isolated product was first treatedwith EtOAc along with some hexanes. The product was then dissolved inMeOH and purified by reverse-phase HPLC (30×100 Varian Polaris C₁₈column, eluent: 10-80% gradient of MeCN in water with 0.1% TFA). Theproduct fractions were combined, most of the solvent was evaporated, anda sat. solution of NaHCO₃ was added. Solids that crashed out werefiltered, air-dried for 15 min, and dried in vacuum-oven overnight. Thesolid product was collected as 87 mg (75%). ¹H NMR (400 MHz, DMSO-d6) δppm 11.38 (br. s., 1H), 8.23 (t, J=4.67 Hz, 1H), 7.77 (d, J=1.01 Hz,1H), 7.60-7.64 (m, 2H), 7.40 (t, J=7.58 Hz, 1H), 7.30 (s, 1H), 7.20-7.26(m, 2H), 5.87 (s, 1H), 4.59-4.68 (m, 1H), 4.36 (s, 1H), 4.35 (s, 1H),3.46 (s, 2H), 2.24 (s, 3H), 2.18 (s, 9H), 2.11 (s, 3H), 1.76-1.88 (m,2H), 1.41 (d, J=6.57 Hz, 3H), 0.74 (t, J=7.33 Hz, 3H); LCMS: 499.4(MH+).

Example 2746-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-1H-indole-4-carboxamide

(R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.23 mmol),N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine,HCl (100 mg, 0.34 mmol) and Palladium Tetrakis (26 mg, 0.023 mmol) inDMF/water (3 mL:1 mL) were stirred for 10 min under nitrogen. Cesiumcarbonate (220 mg, 0.68 mmol) was added and the insoluble mixture wasirradiated (microwave) at 150° C. for 15 min. The contents wereevaporated, dissolved in DCM/MeOH (1:1), and pre-absorbed on silica geland purified using silica gel chromatography (eluent: DCM/MeOH/NH₄OH,gradient 0 to 80:20:2 in DCM). The isolated product was first treatedwith EtOAc along with some hexanes. The product was then dissolved inMeOH and purified by reversed-phase HPLC (30×100 Varian Polaris C₁₈column, eluent: 10-80% gradient of MeCN in water with 0.1% TFA). Theproduct fractions were combined, most of the solvent was evaporated, anda sat. solution of NaHCO₃ was added. Solids that crashed out werefiltered, air-dried for 15 min, and dried in vacuum-oven overnight. Thesolid product was collected as 85 mg (75%). ¹H NMR (400 MHz, DMSO-d6) δppm 11.48 (s, 1H) 8.21 (t, J=5.05 Hz, 1H) 7.77 (d, J=1.26 Hz, 1H)7.60-7.66 (m, 2H) 7.41 (t, J=7.58 Hz, 1H) 7.30 (s, 1H) 7.25 (d, J=7.58Hz, 1H) 7.22 (d, J=1.52 Hz, 1H) 5.87 (s, 1H) 4.60-4.68 (m, 1H) 4.36 (s,1H) 4.35 (s, 1H) 3.49 (br. s., 2H) 2.24 (s, 3H) 2.19 (d, J=8.84 Hz, 9H)2.11 (s, 3H) 1.77-1.88 (m, 2H) 1.41 (d, J=6.57 Hz, 3H) 0.74 (t, J=7.33Hz, 3H); LCMS: 499.4 (MH+).

Example 2751-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a 30 mL microwave vial were added6-bromo-1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(80 mg, 0.175 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(65.9 mg, 0.228 mmol), 1,2-Dimethoxyethane (DME) (3 mL), Water (1.000mL) and sodium carbonate (0.263 mL, 0.526 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(11.45 mg, 0.014 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 72 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 1.65-1.89 (m, 6H),2.08-2.19 (m, 8H), 2.24 (s, 3H), 2.76-2.84 (m, 4H), 3.40-3.48 (m, 4H),4.35 (d, J=5.05 Hz, 2H), 4.92-5.04 (m, 1H), 5.87 (s, 1H), 6.88 (d,J=8.84 Hz, 1H), 7.19 (d, J=1.26 Hz, 1H), 7.25 (s, 1H), 7.74 (d, J=1.26Hz, 1H), 7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.15 (t, J=5.05 Hz, 1H), 8.51(d, J=2.53 Hz, 1H); LCMS: 539.8 (MH+).

Some examples were prepared as above from a boronic acid (or boronate)containing a Boc-protected amine. These examples required removal of theBoc-protecting group to provide the title compounds.

Example 2761-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a suspension of 1,1-dimethylethyl4-{5-[1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinyl}-1-piperazinecarboxylate(70 mg, 0.112 mmol) in dichloromethane (2 mL) was added TFA (0.5 ml,6.49 mmol), and the mixture was stirred for 1 h. The mixture wasconcentrated and the residue was treated with saturated aqueous NaHCO3solution and filtered. The solid was purified using columnchromatography (silica gel, 0 to 15% (9:1 MeOH/NH4OH)/CH2Cl2) to give1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide(51 mg, 84%) as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91(m, 3H), 1.47 (d, J=4.00 Hz, 6H), 1.53-1.60 (m, 2H), 2.14 (s, 3H),2.89-2.98 (m, 4H), 3.51-3.59 (m, 4H), 4.40 (d, J=5.05 Hz, 2H), 4.93(quin, J=6.63 Hz, 1H), 5.92 (s, 1H), 6.87 (d, J=3.03 Hz, 1H), 6.94 (d,J=8.84 Hz, 1H), 7.60 (d, J=3.03 Hz, 1H), 7.66 (d, J=1.26 Hz, 1H), 7.88(s, 1H), 8.00 (dd, J=8.84, 2.53 Hz, 1H), 8.28 (t, J=5.05 Hz, 1H), 8.58(d, J=2.27 Hz, 1H). MS: (M+H)⁺=527.2.

Examples 277-285 were prepared by the methods described above forExamples 276 or routine variations thereof, starting from the requisiteN-Boc protected material:

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 277

1-isopropyl-3-methyl-N-((6- methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)- 6-(4-(2-oxopiperazin-1-yl)phenyl)-1H-indole-4- carboxamide 0.94 (m, 3 H), 1.44 (d, J = 6.57 Hz,6 H), 1.54-1.63 (m, 2 H), 2.12 (s, 3 H), 2.18 (s, 3 H), 3.04 (t, J =5.31 Hz, 2 H), 3.41 (s, 2 H), 3.64 (t, J = 5.31 Hz, 2 H), 4.37 (d, J =5.05 Hz, 2 H), 4.87 (quin, J = 6.63 Hz, 1 H), 5.90 (s, 1 H), 7.25 (d, J= 1.26 Hz, 1 H), 7.34 (s, 1 H), 7.40 (d, J = 8.59 Hz, 2 H), 7.70-7.83(m, 3 H), 8.18 (t, J = 5.05 Hz, 1 H) 554.4 278

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-[6-(3-methyl-1-piperazinyl)-3-pyridinyl]-1H- indole-4-carboxamide 11.47 (s, 1 H) 8.50(d, J = 2.53 Hz, 1 H) 8.16 (t, J = 5.05 Hz, 1 H) 7.92 (dd, J = 8.84,2.53 Hz, 1 H) 7.73 (d, J = 1.26 Hz, 1 H) 7.26 (s, 1 H) 7.17 (d, J = 1.52Hz, 1 H) 6.92 (d, J = 9.09 Hz, 1 H) 5.87 (s, 1 H) 4.56-4.65 (m, 1 H)4.36 (s, 1 H) 4.34 (s, 1 H) 3.49-3.55 (m, 4 H) 2.40-2.44 (m, 4 H) 2.24(s, 3 H) 2.23 (s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.76-1.87 (m, 2 H)1.41 (d, J = 6.57 Hz, 3 H) 0.73 (t, J = 7.33 Hz, 3 H) 527.3 279

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1- (piperidin-4-yl)-1H-pyrazol-4-yl)-1H-indole-4- carboxamide 1.42 (m, 6 H), 1.81 (qd, J = 11.96, 4.04Hz, 2 H), 1.98 (m, 2 H), 2.12 (d, J = 6.57 Hz, 6 H), 2.24 (s, 3 H),2.55-2.66 (m, 2 H), 3.05 (d, J = 12.63 Hz, 2 H), 4.18 (tt, J = 11.49,4.04 Hz, 1 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (quin, J = 6.69 Hz, 1H), 5.87 (s, 1 H), 7.18 (d, J = 1.26 Hz, 1 H), 7.22 (d, J = 1.01 Hz, 1H), 7.71 (d, J = 1.01 Hz, 1 H), 7.89 (s, 1 H), 8.03 (t, J = 5.18 Hz, 1H), 8.24 (s, 1 H) 501.1 280

6-methyl-3-[(2-{3-methyl-1- (1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H- indol-4-yl}-2- oxoethyl)amino]-4-propyl-2(1H)-pyridinone 0.93 (t, J = 7.33 Hz, 3 H), 1.42 (d, J = 6.57 Hz, 6 H),1.56 (qt, J = 7.56, 7.36 Hz, 2 H), 2.12 (s, 3 H), 2.16 (s, 3 H),2.52-2.58 (m, 2 H), 2.77-2.90 (m, 4 H), 3.42-3.51 (m, 4 H), 4.36 (d, J =5.05 Hz, 2 H), 4.84 (dt, J = 13.20, 6.66 Hz, 1 H), 5.90 (s, 1 H), 6.89(d, J = 8.84 Hz, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.29 (s, 1 H), 7.72(s, 1 H), 7.91 (dd, J = 8.84, 2.53 Hz, 1 H), 8.12 (t, J = 4.93 Hz, 1 H),8.49 (d, J = 2.27 Hz, 1 H), 11.49 (br.s., 1 H) 541.5 281

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2- (piperazin-1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide 11.47 (br.s., 1 H), 8.75 (s, 2 H), 8.13 (t,J = 5.1 Hz, 1 H), 7.76 (d, J = 1.5 Hz, 1 H), 7.30 (s, 1 H), 7.19 (d, J =1.3 Hz, 1 H), 5.87 (s, 1 H), 4.83 (m, 1 H), 4.34 (d, J = 5.1 Hz, 2 H),3.71 (m, 4 H), 2.77 (m, 4 H), 2.24 (s, 3 H), 2.15 (s, 3 H), 2.11 (s, 3H), 1.42 (d, J = 6.6 Hz, 6 H) 514.2 282

3-methyl-1-(1-methylethyl)- N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(1H- pyrazol-4-yl)-1H-indole-4- carboxamide 12.85(br.s., 1 H), 11.49 (br.s., 1 H), 8.01 (t, J = 5.2 Hz, 3 H), 7.72 (d, J= 1.3 Hz, 1 H), 7.20 (m, 2 H), 5.90 (s, 1 H), 4.78 (quin, J = 6.6 Hz, 1H), 4.35 (d, J = 5.1 Hz, 2 H), 2.55 (m, 2 H), 2.11 (m, 6 H), 1.57 (sxt,J = 7.5 Hz, 2 H), 1.42 (d, J = 6.6 Hz, 6 H), 0.94 (m, 3 H) 446.0 283

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(5- (piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide 11.48 (br.s., 1 H), 8.36 (d, J = 1.8 Hz, 1 H),8.20 (m, 2 H), 7.84 (d, J = 1.3 Hz, 1 H), 7.55 (t, J = 2.3 Hz, 1 H),7.35 (d, J = 1.0 Hz, 1 H), 7.26 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H),4.91 (quin, J = 6.6 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (m, 4 H),2.88 (m, 4 H), 2.24 (s, 3 H), 2.16 (s, 3 H), 2.11 (s, 3 H), 1.43 (d, J =6.6 Hz, 6 H) 513.3 284

4-[4-({[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1- methylethyl)-1H-indol-6-yl]- L-phenylalanine11.48 (br.s., 1 H) 8.18 (t, J = 4.93 Hz, 1 H) 7.75 (s, 1 H) 7.70 (d, J =8.08 Hz, 2 H) 7.31-7.37 (m, 3 H) 7.24 (s, 1 H) 5.87 (s, 1 H) 4.89-4.82(m, 1 H) 4.35 (d, J = 4.80 Hz, 2 H) 3.85 (br.s., 1 H) 2.97-3.22 (m, 2 H)2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H)515.3 285

6-[6-(aminomethyl)-3- pyridinyl]-N-[(4,6-dimethyl- 2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl- 1-(1-methylethyl)-1H- indole-4-carboxamide11.47 (br.s., 1 H) 8.37 (s, 1 H) 8.13 (br.s., 1 H) 7.79-7.76 (m, 1 H)7.66 (s, 1 H) 7.26 (s, 1 H) 7.14 (s, 1 H) 6.53 (d, J = 8.34 Hz, 2 H)5.87 (br.s., 1 H) 4.88-4.75 (m, 1 H) 4.35 (d, J = 4.04 Hz, 2 H) 2.81 (d,J = 4.29 Hz, 3 H) 2.24 (s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.43 (d, J =6.32 Hz, 6 H) 458.3

Some examples were prepared as above from a boronic acid (or boronate)containing an alkyl ester. These examples required saponification of theester to provide the corresponding carboxylic acids.

Example 2864-[4-({[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoicacid

To a solution of methyl4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoate(30 mg, 0.062 mmol) in MeOH (2 mL) and THF (1 mL) was 3 N NaOH (0.031mL, 0.185 mmol). The reaction was heated at 50° C. for 12 h, at whichtime it was allowed to cool to ambient temperature and treated withacidic ice water to bring pH to 6. The solid was filtered and washedseveral times with water and an 8:2 mixture of acidic (pH2) icewater:MeOH. Purification by reverse phase Gilson HPLC (10-80%,acetonitrile/water+0.1% TFA, YMC ODS-A C₁₈ Column 75×30 mm ID S-5 um, 12nM Column 7 minutes) provided the title compound (12 mg, 0.024 mmol,39.5% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm12.91 (br. s., 1H) 11.48 (br. s., 1H) 8.23 (t, J=5.05 Hz, 1H) 8.02 (d,J=8.34 Hz, 3H) 7.87-7.94 (m, 4H) 7.38 (s, 1H) 7.32 (d, J=1.52 Hz, 1H)5.87 (s, 1H) 4.91 (quin, J=6.63 Hz, 1H) 4.36 (d, J=4.80 Hz, 2H) 2.24 (s,3H) 2.18 (s, 3H) 2.11 (s, 3H) 1.44 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺486.1.

Examples 287-288 were prepared by the methods described above forExample 286, or routine variations thereof, starting from the requisitealkylester

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 287

3-[3-methyl-1-(1-methylethyl)- 4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino}carbon- yl)-1H-indol-6-yl]benzoicacid 13.07 (br.s., 1 H) 11.49 (br.s., 1 H) 8.27 (s, 1 H) 8.23 (t, J =4.67 Hz, 1 H) 8.00 (d, J = 8.08 Hz, 1 H) 7.90 (d, J = 7.58 Hz, 1 H) 7.84(s, 1 H) 7.59 (t, J = 7.71 Hz, 1 H) 7.36 (s, 1 H) 7.26 (s, 1 H) 5.90 (s,1 H) 4.98-4.95 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 2.56 (d, J = 7.58 Hz,2 H) 2.19 (s, 3 H) 2.12 (s, 3H) 1.54-1.62 (m, 2 H) 1.44 (d, J = 6.57 Hz,6 H) 0.94 (t, J = 7.33 Hz, 3 H) 500.1 288

5-[3-methyl-1-(1-methylethyl)- 4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino}carbon- yl)-1H-indol-6-yl]-2-pyridinecarboxylic acid 13.22 (br.s., 1 H) 11.51 (br.s., 1 H) 9.11(br.s., 1 H) 8.31-8.38 (m, 1 H) 8.23 (br.s., 1 H) 8.12 (br.s., 1 H) 8.02(br.s., 1 H) 7.42 (br.s., 1 H) 7.37 (br.s., 1 H) 5.91 (br.s., 1 H)4.88-4.98 (m, 1 H) 4.38 (br.s., 2 H) 2.55-2.61 (m, 2 H) 2.19 (br.s., 3H) 2.12 (br.s., 3 H) 1.54- 1.62 (m, 2 H) 1.46 (br.s., 6 H) 0.90- 0.99(m, 3 H) 501.1

Example 289N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

To a flask under N₂ atmosphere was added 10% palladium on carbon (0.028g, 0.026 mmol) and ethanol (1 mL) (to wet catalyst). The flask was thencharged with6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.11 g, 0.264 mmol), ethanol (4 mL) and tetrahydrofuran (1 mL). Thesuspension was stirred under N₂, then evacuated and refilled with H₂(balloon) and stirred overnight. The reaction was then placed back underN₂ and diluted with 10% methanol/dichloromethane. Celite was added andthe mixture was stirred for 15 min, filtered through a pad of Celite,washed with 10% methanol/dichloromethane, and concentrated. The residuewas dissolved in dimethylsulfoxide and acetonitrile (with 0.1%trifluoroacetic acid and purified by Gilson prep HPLC (Sunfire 30×75 mm;Gradient B: 15-75%; A: water+0.1% TFA; B: acetonitrile+0.1% TFA). Theresulting residue was dissolved in 10% methanol/dichloromethane andtreated with Silicycle carbonate resin (1.5 g). The mixture was stirredfor 30 min, filtered through Celite, washed with 10%methanol/dichloromethane, and concentrated. The residue was dissolved indichloromethane and treated with methyl-t-butylether. The solvents wereremoved by via N₂ stream and the solids dried in a vacuum oven at 45° C.for 18 h to giveN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(56 mg, 0.159 mmol, 60% yield).

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.48 (m, 6H) 2.09-2.15 (m, 3H) 2.24(s, 3H) 4.35 (d, J=5.31 Hz, 2H) 4.79 (quin, J=6.63 Hz, 1H) 5.88 (s, 1H)6.84 (d, J=3.03 Hz, 1H) 7.11-7.18 (m, 1H) 7.39 (d, J=6.57 Hz, 1H) 7.58(d, J=3.28 Hz, 1H) 7.65 (d, J=8.34 Hz, 1H) 8.08 (t, J=5.31 Hz, 1H) 11.54(br. s., 1H). MS(ES) [M+H]⁺ 338.6.

Examples 290-295 were prepared by the methods described above forExample 289, or routine variations thereof, starting from the requisite6-haloindole, alkene, or CBz-protected amine:

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 290

N-((4-benzyl-6-methyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H- indole-4-carboxamide 11.60 (br.s., 1 H)8.10-8.20 (m, 1 H) 7.66 (d, J = 8.34 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H)7.40 (d, J = 7.07 Hz, 1 H) 7.14- 7.31 (m, 6 H) 6.85 (d, J = 3.03 Hz, 1H) 5.82 (s, 1 H) 4.80 (quin, J = 6.69 Hz, 1 H) 4.44 (s, 1 H) 4.42 (s, 1H) 4.01 (s, 2 H) 2.10 (s, 3 H) 1.47 (s, 3 H) 1.45 (s, 3 H) 413.9 291

N-((4-benzyl-6-methyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3- methyl-1H-indole-4- carboxamide 11.55 (s, 1 H)8.08 (t, J = 5.18 Hz, 1 H) 7.50 (d, J = 7.83 Hz, 1 H) 7.20-7.33 (m, 6 H)7.04-7.08 (m, 1 H) 6.90 (d, J = 7.07 Hz, 1 H) 5.79 (s, 1 H) 4.72 (quin,J = 6.63 Hz, 1 H) 4.41 (d, J = 5.31 Hz, 2 H) 3.99 (s, 2 H) 2.15 (s, 3 H)2.09 (s, 3 H) 1.42 (s, 3 H) 1.40 (s, 3 H) 427.8 292

1-cyclopentyl-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4- carboxamide 11.47 (br.s., 1 H) 7.99 (t, J = 4.93Hz, 1 H) 7.51 (d, J = 7.83 Hz, 1 H) 7.24 (s, 1 H) 7.06 (t, J = 7.71 Hz,1 H) 6.93 (d, J = 6.82 Hz, 1 H) 5.87 (s, 1 H) 4.86 (d, J = 7.33 Hz, 1 H)4.33 (s, 1 H) 4.32 (s, 1 H) 2.23 (s, 3 H) 2.07-2.16 (m, 8 H) 1.76-1.86(m, 4 H) 1.69 (d, J = 3.54 Hz, 2 H) 378.3 293

6-methyl-3-({2-[3-methyl-1- (1-methylethyl)-6-(4-piperidinyl)-1H-indol-4-yl]-2- oxoethyl}amino)-4-propyl-2(1H)-pyridinone 0.93 (t, J = 7.33 Hz, 3 H), 1.39 (d, J = 6.57 Hz, 6 H),1.48-1.64 (m, 4 H), 1.68 (br.s., 2 H), 2.12 (s, 6 H), 2.54 (m, 4 H),3.01 (d, J = 11.87 Hz, 2 H), 3.16 (d, J = 4.55 Hz, 1 H), 4.33 (d, J =5.05 Hz, 2 H), 4.70 (dt, J = 13.20, 6.66 Hz, 1 H), 5.89 (s, 1 H), 6.82(s, 1 H), 7.19 (s, 1 H), 7.30 (s, 1 H), 7.93 (t, J = 4.80 Hz, 1 H), 8.55(s, 1 H) 463.1 294

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-[6-(2-piperidinyl)-3-pyridinyl]-1H-indole-4- carboxamide 1H NMR (400 MHz, METHANOL- d4) δ ppm1.51-1.53 (d, 6 H) 1.82- 1.84 (m, 3 H) 1.99-2.05 (m, 2 H) 2.24- 2.26 (d,J = 7.83 Hz, 6 H) 2.26-2.31 (m, 1 H) 2.46 (s, 3 H) 3.13-3.25 (m, 1 H)3.52-3.55 (m, 1 H) 4.36-4.49 (m, 1 H) 4.58 (s, 2 H) 4.83-4.89 (m, 1 H)6.15 (s, 1 H) 7.30 (s, 1 H) 7.39 (s, 1 H) 7.52- 7.54 (d, J = 8.08 Hz, 1H) 7.80 (s, 1 H) 8.19-8.22 (dd, J = 8.08, 2.02 Hz, 1 H) 8.99-9.00 (d, J= 1.77 Hz, 1 H) 512.3 295

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 1H-indole-4-carboxamide 11.47 (s, 1 H) 7.99(t, J = 5.05 Hz, 1 H) 7.49 (d, J = 8.08 Hz, 1 H) 7.28 (s, 1 H) 7.04-7.09(m, 1 H) 6.92 (d, J = 6.32 Hz, 1 H) 5.87 (s, 1 H) 4.71 (quin, J = 6.63Hz, 1 H) 4.33 (s, 1 H) 4.32 (s, 1 H) 2.23 (s, 3 H) 2.14 (s, 3 H) 2.11(s, 3 H) 1.42 (s, 3 H) 1.40 (s, 3 H) 352.2

Example 2961-Cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide

To a vial under a stream of N2 was added copper(II)trifluoromethanesulfonate (0.084 g, 0.233 mmol), sodium methanesulfinate(0.056 g, 0.467 mmol), DMSO (1.3 mL), and N,N-dimethyletylene diamine(0.053 mL, 0.490 mmol). The deep blue reaction was stirred for 5 min,then was added6-bromo-1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide(0.10 g, 0.233 mmol). The vial was sealed and heated at 120° C. for 3 h,at which time it was diluted with water (50 ml). The mixture wasextracted with 30% THF/EtOAc (2×) (needed to warm to break up emulsion).Combined organics, dried over magnesium sulfate, filtered throughCelite, and concentrated. Purification of the residue by columnchromatography (12 gram Isco GOLD silica column; gradient B:5-85%;A:dichloromethane, B:10% (2 M ammonia in MeOH) in chloroform) provided1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide(83 mg, 0.184 mmol, 79% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 11.50 (s, 1H), 8.38 (t, J=5.1 Hz, 1H), 8.06 (d, J=1.8 Hz,1H), 7.46 (dd, J=7.8, 1.3 Hz, 2H), 5.87 (s, 1H), 4.34 (d, J=5.1 Hz, 2H),3.52 (tt, J=7.0, 3.6 Hz, 1H), 3.20 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H),2.14 (s, 3H), 1.09 (m, 2H), 0.96 (m, 2H). MS(ES) [M+H]⁺ 427.8.

Examples 297-302 were prepared by the methods described above forExample 296, or routine variations thereof, starting from the requisite6-bromoindole:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 297

1-cyclopentyl-6- (cyclopropylsulfonyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro- 3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide 11.49 (s, 1 H), 8.39 (t, J = 4.9 Hz, 1 H), 8.04(d, J = 1.5 Hz, 1 H), 7.61 (s, 1 H), 7.35 (d, J = 1.5 Hz, 1 H), 5.87 (s,1 H), 5.03 (t, J = 6.9 Hz, 1 H), 4.34 (d, J = 4.8 Hz, 2 H), 2.85 (m, 1H), 2.23 (s, 3 H), 2.14 (m, 8 H), 1.81 (m, 4 H), 1.74 (m, 2 H), 1.13 (m,2 H), 1.00 (m, 2 H) 481.9 298

1-cyclopentyl-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl- 6-(methylsulfonyl)-1H-indole-4-carboxamide 11.50 (s, 1 H), 8.36 (t, J = 4.9 Hz, 1 H), 8.09 (d, J =1.5 Hz, 1 H), 7.61 (s, 1 H), 7.40 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H),5.01 (t, J = 7.1 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (s, 3 H),2.23 (s, 3 H), 2.15 (m, 8 H), 1.78 (m, 6 H) 455.9 301

1-cyclopentyl-6- (cyclopropylsulfonyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro- 3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide 11.49 (s, 1 H), 8.39 (t, J = 4.9 Hz, 1 H), 8.04(d, J = 1.5 Hz, 1 H), 7.61 (s, 1 H), 7.35 (d, J = 1.5 Hz, 1 H), 5.87 (s,1 H), 5.03 (t, J = 6.9 Hz, 1 H), 4.34 (d, J = 4.8 Hz, 2 H), 2.85 (m, 1H), 2.23 (s, 3 H), 2.14 (m, 8 H), 1.81 (m, 4 H), 1.74 (m, 2 H), 1.13 (m,2 H), 1.00 (m, 2 H) 481.9 302

1-cyclopentyl-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl- 6-(methylsulfonyl)-1H-indole-4-carboxamide 11.50 (s, 1 H), 8.36 (t, J = 4.9 Hz, 1 H), 8.09 (d, J =1.5 Hz, 1 H), 7.61 (s, 1 H), 7.40 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H),5.01 (t, J = 7.1 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (s, 3 H),2.23 (s, 3 H), 2.15 (m, 8 H), 1.78 (m, 6 H) 455.9

Example 303N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide

a) 4-Bromo-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole

To a solution of 4-bromo-6-(trifluoromethyl)-1H-indole (1 g, 3.79 mmol)in DMF (6 mL) was added 60% sodium hydride (0.182 g, 4.54 mmol), and themixture was stirred for 30 min 2-bromopropane (0.533 mL, 5.68 mmol) wasadded and the mixture was stirred overnight. The reaction was thenquenched with 10% NaHCO3 and extracted with EtOAc (3×). The extract wasdried over Na2SO4 and concentrated. The residue was purified usingcolumn chromatography (Silica gel, 0 to 100% EtOAc/hexanes) to give thetitle compound (460 mg, 40%) as white solid. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.56-1.61 (m, 6H), 4.66-4.79 (m, 1H), 6.65 (d,J=3.03 Hz, 1H), 7.27-7.31 (m, 1H), 7.45 (d, J=3.03 Hz, 1H), 7.54 (s,1H), 7.63 (s, 1H). MS: (M+H)⁺=306.2.

b) 1-Isopropyl-6-(trifluoromethyl)-1H-indole-4-carbonitrile

To a 10-mL microwave tube were added4-bromo-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole (330 mg, 1.078mmol), dicyanozinc (146 mg, 1.240 mmol), DMF (4 mL) and water (0.040mL), and the mixture was degassed for 5 min by bubbling N₂. s-Phos (48.7mg, 0.119 mmol) and tris(dibenzylideneacetone)dipalladium(0) (49.4 mg,0.054 mmol) were added. The tube was sealed and the mixture was heatedat 120° C. for 2.5 h. 1 N NaOH (3 mL) was added and the mixture wasextracted with EtOAc (3×). The extract was dried over Na₂SO₄ andconcentrated. The residue was purified using column chromatography(Silica gel, 0 to 70% EtOAc/hexanes) to give the title compound (210 mg,77%) as white solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.61 (m, 6H),4.79 (spt, J=6.69 Hz, 1H), 6.84 (d, J=3.28 Hz, 1H), 7.59 (d, J=3.28 Hz,1H), 7.73 (s, 1H), 7.88 (s, 1H). MS: (M+H)⁺=253.2.

c) 1-Isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxylic acid

To a solution of1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carbonitrile (180 mg,0.714 mmol) in ethanol (5 mL) was added 10% sodium hydroxide (5 mL,0.714 mmol), and the mixture was heated at reflux overnight. The mixturewas concentrated to remove EtOH and the aqueous phase was acidifiedusing 1N HCl to ˜pH 4. The precipitate was collected by filtration anddried under high vacuum to give the title compound (167 mg, 86%) asbrown solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.60 (m, 6H),4.96-5.13 (m, 1H), 7.11 (d, J=3.28 Hz, 1H), 7.89-8.05 (m, 2H), 8.25 (s,1H), 13.15 (br. s., 1H). MS: (M+H)⁺=272.0.

d)N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxamide

To a solution of1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxylic acid (40mg, 0.147 mmol) in dimethyl sulfoxide (1 mL) were added3-(aminomethyl)-4,6-dimethyl-2 (1H)-pyridinone (41.7 mg, 0.221 mmol),N-methylmorpholine (0.065 mL, 0.590 mmol), 1-hydroxy-7-azabenzotriazole(40.1 mg, 0.295 mmol) and EDC (56.5 mg, 0.295 mmol), and the mixture wasstirred overnight. The mixture was quenched with water (5 mL) andstirred for 10 min. The precipitate was collected by filtration anddried under high vacuum to give the title compound (39 mg, 63%) as anoff-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.47 (m, 6H), 2.13 (s,3H), 2.23 (s, 3H), 4.36 (d, J=5.05 Hz, 2H), 4.99 (dt, J=13.20, 6.66 Hz,1H), 5.89 (s, 1H), 6.98 (d, J=3.03 Hz, 1H), 7.68 (s, 1H), 7.86 (d,J=3.28 Hz, 1H), 8.08 (s, 1H), 8.45 (t, J=4.93 Hz, 1H), 11.56 (s, 1H).MS: (M+H)⁺=406.1.

Example 3041-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide

The title compound was prepared using procedures as described forN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxamide.¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91 (t, J=8.00 Hz 3H), 1.39-1.63 (m,8H), 2.14 (s, 3H), 4.39 (d, J=5.05 Hz, 2H), 4.99 (dt, J=13.26, 6.76 Hz,1H), 5.92 (s, 1H), 6.98 (d, J=3.28 Hz, 1H), 7.68 (s, 1H), 7.87 (d,J=3.03 Hz, 1H), 8.08 (s, 1H), 8.44 (t, J=5.05 Hz, 1H), 11.57 (s, 1H).MS: (M+H)⁺=434.1.

Example 305N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)6-(4-((Dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid

To a 10-mL microwave tube were added6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (100 mg,0.338 mmol),1,4-dioxane (2 mL),N,N-dimethyl-1-(4-piperidinyl)methanamine (52.8 mg, 0.371 mmol) andsodium tert-butoxide (71.4 mg, 0.743 mmol), and the mixture was degassedfor 5 min.Choro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]Pd(11)Me-t-butyletheradduct (13.96 mg, 0.017 mmol) was added and the tube was sealed. Themixture was stirred at 98° C. with stirring for 20 h. The mixture wasthen concentrated and the residue was purified using reverse-phase HPLC(Gemini 5u C18(2) 100A, AXIA; 30×100 mm 5 micron; (30 mL/min, 7%ACN/H₂O, 0.1% formic acid to 37% ACN/H₂O, 0.1% formic acid) to give thetitle compound (65 mg, 54%) as pale yellow solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.19-1.34 (m, 2H), 1.39 (d, J=6.57 Hz, 6H), 1.58-1.71 (m,1H), 1.82 (d, J=11.87 Hz, 2H), 2.23-2.31 (m, 10H), 2.66 (td, J=11.94,1.89 Hz, 2H), 3.57-3.71 (m, 2H), 4.70 (quin, J=6.63 Hz, 1H), 7.09 (d,J=2.02 Hz, 1H), 7.15 (dd, J=9.60, 1.52 Hz, 2H). MS: (M+H)⁺=358.2.

b)N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a solution of6-{4-[(dimethylamino)methyl]-1-piperidinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (62 mg, 0.173 mmol) in dimethyl sulfoxide (1 mL) were added3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (42.5 mg, 0.225 mmol),N-methylmorpholine (0.095 mL, 0.867 mmol), 1-hydroxy-7-azabenzotriazole(47.2 mg, 0.347 mmol) and EDC (66.5 mg, 0.347 mmol), and the mixture wasstirred overnight. The mixture was purified using reverse-phase HPLC(Gemini 5u C18(2) 100A, AXIA; 30×100 mm 5 micron; 30 mL/min, 8% ACN/H₂O,0.1% formic acid to 38% ACN/H₂O, 0.1% formic acid) to give the titlecompound (52 mg, 55%) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆)ppm 1.26 (m, 2H), 1.35-1.41 (m, 6H), 1.57-1.71 (m, 1H), 1.80 (d, J=11.12Hz, 2H), 2.10 (d, J=10.36 Hz, 6H), 2.22 (s, 3H), 2.26-2.33 (m, 8H),2.57-2.72 (m, 2H), 3.61 (d, J=12.13 Hz, 2H), 4.31 (d, J=5.05 Hz, 2H),4.58-4.72 (m, 1H), 5.86 (s, 1H), 6.69 (d, J=2.02 Hz, 1H), 6.92 (d,J=1.77 Hz, 1H), 7.05 (d, J=1.01 Hz, 1H), 7.92-7.99 (m, 1H). MS:(M+H)⁺=492.1.

Examples 306-317 were prepared by the methods described above forExample 305, or routine variations thereof, using the requisite amine.

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 306

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)- 6-(3-((dimethylamino)methyl) pyrrolidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4- carboxamide 1.36 (m, 6 H), 1.68 (dd, J = 12.13, 7.58Hz, 1 H), 2.01-2.38 (m, 20 H), 2.99 (dd, J = 9.09, 6.57 Hz, 1 H),3.20-3.30 (m, 1 H), 3.35-3.44 (m, 1 H), 4.31 (d, J = 5.05 Hz, 2 H),4.53-4.67 (m, 1 H), 5.87 (s, 1 H), 6.35 (d, J = 2.02 Hz, 1 H), 6.45 (d,J = 1.77 Hz, 1 H), 6.93 (d, J = 1.01 Hz, 1 H), 7.88 (t, J = 5.18 Hz, 1H), 11.47 (s, 1 H) 478.0 307

1-cyclopentyl-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(pyrrolidin-1-yl)-1H-indole- 4-carboxamide 1.65-1.88 (m, 7 H),1.95-2.02 (m, 5 H), 2.08-2.18 (m, 6 H), 2.24 (s, 3 H), 3.29 (t, J = 6.32Hz, 4 H), 4.34 (d, J = 5.31 Hz, 2 H), 4.74-4.90 (m, 1 H), 5.89 (s, 1 H),6.59- 6.70 (m, 2 H), 6.83 (d, J = 1.77 Hz, 1 H), 7.22 (d, J = 3.28 Hz, 1H), 8.03 (t, J = 5.31 1 H) 433.2 308

6-(1,1- dioxidothiomorpholino)-1- isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide 1.06 (m, 3 H), 1.43-1.54 (m, 6 H), 1.68 (sxt, J= 7.58 Hz, 2 H), 2.19 (s, 3 H), 2.27 (s, 3 H), 2.69-2.82 (m, 2 H),3.17-3.26 (m, 4 H), 3.76-3.86 (m, 4 H), 4.52-4.58 (m, 2 H), 4.69 (dt, J= 13.39, 6.69 Hz, 1 H), 6.11-6.21 (m, 1 H), 6.88 (d, J = 2.02 Hz, 1 H),7.09 (dd, J = 11.75, 1.64 Hz, 2H) 513.2 309

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6- (pyridin-3-ylamino)-1H- indole-4-carboxamide1.39 (m, 6 H), 2.11 (d, J = 3.28 Hz, 6 H), 2.22 (s, 3 H), 4.32 (d, J =4.80 Hz, 2 H), 4.59 (dt, J = 13.14, 6.57 Hz, 1 H), 5.86 (s, 1 H), 6.76(d, J = 1.26 Hz, 1 H), 7.12-7.25 (m, 3 H), 7.41 (d, J = 8.34 Hz, 1 H),7.95 (d, J = 3.54 Hz, 1 H), 8.10 (t, J = 4.80 Hz, 1 H), 8.25 (s, 1 H),8.30-8.39 (m, 1 H), 11.47 (br.s., 1 H) 444.1 310

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)- 6-(4-(4-fluorophenyl)piperidin-1-yl)- 1-isopropyl-3-methyl-1H-indole-4-carboxamide 11.48 (s, 1H), 8.01 (br.s., 1H), 6.48-7.39 (m, 6H),5.87 (s, 1H), 4.68 (dt, J = 6.09, 12.32 Hz, 1H), 4.33 (d, J = 5.05 Hz,2H), 3.74 (d, J = 12.13 Hz, 2H), 2.23 (s, 3H), 2.11 (s, 6H), 1.89(br.s., 3H), 1.39 (d, J = 6.32 Hz, 6H) 528.9 311

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4- (4-methylpiperazin-1-yl)piperidin-1-yl)-1H-indole- 4-carboxamide 7.97 (br.s., 1H), 7.05 (s,1H), 6.92 (d, J = 1.77 Hz, 1H), 6.68 (d, J = 2.02 Hz, 1H), 5.86 (s, 1H),4.60-4.69 (m, J = 6.44, 6.44 Hz, 1H), 4.31 (d, J = 4.80 Hz, 2H), 3.65(d, J = 11.37 Hz, 2H), 3.25-3.32 (m, 4H), 2.68 (ddd, J = 1.89, 2.02,3.66 Hz, 2H), 2.62 (dd, J = 1.14, 11.24 Hz, 2H), 2.33 (dt, J = 1.77,3.54 Hz, 1H), 2.22 (s, 3H), 2.14 (s, 3H), 2.11 (s, 5H), 2.08 (s, 4H),1.80-1.91 (m, J = 10.36 Hz, 2H), 1.55 (br.s., 1H), 1.37 (d, J = 6.57 Hz,6H) 533.0 312

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4- (1-methylpiperidin-4-yl)piperazin-1-yl)-1H-indole- 4-carboxamide 7.04 (s, 1H), 7.00 (d, J =1.77 Hz, 1H), 6.87 (d, J = 2.02 Hz, 1H), 6.13 (s, 1H), 4.66 (quin, J =6.69 Hz, 1H), 4.54 (s, 2H), 3.18-3.29 (m, 4H), 3.11-3.18 (m, 1H), 2.98(d, J = 11.87 Hz, 2H), 2.76-2.85 (m, 4H), 2.43 (s, 3H), 2.27-2.35 (m,5H), 2.26 (s, 3H), 2.17 (s, 3H), 2.04-2.14 (m, 2H), 1.93-2.02 (m, 2H),1.54-1.72 (m, 2H), 1.45 (d, J = 6.57 Hz, 6H) 533.0 313

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(4-fluoropiperidin-1-yl)-1- isopropyl-3-methyl-1H-indole-4-carboxamide 7.01-7.06 (m, 2H), 6.88 (d, J = 2.02 Hz, 1H), 6.14(s, 1H), 4.81-4.88 (m, 1H), 4.59-4.71 (m, 1H), 4.54 (s, 2H), 3.09- 3.19(m, 2H), 2.44 (s, 3H), 2.26 (s, 3H), 2.17 (s, 3H), 1.88-2.15 (m, 4H),1.46 (d, J = 6.82 Hz, 6H) 452.8 314

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)- 6-(4-(3-fluorophenyl)piperidin-1-yl)- 1-isopropyl-3-methyl-1indole-4-carboxamide 8.01 (t, 1H), 7.36 (td, J = 6.32, 7.96 Hz, 1H),7.12-7.19 (m, 2H), 7.07 (d, J = 1.01 Hz, 1H), 7.00-7.06 (m, 1H), 6.98(d, J = 1.77 Hz, 1H), 6.74 (d, J = 2.02 Hz, 1H), 5.87 (s, 1H), 4.68(quin, J = 6.57 Hz, 1H), 4.32 (d, J = 5.05 Hz, 2H), 3.75 (d, J = 11.87Hz, 2H), 2.65-2.82 (m, 3H), 2.23 (s, 3H), 2.10 (d, J = 4.04 Hz, 6H),1.75- 1.96 (m, 4H), 1.38 (d, J = 6.57 Hz, 6H) 529.0 315

N-[(4-ethyl-6-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4- morpholinyl)-1H-indole-4- carboxamide 11.43(br.s., 1 H) 7.96 (t, J = 5.05 Hz, 1 H) 7.08 (d, J = 1.01 Hz, 1 H) 6.95(d, J = 2.02 Hz, 1 H) 6.70 (d, J = 2.02 Hz, 1 H) 5.91 (s, 1 H) 4.67(quin, J = 6.63 Hz, 1 H) 4.34 (s, 1 H) 4.32 (s, 1 H) 3.74-3.77 (m, 4 H)3.07- 3.11 (m, 4 H) 2.54-2.60 (m, 2 H) 2.13 (s, 3 H) 2.09 (s, 3 H) 1.38(s, 3 H) 1.37 (s, 3 H) 1.13 (t, J = 7.58 Hz, 3 H) 451.0 316

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-(4-morpholinyl)-1H-indole- 4-carboxamide11.34 (br.s., 1 H) 7.99 (t, J = 4.93 Hz, 1 H) 7.08 (s, 1 H) 6.94 (d, J =2.02 Hz, 1 H) 6.70 (d, J = 1.77 Hz, 1 H) 5.86 (s, 1 H) 4.67 (quin, J =6.57 Hz, 1 H) 4.32 (s, 1 H) 4.30 (s, 1 H) 3.72-3.80 (m, 4 H) 3.06-3.13(m, 4 H) 2.22 (s, 3 H) 2.11 (s, 3 H) 2.09 (s, 3 H) 1.38 (s, 3 H) 1.37(s, 3 H) 437.1 317

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl) 6-{[3-methyl-1-(1- methylethyl)-1H-pyrazol-5-yl]amino}-1H-indole-4- carboxamide 1.30 (m, 6 H), 1.35 (d, J = 6.82 Hz,6 H), 2.08 (s, 3 H), 2.11 (s, 3 H), 2.13 (s, 3 H), 2.21 (s, 3 H), 4.31(d, J = 5.05 Hz, 2 H), 4.37-4.49 (m, 2 H), 5.70-5.77 (m, 1 H), 5.86 (s,1 H), 6.60 (d, J = 1.77 Hz, 1 H), 6.71 (d, J = 1.77 Hz, 1 H), 6.99-7.07(m, 1 H), 7.67 (s, 1 H), 7.93-8.03 (m, 1 H), 11.46 (br.s., 1 H) 489.0

Example 3186-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

a) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester

To a cooled (0° C.) mixture of6-hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methyl ester (700 mg,3 mmol), 2-dimethylamino-ethanol (320 mg, 3.60 mmol) and PPh₃ (948 mg,3.60 mmol) in THF (10 mL) was added DEAD (620 mg, 3.60 mmol) and stirredfor 16 h at RT. Reaction mixture was concentrated under reduced pressureand the residue was purified by column chromatography by eluting with 2%MeOH in chloroform to afford the title compound (550 mg, 60%) ascolorless gum. LCMS (ES+): m/z=305.36[M+H].

b) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid

To a solution of6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester (500 mg, 1.64 mmol) in THF (5 mL) was added LiOH.H₂O (200mg, 4.93 mmol) in water (5 mL). the reaction was heated at reflux for 5h, at which time the THF was removed under reduced pressure. Theremaining mixture was acidified with 1 N HCl (pH˜6) and extracted with10% MeOH in chloroform (4×30 mL). The combined organic layer was driedover anhydrous Na₂SO₄ and concentrated to yield6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid (400mg), which was used in the next stage without further purification. LCMS(ES+): m/z=291.30 [M+H].

c) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

To a cooled (0° C.) mixture of6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid (400mg, 1.37 mmol) in DMF (10 mL) was added EDC.HCl (310 mg, 1.65 mmol) andHOBt.H₂O (250 mg, 1.65 mmol). The reaction was stirred for 15 min, thenDIPEA (1.2 mL, 6.89 mmol) and3-aminomethyl-6-methyl-4-propyl-1H-pyridin-2-one (240 mg, 1.37 mmol)were added. The reaction was allowed to warm to RT and stirred for 16 h,at which time it was diluted with water (20 mL) and extracted with DCM(2×15 mL). The combined DCM layer was dried over Na₂SO₄ andconcentrated. The residue was purified by flash column chromatographyeluting with 3% MeOH in chloroform and then further purified bypreparative HPLC to furnish6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide (120 mg,19%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 0.92-0.88 (t,3H), 1.43-1.41 (d, J=6.8 Hz, 6H), 1.56 (m, 2H), 2.12 (s, 3H), 2.22 (s,6H), 2.55-2.53 (m, 2H), 2.06 (m, 2H), 4.11-4.09 (t, 2H), 4.36-4.34 (d,J=4.8 Hz, 2H), 4.76-4.73 (m, 1H), 5.90 (s, 1H), 6.74-6.73 (d, J=2.8 Hz,1H), 7.04 (s, 1H), 7.20 (s, 1H), 7.43-7.42 (d, J=3.2 Hz, 1H), 8.10-8.07(bs, 1H), 11.55 (bs, 1H). LCMS (ES+): m/z=453.23[M+H].

Examples 319-320 were prepared by the methods described above forExample 318, or routine variations thereof, using the requisite alcohol(Mitsunobu reaction) and aminomethylpyridone:

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 319

1-isopropyl-6-[2-(4- methyl-piperazin-1-yl)- ethoxy]-1H-indole-4-carboxylic acid (6- methyl-2-oxo-4-propyl- 1,2-dihydro-pyridin-3-ylmethyl)-amide 0.92 (t, 3H), 1.42 (d, J = 6.8 Hz, 6H), 1.57 (m, 2H),2.14 (d, 6H), 2.32 (m, 8H), 2.54 (m, 2H), 2.71 (t, 2H), 4.13-4.11 (m,2H), 4.35 (d, J = 5.2 Hz, 2H), 4.78-4.72 (m, 1H), 5.90 (s, 1H), 6.74 (d,J = 3.2 Hz, 1H), 7.05 (s, 1H), 7.22 (s, 1H), 7.42 (d, J = 3.2 Hz, 1H),8.12 (t, 1H), 11.55 (bs, 1H) 506.26 320

1-isopropyl-6-(2- morpholin-4-yl-ethoxy)- 1H-indole-4-carboxylic acid(6-methyl- 2-oxo-4-propyl-1,2- dihydro-pyridin-3- ylmethyl)-amide 0.94(t, 3H), 1.42 (d, J = 6.8 Hz, 6H), 1.57 (m, 2H), 2.14 (s, 3H), 2.46-2.50(m, 4H), 2.75 (t, 2H), 2.68-2.75 (t, 4H), 4.15-4.19 (m, 2H), 4.35 (d,2H), 4.78-4.72 (m, 1H), 5.91 (s, 1H), 6.73 (d, 1H), 7.10 (s, 1H), 7.25(s, 1H), 7.62 (d, 1H), 8.12 (t, 1H), 11.55 (bs, 1H) 495.22

Example 3211-Isopropyl-6-(2-piperazin-1-yl-ethoxy)-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

To a stirred solution of4-(2-{1-isopropyl-4-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-carbamoyl]-1H-indol-6-yloxy}-ethyl)-piperazine-1-carboxylicacid tert-butyl ester (280 mg, 0.472 mmol; prepared following theprocedure of Example xx) in dichloromethane (15 mL) was added TFA (1.5mL) at room temperature and then stirred for 3 h at room temperature.Reaction mixture was concentrated under reduced pressure, diluted withwater (20 mL) and washed the resulting aqueous layer with diethyl ether(2×15 mL). The aqueous layer was basified with (pH˜8) with saturatedaqueous NaHCO₃ solution and extracted with dichloromethane (3×20 mL).The combined organic layer was washed with brine solution (2×25 mL) andconcentrated. Purification by preparative HPLC afforded1-isopropyl-6-(2-piperazin-1-yl-ethoxy)-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide (48 mg,20%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 0.93 (t, 3H),1.42 (d, 6H, J=6.8 Hz), 1.57 (m, 2H), 2.14 (s, 3H), 2.45-2.2 (m, 4H),2.68 (t, 2H), 2.75 (t, 4H), 4.15-4.19 (m, 2H), 4.35 (d, 2H), 4.78-4.72(m, 1H), 5.91 (s, 1H), 6.73 (d, 1H), 7.03 (s, 1H), 7.24 (s, 1H), 7.42(d, 1H), 8.12 (t, 1H), 11.58 (bs, 1H). LCMS (ES+): m/z=494.57[M+H].

Example 322N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

a) 4-Chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

Using a 100 ml round bottom with reflux condenser, PCl₅ (6.7 g, 32mmol), POCl₃ (3.0 mL, 32 mmol) and 30 ml CHCl₃ (dry) were stirred for 5min (see: Heterocycles, vol. 60, No. 6, 2003, 1461-1468). Added4-hydroxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (4 g, 26.6mmol) and stirred for 2 h at 80° C. Quenched reaction while hot andpoured into 1 L beaker with 100 “g” ice, 24 mL NH₄OH, pH by paper was8-9. Stirred 5 min and filtered. Washed solid with water. Suspendedsolid in ethanol and filtered and washed with ethanol. Gave:4-chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (1.7 g, 9.58mmol, 40% yield)¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.85 (br. s., 1H) 6.53(s, 1H) 2.28 (s, 3H) MS(ES) [M+H]⁺ 168.9.

b) 4-(Ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a 10 ml microwave vial added4-chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (750 mg, 4.45mmol) and methanol (1 mL) then added ethylamine (5.56 mL, 11.12 mmol).One drop on conc. HCl was added and the vial was capped and the reactionwas microwaved to 120° C. for 1 hr. The reaction was cooled and thesolid was filtered and washed with cold MeOH. Gave4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (500mg, 2.77 mmol, 62.2% yield)¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.05 (br.s., 1H) 7.11 (br. s., 1H) 5.78 (br. s., 1H) 3.22-3.32 (m, 2H) 2.11 (s,3H) 1.10 (t, J=7.07 Hz, 3H)_MS(ES) [M+H]⁺ 177.8.

c) 1,1-Dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate

In a 250 ml, round bottom flask under N₂ added4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (500mg, 2.82 mmol) as a solid then added Methanol (50 mL) and cooled to 0°C. in an ice bath. Next di-tert-butyl dicarbonate (1.310 mL, 5.64 mmol)was added and the suspension stirred for 5 min. NickelChloride-hexahydrate (335 mg, 1.411 mmol) solid was added followed byNaBH₄ (747 mg, 19.75 mmol) as a solid (in 3 portions—allowed 1 min inbetween portions b/c it turns black and there is gas evolution). Afteraddition and stirring at 0° C. for ˜10 min the ice bath was removed andthe mix stirred at rt ON. The next morning the reaction was quenchedwith --Diethylene triamine (0.613 mL, 5.64 mmol) via syringe and the mixcontinued to stir 20 min. The reaction was diluted with EtOAc and wastreated with sat NaHCO₃ and stirred 10 min. The mixture was transferredto a sep funnel and the organic layer was separated out and washed (2×s)with sat NaHCO₃. The organic layer was concentrated in vacuo to a solid.The solid was stirred with 5% MeOH/Water (50 mL) then filtered. Thesolid was washed with 5% MeOH/Water and water (2×s) and dried to give1,1-dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate(500 mg, 1.599 mmol, 56.7% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.64(br. s., 1H) 7.08 (br. s., 1H) 6.25 (br. s., 1H) 5.64 (s, 1H) 3.96 (d,J=6.06 Hz, 2H) 3.09-3.18 (m, 2H) 2.06 (s, 3H) 1.38 (s, 9H) 1.14 (t, 3H)[M+H]⁺ 282.5.

d)6-Bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide

In a 50 mL round bottom was added 1,1-dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate(500 mg, 1.777 mmol) and Dichloromethane (DCM) (20.00 mL). TFA (1.095mL, 14.22 mmol) was added and the reaction stirred at rt for 3.5 h. TheLCMS indicated deprotection. The reaction was evaporated and evaporatedfrom DCM. Dimethyl Sulfoxide (DMSO) (20 mL) was added to the roundbottom followed by 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(501 mg, 1.777 mmol), to the solution was added N-methylmorpholine(1.172 mL, 10.66 mmol) 1-hydroxy-7-azabenzotriazole (363 mg, 2.67 mmol)and EDC (511 mg, 2.67 mmol). The reaction stirred at rt for 12 hr. Thereaction was poured onto Ice water (10 mL) and was stirred for 20 minlet it rest for 10 min and filter. Rinse solid with water (10 mL).Purification of solid by reverse phase Gilson HPLC (10-90%acetonitrile/water+0.1% TFA, YMC ODS-A C₁₈ Column 75×30 mm ID S-5 um, 12nM Column 7 minutes) provided the desired product as a white solid afterneutralization with 0.1N NaOH and evaporation and precipitation fromwater.6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide(240 mg, 0.523 mmol, 29.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.70(s, 1H) 8.87 (m, 1H) 7.93 (s, 1H) 7.57-7.71 (m, 2H) 6.89 (d, J=3.28 Hz,1H) 6.71 (m, 1H) 5.66 (s, 1H) 4.82 (m, 1H) 4.34 (d, J=5.81 Hz, 2H)3.12-3.23 (m, 2H) 2.08 (s, 3H) 1.43 (d, J=6.57 Hz, 6H) 1.18 (t, 3H)MS(ES) [M+H]⁺ 445.1.

e)N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 20 mL microwave vial was added6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide(70 mg, 0.170 mmol), and1-methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(59.9 mg, 0.198 mmol). PdCl2(dppf)-CH2C₁₂ adduct (14.67 mg, 0.018 mmol)and sodium bicarbonate (45.3 mg, 0.539 mmol) were added followed by1,2-Dimethoxyethane (DME) (5 mL) and Water (2 mL). The vial was sealedand the reaction was heated to 85° C. for 1 hr. The reaction was cooledand evaporated. The material was taken into Methanol/DMSO and wasfiltered through an acrodisk and purified by reverse phase Gilson HPLC(5-80% acetonitrile/water+0.1% TFA, YMC ODS-A C₁₈ Column 75×30 mm ID S-5um, 12 nM Column, 6 minutes) the desired fractions were collected andevaporated from 0.1N NaOH which provided the desired productN-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide(57 mg, 0.101 mmol, 56.2% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.68(s, 1H) 8.89 (t, J=5.94 Hz, 1H) 8.66 (d, J=2.02 Hz, 1H) 8.09 (dd,J=8.59, 2.02 Hz, 1H) 7.91 (s, 1H) 7.80 (s, 1H) 7.60 (d, J=3.03 Hz, 1H)6.99 (d, J=8.84 Hz, 1H) 6.89-6.96 (m, 2H) 5.66 (s, 1H) 4.85-4.98 (m, 1H)4.39 (d, J=5.81 Hz, 2H) 3.63 (br. s., 4H) 3.11-3.24 (m, 2H) 2.7 (bs, 4H)2.08 (s, 3H) 1.47 (d, J=6.57 Hz, 6H) 1.20 (t, 3H). MS(ES) [M+H]⁺ 542.4.

Examples 323-324 were prepared by the methods described above forExample 322, or routine variations thereof, using the requisite amine.

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 323

6-bromo-1-(1-methylethyl)- N-{[6-methyl-2-oxo-4-(1-pyrrolidinyl)-1,2-dihydro-3- pyridinyl]methyl}-1H-indole- 4-carboxamide10.86 (s, 1 H) 8.22 (t, J = 4.29 Hz, 1 H) 7.93 (s, 1 H) 7.64 (d, J =3.28 Hz, 1 H) 7.53 (d, J = 1.77 Hz, 1 H) 6.85 (d, J = 3.28 Hz, 1 H) 5.74(s, 1 H) 4.78-4.89 (m, 1 H) 4.42 (d, J = 4.29 Hz, 2 H) 3.43-3.54 (m, 4H) 2.09 (s, 3 H) 1.80-1.89 (m, 4 H) 1.44 (d, J = 6.57 Hz, 6 H) 473.0 324

6-bromo-1-(1-methylethyl)- N-{[6-methyl-2-oxo-4-(phenylamino)-1,2-dihydro- 3-pyridinyl]methyl}-1H- indole-4-carboxamide11.02 (s, 1 H) 9.45 (s, 1 H) 9.15-9.21 (m, 1 H) 7.96 (s, 1 H) 7.67 (dd,J = 10.11, 2.53 Hz, 2 H) 7.34-7.40 (m, 2 H) 7.15 (d, J = 7.33 Hz, 2 H)7.04-7.09 (m, 1 H) 6.91 (d, J = 3.03 Hz, 1 H) 5.91 (s, 1 H) 4.80-4.87(m, 1 H) 4.39 (d, J = 5.81 Hz, 2 H) 2.06 (s, 3 H) 1.44 (d, J = 6.57 Hz,6 H) 493.0

Example 325N-((6-Amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)tert-Butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

To a stirred solution oftert-butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.40 g, 1.496 mmol),6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (0.44 g, 1.486mmol), and HOAt (0.21 g, 1.543 mmol) in DMF (25 mL) was added EDC freebase (0.25 g, 1.610 mmol). The reaction was stirred at RT overnight thenevaporated to dryness under vacuum. The remaining was purified by silicagel chromatography (Analogix, SF25-60 g, 0 to 30% EtOAc in hexanes) togive the producttert-butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.81 g, 1.485 mmol, 99% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=9.42 (s, 1H), 8.41 (t, J=4.8 Hz, 1H), 7.77 (d, J=1.5 Hz, 1H),7.33 (s, 1H), 7.21 (s, 1H), 6.99 (d, J=1.8 Hz, 1H), 4.40 (d, J=5.1 Hz,2H), 3.81 (s, 3H), 2.35 (s, 3H), 2.10 (d, J=1.0 Hz, 3H), 1.47 (s, 9H),1.38 (d, J=6.6 Hz, 6H). MS(ES)+m/e 545.2 [M+H]⁺.

b)N-((6-Amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution oftert-butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.80 g, 1.467 mmol) in acetonitrile (20 mL) was added dropwise at RTTMSI (0.50 ml, 3.67 mmol). A reflux condenser was attached and thereaction was purged with N₂ and heated to 70° C. After stirring for 30minutes LCMS indicated that the reaction was complete (89% pure with 11%possible iodinated side product as the only other impurity). After 1 hrthe reaction was quenched with MeOH (5 mL) and stirred for 30 minutes.The clear brown solution was evaporated to dryness under vacuum, takenup in CH₂Cl₂, washed with aq. Na₂S₂O₃, (a ppt. formed that was filteredoff), dried (Na₂SO₄), filtered, and concentrated under vacuum.Purification by silica gel chromatography (Analogix, SF25-10 g, 0 to 7%(5% NH₄OH/MeOH) in CH₂Cl₂) gave the productN-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide(59.6 mg, 0.138 mmol, 9.4% yield) as a white solid. Note: The ppt. thatwas filtered off during the aq. Na₂S₂O₃ wash was later shown to containproduct. This solid was washed with water and dried under vacuum to giveadditional product as an off-white solid (602 mg, 1.4 mmol, 95%, 100%pure by LCMS). ¹H NMR (400 MHz, DMSO-d₆) 6=10.59 (br. s., 1H), 8.13 (t,J=4.4 Hz, 1H), 7.76 (d, J=1.5 Hz, 1H), 7.33 (s, 1H), 6.99 (d, J=1.5 Hz,1H), 5.83 (br. s., 2H), 5.19 (s, 1H), 4.74 (dt, J=6.6, 13.3 Hz, 1H),4.22 (d, J=4.8 Hz, 2H), 2.14 (s, 3H), 2.11 (s, 3H), 1.39 (d, J=6.6 Hz,6H). MS(ES)+m/e 431.1 [M+H]⁺.

Examples 326-334 were prepared by the methods described above forExample 325, or routine variations thereof, using the requisite amine.

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 326

N-((6-amino-4-methyl-2-oxo- 1,2-dihydropyridin-3- yl)methyl)-6-chloro-1-isopropyl-3-methyl-1H- indole-4-carboxamide 10.62 (br.s., 1 H), 8.14 (t,J = 4.4 Hz, 1 H), 7.63 (d, J = 1.8 Hz, 1 H), 7.34 (s, 1 H), 6.89 (d, J =1.8 Hz, 1 H), 5.85 (br.s., 2 H), 5.20 (s, 1 H), 4.73 (dt, J = 6.7, 13.2Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3 H), 2.12 (s, 3 H), 1.39(d, J = 6.6 Hz, 6 H) 387.2 327

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 10.49 (br.s., 1 H), 8.51 (d, J = 2.5Hz, 1 H), 7.98 (t, J = 4.8 Hz, 1 H), 7.93 (dd, J = 2.5, 8.8 Hz, 1 H),7.71 (d, J = 1.3 Hz, 1 H), 7.29 (s, 1 H), 7.17 (d, J = 1.5 Hz, 1 H),6.92 (d, J = 8.8 Hz, 1 H), 5.77 (s, 2 H), 5.16 (s, 1 H), 4.84 (quin, J =6.6 Hz, 1 H), 4.26 (d, J = 5.1 Hz, 2 H), 3.61-3.46 (m, 4 H), 2.43 (t, J= 4.7 Hz, 4 H), 2.24 (s, 3 H), 2.18 (s, 3 H), 2.13 (s, 3 H), 1.43 (d, J= 6.6 Hz, 6 H) 528.6 328

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-{3-[(dimethylamino)methyl] phenyl}-3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 10.48 (br.s., 1 H), 8.03 (t, J = 4.9 Hz, 1 H), 7.75 (d, J =1.3 Hz, 1 H), 7.64 (s, 1 H), 7.63 (d, 1 H), 7.40 (t, J = 7.6 Hz, 1 H),7.33 (s, 1 H), 7.24 (d, J = 7.6 Hz, 1 H), 7.22 (d, J = 1.5 Hz, 1 H),5.77 (s, 2 H), 5.16 (s, 1 H), 4.88 (quin, J = 6.6 Hz, 1 H), 4.26 (d, J =5.1 Hz, 2 H), 3.48 (s, 2 H), 2.19 (s, 9 H), 2.13 (s, 3 H), 1.44 (d, J =6.6 Hz, 6 H) 486.3 329

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)- 1H-indole-4-carboxamide 0.70 (t, J = 7.33 Hz,3 H) 1.36 (d, J = 6.82 Hz, 3 H) 1.69-1.84 (m, 2 H) 2.15 (s, 2 H) 2.10(s, 4 H) 4.21 (d, J = 4.80 Hz, 2 H) 4.41- 4.58 (m, 1 H) 5.15 (s, 1 H)5.77 (s, 2 H) 6.97 (d, J = 1.52 Hz, 1 H) 7.29 (s, 1 H) 7.76 (d, J = 1.77Hz, 1 H) 8.06 (t, J = 4.80 Hz, 1 H) 10.47 (br.s., 1 H) 447.2 330

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)- 1H-indole-4-carboxamide 0.668 (t, J = 7.4 Hz,3H), 1.36 (d, J = 6.8 Hz, 3H), 1.76-1.78 (m, 2H), 2.11 (s, 3H), 2.15 (s,3H), 4.21 (d, J = 4.8 Hz, 2H), 4.35-4.38 (m, 1H), 5.15 (s, 1H), 5.78 (s,2H), 6.97 (s, 1H), 7.30 (s, 1H), 7.76 (s, 1H), 8.07-8,.09 (m, 1H),10.4-10.5 (br s, 1H) 445.2 331

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)- 1H-indole-4-carboxamide 0.668 (t, J = 7.4 Hz,3H), 1.36 (d, J = 6.8 Hz, 3H), 1.76-1.78 (m, 2H), 2.11 (s, 3H), 2.15 (s,3H), 4.21 (d, J = 4.8 Hz, 2H), 4.35-4.38 (m, 1H), 5.15 (s, 1H), 5.78 (s,2H), 6.97 (s, 1H), 7.30 (s, 1H), 7.76 (s, 1H), 8.07-8,.09 (m, 1H),10.4-10.5 (br s, 1H) 445.2 332

N-[(6-amino-4-methyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)- 3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4- carboxamide 10.47 (br.s., 1 H) 8.50 (d, J =2.53 Hz, 1 H) 7.98 (br.s., 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.71-7.74 (m, 1 H) 7.26 (s, 1 H) 7.16 (d, J = 1.26 Hz, 1 H) 6.92 (d, J =9.09 Hz, 1 H) 5.76 (s, 2 H) 5.16 (br.s., 1 H) 4.57-4.65 (m, 1 H) 4.26(br.s., 1.H) 4.25 (br.s., 1 H) 3.52 (br.s., 4 H) 2.42 (br.s., 4 H) 2.23(s, 3 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.81 (td, J = 7.20, 3.03 Hz, 2 H)1.41 (d, J = 6.82 Hz, 3 H) 0.73 (t, J = 7.20 Hz, 3 H) 542.6 333

N-((6-amino-2-oxo-4-propyl- 1,2-dihydropyridin-3- yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H- indole-4-carboxamide 10.52 (br.s., 1 H), 8.04 (t,J = 4.7 Hz, 1 H), 7.76 (d, J = 1.8 Hz, 1 H), 7.33 (s, 1 H), 6.98 (d, J =1.8 Hz, 1 H), 5.77 (s, 2 H), 5.17 (s, 1 H), 4.74 (quin, J = 6.6 Hz, 1H), 4.23 (d, J = 4.8 Hz, 2 H), 2.45-2.34 (m, 2 H), 2.15 (s, 3 H), 1.52(dq, J = 7.4, 15.1 Hz, 2 H), 1.39 (d, J = 6.6 Hz, 6 H), 0.93 (t, J = 7.3Hz, 3 H) 459.2 334

6-bromo-1-isopropyl-3- methyl-N-((4-methyl-6- (methylamino)-2-oxo-1,2-dihydropyridin-3-yl)methyl)- 1H-indole-4-carboxamide 10.48 (br.s., 1 H),8.11 (t, J = 4.5 Hz, 1 H), 7.75 (d, J = 1.5 Hz, 1 H), 7.33 (s, 1 H),6.99 (d, J = 1.5 Hz, 1 H), 5.76 (q, J = 4.4 Hz, 1 H), 5.13 (br.s., 1 H),4.74 (quin, J = 6.6 Hz, 1 H), 4.24 (d, J = 4.8 Hz, 2 H), 2.67 (d, J =5.1 Hz, 3 H), 2.17 (s, 3 H), 2.15 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H)445.2

Example 335N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide

a) (R)-tert-Butyl4-(5-(4-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-3-methyl-1H-indol-6-yl)pyridin-2-yl)-3-methylpiperazine-1-carboxylate

Added6-(6-chloropyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(131 mg, 0.283 mmol), (R)-tert-butyl 3-methylpiperazine-1-carboxylate(70.8 mg, 0.354 mmol), sodium tert-butoxide (59.8 mg, 0.623 mmol) and1,4-Dioxane (2 mL) to a microwave vial and degassed for 10 minutes.Added Pd XPhos (10.45 mg, 0.014 mmol) and heated to 100° C. for 16hours. Concentrated, added DCM and water. Filtered, separated phases.Extracted aqueous phase twice more with DCM. Combined DCM extracts andwashed with water, brine, dried (MgSO4), filtered and rotovapped offDCM. The residue was purified via Biotage (0% to 5% MeOH:DCM; 10g-HP-silica gel column) Obtained 28 mg of the title compound. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.16 (d, J=6.32 Hz, 3H), 1.44-1.57 (m,15H), 2.06 (s, 3H), 2.28 (s, 3H), 2.39 (s, 3H), 2.87-3.36 (m, 3H), 3.57(s, 1H), 3.86-4.30 (m, 3H), 4.50 (d, J=9.35 Hz, 1H), 4.58-4.79 (m, 3H),5.87 (s, 1H), 6.64 (d, J=8.59 Hz, 1H), 7.01 (s, 1H), 7.45 (s, 1H), 7.76(d, J=8.08 Hz, 1H), 8.46 (d, J=2.27 Hz, 1H), 12.42 (br. s., 1H). LCMS:[M+H]⁺ 627.5.

b)N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide

Added trifluoroacetic acid (1 ml, 12.98 mmol) to a solution of(R)-tert-butyl4-(5-(4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-3-methyl-1H-indol-6-yl)pyridin-2-yl)-3-methylpiperazine-1-carboxylate(57 mg, 0.091 mmol) in DCM (3 mL) and let stir at RT for 1 hour.Concentrated on rotovap. Partitioned between DCM and sat'd Na2CO3,separated and washed DCM phase with water, brine, dried (MgSO4),filtered and rotovapped off DCM. Obtained 25 mg of the title compound asa tan solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.19 (d, 2H),1.46-1.59 (m, 6H), 2.21 (s, 3H), 2.27 (s, 3H), 2.44 (s, 3H), 2.83 (dd,J=12.13, 3.54 Hz, 1H), 2.96-3.29 (m, 4H), 3.90 (br. s., 1H), 4.47-4.76(m, 5H), 6.00 (s, 1H), 6.51 (d, J=8.59 Hz, 1H), 7.05 (s, 1H), 7.45 (s,1H), 7.68 (dd, J=8.72, 2.40 Hz, 1H), 8.43 (d, J=2.27 Hz, 1H),10.11-12.70 (m, 1H). LCMS: [M+H]⁺ 527.5.

Examples 336-346 were prepared by the methods described above forExample 335, or routine variations thereof, using the requisite amine.

MS (ES) ¹H NMR [M + Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺ 336

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(3,4-dimethyl-1- piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)- 1H-indole-4-carboxamide (CHLOROFORM-d) 1.16(d, J = 6.06 Hz, 3 H), 1.47 (d, J = 6.57 Hz, 6 H), 2.03 (s, 3 H),2.14-2.29 (m, 4 H), 2.30-2.42 (m, 7 H), 2.69 (dd, J = 12.25, 10.74 Hz, 1H), 2.91 (d, J = 11.62 Hz, 1 H), 3.00-3.13 (m, 1 H), 4.06 (d, J = 12.63Hz, 2 H), 4.38-4.75 (m, 3 H), 5.85 (s, 1 H), 6.64 (d, J = 8.59 Hz, 1 H),6.99 (s, 1 H), 7.42 (d, J = 1.52 Hz, 1 H), 7.70 (dd, J = 8.84, 2.53 Hz,1 H), 8.43 (d, J = 2.27 Hz, 1 H), 12.55 (br.s., 1 H) 541.3 337

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(6-(4-amino-4- methylpiperidin-1-yl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4- carboxamide (CHLOROFORM-d) 1.24 (s, 3 H), 1.49(d, J = 6.57 Hz, 6 H), 1.60-1.73 (m, 4 H), 2.10 (s, 3 H), 2.28 (s, 3 H),2.38 (s, 2 H), 3.39-3.53 (m, 2 H), 3.57-3.70 (m, 2 H), 4.54-4.75 (m, 3H), 5.88 (s, 1 H), 6.61 (d, J = 8.84 Hz, 1 H), 7.01 (s, 1 H), 7.26(br.s., 1 H), 7.29 (d, J = 5.81 Hz, 1 H), 7.44 (s, 1 H), 7.66 (dd, J =8.84, 2.27 Hz, 2 H), 8.41 (d, J = 2.02 Hz, 2 H), 10.07- 13.76 (m, 1 H)541.5 338

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4- b]pyrrol-5(1H)-yl)-3-pyridinyl]-3-methyl-1-(1- methylethyl)-1H-indole-4- carboxamide(CHLOROFORM-d) 1.48 (t, J = 6.57 Hz, 6 H), 1.54-1.69 (m, 1 H), 2.10 (s,3 H), 2.31 (s, 3 H), 2.42 (s, 3 H), 2.77-3.05 (m, 3 H), 3.22 (dd, J =10.86, 4.55 Hz, 1 H), 3.31-3.46 (m, 2 H), 3.46-3.58 (m, 1 H), 4.03 (d, J= 5.56 Hz, 1 H), 4.39-4.86 (m, 3 H), 5.90 (s, 1 H), 6.16 (d, J = 8.59Hz, 1 H), 7.03 (s, 1 H), 7.21 (s, 1 H), 7.41 (s, 1 H), 7.53 (d, J = 6.32Hz, 2 H), 8.32 (d, J = 2.02 Hz, 1 H) 539.5 339

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(3,3-dimethyl-1- piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)- 1H-indole-4-carboxamide (CHLOROFORM-d) 1.21(s, 6 H), 1.49 (d, J = 6.82 Hz, 6 H), 2.09 (s, 3 H), 2.28 (s, 3 H), 2.40(s, 3 H), 2.99-3.12 (m, 2 H), 3.33 (s, 2 H), 3.45-3.60 (m, 2 H), 4.55-4.77 (m, 3 H), 5.89 (s, 1 H), 6.63 (d, J = 8.84 Hz, 1 H), 7.01 (s, 1 H),7.22-7.26 (m, 1 H), 7.28 (d, J = 1.26 Hz, 1 H), 7.44 (d, J = 1.01 Hz, 1H), 7.70 (dd, J = 8.84, 2.53 Hz, 1 H), 8.42 (d, J = 2.27 Hz, 1 H) 541.6340

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-{6-[(2S)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H- indole-4-carboxamide (CHLOROFORM-d) 1.21(d, J = 6.57 Hz, 3 H), 1.49 (d, J = 6.82 Hz, 6 H), 2.07 (s, 3 H), 2.28(s, 3 H), 2.39 (s, 3 H), 2.76-2.99 (m, 2 H), 3.02-3.21 (m, 3 H), 3.94(d, J = 12.63 Hz, 1 H), 4.38-4.48 (m, 1 H), 4.56-4.77 (m, 3 H), 5.88 (s,1 H), 6.59 (d, J = 9.09 Hz, 1 H), 7.01 (s, 1 H), 7.30 (d, 1 H), 7.45 (d,J = 1.01 Hz, 1 H), 7.71 (dd, J = 8.84, 2.53 Hz, 1 H), 8.45 (d, J = 2.27Hz, 1 H) 527.5 341

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)-3-pyridinyl]-3-methyl-1-(1- methylethyl)-1H-indole-4- carboxamide(CHLOROFORM-d) 1.49 (d, 6 H), 2.18 (s, 3 H), 2.33 (s, 3 H), 2.44 (s, 3H), 2.63 (d, J = 6.32 Hz, 2 H), 2.89 (br.s., 2 H), 3.02 (d, J = 9.60 Hz,2 H), 3.24 (dd, J = 10.99, 6.19 Hz, 2 H), 3.35 (dd, J = 9.85, 7.07 Hz, 2H), 4.55-4.72 (m, 3 H), 5.91- 6.01 (m, 2 H), 7.09 (s, 1 H), 7.13 (s, 1H), 7.35-7.49 (m, 2 H), 7.60-7.81 (m, 1 H), 8.26 (d, J = 2.02 Hz, 1 H)539.5 342

6-{6-[(1S,4S)-2,5- diazabicyclo[2.2.1]hept-2- yl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro- 3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole- 4-carboxamide 1.43 (d, J = 6.57 Hz, 6 H),1.68 (d, J = 9.35 Hz, 1 H), 1.80 (d, J = 8.84 Hz, 1 H), 2.11 (s, 3 H),2.16 (s, 3 H), 2.24 (s, 3 H), 2.82 (d, J = 9.35 Hz, 1 H) ,2.89-2.97 (m,1 H), 3.16-3.25 (m, 2 H), 3.49 (d, J = 8.34 Hz, 1 H), 3.69 (br.s., 1 H),4.35 (d, J = 4.80 Hz, 2 H), 4.69 (s, 1 H), 4.83 (quin, J = 6.63 Hz, 1H), 5.87 (s, 1 H), 6.56 (d, J = 8.84 Hz, 1 H), 7.16 (d, J = 1.26 Hz, 1H), 7.27 (s, 1 H), 7.68 (d, J = 1.26 Hz, 1 H), 7.86 (dd, J = 8.72, 2.40Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1 H), 8.44 (d, J = 2.27 Hz, 1 H) 525.3343

6-{6-[(1R,4R)-2,5- diazabicyclo[2.2.1]hept-2- yl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro- 3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole- 4-carboxamide 1.43 (d, 6 H), 1.70 (m, 1 H),1.80 (m, 1 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.80-2.87(m, 1 H), 2.91-2.98 (m, 1 H,) 3.23 (d, J = 9.35 Hz, 1 H), 3.49 (dd, J =9.35, 2.02 Hz, 1 H), 3.72 (s, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.70 (s,1 H), 4.83 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 6.56 (d, J = 8.84Hz, 1 H), 7.16 (d, J = 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.68 (d, J = 1.26Hz, 1 H), 7.87 (dd, J = 8.84, 2.53 Hz, 1 H), 8.14 (t, J = 4.93 Hz, 1 H),8.44 (d, J = 2.27 Hz, 1H) 525.7 344

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-{6-[(2S,5S)-2,5-dimethyl- 1-piperazinyl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)- 1H-indole-4-carboxamide 1.10 (m, 6 H), 1.43(d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.14-2.19 (m, 3 H), 2.24 (s, 3 H),2.61-2.74 (m, 1 H), 2.79-2.96 (m, 2 H), 3.93-4.04 (m, 1 H), 4.35 (d, J =5.05 Hz, 3 H), 4.76-4.90 (m, 1 H), 5.87 (s, 1 H), 6.82 (d, J = 8.84 Hz,1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.28 (s, 1 H), 7.70 (d, J = 1.26 Hz, 1H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1 H), 8.49(d, J = 2.53 Hz, 1 H) 541.6 345

6-[6-(3,8- diazabicyclo[3.2.1]oct-3-yl)- 3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4- carboxamide 1.38-1.48 (m, 6 H), 1.60-1.74(m, 4 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.79-2.95 (m, 2H), 3.35 (d, J = 1.26 Hz, 5 H), 3.54 (br.s., 2 H), 3.83-3.91 (m, 2 H),4.35 (d, J = 5.05 Hz, 2 H), 4.83 (quin, J = 6.57 Hz, 1 H), 5.87 (s, 1H), 6.75 (d, J = 8.84 Hz, 1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.28 (s, 1H), 7.70 (d, J = 1.26 Hz, 1 H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.15(t, J = 5.05 Hz, 1 H), 8.45-8.51 (m, 1 H) 539.6 346

N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(6-((2R,5R)-2,5- dimethylpiperazin-1- yl)pyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4- carboxamide (METHANOL-d4)1.25 (d, 3 H), 1.31 (d, J= 6.32 Hz, 3 H), 1.49 (d, J = 6.57 Hz, 6 H), 2.23 (d, J = 10.11 Hz, 6H), 2.43 (s, 3 H), 2.81 (dd, J = 13.39, 11.37 Hz, 1 H), 2.92- 3.28 (m, 3H), 4.16 (dd, J = 13.52, 3.16 Hz, 1 H), 4.62 (br.s., 1 H), 4.80 (quin, J= 6.69 Hz, 1 H), 6.12 (s, 1 H), 6.90 (d, J = 8.84 Hz, 1 H), 7.20 (s, 1H), 7.27 (d, J = 1.52 Hz, 1 H), 7.63 (d, J = 1.26 Hz, 1 H), 7.92 (dd, J= 8.84, 2.53 Hz, 1 H), 8.44 (d, J = 2.27 Hz, 1 H) 541.3

Example 347N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indole-4-carboxamide

To a solution ofN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-formylpyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(100 mg, 0.219 mmol), in DCM (10 mL) and methanol (2 mL) was addedpyrrolidine (0.035 mL, 0.438 mmol), followed by sodium sulfate (31.1 mg,0.219 mmol). The reaction stirred at rt for 12 h, at which time sodiumborohydride (16.57 mg, 0.438 mmol) was added and the reaction stirred rtfor 2 h and 45° C. for 2 h. The reaction was quenched with water andextracted with EtOAc. The organic layer was evaporated. Purification byreverse phase Gilson HPLC (10-60% acetonitrile/water+0.1% TFA, YMC ODS-AC₁₈ Column 75×30 mm ID S-5 um, 12 nM Column 7 minutes), followed byisolation and extraction with EtOAc/0.1 N NaOH providedN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indole-4-carboxamide,which was evaporated from the organic layer as a yellow foam solid (68mg, 0.125 mmol, 57.0% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.48 (br.s., 1H) 9.06 (d, J=2.02 Hz, 1H) 8.30 (dd, J=8.08, 2.27 Hz, 1H) 8.20 (t,J=5.18 Hz, 1H) 7.94 (d, J=1.26 Hz, 1H) 7.60 (d, J=8.08 Hz, 1H) 7.40 (s,1H) 7.32 (s, 1H) 5.88 (s, 1H) 4.92-4.89 (m, 1H) 4.59 (d, J=5.56 Hz, 2H)4.36 (d, J=5.05 Hz, 2H) 3.34 (br. s., 4H) 2.25 (s, 3H) 2.17 (d, J=1.01Hz, 3H) 2.11 (s, 3H) 1.99 (br.s., 4H) 1.45 (d, J=6.57 Hz, 6H). LCMS:[M+H]⁺=512.3.

Examples 348-350 were prepared by the methods described above forExample 347, or routine variations thereof, using the requisite amine.

MS (ES) ¹H NMR [M + EZH2 Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺pIC50 348

6-(6-{[(2R,6S)-2,6-dimethyl- 4-morpholinyl]methyl}-3-pyridinyl)-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1- (1-methylethyl)-1H-indole-4- carboxamide11.48 (br.s., 1 H) 9.09 (d, J = 2.02 Hz, 1 H) 8.32 (dd, J = 8.08, 2.27Hz, 1 H) 8.19 (t, J = 5.05 Hz, 1 H) 7.94 (d, J = 1.26 Hz, 1 H) 7.62 (d,J = 8.08 Hz, 1 H) 7.41 (s, 1 H) 7.33 (d, J = 1.52 Hz, 1 H) 5.88 (s, 1 H)4.87- 4.94 (m, 1 H) 4.52 (br.s., 2 H) 4.36 (d, J = 4.80 Hz, 2 H)3.87-3.96 (m, 2 H) 3.35-3.45 (m, 2 H) 2.75-2.85 (m, 2 H) 2.25 (s, 3 H)2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 1.14 (d, J = 6.06Hz, 6 H) 556.4 7.44 349

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-{6-[(4-methyl-1- piperazinyl)methyl]-3-pyridinyl}-1H-indole-4- carboxamide 11.50 (br.s., 1 H) 9.03 (d, J = 2.02Hz, 1 H) 8.37 (dd, J = 8.08, 2.02 Hz, 1 H) 8.21 (t, J = 5.05 Hz, 1 H)7.93 (d, J = 1.26 Hz, 1 H) 7.65 (d, J = 8.08 Hz, 1 H) 7.41 (s, 1 H) 7.32(d, J = 1.52 Hz, 1 H) 5.88 (s, 1 H) 4.90 (quin, J = 6.63 Hz, 1 H) 4.36(d, J = 5.05 Hz, 2 H) 4.08 (br.s., 2 H) 3.07-3.56 (m, 8 H) 2.83 (s, 3 H)2.24-2.28 (m, 3 H) 2.17 (s, 3 H) 2.12 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6H) 541.3 7.6 350

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-[6-(4-morpholinylmethyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.49 (br.s., 1 H) 8.88 (d, J =2.02 Hz, 1 H) 8.21 (t, J = 4.93 Hz, 1 H) 8.12 (dd, J = 8.08, 2.27 Hz, 1H) 7.86 (d, J = 1.26 Hz, 1 H) 7.51 (d, J = 8.08 Hz, 1 H) 7.36 (s, 1 H)7.27 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.85-4.93 (m, 1 H) 4.36 (d, J =4.80 Hz, 2 H) 3.62 (dd, J = 9.47, 4.93 Hz, 6 H) 2.45 (br.s., 4 H) 2.24(s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H) 528.37.64

Example 3516-Bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)6-Bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol (0.29 g, 1.591mmol), 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (0.48 g,1.621 mmol), and HOAt (0.22 g, 1.616 mmol) in Dichloromethane (15 mL)and DMF (5 mL) was added EDC free base (0.30 g, 1.932 mmol). Thereaction was stirred at RT for 3 h then evaporated to dryness undervacuum. The remaining was purified by silica gel chromatography(Analogix, SF25-60 g, 0 to 20% EtOAc in CH₂Cl₂) to give the product6-bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(0.73 g, 1.586 mmol, 100% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=8.46 (t, J=4.9 Hz, 1H), 7.77 (d, J=1.8 Hz, 1H), 7.33 (d,J=1.0 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 6.90 (s, 1H), 5.31 (t, J=5.9 Hz,1H), 4.74 (quin, J=6.6 Hz, 1H), 4.45 (d, J=5.1 Hz, 1H), 4.43 (d, J=5.8Hz, 2H), 3.83 (s, 3H), 2.40 (s, 3H), 2.10 (s, 3H), 1.38 (d, J=6.8 Hz,6H). MS(ES)+m/e 460.2 [M+H]⁺.

b)6-Bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of6-bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(500 mg, 1.086 mmol) in tetrahydrofuran (5 mL) was added 6 N HCl (15 mL,15.00 mmol). The reaction was stirred under N₂ with heating at 80° C.for 18 hr. The reaction was cooled to RT and evaporated to dryness undervacuum. The remaining was purified by silica gel chromatography(Analogix, SF25-60 g, 4% MeOH in CH₂Cl₂). The pure fractions werecombined and evaporated to dryness under vacuum. Triturated with a smallvolume of water, filtered, washed with water and dried under vacuum togive the product6-bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(189 mg, 0.423 mmol, 39.0% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=11.30 (s, 1H), 8.27 (t, J=4.9 Hz, 1H), 7.76 (d, J=1.8 Hz,1H), 7.33 (s, 1H), 7.01 (d, J=1.8 Hz, 1H), 6.05 (s, 1H), 5.38 (t, J=5.9Hz, 1H), 4.74 (dt, J=6.7, 13.2 Hz, 1H), 4.32 (d, J=5.1 Hz, 2H), 4.25 (d,J=5.8 Hz, 2H), 2.26 (s, 3H), 2.13 (s, 3H), 1.39 (d, J=6.6 Hz, 6H).MS(ES)+m/e 446.1 [M+H]⁺.

Example 352N-((6-(aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)tert-Butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

To a stirred solution oftert-butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(0.55 g, 1.955 mmol),6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (0.63 g, 2.127mmol), and HOAt (0.27 g, 1.984 mmol) in Dichloromethane (20 mL) and DMF(5 mL) was added EDC free base (0.34 g, 2.190 mmol). The reaction wasstirred at RT for 2 hr then evaporated to dryness under vacuum. Theremaining was purified by silica gel chromatography (Analogix, SF25-60g, 0 to 40% EtOAc in hexanes) to give the producttert-butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(1.07 g, 1.912 mmol, 98% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=8.47 (t, J=4.8 Hz, 1H), 7.76 (d, J=1.8 Hz, 1H), 7.35 (t, 1H),7.33 (d, J=1.0 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 6.67 (s, 1H), 4.74(quin, J=6.6 Hz, 1H), 4.44 (d, J=4.8 Hz, 2H), 4.08 (d, J=6.3 Hz, 2H),3.85 (s, 3H), 2.37 (s, 3H), 2.10 (s, 3H), 1.41 (s, 9H), 1.38 (d, J=6.6Hz, 6H). MS(ES)+m/e 559.3 [M+H]⁺.

b)N-((6-(Aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution oftert-butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(500 mg, 0.894 mmol) in Tetrahydrofuran (THF) (5 mL) was added 6N HCl(15 mL, 15.00 mmol). The reaction was stirred under N2 with heating at80° C. for 18 hr. The reaction was cooled to RT and evaporated todryness under vacuum. The remaining was purified by silica gelchromatography (Analogix, SF25-40 g, 0 to 10% (5% NH4OH in MeOH) inCH2C₁₂). The pure fractions were combined and evaporated to drynessunder vacuum. Dissolved with a small volume of CH2C₁₂, scratched out byslowly adding hexanes, filtered, washed with hexanes and dried undervacuum to give the productN-((6-(aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide(328 mg, 0.736 mmol, 82% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=8.26 (t, J=5.1 Hz, 1H), 7.76 (d, J=1.8 Hz, 1H), 7.33 (d,J=1.0 Hz, 1H), 7.01 (d, J=1.5 Hz, 1H), 6.01 (s, 1H), 5.77 (s, 0H), 4.74(quin, J=6.6 Hz, 1H), 4.32 (d, J=5.1 Hz, 2H), 3.46 (s, 2H), 2.25 (s,3H), 2.14 (s, 3H), 1.39 (d, J=6.8 Hz, 6H). MS(ES)+m/e 445.2 [M+H]⁺.

Example 3533-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylicacid

To a 5 ml microwave vial was added,6-cyano-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide(100 mg, 0.247 mmol), KOH (41.6 mg, 0.742 mmol) was ground and addedfollowed by Ethanol (8 mL) the reaction was microwaved at 145° C. for 22hr. The reaction was poured onto acidic Ice water (20 mL) and wasstirred for 20 min. EtOAc was added and the mix was stirred anadditional 10 min. The layers were separated and the majority of theproduct was in the EtOAc which was evaporated. The residue was dissolvedin MeOH (1 mL) and material was crashed out with ice and was filtered togive product3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylicacid (70 mg, 0.160 mmol, 64.9% yield) ¹H NMR (400 MHz, DMSO-d₆) δ ppm11.49 (br. s., 1H) 8.18 (s, 1H) 8.10 (s, 1H) 7.53 (d, J=7.58 Hz, 2H)5.90 (s, 1H) 4.76-4.90 (m, 1H) 4.36 (d, J=4.80 Hz, 2H) 2.55 (br. s., 1H)2.18 (s, 3H) 2.13 (s, 3H) 1.52-1.61 (m, 2H) 1.44 (d, J=6.57 Hz, 6H) 0.94(t, J=7.33 Hz, 3H) MS(ES) [M+H]⁺423.8

Example 3543-[3-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid

a)Ethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate

Following the general procedure detailed above for Suzukicross-couplings (see Example 2),ethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate(120 mg, 0.234 mmol, 53.6% yield) was prepared. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 11.49 (s, 1H) 8.12 (t, J=4.93 Hz, 1H) 7.97 (d, J=1.01 Hz,1H) 7.74 (d, J=15.92 Hz, 1H) 7.43 (s, 1H) 7.27 (d, J=1.26 Hz, 1H) 6.61(d, J=15.92 Hz, 1H) 5.90 (s, 1H) 4.78-4.86 (m, 1H) 4.35 (d, J=5.05 Hz,2H) 4.19 (q, J=7.07 Hz, 2H) 2.53-2.58 (m, 2H) 2.14 (d, J=11.12 Hz, 6H)1.53-1.62 (m, 2H) 1.43 (d, J=6.82 Hz, 6H) 1.27 (t, J=7.07 Hz, 3H)0.93-0.97 (m, 3H). MS(ES) [M+H]⁺ 477.9

b) Ethyl3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoate

In a 50 ml flask was addedethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate(120 mg, 0.251 mmol), and Ethanol (10 mL). PdOH2 (70.6 mg, 0.503 mmol)was added and the reaction was degassed with N2 for 15 min then H2 wasbubbled in (via balloon) and the reaction stirred for 12 hr. Thereaction was purged with N2 for 30 min and then filtered through an acrodisc and evaporated. The residue was suspended in MeOH/Water (2 mL/4 mL)and filtered and washed with water to give a white solid. ethyl3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoate(70 mg, 0.146 mmol, 58.1% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.49(br. s., 1H) 7.90 (br. s., 1H) 7.34 (s, 1H) 7.21 (s, 1H) 6.82 (s, 1H)5.90 (s, 1H) 4.63-4.73 (m, 1H) 4.34 (d, J=4.55 Hz, 2H) 4.04 (q, J=7.07Hz, 2H) 2.92 (t, J=7.33 Hz, 2H) 2.64 (t, J=7.45 Hz, 2H) 2.55-2.62 (m,2H) 2.12 (s, 6H) 1.52-1.62 (m, 2H) 1.40 (d, J=6.32 Hz, 6H) 1.16 (t,J=7.07 Hz, 3H) 0.94 (t, J=7.20 Hz, 3H). MS(ES) [M+H]⁺ 479.8.

c)3-[3-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid

Following the general procedure detailed above for Suzukicross-couplings (see Example 2),3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid (45 mg, 0.095 mmol, 64.9% yield) was prepared. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 12.05 (br.s, 1H) 11.49 (br. s., 1H) 7.88-7.95 (m, 1H)7.34 (s, 1H) 7.20 (s, 1H) 6.82 (s, 1H) 5.90 (s, 1H) 4.64-4.73 (m, 1H)4.34 (d, J=4.80 Hz, 2H) 2.89 (t, J=7.71 Hz, 2H) 2.55-2.60 (m, 4H) 2.12(s, 6H) 1.53-1.61 (m, 2H) 1.40 (d, J=6.57 Hz, 6H) 0.92-0.96 (m, 3H).MS(ES) [M+H]⁺ 451.9.

Example 3556-(2-Aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

a)6-[2-({[(1,1-Dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid

In a glass pressure bottle was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (1.00 g, 2.77mmol), potassium t-butyl-N-[2-(trifluoroboranuidyl)ethyl]carbamate (900mg, 3.58 mmol), cesium carbonate (3.2 g, 9.82 mmol), toluene (24 mL) andwater (8 mL). The mixture was stirred and purged with N2. To thereaction was added palladium(II) acetate (40 mg, 0.178 mmol) and RuPhos(160 mg, 0.342 mmol), the reaction capped and stirred at 95° C. for 18hr. LCMS showed that the reaction was complete. The reaction was takenup in EtOAc, diluted with water, and filtered to remove insolubles. Theorganic phase was removed, dried (MgSO4), filtered and concentratedunder vacuum. Purification by silica gel chromatography (Analogix,SF25-60 g, 0 to 20% EtOAc in hexanes gave the methyl ester.

To the ester in THF (10 mL) and MeOH (30 mL) was added 1 N NaOH (10 mL,10 mmol). The solution was stirred at reflux 80° C. for 24 hr (slowsaponification). After cooling to RT the reaction was concentrated undervacuum, neutralized with 1 N HCl (10 mL), triturated with water,filtered and dried under vacuum to give the product6-[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (865 mg, 2.31 mmol, 83.0% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 12.69 (br. s., 1H), 7.43 (s, 1H), 7.31 (s, 1H), 7.25 (s, 1H),6.89 (t, J=5.6 Hz, 1H), 4.71 (dt, J=6.6, 13.3 Hz, 1H), 3.23-3.10 (m,2H), 2.80 (t, J=7.3 Hz, 2H), 2.30 (s, 3H), 1.42 (d, J=6.6 Hz, 6H), 1.37(s, 9H). MS(ES)+m/e 361.2 [M+H]⁺.

b)6-(2-Aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamidehydrochloride salt

To a stirred suspension of6-[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (500 mg, 1.387 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinoneHCl salt (340 mg, 1.802 mmol), HOAt (245 mg, 1.800 mmol) in DMF (20 mL)was added N-methylmorpholine (200 μL, 1.819 mmol) and EDC free base (280mg, 1.804 mmol). The reaction was stirred overnight at RT. LCMS showedthat the reaction was complete. The reaction was evaporated to drynessand purified by silica gel chromatography (Analogix, SF25-40 g, 0 to 10%CH₂Cl₂/20%(5% NH₄OH in MeOH) in CH₂Cl₂). The pure fractions werecombined and evaporated to dryness. Triturated with 50% MeOH in water,filtered and dried under vacuum to give the Boc protected product as anoff-white solid. The Boc protected product was suspended in a smallvolume of MeOH (2 mL) and treated with 4 N HCl in dioxane (25 mL) andstirred at RT for 1 hr. LCMS showed that the reaction was complete. Thereaction was evaporated to dryness, triturated with Et₂O, filtered anddried under vacuum to give the product6-(2-aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(460 mg, 1.067 mmol, 77% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆+D₂O) δ 8.05 (t, J=5.2 Hz, 1H), 8.00 (br. s., 2H), 7.39 (d, J=1.0Hz, 1H), 7.25 (s, 1H), 6.86 (d, J=1.3 Hz, 1H), 5.93 (s, 1H), 4.69 (dt,J=6.6, 13.3 Hz, 1H), 4.34 (d, J=5.1 Hz, 2H), 3.06 (dd, J=5.8, 7.6 Hz,2H), 3.01-2.91 (m, 2H), 2.25 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 1.41(d, J=6.8 Hz, 6H). MS(ES)+m/e 394.9 [M+H]⁺.

Example 3566-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

a) Methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

To a glass pressure vessel was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (500 mg,1.612 mmol), 4-fluoro-3-formylbenzeneboronic acid (375 mg, 2.233 mmol),Potassium phosphate (1.1 g, 5.18 mmol), dioxane (12 mL) and water (3mL). The reaction was purged with N₂ and charged with PdCl₂(dppf)-CH₂Cl₂adduct (120 mg, 0.147 mmol). The reaction was capped and stirred at 110°C. for 4 hr. LCMS showed that the reaction was complete. The reactionwas diluted with water, extracted with EtOAc, washed with brine, dried(MgSO₄), filtered, and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF25-60 g, 0 to 50% EtOAc in hexanes) gavethe product methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(560 mg, 1.585 mmol, 98% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=10.30 (s, 1H), 8.24-8.13 (m, 2H), 8.10 (d, J=1.5 Hz, 1H),7.75 (d, J=1.8 Hz, 1H), 7.57-7.46 (m, 2H), 4.98 (quin, J=6.6 Hz, 1H),3.91 (s, 3H), 2.31 (s, 3H), 1.46 (d, J=6.6 Hz, 6H). MS(ES)+m/e 354.2[M+H]⁺.

b)6-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid

To a stirred solution of methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(550 mg, 1.556 mmol) in CH₂Cl₂ (25 mL) was added 2N dimethylamine in THF(3.0 mL, 6.00 mmol) and acetic acid (170 μL, 2.97 mmol). After stirringat RT for 1 hr sodium triacetoxyborohydride (1.0 g, 4.72 mmol) was addedportionwise over 10 minutes. The reaction was stirred at RT overnight.LCMS showed the product as well as a substantial amount of the alcoholand one unidentifiable side product. The reaction was purified by silicagel chromatography (Analogix, SF25-60 g, 0 to 50% CH₂Cl₂/20%(5% NH₄OH inMeOH) in CH₂Cl₂). The last fraction contained the desired product andwas combined and evaporated to dryness. Trituration with hexanes,filtration and drying under vacuum gave the methyl ester product (0.25g, 0.65 mMol, 41%) as an off-white solid.

The ester was taken up in THF (15 mL) and MeOH (5 mL) and treated with 1N NaOH (4 mL). The reaction was refluxed (80° C. oil bath) overnight.LCMS showed that the reaction was complete. The reaction was cooled toRT and concentrated under vacuum. Neutralization with 1 N HCl (4 mL)ppt. out the product, which was triturated with a small amount of coldwater, filtered, and dried under vacuum to give the product6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (210 mg, 0.570 mmol, 36.6% yield) as a white solid. ¹H NMR (400MHz, DMSO-d₆) 6=12.84 (br. s., 1H), 10.80 (br. s., 1H), 8.18 (dd, J=2.0,7.1 Hz, 1H), 8.12 (s, 1H), 8.01-7.85 (m, 1H), 7.76 (d, J=1.3 Hz, 1H),7.49 (s, 1H), 7.43 (t, J=9.1 Hz, 1H), 4.95 (dt, J=6.6, 13.1 Hz, 1H),4.43 (br. s., 2H), 2.80 (s, 6H), 2.34 (s, 3H), 1.46 (d, J=6.6 Hz, 6H).MS(ES)+m/e 369.0 [M+H]⁺.

c)6-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

To a stirred suspension of6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (210 mg, 0.570 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinoneHCl salt (140 mg, 0.742 mmol) and HOAt (100 mg, 0.735 mmol) in DMF (15mL) was added N-methylmorpholine (82 μl, 0.746 mmol) and EDC free base(110 mg, 0.709 mmol). The reaction was stirred for 4 h at RT andconcentrated to near dryness under vacuum. Water was added till theproduct ppt. out. The suspension was triturated, filtered, rinsed withcold water then dried under vacuum to give the product6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(186 mg, 0.370 mmol, 64.9% yield) as a light tan solid. ¹H NMR (400 MHz,DMSO-d₆) 6=11.47 (br. s., 1H), 8.15 (t, J=4.9 Hz, 1H), 8.04 (d, J=5.3Hz, 1H), 7.90-7.86 (m, 1H), 7.39 (t, J=9.2 Hz, 1H), 7.35 (s, 1H), 7.27(d, J=1.3 Hz, 1H), 5.87 (s, 1H), 4.88 (dt, J=6.6, 13.3 Hz, 1H), 4.36 (d,J=5.1 Hz, 2H), 4.26 (br. s., 2H), 2.69 (s, 6H), 2.24 (s, 3H), 2.17 (s,3H), 2.11 (s, 3H), 1.44 (d, J=6.6 Hz, 6H). MS(ES)+m/e 503.0 [M+H]⁺.

Example 3576-(4,5-Dihydro-1H-imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a 10-mL microwave tube were added6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(33 mg, 0.088 mmol), ethylenediamine (1 mL, 14.81 mmol), and phosphoruspentasulfide (0.585 mg, 2.63 μmol), and the mixture was degassed for 5min. The tube was sealed and the mixture was heated at 120° C. in amicrowave. The mixture was concentrated and the residue was purifiedusing reverse-phase HPLC under acidic conditions to give 32 mg ofproduct as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) ppm 1.46 (m, 6H),2.11 (s, 3H), 2.17 (s, 3H), 2.24 (s, 3H), 4.35 (d, J=5.05 Hz, 2H), 4.75(quin, J=6.69 Hz, 1H), 5.87 (s, 1H), 7.49-7.60 (m, 2H), 8.16-8.26 (m,2H), 8.39 (s, 1H). MS: (M+H)⁺=419.9.

Examples 358-366 were prepared following the general methods describedabove and/or well established synthetic procedures:

MS (ES) ¹H NMR [M + EZH2 Ex Structure Name (400 MHz, DMSO-d₆) δ ppm H]⁺pIC50 358

[4-({[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1- methylethyl)-1H-indol-6- yl]boronic acid 11.48(br.s., 1H), 8.04 (s, 2H), 7.95 (s, 1H), 7.88 (t, J = 5.05 Hz, 1H), 7.40(s, 1H), 7.31 (s, 1 H), 5.87 (s, 1 H), 4.64-4.76 (m, 1 H), 4.34 (d, J =5.05 Hz, 2H), 2.23 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 1.44 (d, J =6.57 Hz, 6H) 396.3 6.33 359

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-[6-(hydroxymethyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4- carboxamide 11.51 (br.s., 1 H) 9.01 (br.s., 1H) 8.55 (br.s., 1 H) 8.23 (t, J = 5.18 Hz, 1 H) 7.99 (s, 1 H) 7.79 (d, J= 8.08 Hz, 1 H) 7.41 (s, 1 H) 7.35 (d, J = 1.26 Hz, 1 H) 5.88 (s, 1 H)4.86- 4.98 (m, 1 H) 4.76 (s, 2 H) 4.36 (d, J = 5.05 Hz, 2 H) 2.25 (s, 3H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 459.1 7.23 360

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-(3-oxetanyl)-1H-indole-4- carboxamide 1.41(d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.14 (s, 3 H), 2.23 (s, 3 H),4.30-4.39 (m, 3 H), 4.67-4.81 (m, 3 H), 4.96 (dd, J = 8.46, 5.68 Hz, 2H), 5.87 (s, 1 H), 7.03 (d, J = 1.26 Hz, 1 H), 7.25 (d, J = 1.01 Hz, 1H), 7.48 (d, J = 1.26 Hz, 1 H), 8.05 (t, J = 5.05 Hz, 1 H), 11.47(br.s., 1 H). 408 6.54 361

[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-{[6-(4-methyl-1- piperazinyl)-3-pyridinyl]amino}-1H-indole- 4-carboxamide 1.36 (m, 6 H), 2.08 (s, 3 H),2.11 (s, 3 H), 2.21 (s, 3 H), 2.24 (s, 3 H), 2.40-2.47 (m, 4 H),3.33-3.42 (m, 4 H), 4.30 (d, J = 5.05 Hz, 2 H), 4.47 (quin, J = 6.63 Hz,1 H), 5.86 (s, 1 H), 6.60 (d, J = 2.02 Hz, 1 H), 6.81 (d, J = 8.84 Hz, 1H), 6.88 (d, J = 1.77 Hz, 1 H), 7.02 (d, J = 1.01 Hz, 1 H), 7.39 (dd, J= 8.84, 2.78 Hz, 1 H), 7.66 (s, 1 H), 7.95-8.04 (m, 2 H) 542.1 7.26 362

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)- 6-{[(4-methyl-1-piperazinyl)carbonyl]amino}- 1H-indole-4-carboxamide 1.40 (m, 6 H), 2.11(s, 6 H), 2.21 (d, J = 9.09 Hz, 6 H), 2.28-2.35 (m, 4 H), 3.40-3.47 (m,4 H), 4.32 (d, J = 5.31 Hz, 2 H), 4.51 (quin, J = 6.63 Hz, 1 H), 5.87(s, 1 H), 7.03 (d, J = 1.77 Hz, 1 H), 7.12 (d, J = 1.01 Hz, 1 H), 7.73(d, J = 1.77 Hz, 1 H), 7.90 (t, J = 5.05 Hz, 1 H), 8.47 (s, 3 H) 11.47(br.s., 2 H) 493.3 6.89 363

6-{[3- (dimethylamino)propyl]thio}- N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]- 3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide 11.47 (s, 1 H), 8.12 (t, J = 5.1 Hz, 1 H), 7.51(d, J = 1.5 Hz, 1 H), 7.27 (s, 1 H), 6.91 (d, J = 1.3 Hz, 1 H), 5.86 (s,1 H), 4.74 (m, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 2.95 (t, J = 7.2 Hz, 2H), 2.29 (t, J = 7.1 Hz, 2 H), 2.22 (s, 3 H), 2.10 (m, 12 H), 1.65(quin, J = 7.1 Hz, 2 H), 1.39 (d, J = 6.6 Hz, 6 H) 469.1 364

N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-6-(3-hydroxy-3-methyl-1- butyn-1-yl)-3-methyl-1-(1-methylethyl)-1H-indole-4- carboxamide 11.46 (s, 1 H), 8.16 (t, J = 5.1Hz, 1 H), 7.54 (d, J = 1.3 Hz, 1 H), 7.37 (s, 1 H), 6.90 (d, J = 1.3 Hz,1 H), 5.86 (s, 1 H), 5.41 (s, 1 H), 4.75 (m, 1 H), 4.31 (d, J = 5.1 Hz,2 H), 2.21 (s, 3 H), 2.11 (s, 3 H), 2.14 (s, 3 H), 1.47 (s, 6 H), 1.39(d, J = 6.6 Hz, 6 H) 434.0 365

6-(3-hydroxy-3-methyl-1- butyn-1-yl)-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2- oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole- 4-carboxamide 11.48 (s, 1 H), 8.12 (t, J =5.1 Hz, 1 H), 7.55 (d, J = 1.3 Hz, 1 H), 7.38 (s, 1 H), 6.90 (d, J = 1.3Hz, 1 H), 5.89 (s, 1 H), 5.41 (s, 1 H), 4.76 (m, 1 H), 4.32 (d, J = 4.8Hz, 2 H), 2.54 (s, 1 H), 2.13 (d, J = 9.3 Hz, 6 H), 1.55 (m, 2 H), 1.47(s, 6 H), 1.40 (m, 6 H), 0.93 (t, J = 7.3 Hz, 3 H) 462.1 366

6-(cyclopropylethynyl)-3- methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.48 (s, 1 H), 8.09 (t, J = 4.9 Hz, 1 H), 7.54 (d, J =1.3 Hz, 1 H), 7.35 (s, 1 H), 6.87 (d, J = 1.3 Hz, 1 H), 5.89 (s, 1 H),4.72 (quin, J = 6.6 Hz, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 2.13 (d, J =4.0 Hz, 6 H), 1.54 (m, 3 H), 1.38 (d, J = 6.6 Hz, 6H), 0.93 (t, J = 7.3Hz, 3 H), 0.87 (m, 2 H), 0.71 (m, 2 H) 444.1

Example 367N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamidea) Methyl 7-methyl-1H-indole-4-carboxylate

Under N2 atmosphere, 7-methyl-1H-indole-4-carboxylic acid (1 g, 5.71mmol), sulfuric acid (300 μL, 5.63 mmol) and methanol (50 mL) wereheated at reflux for 10 h. The MeOH was removed in vacuo and the residuedissolved in 30 mL DCM. The solution was washed with water and saturatedNaHCO₃, dried over MgSO₄, filtered and concentrated. The residue waspurified by column chromatography (Biotage; 0% to 100% EtOAc:Hex; 25g-HP-silica gel column) to give the title compound. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.59 (s, 3H), 4.00 (s, 3H), 7.08 (d, J=7.58 Hz, 1H),7.20-7.26 (m, 1H), 7.38 (t, J=2.78 Hz, 1H), 7.88 (d, J=7.58 Hz, 1H),8.32 (br. s., 1H).

b) Methyl 7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

A cooled (ice/water bath) solution of methyl7-methyl-1H-indole-4-carboxylate (260 mg, 1.374 mmol) in DMF (20 mL) wasadded sodium hydride (43.4 mg, 1.718 mmol). After 10 minutes2-iodopropane (0.151 mL, 1.512 mmol) was added and the reaction wasstirred for 16 h. LCMS showed reaction only 10% complete. Added sodiumhydride (43.4 mg, 1.718 mmol) followed by 2-iodopropane (0.151 mL, 1.512mmol). After 2 hours LCMS showed reaction was 15% compete. Added moresodium hydride (43.4 mg, 1.718 mmol) and let stir for 5 minutes, thenadded more 2-bromopropane (0.142 mL, 1.512 mmol). Heated to 70° C. for16 h. LCMS showed reaction 50% complete. Concentrated reaction mixture.Added DCM and washed with water and brine, dried over MgSO₄, filteredand concentrated. The residue was purified by column chromatography(Biotage; 0% to 100% DCM:Hex; 25 g-HP-silica gel column) to give 137 mgof the title compound. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48-1.60(m, 6H), 2.78 (s, 3H), 3.94-4.02 (m, 3H), 5.17 (dt, J=13.20, 6.66 Hz,1H), 6.96 (d, J=7.83 Hz, 1H), 7.28 1H, 7.40 (d, J=3.28 Hz, 1H), 7.81 (d,J=7.58 Hz, 1H). MS(ES) [M+H]⁺ 232.1

c) 7-Methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (137 mg, 0.592 mmol)in ethanol (30 mL) was added 1 N sodium hydroxide (2.369 mL, 2.369mmol). The mixture was heated at reflux for 2 h, at which time it wasconcentrated. The residue was dissolved in water (20 mL) and acidifiedby addition of 1 N HCl. The mixture was extracted with DCM (4×30 mL) andthe combined extracts and washed with water and brine, dried over MgSO₄,filtered and concentrated to give 104 mg of the title compound. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.55 (d, 6H), 2.82 (s, 3H), 5.11-5.28 (m,1H), 7.00 (d, J=7.83 Hz, 1H), 7.31 (d, J=3.54 Hz, 1H), 7.44 (d, J=3.28Hz, 1H), 7.89 (d, J=7.58 Hz, 1H). MS(ES) [M+H]⁺ 218.3.

d)N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

Added 7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (52 mg,0.239 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (56.4 mg,0.299 mmol), 1-hydroxy-7-azabenzotriazole (65.2 mg, 0.479 mmol), EDC (92mg, 0.479 mmol) and N-methylmorpholine (0.105 mL, 0.957 mmol) toDimethyl Sulfoxide (DMSO) (10 mL) and stirred at RT for 16 h. Added 25ml of water and let stir for 10 minutes. Filtered off solids. Dissolvedsolids in DCM, washed with water, dried over MgSO₄, filtered andconcentrated. The residue was purified by column chromatography(Biotage; 0% to 20% gradient MeOH:DCM; 10 g-HP-silica gel column) togive 55 mg ofN-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 (d, 6H), 2.24 (s, 3H), 2.44(s, 3H), 2.75 (s, 3H), 4.63 (d, J=4.55 Hz, 2H), 5.17 (dt, J=13.20, 6.66Hz, 1H), 5.97 (s, 1H), 6.91 (d, J=7.58 Hz, 1H), 7.01 (d, J=3.54 Hz, 1H),7.29 (d, J=3.28 Hz, 1H), 7.39 (d, J=7.33 Hz, 1H), 7.69 (br. s., 1H),12.59 (br. s., 1H). MS(ES) [M+H]⁺ 352.4.

Example 3687-Methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide

7-Methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamidewas prepared following the procedure of Example 367. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.95-1.07 (m, 3H), 1.50 (d, J=6.57 Hz, 6H), 1.63(qt, J=7.56, 7.36 Hz, 2H), 2.27 (s, 3H), 2.68-2.82 (m, 5H), 4.64 (d,J=2.53 Hz, 2H), 5.17 (dq, J=6.82, 6.65 Hz, 1H), 6.04 (s, 1H), 6.91 (d,J=7.58 Hz, 1H), 7.00 (d, J=3.54 Hz, 1H), 7.31 (d, J=3.54 Hz, 1H), 7.39(d, J=7.33 Hz, 1H), 7.64 (br. s., 1H), 12.13 (br. s., 1H). MS(ES) [M+H]⁺380.2.

Example 3691-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide

a) 7-(Methyloxy)-1-(phenylsulfonyl)-1H-indole

To a cooled (ice water bath) solution of 7-(methyloxy)-1H-indole (3 g,20.38 mmol) in DMF (100 mL) was added sodium hydride (0.618 g, 24.46mmol) portionwise. After 15 minutes a solution of benzenesulfonylchloride (3.94 mL, 30.6 mmol) in 20 ml of DMF was added dropwise. Thereaction mixture was stirred at RT for 24 h, at which time it wasconcentrated. The residue was dissolved in DCM (100 ml) and washed withwater and brine, dried over MgSO₄, filtered and concentrated. Theresidue was purified by column chromatography (Biotage; 0% to 100%DCM:Hex; 50 g-HP-silica gel column) to give 3.65 g of the titlecompound. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.65 (s, 3H), 6.60-6.75(m, 2H), 7.08-7.22 (m, 2H), 7.40-7.62 (m, 3H), 7.77-7.92 (m, 3H). MS(ES)[M+H]⁺ 288.0.

b) Methyl 7-(methyloxy)-1-(phenylsulfonyl)-1H-indole-4-carboxylate

To a cooled (0° C.) suspension of aluminium chloride (8.47 g, 63.5 mmol)in DCM (100 mL) was added oxalyl chloride (5.56 mL, 63.5 mmol) dropwise.After stirring for 30 minutes a solution of7-(methyloxy)-1-(phenylsulfonyl)-1H-indole (3.65 g, 12.70 mmol) in DCM(15 ml) was added dropwise. The reaction was stirred at RT for 1 h, atwhich time it was poured into brine and extracted with DCM. The DCMextracts were dried over MgSO₄, filtered, and evaporated to dryness.Added 100 ml of MeOH to the residue and heated at reflux for 3 h. Themixture was concentrated and the residue purified by columnchromatography (Biotage; 0% to 100% DCM:Hex; 50 g-HP-silica gel column)to give 2.3 g of the title compound. ¹H NMR (400 MHz, CHLOROFORM-d) δppm 3.70 (s, 3H), 3.95 (s, 3H), 6.67 (d, J=8.59 Hz, 1H), 7.41 (d, J=3.79Hz, 1H), 7.46-7.53 (m, 2H), 7.54-7.62 (m, 1H), 7.79-7.86 (m, 2H), 7.94(d, J=8.59 Hz, 1H), 7.98 (d, J=3.54 Hz, 1H). MS(ES) [M+H]⁺ 346.0.

c) Methyl 1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylate

To a cooled (ice/water bath) solution of methyl7-(methyloxy)-1H-indole-4-carboxylate (350 mg, 1.706 mmol) in DMF (20mL) was added sodium hydride (56.0 mg, 2.217 mmol). After 10 minutesadded 2-iodopropane (0.188 mL, 1.876 mmol). The reaction was stirred atRT for 1 h, followed by heating at 50° C. for 2 h. The reaction was thencooled in an ice water bath and more sodium hydride (56.0 mg, 2.217mmol) and 2-iodopropane (0.188 mL, 1.876 mmol) were added. The reactionwas heated at 50° C. for 3 h, at which time it was concentrated. Theresidue was dissolved in DCM and washed with water and brine, dried overMgSO₄, filtered and concentrated to give 400 mg of the title compound.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 (d, 6H), 3.95 (s, 3H), 4.01(s, 3H), 5.46 (dt, J=13.39, 6.69 Hz, 1H), 6.66 (d, J=8.34 Hz, 1H), 7.15(d, J=3.03 Hz, 1H), 7.34 (d, J=3.28 Hz, 1H), 7.87 (d, J=8.34 Hz, 1H).MS(ES) [M+H]⁺ 248.2.

d) 1-(1-Methylethyl)-7-(methyloxy)-1H-indole-4-carboxylic acid

Added 1 N sodium hydroxide (6.47 mL, 6.47 mmol) to a solution of methyl1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylate (400 mg, 1.618mmol) in ethanol (30 mL) and heated at reflux for 3 h. The EtOH wasremoved in vacuo and the residue dissolved in 20 ml of water. Acidifedsolution by addition of 1 N HCl and extracted with DCM. the combined DCMextracts were washed with water and brine, dried over MgSO₄, filteredand concentrated to give 350 mg of the title compound. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.51 (d, 6H), 4.03 (s, 3H), 5.47 (dt, J=13.39, 6.69Hz, 2H), 6.70 (d, J=8.34 Hz, 2H), 7.23 (d, J=3.28 Hz, 2H), 7.37 (d,J=3.03 Hz, 2H), 7.99 (d, J=8.34 Hz, 2H). MS(ES) [M+H]⁺ 234.0.

e)1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide

Added 1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylic acid (160mg, 0.686 mmol), 3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (186mg, 0.857 mmol), 1-hydroxy-7-azabenzotriazole (187 mg, 1.372 mmol), EDC(263 mg, 1.372 mmol) and N-methylmorpholine (0.302 mL, 2.74 mmol) toDMSO (10 mL) and stirred mixture at RT for 16 h. Added 25 ml of waterand stirred for 10 minutes. Filtered off solids and dried in vacuo. Thesolids were purified by column chromatography (Biotage; 0% to 15%gradient MeOH:DCM; 10 g-HP-silica gel column) to give 165 mg of1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.01 (t, 3H), 1.45 (d, J=6.57 Hz,6H), 1.63 (m, J=7.45, 7.45, 7.45, 7.45, 7.33 Hz, 2H), 2.24 (s, 3H), 2.74(t, J=7.58 Hz, 2H), 3.96 (s, 3H), 4.64 (br. s., 2H), 5.45 (quin, J=6.63Hz, 1H), 5.97 (s, 1H), 6.62 (d, J=8.08 Hz, 1H), 6.94 (d, J=3.28 Hz, 1H),7.24 (d, J=3.28 Hz, 1H), 7.53 (d, J=8.08 Hz, 1H), 7.74 (br. s., 1H),12.46 (br. s., 1H). MS(ES) [M+H]⁺ 395.7.

Example 370N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxamide

N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxamidewas prepared following the procedure of Example 369. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.45 (d, 6H), 2.21 (s, 3H), 2.43 (s, 3H), 3.96 (s,3H), 4.63 (d, J=5.56 Hz, 2H), 5.35-5.57 (m, 1H), 5.94 (s, 1H), 6.61 (d,J=8.34 Hz, 1H), 6.94 (d, J=3.28 Hz, 1H), 7.23 (d, J=3.03 Hz, 1H), 7.52(d, J=8.08 Hz, 1H), 7.66 (br. s., 1H), 12.73 (br. s., 1H). MS(ES) [M+H]⁺368.1.

Example 3716-chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl 6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate

To a stirred solution of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.50 g,1.451 mmol), Trimethylboroxine (0.30 mL, 2.146 mmol) and potassiumcarbonate (0.31 g, 2.243 mmol) in 1,4-Dioxane (20 mL) under N₂ was addedpalladium tetrakis (0.18 g, 0.156 mmol). The reaction was heated to 110°C. and stirred for 18 hr. After 3 hr an additional 100 uLTrimethylboroxine was added. The reaction was concentrated under vacuum,taken up in EtOAc, washed with water, dried (MgSO₄), filtered andconcentrated under vacuum. Purification by silica gel chromatography(Analogix, SF25-60 g, 0 to 10% EtOAc in hexanes) gave the product methyl6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate (0.33 g, 1.180mmol, 81% yield) as a clear thick oil. ¹H NMR (400 MHz, DMSO-d₆) 6=7.80(d, J=2.0 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 4.81 (dt, J=6.9, 13.9 Hz,1H), 3.87 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H), 1.51 (d, J=7.1 Hz, 6H)

MS(ES)+m/e 280.1 [M+H]⁺.

b)6-Chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

To a stirred solution of methyl6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate (320 mg, 1.144mmol) in Methanol (12 mL) and Tetrahydrofuran (THF) (4 mL) was added 1 NNaOH (4 mL, 4.00 mmol). The reaction was refluxed (70° C. oil bath) for18 h. The reaction was concentrated under vacuum, diluted with water,acidified with 1 N HCl (4 mL), filtered, washed with water and driedunder vacuum to give the carboxylic acid (0.30 g, 1.14 mmol, 100%) as alight yellow solid. MS(ES)+m/e 266.1 [M+H]⁺.

To the carboxylic acid above was added3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (230 mg, 1.276 mmol),HOAt (160 mg, 1.176 mmol), Dichloromethane (12 mL) andN,N-Dimethylformamide (4.00 mL) to dissolve. With stirring was added EDCfree base (210 mg, 1.353 mmol) and the reaction stirred at RT for 3 hr.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness under vacuum then purified by silica gel chromatography(SF25-40 g, 50 to 100% EtOAc in CH₂Cl₂) (streaked off). The purefractions were combined and evaporated under vacuum. The remaining solidwas triturated with 25% CH₂Cl₂ in hexanes, filtered, washed with hexanesand dried under vacuum to give the product6-chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide(431 mg, 1.007 mmol, 88% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=11.49 (s, 1H), 8.16 (t, J=5.1 Hz, 1H), 7.58 (d, J=1.8 Hz,1H), 6.82 (d, J=1.8 Hz, 1H), 5.89 (s, 1H), 4.75 (dt, J=6.9, 13.9 Hz,1H), 4.31 (d, J=5.1 Hz, 2H), 2.52 (2H under DMSO), 2.33 (s, 3H), 2.12(s, 3H), 2.04 (s, 3H), 1.61-1.51 (m, 2H), 1.49 (d, J=6.8 Hz, 6H), 0.94(t, J=7.3 Hz, 3H). MS(ES)+m/e 428.3 [M+H]⁺.

Example 3726-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred mixture of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (1.0 g,2.90 mmol), potassium ((dimethylamino)methyl)trifluoroborate (0.5 g,3.03 mmol) and Potassium phosphate (1.9 g, 8.95 mmol) (purged with N₂))in dioxane (3 mL) and water (3 mL) was added palladium(II) acetate (25mg, 0.111 mmol) and sPhos (90 mg, 0.219 mmol). The reaction was heatedto 100° C. and stirred for 18 hr under N₂. LCMS showed that the reactionwas complete. The reaction was diluted with EtOAc and water, andfiltered to remove insolubles. The EtOAc phase was removed, dried(Na₂SO₄), filtered, and concentrated under vacuum. The crude waspurified by silica gel chromatography (Analogix, SF25-40 g, 0 to 2% (5%NH₄OH/MeOH) in CH₂Cl₂). The product fractions were combined, evaporatedto dryness under vacuum to give the product methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate(0.45 g, 1.394 mmol, 48.0% yield) as a light yellow oil (Only 84% pureby LCMS). This was used as is in the next reaction. ¹H NMR (400 MHz,DMSO-d₆) 6=7.82 (d, J=1.8 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 4.96 (dt,J=7.1, 14.1 Hz, 1H), 3.88 (s, 3H), 3.52 (s, 2H), 2.17 (s, 3H), 2.16 (s,6H), 1.53 (d, J=7.1 Hz, 6H). MS(ES)+m/e 323.2 [M+H]⁺, 278.1 [M+H]⁺ −45(HNMe₂).

b)6-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt

To methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate(0.44 g, 1.363 mmol) was added 6 N HCl (20 ml, 120 mmol). The reactionwas purged with N₂, attached a reflux condensor, heated to 80° C., andstirred for 18 hr. LCMS showed that the reaction was complete. Thereaction was cooled to RT, diluted with an equal volume of water, washedwith EtOAc, and evaporated to dryness under vacuum to give the product6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt (0.42 g, 1.216 mmol, 89% yield) as a beigesolid. (86% pure by LCMS, contains ˜10% of the des-chloro side productfrom the previous reaction.) Used as is in the next step. ¹H NMR (400MHz, DMSO-d₆) 6=13.19 (br. s., 1H), 10.45 (br. s., 1H), 7.90 (d, J=1.8Hz, 1H), 7.33 (d, J=1.8 Hz, 1H), 4.91 (quin, J=6.9 Hz, 1H), 4.58 (d,J=5.6 Hz, 2H), 2.79 (d, J=4.8 Hz, 6H), 2.34 (s, 3H), 1.58 (d, J=6.8 Hz,6H). MS(ES)+m/e 309.2 [M+H]⁺, 264.1 [M+H]⁺-45 (HNMe₂).

c)6-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

To6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt (0.42 g, 1.216 mmol),3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (0.22 g, 1.221 mmol),HOAt (0.17 g, 1.249 mmol) was added Dichloromethane (16 mL),N,N-Dimethylformamide (4 mL) and N-methylmorpholine (135 μL, 1.228mmol). The mixture was stirred and EDC free base (0.20 g, 1.288 mmol)was added. After stirring for 2 hr LCMS showed that the reaction wascomplete. The reaction was evaporated to dryness under vacuum andpurified by silica gel chromatography (Analogix, SF25-60 g, 0 to 8% (5%NH₄OH in MeOH) in CH₂Cl₂). The pure fractions were combined, evaporatedto dryness then taken up in 20% EtOAc in hexanes. Scratchingcrystallized out the product which was filtered and washed with hexanesto give the product6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide(362 mg, 0.769 mmol, 63.2% yield) as an off-white solid. ¹H NMR (400MHz, DMSO-d₆) 6=11.49 (s, 1H), 8.24 (t, J=4.9 Hz, 1H), 7.61 (d, J=1.8Hz, 1H), 6.83 (d, J=1.8 Hz, 1H), 5.89 (s, 1H), 4.91 (quin, J=7.0 Hz,1H), 4.31 (d, J=5.1 Hz, 2H), 3.47 (s, 2H), 2.52 (2H under DMSO), 2.14(s, 6H), 2.12 (s, 3H), 2.10 (s, 3H), 1.62-1.53 (m, 2H), 1.51 (d, J=7.1Hz, 6H), 0.94 (t, J=7.3 Hz, 3H). MS(ES)+m/e 471.3 [M+H]⁺.

Example 3732-(2-Aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl2-(2-((tert-butoxycarbonyl)amino)ethyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred mixture of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.37 g,1.074 mmol), potassium(2-((tert-butoxycarbonyl)amino)ethyl)trifluoroborate (0.30 g, 1.195mmol) and Cs₂CO₃ (1.0 g, 3.07 mmol) (purged with N₂) in toluene (12 mL)and water (4 mL) was added palladium(II) acetate (20 mg, 0.089 mmol) andRuPhos (80 mg, 0.171 mmol). The reaction was heated to 95° C. andstirred for 18 hr under N₂. LCMS still showed SM. Another portion ofpalladium(II) acetate (20 mg, 0.089 mmol) and RuPhos (80 mg, 0.171 mmol)was added and the reaction stirred at 95° C. for another 18 hr. LCMSshowed that the reaction was now mostly done. The reaction was dilutedwith EtOAc and water, and filtered to remove insolubles. The EtOAc phasewas removed, dried (MgSO₄), filtered, and concentrated under vacuum. Thecrude was purified by silica gel chromatography (Analogix, SF25-60 g, 0to 25% EtOAc in hexanes). Three fractions were collected. The firstfraction contained a significant amount of the desbromo product, thesecond fraction was a mixture of unknowns, and the last fractioncontained product (Note; opposite order from the TLC). The productfractions were combined, evaporated to dryness under vacuum, trituratedwith hexanes, filtered and dried under vacuum to give the product methyl2-(2-((tert-butoxycarbonyl)amino)ethyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate(148 mg, 0.362 mmol, 33.7% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) 6=7.81 (d, J=1.5 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 7.00 (t,J=5.6 Hz, 1H), 3.87 (s, 3H), 3.07 (q, J=6.7 Hz, 2H), 2.97-2.85 (m, 2H),2.13 (s, 3H), 1.56 (d, J=7.1 Hz, 6H), 1.36 (s, 9H). MS(ES)+m/e 409.2[M+H]⁺.

b)2-(2-Aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

3-Methyl-1H-indole-4-carboxylate (140 mg, 0.342 mmol) in Methanol (9 mL)and Tetrahydrofuran (3 mL) was added 1 N NaOH (2 mL, 2.000 mmol). Thereaction was refluxed (70° C. oil bath) for 18 h (reaction proceededvery slowly at 60° C. with only 1 mL 1 N NaOH). The reaction wasconcentrated under vacuum, diluted with water, acidified with 1 N HCl (2mL), filtered, washed with water and dried under vacuum to give thecarboxylic acid (0.14 g, 0.354 mmol, 100%) as a white solid. MS(ES)+m/e395.0 [M+H]⁺.

To the carboxylic acid above was added3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (80 mg, 0.444 mmol),HOAt (60 mg, 0.441 mmol), Dichloromethane (12 mL) andN,N-Dimethylformamide (3.00 mL) to dissolve. With stirring was added EDCfree base (70 mg, 0.451 mmol) and the reaction stirred at RT overnight.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness under vacuum then purified by silica gel chromatography(SF25-40 g, 50 to 100% EtOAc in CH₂Cl₂) to give the Boc protected finalproduct (0.20 g, 3.59 mmol, 100%) as a white solid. MS(ES)+m/e 557.3[M+H]⁺.

The above was dissolved with MeOH (5 mL) then treated, while stirring,with a solution of 4 N HCl in dioxane (10 mL, 40.0 mmol). The reactionwas stirred for 30 minutes then evaporated to dryness under vacuum. Thesolid was triturated with Et₂O, filtered, washed with hexanes and driedunder vacuum to give the product2-(2-aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamidehydrochloride salt (161 mg, 0.326 mmol, 95% yield) as a light yellowsolid. MS(ES)+m/e 457.2 [M+H]⁺.

Intermediates Intermediate 13-(Aminomethyl)-4,6-dimethyl-2(1H)-pyridinone hydrochloride

Palladium on carbon (10%) (3.24 g) was charged into a 2 L dry Parrbottle and a small amount of acetic acid was added. Next added4,6-dimethyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile (30 g, 202.7mmol), sodium acetate (30.75 g, 375.0 mmol), platinum oxide (0.218 g),and acetic acid (1 L). The bottle was capped, placed on Parr apparatus,and shaken under an atmosphere of H₂ (100 psi) for 2 days. The reactionmixture was filtered. The solvent was removed to give a residue, whichwas treated with 150 mL of conc. HCl, and the formed solids werefiltered. The yellow filtrate was concentrated. To the crude compoundwas added 30 mL of conc. HCl and 150 mL EtOH, the contents cooled to 0°C., and stirred at 0° C. for 2 h. The formed solids were filtered,washed with cold EtOH, ether, and dried. The product was collected as 36g. This batch was combined with other batches prepared on smaller scalesand triturated with ether to give 51 g of pure compound. ¹H NMR (400MHz, DMSO-d₆) δ ppm 11.85 (br s, 1H) 8.13 (br s, 3H) 5.93-6.01 (m, 1H)3.72-3.80 (m, 2H) 2.22 (s, 3H) 2.16 (s, 3H).

Intermediate 23-(Aminomethyl)-6-methyl-4-(trifluoromethyl)-2(1H)-pyridinone

To a dried 500 mL Parr bottle equipped with nitrogen inlet were addedsodium acetate (1.502 g, 18.30 mmol), 10% palladium on carbon (1.579 g,0.742 mmol), platinum(IV) oxide (0.011 g, 0.049 mmol) and a small amountof acetic acid to wet the catalysts, under nitrogen stream. Next wasadded 2-hydroxy-6-methyl-4-(trifluoromethyl)-3-pyridinecarbonitrile (2.0g, 9.89 mmol) followed by acetic acid (175 mL) while under nitrogenatmosphere. The contents were sealed, placed on a Parr shaker, andreacted at 40 psi of H₂ for ca. 6 hr, keeping the H₂ psi between 20 and40 psi (vessel was refilled twice). The vessel was purged with nitrogenand the reaction mixture filtered through Celite, and the filter pad wasfurther washed with a small amount of acetic acid. The volatiles wereremoved in vacuo to afford a residue, which was dried under high vacuumfor 45 min. The solid was suspended in conc. HCl (12 mL), stirred, andfiltered. The clear filtrate was concentrated in vacuo and the residuedried under high vacuum. The collected solid was suspended in conc. HCl(2 mL) and diluted with EtOH (13 mL). The contents were agitated andstored at ca. 0° C. (freezer) for 30 min to give a white solid. Thesolid was filtered and washed with cold ethanol (5 mL). The solid wasfiltered and dried in vacuum oven for 1 h to give3-(aminomethyl)-6-methyl-4-(trifluoromethyl)-2(1H)-pyridinone (0.95 g,40%). LCMS E-S(M+H)=206.9. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.31 (s, 3H),3.40-3.62 (m, 2H), 3.87 (d, J=5.05 Hz, 2H), 8.12-8.37 (m, 3H).

Intermediate 3 3-(Aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone

3a) 4-Cyclohexyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred suspension of CrCl₂ (58 g, 472.8 mmol) in THF (1500 mL) wasadded a THF solution (500 mL) of 1,1-dichloro-2-propanone (10 g, 78.8mmol) and cyclohexanecarbaldehyde (8.84 g, 78.8 mmol). The reactionmixture was heated at reflux for 2 h, and then quenched by the additionof 1.0 M HCl. The reaction mixture was filtered through a pad of Celiteand concentrated in vacuo. The crude residue (10 g) was added to asolution of DMSO (150 mL) containing t-BuOK (7.5 g, 65.7 mmol) andcyanoacetamide (6.1 g, 72.3 mmol) and stirred at room temperature for 30min. Additional t-BuOK (22.5 g, 197.1 mmol) was added and the reactionmixture was stirred under an atmosphere of oxygen for an additional 1 h.The contents were purged with argon, diluted with 4 volumes of H₂O, andthen 5 volumes of 4 N HCl, which were added slowly. The reaction mixturewas filtered, washed with water and dried to give4-cyclohexyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (4.5 g,32%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 6.25 (s, 1H), 2.61-2.65 (m, 1H),2.22 (s, 3H), 1.66-1.79 (m, 4H), 1.24-1.46 (m, 6H).

3b) 3-(Aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone

To an ice-bath cooled THF (100 mL) solution of the product from step 1(2 g, 9.26 mmol) was added NaBH₄ (0.81 g, 21.3 mmol) and I₂ (2.3 g, 9.26mmol), and the mixture stirred for 30 min. The reaction mixture was thenheated at reflux for 3 h, and then allowed to cool to room temperature.After cooling to 0° C., the reaction mixture was acidified by slowaddition of 3 N HCl (1 mL). The reaction mixture was concentrated invacuo and the crude product purified by reverse phase HPLC to give3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone as a solid (0.5g, 25%). LCMS E-S(M+H)=221.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9(br s, 1H), 7.80-7.93 (br s, 3H), 6.07 (s, 1H), 3.69 (s, 2H), 2.67-2.75(m, 1H), 2.17 (s, 3H), 1.58-1.72 (m, 5H), 1.19-1.41 (m, 5H).

Intermediate 4 3-(Aminomethyl)-4-cyclopropyl-6-methyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone (Intermediate 3)using 4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (5g, 28.7 mmol). Obtained: 0.50 g (10%). LCMS E-S(M+H)=179.1. ¹H NMR (400MHz, DMSO-d₆) δ ppm 11.76-11.78 (br s, 1H), 7.82-7.92 (br s, 3H), 5.61(s, 1H), 3.94-3.99 (m, 2H), 2.11 (s, 3H), 1.98-2.05 (m, 1H), 0.95-1.01(m, 2H), 0.74-0.79 (m, 2H).

Intermediate 5 3-(Aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone

5a) 6-Methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile

To a solution of DMSO (300 mL) containing t-BuOK (20 g, 178 mmol) andcyanoacetamide (16.5 g, 196 mmol) was added (3E)-3-hepten-2-one (20 g,178 mmol), and the contents were stirred at room temperature for 30 min.Additional t-BuOK (60 g, 534 mmol) was added and the reaction mixturewas placed under an atmosphere of oxygen for an additional 1 h. Thereaction mixture was purged with argon, diluted with 4 volumes of H₂O,and then 5 volumes of 4 N HCl, which were added slowly. The reactionmixture was filtered, washed with water, and dried to give6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile (10 g, 32%).¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.25-12.40 (br s, 1H), 6.18 (s, 1H),2.53 (t, 2H), 2.22 (s, 3H), 1.57-1.64 (m, 2H), 0.84 (t, 3H).

5b) 3-(Aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone (Intermediate 3)using 6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile (2 g,11.2 mmol). Obtained: 1.2 g (60%). LCMS E-S(M+H)=181.1. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 7.85-7.95 (br s, 3H), 5.99 (s, 1H), 3.80-3.85 (m, 2H),2.42 (t, 2H), 2.14 (s, 3H), 1.43-1.49 (m, 2H), 0.86 (t, 3H).

Intermediate 6 3-(Aminomethyl)-6-methyl-4-phenyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (Intermediate 5)using (3E)-4-phenyl-3-buten-2-one (20 g, 137 mmol). LCMS E-S(M+H)=215.0.¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.2-12.3 (br s, 1H), 7.88-8.00 (br s,3H), 7.43-7.51 (m, 3H), 7.29-7.38 (m, 2H), 6.08 (s, 1H), 3.67-3.70 (m,2H), 2.23 (s, 3H).

Intermediate 73-(Aminomethyl)-6-methyl-4-(1-methylethyl)-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (Intermediate 5)using (3E)-5-methyl-3-hexen-2-one (20 g, 137 mmol). LCMS E-S(M+H)=181.1.¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9 (br s, 1H), 7.86-7.96 (br s,3H), 6.10 (s, 1H), 3.82-3.86 (m, 2H), 3.02-3.09 (m, 1H), 2.17 (s, 3H),1.08 (d, 6H).

Intermediate 8 3-(Aminomethyl)-4-methyl-6-propyl-2(1H)-pyridinone

8a) 4-Methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinecarbonitrile

To a solution of NaNH₂ (32.5 g, 862 mmol) in anhydrous ether (500 mL) at30° C. was added dropwise a mixture of butyric acid ethyl ester (50 g,431 mmol) and acetone (37.5 g, 646.5 mol). After addition, the reactionmixture was stirred for 4 h. The reaction mixture was poured onto icewater with stirring. Additional ether was added, and the layers wereseparated. The aqueous layer was acidified to pH 5.0 with 2 N HCl andthen to pH 7.5 with Na₂CO₃. The aqueous layer was then extracted withether. The combined organic layers were dried over Na₂SO₄, filtered, andconcentrated in vacuo. The crude product, 2,4-heptanedione (20 g, 156mmol), and 2-cyanoacetamide (13.12 g, 156 mmol) were suspended in EtOH(160 mL) at 75° C., followed by addition of piperidine (13.2 g, 156mmol). The contents were stirred and heated at reflux for 1 h. Themixture was cooled to room temperature and filtered. The collected solidwas suspended in water and stirred for 1 h. The mixture was filtered anddried to give 4-methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinecarbonitrile(11 g, 40%). LCMS E-S(M+H)=181.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm12.3-12.4 (br s, 1H), 6.25 (s, 1H), 3.64 (s, 3H), 2.50 (t, 2H), 1.63 (m,2H), 0.94 (t, 3H).

8b) 3-(Aminomethyl)-4-methyl-6-propyl-2(1H)-pyridinone

Sodium acetate (3.5 g, 42.6 mmol), palladium on carbon (0.81 g) andplatinum oxide (0.1 g) were placed in a dried Parr bottle flushed withnitrogen, followed by addition of a small amount of acetic acid (to wetthe catalysts). A solution of4-methyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carbonitrile (5 g, 28mmol) in acetic acid was added to the Parr bottle followed by additionalacetic acid (200 mL). The vessel was capped, placed on Parr apparatusand hydrogenated at 45 psi for 12 h. The reaction mixture was filteredand the filtrate concentrated in vacuo. The crude product was purifiedby preparative HPLC to afford the title compound (TFA salt) as 4.1 g(87%). LCMS E-S (M+H))=181.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9(br s, 1H), 7.83-7.88 (br s, 3H), 5.99 (s, 1H), 3.77-3.81 (m, 2H), 2.37(t, 2H), 1.53 (m, 2H), 0.83 (t, 3H).

Intermediate 9 3-(Aminomethyl)-6-cyclopropyl-4-methyl-2(1H)-pyridinonehydrochloride

9a) 1-Cyclopropyl-1,3-butanedione

To a stirring solution of THF (100 mL) was added potassium tert-butoxide(5.60 g, 49.5 mmol), followed by a mixture of cyclopropyl methyl ketone(3.27 mL, 33 mmol) and ethyl acetate (9.69 mL, 99 mmol) in 30 mL THF at35° C., via addition funnel over a 25 min period. The contents wereheated and stirred at 60° C. After 3 h, the contents were removed fromheating, and allowed to cool to room temperature. The reaction mixturewas carefully diluted with 30 mL 2 N HCl and stirred for 10 min. Themixture was extracted with diethyl ether (3×50 mL), and the combinedorganic layers washed with brine (1×50 mL). The organic layer was driedover MgSO₄, filtered, and concentrated in vacuo. Purification bychromatography on silica gel (eluent: 0 to 15% EtOAc in hexanes) withgood separation afforded 1-cyclopropyl-1,3-butanedione as a light yellowcolored oil, 3.9 g in ˜75% purity (residual solvent), for an overallyield of 70%. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.89-0.96 (m, 2H), 1.09-1.15(m, 2H), 1.59-1.69 (m, 1H), 2.04 (s, 3H), 5.63 (s, 1H), 15.5-16.0 (br s,1H).

9b) 6-Cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred solution of ethanol (5 mL) were added1-cyclopropyl-1,3-butanedione (505 mg, 3.00 mmol) and cyanoacetamide(252 mg, 3.00 mmol), and the heterogenous contents heated untilhomogenous (ca. 75° C.). Piperidine was added (0.395 mL, 4.00 mmol) andthe mixture was heated at reflux for 30 min. The reaction mixture wasallowed to cool to room temperature, wherein precipitation ensued. Thesolid precipitate was filtered and set aside. The filtrate wasconcentrated in vacuo and the oily residue treated with minimal EtOAcand then 10 mL hexanes to afford a second crop of solid. The solidproduct crops were combined, suspended in water (7 mL), vigorouslystirred, and vacuum filtered to afford6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile as anearly white solid (380 mg, 73%). LCMS E-S(M+H)=175.1. ¹H NMR (400 MHz,CDCl₃) δ ppm 1.01-1.09 (m, 2H), 1.28 (dd, J=8.59, 2.27 Hz, 2H),1.95-2.01 (m, 1H), 2.43 (s, 3H), 5.82 (s, 1H).

9c)1,1-Dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate

6-Cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (0.35 g,2.01 mmol) was added to methanol (20 mL) and the stirred contents cooledto −10° C. Next was added di-tert-butyloxycarbonyl (0.933 mL, 4.02 mmol)and the suspension stirred for 15 min. Next was added in NiCl₂-6H₂O(0.055 g, 0.201 mmol) as a solid and stirred for 5 min. Then NaBH₄(0.532 g, 14.06 mmol) was added in 6 portions with 5 min. incrementsbetween each portion. Then the ice bath was removed and the contentswere stirred with warming to room temperature overnight. The reactionmixture was returned to −10° C., followed by addition of 3 more portionsof NaBH₄ (0.532 g, 14.06 mmol). The ice bath was removed and the mixturestirred at room temperature for 1 h. The contents were quenched byaddition of diethylethylene amine (0.218 mL, 2.01 mmol) and stirred for45 min at room temperature. The volatiles were removed in vacuo and theresidue suspended in EtOAc and saturated NaHCO₃. The organic layer waswashed with additional NaHCO₃. The layers were separated, and theorganic layer dried over MgSO₄, filtered, and concentrated in vacuo. Thecrude product was purified by silica gel chromatography (eluent: 10%methanol in dichloromethane). The collected product was dried underhi-vacuum for 1 h, and then treated with ether and filtered. Afterdrying in vacuum oven at 45° C. for 2 h,1,1-dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamatewas collected (0.28 g, 50%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.73-0.80(m, 2H), 0.88-0.96 (m, 2H), 1.36 (s, 9H), 1.70-1.82 (m, 1H), 2.11 (s,3H), 3.95 (d, J=5.31 Hz, 2H), 5.66 (s, 1H), 6.51 (t, J=4.80 Hz, 1H),11.50 (br. s., 1H).

9d) 3-(Aminomethyl)-6-cyclopropyl-4-methyl-2(1H)-pyridinonehydrochloride

1,1-Dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(0.28 g, 1.006 mmol) was added to EtOAc (9 mL) and methanol (1.0 mL).The suspension was stirred at room temperature for 5 min, followed byaddition of 4 M HCl in dioxane (5.03 mL, 20.12 mmol), and the contentswere stirred at room temperature overnight. The volatiles were thenremoved in vacuo to afford a solid. The solid was triturated with ether,filtered, and dried in a vacuum oven at 45° C. for 4 h. The titlecompound was collected (0.22 g, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δppm 0.78-0.86 (m, 2H), 0.95-1.03 (m, 2H), 1.83 (tt, J=8.46, 5.05 Hz,1H), 2.16-2.22 (m, 3H), 3.75 (q, J=5.47 Hz, 2H), 5.79 (s, 1H), 8.02 (br.s., 3H), 11.92 (br. s., 1H).

Intermediate 10 3-(Aminomethyl)-4-ethyl-6-methyl-2(1H)-pyridinonehydrochloride

10a) Hex-3-en-2-one

To a stirred solution of 1-(triphenylphosphoranylidene)-2-propanone (100g, 307 mmol) in DCM (500 mL) was added propionaldehyde (140 mL, 1929mmol) at room temperature. The reaction mixture was then stirred at roomtemperature for 18 hours. The reaction was monitored by TLC. The solvent(DCM) was distilled off using ordinary distillation. The residue wasthen distilled using fractional distillation under vacuum (˜450 mbar)and the desired product was isolated. The title compound, hex-3-en-2-one(20 g, 66%), was collected at 110° C. ¹H NMR (CDCl₃, 400 MHz) δ ppm1.071-1.121 (t, 3H, J=7.4 Hz), 2.250-2.299 (m, 5H), 6.054-6.094 (d, 1H,J=16 Hz), 6.823-6.895 (m, 1H).

10b) 4-Ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile

To a stirred solution of t-BuOK (22.85 g, 204.08 mmol) andcyanoacetamide (18.8 g, 224.1 mmol) in DMSO (300 mL) was addedhex-3-en-2-one (20 g, 204.08 mmol) under argon atmosphere at roomtemperature. The reaction mixture was then stirred at room temperaturefor 30 min and then added additional t-BuOK (68.5 g, 612.05 mmol) wasadded. Argon gas was displaced by oxygen gas and the mixture stirred for48 hrs at room temperature in presence of oxygen. Reaction was monitoredby TLC. The reaction mixture was cooled to 0° C. and diluted with water(100 mL) followed by 4 N HCl (120 mL). The mixture was stirred for 15min and the resulting solid was filtered. The solid was washed withwater (1 L) and dried to afford the title compound,4-ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile (10.5 g, 31%),as an off white solid. ¹H NMR (CDCl₃, 400 MHz): δ ppm 1.148-1.185 (t,3H, J=7.4 Hz), 2.237 (s, 3H), 2.557-2.614 (m, 2H), 6.211 (s, 1H), 12.330(broad s, 1H). MS(ES) [M+1-1]⁺161.06.

10c) 3-(Amino methyl)-4-ethyl-6-methylpyridin-2(1H)-one

To a suspension of Raney Nickel (6 g) in methanol (200 mL) was added4-ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile (10 g, 61.7mmol) and methanolic ammonia (750 mL). The reaction mixture was stirredat room temperature under hydrogen pressure (80 psi) for 48 hrs. Thereaction mixture was filtered through Celite and washed with methanol(250 mL). The filtrate was concentrated under reduced pressure and theresidue purified by filter column using silica gel (60-120 mesh), elutedwith 10% MeOH in CHCl₃, to afford 3-(aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one (5.6 g, 54%) as an off whitesolid. ¹H NMR (DMSO-D₆, 400 MHz) (free amine): δ ppm 1.063-1.101 (t, 3H,J=7.6 Hz), 2.101 (s, 3H), 2.412-2.449 (m, 2H), 3.448 (s, 2H), 5.835 (s,1H). MS(ES) [M+H]⁺ 167.06.

10d) 3-(Aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one hydrochloride

3-(Amino methyl)-4-ethyl-6-methylpyridin-2(1H)-one, (5.6 g, 33 mmol) wassuspended in DCM (560 mL) and the insoluble contents/particles werefiltered. The filtrate was concentrated and dried. The residue wasdissolved in DCM (10 mL) and 4 M HCl in 1,4-dioxane (16 mL, 66 mmol) wasadded at 0° C. and stirred for 10 min, at which time the reactionmixture was concentrated under high-vacuum and dried. The resultingcrude solid was triturated with hexane (150 mL) and filtered. The solidwas dried under vacuum. Collected 3-(aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one hydrochloride (5.9 g, 86%). ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.082-1.120 (t, 3H, J=7.6 Hz), 2.179 (s,3H), 2.503-2.544 (m, 2H), 3.785-3.798 (d, 2H, J=5.2 Hz), 6.024 (s, 1H),7.985 (broad s, 2H), 11.858 (broad s, 1H). MS(ES) [M+H]⁺167.2.

Intermediate 11 3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone

11a) 4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a solution of t-BuOK (17.2 g, 153 mmol) and cyanoacetamide (13 g, 153mmol) in CH₃CN (225 mL) was added (3E)-3-hexen-2-one (15 g, 153 mmol) atroom temperature under N₂ atmosphere. The reaction mixture was stirredfor 30 min. To the reaction mixture was added additional t-BuOK (51.4g), and the N₂ was displaced by oxygen. After stirring for 1 h withoutexternal cooling, the mixture was diluted with 4 N HCl, which was addedslowly and with good stirring. The mixture was filtered, washed withEtOH, dried to give6-ethyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (5 g, 21%). ¹HNMR (400 MHz, DMSO-d₆) δ 12.33 (br. s., 1H), 6.18 (s, 1H), 2.45 (q, 2H),2.30 (s, 3H), 1.11 (t, 3H).

11b) 3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone

To an ice bath cooled THF solution (200 mL) of6-ethyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (7 g, 43.2mmol) was added NaBH₄ (4.2 g, 108 mmol), and I₂ (11.2 g, 43.2 mmol), andthe contents were stirred for 30 min. The reaction mixture was thenheated at reflux overnight. The reaction mixture was cooled, andcarefully neutralized by slow addition of 4 N HCl at 0° C. The mixturewas dried over MgSO₄, filtered, and concentrated in vacuo. The productwas purified by HPLC to give3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone as a TFA salt (1.9 g,26.4%). LCMS MH+=167.1 ¹H NMR (400 MHz, DMSO-d₆) δ 11.82 (br. s., 1H),7.82 (br s, 3H), 5.97 (s, 1H), 3.75-3.77 (m, 2H), 2.39 (q, 2H), 2.17 (s,3H), 1.09 (t, 3H).

Intermediate 12 3-(aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one

12a) (2Z)-3-Hydroxy-1-(4-pyridinyl)-2-buten-1-one

To a solution of ethyl 4-pyridinecarboxylate (30 g, 198 mmol) andacetone (34.58 g, 595 mmol) in THF (150 mL) was slowly added NaOMe(12.87 g, 238 mmol) at 35-40° C. The mixture was stirred at roomtemperature for 0.5 h, and then heated at reflux for 3 h. The mixturewas cooled to room temperature and filtered to give a solid, which waswashed with t-BuOMe, and dissolved in H₂O. The solution was acidifiedwith acetic acid and the resulting oily product was extracted withCHCl₃. The solvent was removed in vacuo, and the crude product wasobtained (12 g, 37%) and used without further purification. ¹H NMR (400MHz, DMSO-d₆) δ 8.73 (d, 2H), 7.76 (d, 2H), 6.63 (s, 1H), 2.21 (s, 3H);note: enolic OH does not appear.

12b) 6-Methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile and4-methyl-6-oxo-1,6-dihydro-2,4′-bipyridine-5-carbonitrile

To a solution of (2Z)-3-hydroxy-1-(4-pyridinyl)-2-buten-1-one (8 g,crude, 49 mmol) and cyanoacetamide (4.12 g, 49 mmol) in anhydrous EtOH(100 mL) was added piperidine (4.17 g, 49 mmol) under N₂ at 75° C. Themixture was heated at reflux for 1 h, and then cooled to roomtemperature. After filtration, the solid was collected and washed withH₂O to give the crude product (4 g) as two isomers. After separation byHPLC, 1.8 g of 6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrileand 1.2 g of 4-methyl-6-oxo-1,6-dihydro-2,4′-bipyridine-5-carbonitrilewere obtained. The identity of6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile wasestablished by nOE analysis. ¹H NMR (400 MHz, DMSO-d₆) δ 12.79 (br. s.,1H), 8.75 (d, 2H), 7.58 (d, 2H), 6.37 (s, 1H), 2.31 (s, 3H).

12c) 3-(Aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one

To an ice bath cooled THF (100 mL) solution of6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile (4 g, 18.9mmol) was added NaBH₄ (1.43 g, 37.9 mmol), and I₂(4.81 g, 18.9 mmol),and the mixture was stirred for 0.5 h. The reaction mixture was thenheated at reflux for 4 h. After cooling to 0° C., the reaction mixturewas adjusted to pH 5 with 4 N HCl. The mixture was concentrated in vacuoto give the crude compound, which was purified by HPLC to give3-(aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one (1.9 g, 31%) as a TFAsalt. LCMS MH+=216.0 ¹H NMR (400 MHz, DMSO-d₆ in D₂O) δ 8.87 (d, 2H),7.87 (d, 2H), 6.13 (s, 1H), 3.65 (br s, 2H), 2.17 (s, 3H).

Intermediate 13 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone

13a) Ethyl cyclobutanecarboxylate

To a solution of cyclobutanecarboxylic acid (50 g, 500 mmol) in EtOH(1.2 L) was slowly added H₂SO₄ (20 mL) at room temperature. The solutionwas stirred at reflux overnight, and then cooled and poured into H₂O.The aqueous layer was extracted with ether. The combined organic layerswere washed with brine, dried over Na₂SO₄, and concentrated in vacuo togive ethyl cyclobutanecarboxylate as a colorless oil (44 g, 69%). ¹H NMR(400 MHz, CDCl3-d₃) δ 4.04 (q, 2H), 3.04 (m, 1H), 2.12 (m, 4H), 1.88 (m,2H), 1.18 (t, 3H).

13b) 1-Cyclobutyl-1,3-butanedione

To a solution of NaNH₂ (11.7 g, 91 mmol) in anhydrous ether (150 mL)under N₂ at 30° C. was added dropwise a mixture of ethylcyclobutanecarboxylate (19.2 g, 150 mmol) and acetone (21.75 g, 375mmol). After addition, the reaction mixture was stirred for 4 h, thenpoured onto ice water with stirring. Ether was added and the unreactedcomponents were extracted into the organic phase. The clear aqueousextract was acidified to pH 5.0 with 2 N HCl, and then to pH 7.5 withNa₂CO₃. The solution was extracted with ether. The combined organiclayers were dried (Na₂SO₄), filtered, and concentrated to give the crudeproduct of 1-cyclobutyl-1,3-butanedione (9.7 g, 76%), which was used inthe next step without further purification. ¹H NMR (400 MHz, CDCl3-d₃) δ5.42 (s, 1H), 3.66 (s, 1H), 2.11-2.23 (m, 4H), 2.02 (s, 3H), 1.93-1.99(m, 2H).

13c) 6-Cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a solution of 1-cyclobutyl-1,3-butanedione (1.5 g, 10.7 mmol) andcyanoacetamide (1.07 g, 12.8 mmol) in EtOH (25 mL) was added piperidine(1.08 g, 12.8 mmol) at 75° C. After addition, the mixture was stirredwith warming to reflux. After 1 h, the mixture was cooled to roomtemperature during which time precipitation occurred. The contents werefiltered, and the filtered solid suspended in water and stirred for 1 h.The heterogenous mixture was filtered and dried to give a mixture of6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (1.14 g,57%). ¹H NMR (400 MHz, DMSO-d₆ in D₂O) δ 12.15-12.30 (br s, 2H), 6.39(s, 1H), 6.34 (s, 1H), 2.40-2.28 (m, 7H), 2.23-2.25 (m, 3H), 2.18-2.21(m, 4H), 1.99-2.11 (m, 2H), 1.84-1.90 (m, 2H).

13d) 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone

To an ice bath cooled THF (100 mL) solution of6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (6 g, 32mmol) was added NaBH₄ (2.73 g, 71.8 mmol), and I₂(8.3 g, 32 mmol), andthe mixture was stirred for 30 min. The reaction mixture was then heatedat reflux for 3 h. After cooling to 0° C., the reaction mixture wasadjusted to pH 5 with 6N HCl. The contents were dried, filtered, andconcentrated in vacuo. The crude product was purified by HPLC to give amixture of 3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone (5.6 g, 91%). ¹HNMR (400 MHz, DMSO-d₆) δ 11.60-11.70 (br s, 2H), 7.85 (br s, 4H), 6.15(s, 1H), 6.03 (s, 1H), 3.72-3.79 (m, 2H), 3.29-3.33 (m, 2H), 2.16 (s,6H), 2.05-2.10 (m, 6H), 1.88-1.93 (m, 4H), 1.69-1.79 (m, 4H).

13e)1,1-Dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamateand1,1-dimethylethyl[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate

To an ice bath cooled solution of3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone (3.5 g, 18 mmol)in THF (10 mL) and DMF (10 mL) were added Boc₂O (4.68 g, 21.8 mmol) andtriethylamine (5.4 g, 54 mmol). The contents were then stirred for 30min at 30° C. The reaction was quenched by addition of ice water, duringwhich time precipitation occurred. The reaction mixture was filtered anddried to give a mixture of the crude products. The crude products wereseparated by HPLC to give1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(2.1 g, 20%) and1,1-dimethylethyl[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(1 g, 9.5%). Data for1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate:¹H NMR (400 MHz, DMSO-d₆) δ 11.28 (br s, 1H), 6.49 (br s, 1H), 5.86 (brs, 1H), 3.85 (br s, 2H), 1.97-2.14 (m, 7H), 1.87-1.94 (m, 1H), 1.72-1.77(m, 1H), 1.28 (s, 9H).

13f) 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinonehydrochloride

A solution of1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3pyridinyl)methyl]carbamate(2.1 g, 7.2 mmol) in 4 N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone as an HCl salt(1.95 g, 90%). LCMS MH+=193.1 ¹H NMR (400 MHz, DMSO-d₆) δ 11.70 (br s,1H), 8.01 (s, 3H), 6.04 (s, 1H), 3.74 (d, 2H), 3.32-3.39 (m, 1H), 2.22(s, 3H), 2.17-2.20 (m, 2H), 2.06-2.11 (m, 2H), 1.85-1.95 (m, 1H),1.71-1.79 (m, 1H).

Intermediate 143-(Aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone

14a) 1-(Methyloxy)-2,4-pentanedione

To a solution of sodium (5.83 g, 243.3 mmol) in dry toluene (62.5 mL)was added ethyl (methyloxy)acetate (24 g, 203.4 mmol) at −5° C. Afterstirring for 3 h, acetone (14 g, 231.4 mmol) was slowly added, uponwhich the mixture became brown and viscous. Next added 72 mL oftert-butyl methyl ether, and the reaction mixture was stirred at roomtemperature for 12 h, after which time the sodium salt precipitated.After collection and washing with additional tert-butyl methyl ether,the sodium salt was dissolved in 46 mL of 20% H₂SO₄. The contents wereextracted with tert-butyl methyl ether and the organic layersconcentrated to afford 1-(methyloxy)-2,4-pentanedione (9.76 g, 36.9%).¹H NMR (400 MHz, CDCl3-d₃) δ 5.76 (s, 1H), 3.96 (s, 2H), 3.38 (s, 3H),2.07 (s, 3H).

14b)6-Methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

1-(Methyloxy)-2,4-pentanedione (9.51 g, 73.12 mmol) and cyanoacetamide(6.17 g, 73.12 mmol) were dissolved in EtOH (76 mL) and heated untilhomogenous (ca. 75° C.). Piperidine (6.25 g, 73.12 mmol) was added andthe reaction mixture heated at reflux for 20 mins, followed by coolingto room temperature. The contents were filtered to give a solid whichwas suspended in 140 mL water and stirred vigorously for 20 min. Theheterogenous mixture was filtered to afford6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(7.8 g, 65.6%). LCMS MH+=179.0 ¹H NMR (400 MHz, DMSO-d₆) δ 12.47 (br s,1H), 6.26 (s, 1H), 4.40 (s, 2H), 3.29 (s, 3H), 2.25 (s, 3H).

14c) 3-(Aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone

6-Methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(1.000 g, 5.61 mmol) was suspended in acetic acid (150 ml) and thesolution passed through an H-cube instrument equipped with Raney-Nicartridge at a rate of 1 mL/min at 50psi and 60° C. After 18 h. theacetic acid was removed under reduced pressure and the remaining residuewas dissolved in MeOH. The methanolic solution was passed through a 0.2μm teflon syringe filter. The methanolic filtrate was purified byreverse phase HPLC (Gemini 50×100 5 μm column. Run 1: 3 min, 90-10%. Run2, 5 min 0-10%. Run 3, 10 min, 0-20%. The product fractions wereconcentrated to dryness on a Genevac HT-4 instrument to afford3-(aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone as apale grey waxy solid (900 mg, 70.2% yield) LCMS MH+=183.0 ¹H NMR (400MHz, DMSO-d₆) δ 8.40 (br. s., 1H), 6.10 (s, 1H), 4.39 (s, 2H), 3.66 (br.s., 2H), 3.32 (s, 3H), 2.19 (s, 3H).

Intermediate 153-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone

15a) 1-Phenyl-2,4-pentanedione

To a solution of NaNH₂ (19.02 g, 480 mmol) in anhydrous ether (400 mL)under N₂ at −5° C. was added dropwise ethyl phenylacetate (19.2 g, 150mmol) and then acetone (21.23 g, 370 mmol) with vigorous stirring. Afteraddition, the reaction mixture was stirred at room temperatureovernight. The mixture was then acidified to pH 4.0-5.0 with 1N HCl. Theorganic layer was separated and concentrated in vacuo. The crude productwas purified by silica gel chromatography to give1-phenyl-2,4-pentanedione (18.32 g, 44%). ¹H NMR (400 MHz, CDCl3-d₃) δ15.49 (br s, 1H), 7.33-7.45 (m, 5H), 5.53 (s, 1H), 3.66 (s, 2H), 2.10(s, 3H).

15b) 6-Methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrileand 4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile

1-Phenyl-2,4-pentanedione (18.32 g, 104 mmol) and cyanoacetamide (8.74g, 104 mmol) were dissolved in EtOH (104 mL) and heated until homogenous(ca. 75° C.). Piperidine (8.86 g, 104 mmol) was added and the reactionmixture heated at reflux for 15-30 min. followed by cooling to roomtemperature, during which time precipitation occurred. The heterogenouscontents were filtered to give a solid which was suspended in 200 mLwater and stirred vigorously for 20 min. The heterogenous mixture wasfiltered to afford6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile and4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile(12.06 g, 52%). LCMS MH+=225.1 ¹H NMR (400 MHz, DMSO-d₆) (mixture ofcompounds) δ 7.21-7.31 (m, 10H), 6.06 (s, 2H), 3.89 (s, 2H), 3.79 (s,2H), 2.24 (s, 3H), 2.15 (s, 3H).

15c) 3-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone

Sodium acetate (6.14 g, 74.8 mmol), Pd/C (0.65 g, 1 mmol), and platinum(II) oxide (45 mg, 1 mmol) were placed in a dried Parr bottle equippedwith nitrogen inlet. A small amount of acetic acid was added to wet thecatalysts. A solution of6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile and4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile (6 g,26.7 mmol) in acetic acid (300 mL) was added to the vessel. The contentswere sealed and hydrogenated on Parr shaker at 45 psi for 12 h. Thereaction mixture was filtered and washed with acetic acid. The filtratewas removed under reduced pressure. The residue was washed with methanoland filtered to afford a crude mixture of3-(aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone. The reactionwas run in duplicate to afford a total crude recovery of 14.5 g. To asolution of the above crude product mixture (4.0 g, 17.5 mmol) in THF(10 mL) and DMF (10 mL) was added di-tert-butoxycarbonyl anhydride (5.0g, 23.4 mmoL) and triethylamine (5.2 g, 52.5 mmol) at 0° C. The reactionmixture was stirred with warming to room temperature and then stirredfor an additional 4 h. The contents were diluted with ice water and thenfiltered. The collected solid was dried and the products separated byHPLC to furnish 1.2 g of 1,1-dimethylethyl{[4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(¹H NMR (400 MHz, DMSO-d₆) δ 11.55-1.60 (br s, 1H), 7.20-7.29 (m, 5H),5.85 (s, 1H), 3.92 (s, 2H), 3.90 (s, 2H), 2.10 (s, 3H), 1.32 (s, 9H) and1.0 g of 1,1-dimethylethyl{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(¹H NMR (400 MHz, DMSO-d₆) δ 11.50-11.55 (br s, 1H), 7.18-7.25 (m, 5H),5.75 (s, 1H), 4.02 (s, 2H), 3.85 (s, 2H), 2.05 (s, 3H), 1.32 (s, 9H).

15d) 3-(Aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinonehydrochloride

A solution of 1,1-dimethylethyl{[4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(1.2 g, 3.66 mmol) in 4N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone as an HClsalt (0.725 g, 87%). LCMS MH+=229.1 ¹H NMR (400 MHz, DMSO-d₆) δ11.9-12.0 (br s, 1H), 7.99 (br s, 3H), 7.20 (s, 5H), 5.97 (s, 1H),3.72-3.75 (m, 4H), 2.17 (s, 3H).

15e) 3-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinonehydrochloride

A solution of 1,1-dimethylethyl{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(1.0 g, 3.0 mmol) in 4N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone as an HClsalt (0.600 g, 86%). LCMS MH+=229.1 ¹H NMR (400 MHz, DMSO-d₆) δ11.9-12.0 (br s, 1H), 8.03 (br s, 3H), 7.16-7.30 (m, 5H), 5.84 (s, 1H),3.91 (s, 2H), 3.81 (s, 2H), 2.10 (s, 3H).

Intermediate 163-(Aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone

a) 5-(4-Morpholinyl)-3-pentyn-2-one

To a cooled (˜40° C., CH₃CN/CO₂) solution of 4-(2-propyn-1-yl)morpholine(2.2 g, 17.58 mmol) in THF (5 mL) was added dropwise via. syringe underN₂ a solution of 2 M isopropylmagnesium chloride in THF (10 mL, 20.00mmol). The reaction was stirred for 1 hr then a solution ofN-methoxy-N-methylacetamide (2.2 mL, 20.69 mmol) in THF (5 mL) was addedin one portion. The reaction was stirred for 2 hr (allowed to slowlywarm to RT), quenched with aq. NH₄Cl, extracted with EtOAc, washed withbrine, dried (Na₂SO₄), filtered and evaporated to dryness under vacuum.The remaining was purified by silica gel chromatography (Analogix,SF25-60 g, 0 to 80% EtOAc in hexanes). The pure fractions were combinedand evaporated to dryness to give the product5-(4-morpholinyl)-3-pentyn-2-one (2.09 g, 12.50 mmol, 71.1% yield) as ayellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 3.62-3.57 (m, 4H), 3.56 (s, 2H),2.49-2.43 (m, 4H), 2.34 (s, 3H). MS(ES)+m/e 168.0 [M+H]⁺.

b)6-Methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred solution of 21 wt % sodium ethoxide in EtOH (4.2 g, 12.96mmol) in EtOH (30 mL) was added 2-cyanoacetamide (1.1 g, 13.08 mmol).The reaction was stirred for 15 min. then a solution of5-(4-morpholinyl)-3-pentyn-2-one (2.0 g, 11.96 mmol) in EtOH was addedto the reaction in one portion. (The reaction quickly turned dark red.)The reaction was stirred overnight at RT, neutralized with 6 N HCl (2.17mL, 13.02 mmol) and evaporated to dryness under vacuum. Dried undervacuum overnight. The remaining dark solid was triturated with asolution of (9:1) CH₂Cl₂, MeOH (50 mL), filtered from insolublematerial, washed with (9:1) CH₂Cl₂, MeOH, and the filtrate evaporated todryness under vacuum. The dark solid was triturated with a solution of(1:1) EtOAc in hexanes, filtered, washed with (1:1) EtOAc in hexanes,and dried under vacuum to give a brown solid (removed a lot of fastrunning non-polar impurities). The crude product was purified by silicagel chromatography (Analogix, SF25-60 g, 0 to 15% CH₂Cl₂/20%(5% NH₄OH inMeOH) in CH₂Cl₂). The pure fractions were combined, evaporated todryness, triturated with hexanes and dried under vacuum to give theproduct6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(0.90 g, 3.86 mmol, 32.3% yield) as a light tan solid.

¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (br. s., 1H), 6.34 (s, 1H), 3.63-3.56(m, 4H), 3.48 (s, 2H), 2.45-2.36 (m, 4H), 2.27 (s, 3H)

MS(ES)+m/e 234.1 [M+H]⁺.

c) 3-(Aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone

A clear solution of6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(0.60 g, 2.57 mmol) in HOAc (20 mL) was treated on an H-Cube apparatus(50 psi, 60° C., 1 mL/min., Raney Nickel cartridge) for 18 hr overnight.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness, taken up in a small volume of MeOH and treated with 4 N HClin dioxane (5 mL, 20.00 mmol). The mixture was evaporated to drynessunder vacuum (began to ppt. out during evaporation), triturated withEt2O, filtered and dried under vacuum to give the product3-(aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone (0.76g, 2.450 mmol, 95% yield) as a light grey solid. ¹H NMR (400 MHz,DMSO-d₆) δ 6.39 (s, 1H), 4.28 (s, 2H), 3.99 (s, 2H), 3.87 (br. s., 4H),3.27 (br. s., 4H), 2.22 (s, 3H). MS(ES)+m/e 238.0 [M+H]⁺ (weak), 221.3[M+H]⁺—NH₃ (strong).

Intermediate 17tert-Butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

a) Ethyl 4-ethoxy-2-oxopent-3-enoate

To a stirred solution of ethyl 2,4-dioxopentanoate (36.5 g, 231 mmol)and triethyl orthoformate (41 mL, 246 mmol) in ethanol (60 mL) was addedammonium chloride (3.7 g, 69 mmol). The suspension was stirred at RTovernight. LCMS showed that the reaction was mostly complete.(Hydrolyzes on LCMS to some degree?) The reaction was concentrated undervacuum. The remaining oil was taken up in Et₂O (300 mL), filtered toremove insolubles, rinsed with Et₂O, and concentrated under vacuum. Theproduct was obtained by short path distillation under vacuum (bp 70 to77° C. at 0.09 mmHg) to give the product ethyl4-ethoxy-2-oxopent-3-enoate (36.5 g, 47.3 mmol, 79% yield) as a lightyellow oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ 6.24 (s, 1H), 4.32 (q, J=7.2 Hz, 2H),4.02 (q, J=6.9 Hz, 2H), 2.41 (s, 3H), 1.41 (t, J=7.1 Hz, 3H), 1.39 (t,J=7.2 Hz, 3H). MS(ES)+m/e 186.8

[M+H]⁺, 208.8 M+Na⁺.

b) Ethyl 5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate

To a stirred solution of ethyl 4-ethoxy-2-oxopent-3-enoate (22.5 g, 121mmol) and 2-cyanoacetamide (9.0 g, 107 mmol) in acetone (250 mL) wasadded potassium carbonate (15.8 g, 114 mmol). The reaction was refluxed(85° C. oil bath) for 10 hr (the reaction formed a thick ppt. in a deepred solution). The slurry was added to cold 1 N HCl (230 mL) in ice.After stirring for 30 min. the suspension was filtered, washed withwater and dried under vacuum to give the product ethyl5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (14.51 g, 70.4mmol, 65.7% yield) as a light pink solid.

¹H NMR (400 MHz, DMSO-d₆) 612.60 (br. s., 1H), 7.05 (br. s., 1H), 4.34(q, J=7.1 Hz, 2H), 2.45 (s, 3H), 1.32 (t, J=7.1 Hz, 3H). MS(ES)+m/e206.8 [M+H]⁺.

c) Ethyl 5-cyano-6-methoxy-4-methylpicolinate

To a stirred suspension of ethyl5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (2.0 g, 9.70mmol) in CH₂Cl₂ (25 mL) was added trimethyloxonium tetrafluoroborate(2.0 g, 13.52 mmol). The reaction was rinsed down with CH₂Cl₂ andstirred at RT for 24 hr. (The reaction eventually cleared up.) To thereaction was added 1N NaOH (75 mL). After stirring for 10 minutes themixture was poured into a separatory funnel. The CH₂Cl₂phase wasremoved, dried (Na2SO₄), filtered and concentrated under vacuum.Purification by silica gel chromatography (Analogix SF25-40 g, 50 to100% CH₂Cl₂ in hexanes) gave the product ethyl5-cyano-6-methoxy-4-methylpicolinate (1.13 g, 5.13 mmol, 52.9% yield) asa white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.75 (s, 1H), 4.37 (q, J=7.1Hz, 2H), 4.03 (s, 3H), 2.55 (s, 3H), 1.33 (t, J=7.2 Hz, 3H). MS(ES)+m/e221.2 [M+H]⁺.

d) 5-Cyano-6-methoxy-4-methylpicolinic acid

To a stirred solution of ethyl 5-cyano-6-methoxy-4-methylpicolinate (1.0g, 4.54 mmol) in MeOH (30 mL) and THF (10 mL) was added 6N NaOH (2 mL,12.00 mmol). The suspension was heated to 60° C. and stirred for 2 hr.(The reaction cleared up right away.) LCMS indicated that the reactionwas complete. The reaction was cooled to RT and concentrated to neardryness. The slurry was neutralized with 6N HCl (2 mL) diluted withwater, filtered, washed with water and dried under vacuum to give theproduct 5-cyano-6-methoxy-4-methylpicolinic acid (0.76 g, 3.95 mmol, 87%yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.65 (br. s., 1H),7.73 (s, 1H), 4.03 (s, 3H), 2.54 (s, 3H). MS(ES)+m/e 192.9 [M+H]⁺.

e) tert-Butyl(5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate

To a stirred solution of 5-cyano-6-methoxy-4-methylpicolinic acid (0.75g, 3.90 mmol) in tert-butanol (25 mL) was added triethylamine (0.7 mL,5.02 mmol). After the reaction became clear DPPA (1 mL, 4.64 mmol) wasadded dropwise over 5 minutes. The reaction was slowly heated to 100° C.and stirred for 4 hr. The reaction was cooled to RT and evaporated todryness under vacuum. Purified by silica gel chromatography (Analogix,SF25-60 g, 0 to 20% EtOAc in hexanes) to give, after trituration andfiltration from hexanes, the producttert-butyl(5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate (0.61 g,2.317 mmol, 59.4% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ10.20 (s, 1H), 7.44 (s, 1H), 3.91 (s, 3H), 2.40 (s, 3H), 1.48 (s, 9H).MS(ES)+m/e 264.0 [M+H]⁺.

f) tert-Butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

A clear solution oftert-butyl(5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate (0.60 g,2.279 mmol) in HOAc (5 mL) and ethanol (20 mL) was treated on an H-Cubeapparatus (50 psi, 40° C., 1 mL/min., Raney Nickel cartridge) for 18 hr.LCMS showed that the reaction was complete (86% pure). The reaction wasevaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-60 g, 0 to 12% (5% NH₄OH/MeOH) inCH₂Cl₂). The pure fractions were combined and evaporated to drynessunder vacuum to give the producttert-butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.42 g, 1.571 mmol, 68.9% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 9.33 (s, 1H), 7.16 (s, 1H), 3.80 (s, 3H), 3.57 (s, 2H), 2.28(s, 3H), 1.46 (s, 9H). MS(ES)+m/e 268.1 [M+H]⁺.

Intermediate 18[5-(Aminomethyl)-4-methyl-6-(methyloxy)-2-pyridinyl]methanol

a) 6-(Hydroxymethyl)-2-methoxy-4-methylnicotinonitrile

To a stirred suspension of ethyl 5-cyano-6-methoxy-4-methylpicolinate(5.0 g, 22.70 mmol) and calcium chloride (10 g, 90 mmol) intetrahydrofuran (50 mL) and ethanol (50.0 mL) at 0° C. in an ice bathwas added sodium borohydride (2.5 g, 66.1 mmol). The reaction was slowlyallowed to warm to RT and stirred for 18 hr. A large amount of ppt.formed and LCMS showed that the reaction was complete. An equal volumeof EtOAc was added and the reaction stirred for 1 hr. The suspension wasfiltered through a pad of Celite and washed with EtOAc. The filtrate wastransferred to a separatory funnel, washed with aq. NH₄Cl, brine, dried(Na₂SO₄), filtered and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF40-120 g, 0 to 30% EtOAc in CH₂Cl₂) gavethe product 6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile (3.75 g,21.05 mmol, 93% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ7.16 (s, 1H), 5.61 (t, J=5.8 Hz, 1H), 4.51 (d, J=5.8 Hz, 2H), 3.94 (s,3H), 2.47 (s, 3H). MS(ES)+m/e 179.1 [M+H]⁺.

b) (5-(Aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol

A clear solution of 6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile(0.50 g, 2.81 mmol) in HOAc (5 mL) and Ethanol (20 mL) was treated on anH-Cube apparatus (50 psi, 40° C., 1 mL/min, Raney Nickel cartridge) for18 hr overnight. LCMS showed that the reaction was complete (crudecontained 57% product and 43% dimeric side product). The reaction wasevaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-40 g, 0 to 12% (5% NH₄OH in MeOH) inCH₂Cl₂) (step gradient to 8% to elute off the dimeric side product thento 12% to elute off the product). The pure fractions were combined andevaporated to dryness under vacuum to give the product(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol (0.30 g, 1.646mmol, 58.7% yield) as a white solid. MS(ES)+m/e 183.1

[M+H]⁺, 166.1 [M+H]⁺—NH₃.

Intermediate 19tert-Butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

a)6-((1,3-Dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile

To a stirred solution of6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile (1.50 g, 8.42 mmol),phthalimide (1.3 g, 8.84 mmol) and triphenylphosphine (2.3 g, 8.77 mmol)in Tetrahydrofuran (THF) (50 mL) at 0° C. in an ice bath was addeddropwise DIAD (1.8 mL, 9.26 mmol). Within minutes a white suspensionformed. Additional THF (˜50 mL) was added to allow stirring. Thereaction was allowed to warm to RT and stirred for 3 h. LCMS showed thatthe reaction was complete. The reaction was evaporated to dryness undervacuum. The remaining solid was triturated with a small volume of EtOAc,filtered, washed with a small volume of EtOAc, then dried under vacuumto give the product6-((1,3-dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile(2.12 g, 6.90 mmol, 82% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 8.00-7.92 (m, 2H), 7.92-7.87 (m, 2H), 7.15 (s, 1H), 4.86 (s,2H), 3.74 (s, 3H), 2.43 (s, 3H). MS(ES)+m/e 308.2 [M+H]⁺.

b) tert-Butyl((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

To a stirred fine suspension of6-((1,3-dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile(2.1 g, 6.83 mmol) in Ethanol (100 mL) was added hydrazine monohydrate(1.4 ml, 28.9 mmol). The reaction was stirred at RT for 18 hr. LCMSshowed that the reaction was done. The thick white suspension wasfiltered, pressed dry, washed with EtOH, and the filtrate evaporated todryness under vacuum. The remaining solid was taken up inDichloromethane (50 ml), filtered to remove additional insolublematerial, and washed with CH₂Cl₂. To the clear filtrate with stirringwas added Boc₂O (1.809 ml, 7.79 mmol). After stirring at RT for 1 hrLCMS showed that the reaction was complete. The reaction wasconcentrated under vacuum and purified by silica gel chromatography(Analogix, SF25-60, 0 to 10% EtOAc in hexanes). The pure fractions werecombined and evaporated to dryness to give the producttert-butyl((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(1.42 g, 5.12 mmol, 74.9% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 7.48 (t, J=6.1 Hz, 1H), 6.91 (s, 1H), 4.16 (d, J=6.1 Hz, 2H),3.96 (s, 3H), 2.45 (s, 3H), 1.41 (s, 9H). MS(ES)+m/e 278.2 [M+H]⁺.

c)tert-Butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

A clear solution oftert-butyl((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(0.65 g, 2.344 mmol) in HOAc (5 mL) and Ethanol (20 mL) was treated onan H-Cube apparatus (50 psi, 40° C., 1 mL/min., Raney Nickel cartridge)for 18 hr overnight. LCMS showed that the reaction was complete. Thereaction was evaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-60 g, 0 to 10% (5% NH₄OH/MeOH) inCH₂Cl₂). The pure fractions were combined and evaporated to drynessunder vacuum to give the producttert-butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(0.58 g, 2.061 mmol, 88% yield) as a clear thick oil. ¹H NMR (400 MHz,DMSO-d₆) δ 7.31 (t, J=6.1 Hz, 1H), 6.63 (s, 1H), 4.06 (d, J=6.3 Hz, 2H),3.84 (s, 3H), 3.61 (s, 2H), 2.29 (s, 3H), 1.53 (br. s., 2H), 1.41 (s,9H). MS(ES)+m/e 282.2 [M+H]⁺.

Intermediate 20

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-ethyl-6-methyl-2(1H)-pyridinone (Intermediate 10c).LCMS (ES+) m/z=195.22 (M+H). ¹H NMR (DMSO-d₆, 400 MHz): δ 0.809-0.774(t, 3H, J=6.8 Hz), 1.113-1.097 (d, 3H, J=6.4 Hz), 1.504-1.468 (t, 2H,J=7.2 Hz), 2.184 (s, 3H), 2.839-2.822 (d, 1H, J=6.8 Hz), 3.822 (s, 2H),6.059 (s, 1H), 8.315 (bs, 2H).

Intermediate 21 Methyl 6-bromo-1-isopropyl-1H-indole-4-carboxylate a)5-Bromo-2-methyl-3-nitro-benzoic acid

To a stirred solution of 2-methyl-3-nitro benzoic acid (300 g, 1647mmol) in conc. H₂SO₄ (1.5 L) was added 1,3-dibromo-5,5dimethyl-2,4-imadazolidinedione (258 g, 906 mmol) and the mixture wasstirred at room temperature for 5 h. The reaction mixture was slowlyadded to ice water (4 L), and solid was precipitated out. The solid wasfiltered off and washed with water (1.2 L), pet ether (1 l) and dried toafford the title compound as a white solid (411 g, 96%), which was usedwithout further purification. ¹H NMR (DMSO, 400 MHz): δ 2.446 (s, 3H),8.136 (s, 1H), 8.294 (s, 1H). LCMS (ES−) m/z=257.93 (M−H)⁻

b) Methyl 6-bromo-1H-indole-4-carboxylate

To a stirred solution of 5-bromo-2-methyl-3-nitro-benzoic acid (140 g,538.4 mmol) in DMF (550 ml) was added DMF-DMA (599 mL, 4846 mmol) atroom temperature. The reaction mixture was stirred at 115° C. for 18 h.The reaction mixture was then concentrated in vacuo. The residualcontents (176 g, 536.5 mmol) were dissolved in acetic acid (696 mL) andadded to a suspension of iron (329.2 g, 5902 mmol) in acetic acid (1.4L) at 50° C. After completion of addition, the reaction mixture wasstirred at 80-90° C. for 4 h. The reaction mixture was then filteredthrough a Celite pad. The filtrate was poured onto ice water (1 L) andextracted with diethyl ether (3×700 ml). The combined organic layerswere washed with sat NaHCO₃, brine, and dried over anhydrous Na₂SO₄,filtered, and evaporated under vacuum. The crude product was purified bysilica gel chromatography (eluent: 10% ethyl acetate in pet ether) andafforded the title compound as a solid (80 g, 59%). ¹H NMR (DMSO-d₆, 400MHz) δ: 3.980 (s, 3H), 7.168 (d, J=3.2 Hz, 1H), 7.334 (d, J=3.2 Hz, 1H),7.734 (s, 1H), 8.017 (s, 1H), 8.384 (brs, 1H); LCMS (ES−) m/z=251.9(M−H).

c) Methyl 6-bromo-1-isopropyl-1H-indole-4-carboxylate

To a stirred solution of methyl 6-bromo-1H-indole-4-carboxylate (100 g,393.7 mmol) in DMF (800 mL) was added 2-iodopropane (160 g, 944.8 mmol)followed by portionwise addition of sodium hydride (20.4 g, 511.8 mmol)at 0° C. The reaction mixture was stirred at room temperature for 18 h.Diluted the reaction mixture with cold water and extracted withethylacetate (200 mL×4), finally organic layer was washed with coldwater, brine solution dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford crude, which was purified by columnchromatography using silica gel (60-120 mesh) with 5% EtOAC: pet etheras an eluent to afford methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (65 g, 55.7%) as a solid. ¹HNMR (CDCl₃, 400 MHz) δ 1.53 (d, 6H, J=6.4 Hz), 3.973 (s, 3H),4.598-4.664 (m, 1H), 7.111 (d, 1H, J=2.4 Hz), 7.338 (d, 1H, J=2.8 Hz),7.711 (s, 1H), 7.987 (s, 1H).

d) 6-Bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.52 g, 1.756 mmol)in methanol (15 mL) and tetrahydrofuran (3 mL) was added 3 M NaOH (1.756mL, 5.27 mmol) via syringe drop wise (over 2 min) The solution wasmaintained at RT for 2 h, at which time LCMS showed only 12% conversionto product. Then 1.5 mL 3 M NaOH was added and the solution wasmaintained at RT overnight. LCMS showed complete conversion to product.Removed volatiles in vacuo and dissolved the residue in water and slowlyacidified with 1 M HCl (solids precipitated). Extracted with EtOAc (2×),combined organics and dried over MgSO₄. Filtered and concentrated invacuo to give 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.50 g, 1.737 mmol, 99% yield) as a white solid.

Alternatively, the alkylation of the indole nitrogen could be performedas follows: To a cooled (0° C.) suspension of methyl6-bromo-1H-indole-4-carboxylate (10 g, 39.4 mmol) and(cyanomethyl)(trimethyl)phosphonium chloride (14.91 g, 98 mmol) in THF(400 mL) was added 2-propanol (6.06 mL, 79 mmol), followed by sodiumhydride (3.46 g, 87 mmol). The mixture was stirred at ambienttemperature for 2 h, at which time LCMS showed no product formation.Heated at 50° C. for 18 h. LC/MS showed reaction complete. Filteredreaction mixture and concentrated in vacuo. The residue was diluted withmethylene chloride and passed through a pad of silica (washed withmethylene chloride). Purification by flash chromatography (AnalogixSF65-200 g; 5-10% EtOAc/hexanes) gave methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (9.7 g, 31.4 mmol, 80%yield). MS(ES) [M+H]⁺ 296.2, 298.4.

Examples 22-23 were prepared by the methods described above forIntermediate 16 or routine variations thereof, starting from therequisite 2-methyl-3-nitrobenzoic acid:

MS(ES) Ex Structure Name 1H NMR [M + H]⁺ 22

6-fluoro-1-(1-methylethyl)-1H- indole-4-carboxylic acid 1.44 (d, 6 H),4.63-4.96 (m, 1 H), 6.97 (d, J = 3.03 Hz, 1 H), 7.46 (dd, J = 10.36,2.27 Hz, 1 H), 7.67 (d, J = 3.28 Hz, 1 H), 7.75 (dd, J = 10.11, 2.02 Hz,1 H), 12.97 (s, 1 H) 222.1 23

6-chloro-1-(1-methylethyl)-1H- indole-4-carboxylic acid (CHLOROFORM-d)1.57 (d, 6 H), 4.67 (spt, J = 6.69 Hz, 1 H), 7.19 (d, J = 3.03 Hz, 1 H),7.41 (d, J = 3.28 Hz, 1 H), 7.63 (d, J = 1.01 Hz, 1 H), 7.97 (d, J =1.77 Hz, 1 H) 237.9

Intermediate 24 6-Bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

24a) Methyl 6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate

To a stirred solution of DMF (1.04 lit) POCl₃ (40.3 g, 263 mmol) wasadded at 0° C. and stirred for 20 min. Then methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (65 g, 219.5 mmol) in DMF(260 mL) was added to the reaction mixture at 0° C. The reaction mixturewas stirred at room temperature for 3 h. Diluted the reaction mixturewith cold water and adjusted PH-8 using with 2N NaOH solution, extractedwith ethylacetate (4×1 lit). The organic layer washed with cold water,brine solution, dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford desired product methyl6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate (65 g, 91.3%). ¹HNMR (CDCl₃, 400 MHz): δ 1.588 (d, 6H, J=6.8 Hz), 3.994 (s, 3H),4.634-4.701 (m, 1H), 7.760 (d, 1H, J=1.6 Hz), 7.958 (d, 1H, J=1.6 Hz),8.122 (s, 1H), 10.446 (s, 1H). LC-MS (ES+) m/z=324.02 (M+H)

24b) Methyl 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate (60 g, 185 mmol) inDMF (220 mL) was added p-toluenesulfonic acid mono hydride (4.57 g, 24mmol), p-toluenesulfonyl hydrazide (44.8 g, 240 mmol) followed bysulfolane (220 mL). The mixture was stirred at 100° C. for 1 h. Thecontents were cooled to room temperature and then sodiumcyanoborohydride (46.5 g, 740 mmol) was added portion wise over a periodof 25 min. Then the mixture was stirred at 100° C. for 2 h. Then thereaction mixture was stirred for 16 h at room temperature. The reactionmixture was diluted with water and extracted with 20% EtOAc: Pet ether,finally organic layer was washed with cold water, brine solution driedover anhydrous Na₂SO₄ and concentrated. Crude compound was purified bycolumn chromatography using silica gel (100-200 mesh) and 20% DCM: Petether as an eluent to afford desired product methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (24 g, 89.2%purity), (16 g, and 62.2% purity). ¹H NMR (CDCl₃, 400 MHz) δ 1.486 (d,J=6.4 Hz, 6H), 2.361 (s, 3H), 3.947 (s, 3H), 4.535-4.602 (m, 1H), 7.080(s, 1H), 7.619 (s, 1H), 7.684 (s, 1H). LCMS (ES+) m/z=310.07 (M+H)

24c) 6-Bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

To a stirred solution of methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (24 g, 77.4 mmol)in ethanol (400 mL) was added sodium hydroxide (4.02 g, 100.6 mmol),water (11 mL) and the mixture was stirred at reflux condition for 6 h.Ethanol was distilled off and residue was diluted with water, extractedwith ethylacetate (40 mL) adjusted aqueous layer to PH-3 with 1N HCl andextracted with ethyl acetate (3×250 mL), finally organic layer waswashed with brine solution, dried over anhydrous Na₂SO₄ andconcentrated. The crude was washed with pet ether, filtered the solidand dried to afford desired product6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (20.6 g,89.8%). ¹H NMR (DMSO-d₆, 400 MHz): δ 1.407 (d, J=6.4 Hz, 6H), 2.296 (s,3H), 4.754-4.819 (m, 1H), 7.455 (s, 1H), 7.472 (s, 1H), 7.938 (s, 1H),12.950 (brs, 1H). LCMS (ES+) m/z=296.15 (M+H).

Intermediate 25 6-Bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylicacid

a) Methyl 6-bromo-1-sec-butyl-1H-indole-4-carboxylate

To a stirred suspension of sodium hydride (5.66 g, 141.7 mmol) in DMF(100 mL) was added a solution of methyl 6-bromo-1H-indole-4-carboxylate(4) (30 g, 118.1 mmol) in DMF (50 mL) at 0° C. and stirred for 20 min.Then 2-Bromo butane (29.1 g, 212.5 mmol) was added at 0° C. and thereaction mixture was stirred at room temperature for 16 h. The reactionmixture was diluted with cold water and extracted with ethyl acetate(4×150 mL). The combined organic layer was washed with cold water (150mL), brine (100 mL) and dried over anhydrous Na₂SO₄ and concentratedunder reduced pressure to afford crude, which was purified by columnchromatography over silica gel (60-120 mesh) using 5% EtOAc: Pet etheras eluent to afford the title compound methyl6-bromo-1-sec-butyl-1H-indole-4-carboxylate, 5 (14 g, 40.1%) as paleyellow solid. ¹H NMR (CDCl₃, 400 MHz) δ 0.843-0.870 (m, 3H), 1.512 (d,J=6.4 Hz, 3H), 1.844-1.926 (m, 2H), 3.976 (s, 3H), 4.333-4.385 (m, 1H),7.132 (d, J=3.2 Hz, 1H), 7.302 (d, J=3.6 Hz, 1H), 7.707 (s, 1H), 7.984(d, J=1.6 Hz, 1H).

b) Methyl 6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate

POCl₃ (8.3 g, 54.3 mmol) was added at 0° C. to anhydrous DMF (230 mL) ina round bottom flask and stirred for 30 min. Then a solution of methyl6-bromo-1-sec-butyl-1H-indole-4-carboxylate, 5 (14 g, 45.3 mmol) in DMF(60 mL) was added to the reaction mixture at 0° C. and stirred at roomtemperature for 2.5 h. The reaction mixture was diluted with cold water,adjusted pH-8 using with 2N NaOH solution and extracted with ethylacetate (4×200 mL). The combined organic layer was washed with coldwater (2×100 mL), brine (100 mL), dried over anhydrous Na₂SO₄ andconcentrated under reduced pressure to afford desired product methyl6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate, 6 (15.2 g, 99%) aspale yellow solid. This was used as such in the next step withoutpurification. ¹H NMR (CDCl₃, 400 MHz) δ (0.831-0.859 (m, 3H),1.515-1.574 (d, J=6.8 Hz, 3H), 1.729-1.972 (m, 2H) 3.997 (s, 3H),4.394-4.445 (m, 1H), 7.756 (d, J=1.2 Hz, 1H), 7.958 (d, J=2 Hz, 1H),8.079 (s, 1H), 10.452 (s, 1H).

c) Methyl 6-bromo-1-sec-butyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate (15 g, 44.6 mmol)in DMF (115 mL) was added p-toluenesulfonic acid mono hydrate (1.1 g,5.8 mmol), p-toluenesulfonyl hydrazide (10.8 g, 58 mmol) followed bysulfolane (115 mL) at RT and the reaction mixture was stirred at 100° C.for 1 h. The reaction mixture was cooled to room temperature, treatedwith sodium cyanoborohydride (11.9 g, 178.5 mmol) portion wise over aperiod of 5 min and stirred at 100° C. for 2 h. The reaction mixture wascooled to room temperature and stirred at the same temperature for 16 h.The reaction mixture was diluted with water and extracted with 30%EtOAc: Pet ether. The organic layer was washed with cold water (100 mL),brine (100 mL) and dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford crude, which was purified by columnchromatography over silica gel (100-200 mesh) using 5% EtOAc: Pet etheras eluent to afford title compound methyl6-bromo-1-sec-butyl-3-methyl-1H-indole-4-carboxylate (7.88 g, 54.6%) aspale yellow gum. ¹H NMR (CDCl₃, 400 MHz): δ 0.804-0.841 (t, J=7.4 Hz,3H), 1.454-1.470 (d, J=6.4 Hz, 3H), 1.865-1.884 (m, 2H), 2.363 (s, 3H),3.950 (s, 3H), 4.265-4.316 (m, 1H), 7.038 (s, 1H), 7.609 (d, J=1.2 Hz,1H), 7.671 (d, J=2 Hz, 1H). MS (ES+): 324.19 [M+H] ion present.

d) 6-Bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylic acid

Methyl 6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylate (3.24 g,9.99 mmol) was dissolved in methanol (30 mL) and tetrahydrofuran (THF)(7 mL). The contents were stirred for 5 min., and then aq. 3N NaOH(19.99 mL, 60.0 mmol) was added via addition funnel over 3 min. Thecontents rapidly became a yellow suspension and were stirred at roomtemperature for 65 h. The volatiles were removed in vacuo and theresidue dissolved in water (60 mL). The contents were washed with ether(1×50 mL). The aq layer was cooled in an ice bath and adjusted to pH 3-4with 1M HCl, from which an oily residue precipitated. The contents wereextracted with EtOAc (2×60 mL). The combined organic layers were driedover magnesium sulfate, filtered through celite, and concentrated invacuo. The residue obtained was treated with TBME, concentrated invacuo, and then dried under hi vacuum to afford a yellow foam as 3.08 g(93%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.70 (t, J=7.33 Hz, 3H), 1.39 (d,J=6.82 Hz, 3H), 1.71-1.86 (m, 2H), 2.30 (s, 3H), 4.48-4.62 (m, 1H),7.40-7.49 (m, 2H), 7.96 (d, J=1.77 Hz, 1H), 12.99 (s, 1H);LCMS=310.0/312.0 (MH+).

Examples 26-27 were prepared by the methods described above forIntermediate 16 or routine variations thereof, starting from therequisite 6-substituted indole:

MS(ES) Ex Structure Name 1H NMR [M + H]⁺ 26

6-chloro-3-methyl-1-(1-methylethyl)- 1H-indole-4-carboxylic acid 12.99(br.s., 1 H), 7.82 (d, J = 2.0 Hz, 1 H), 7.47 (d, J = 1.0 Hz, 1 H), 7.36(d, J = 2.0 Hz, 1 H), 4.78 (quin, J = 6.6 Hz, 1 H), 2.30 (d, J = 1.0 Hz,3 H), 1.41 (d, J = 6.6 Hz, 6 H) 252.4 27

6-bromo-1-(sec-butyl)-3-methyl-1H- indole-4-carboxylic acid 0.70 (t, J =7.33 Hz, 3 H) 1.39 (d, J = 6.82 Hz, 3 H) 1.71-1.86 (m, 2 H) 2.30 (s, 3H) 4.48-4.62 (m, 1 H) 7.40-7.49 (m, 2 H) 7.96 (d, J = 1.77 Hz, 1 H)12.99 (s, 1 H) 310.0

Intermediate 28 6-Bromo-1-cyclopropyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-1-cyclopropyl-1H-indole-4-carboxylate

In a oven dried 100 ml RBF equipped, stir bar, septum and Nitrogen inletwas added methyl 6-bromo-1H-indole-4-carboxylate (0.508 g, 2.0 mmol) and1,2-dichloroethane (7 mL). The solution was stirred for 15 min, thencyclopropylboronic acid (0.344 g, 4.00 mmol) and sodium carbonate (0.424g, 4.00 mmol) were added. Diluted copper(II) acetate (0.363 g, 2.000mmol) and 2,2′-bipyridine (0.312 g, 2.000 mmol) in 1,2-dichloroethane(12 mL), heated the mixture, and added the hot suspension to thereaction. The reaction was heated at 70° C. and monitored by LCMS.Stopped heating after 6 h and allowed to sit for 3 days at RT. Added toreaction saturated NH4C₁ and water. Extracted with DCM (2×). Thecombined organics were washed with brine, dried over magnesium sulfate,filtered and concentrated in vacuo. Purification of the residue bycolumn chromatography (24 g Isco silica column; gradient B: 3-25%.A:hexane. B:ethyl acetate) to give methyl6-bromo-1-cyclopropyl-1H-indole-4-carboxylate (0.43 g, 1.433 mmol, 71.6%yield) as a yellow residue. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.96-1.01(m, 2H) 1.06-1.12 (m, 2H) 3.52 (dt, J=7.20, 3.47 Hz, 1H) 3.90 (s, 3H)6.85-6.91 (m, 1H) 7.57 (d, J=3.03 Hz, 1H) 7.82 (d, J=1.77 Hz, 1H) 8.04(d, J=1.01 Hz, 1H). MS(ES) [M+H]⁺ 294.1.

b) 6-Bromo-1-cyclopropyl-1H-indole-4-carboxylic acid

To a solution of methyl 6-bromo-1-cyclopropyl-1H-indole-4-carboxylate(0.43 g, 1.462 mmol) in MeOH (12 mL) and THF (3 mL) was added 3 M NaOH(1.949 mL, 5.85 mmol). The reaction was stirred for 18 h at RT, at whichtime the volatiles were removed in vacuo. The residue was diluted withwater and slowly acidifed with 1 N HCl to pH 4-5, then extracted withEtOAc (2×). The combine organics were wash with brine, dried overmagnesium sulfate, filtered, and concentrated to give6-bromo-1-cyclopropyl-1H-indole-4-carboxylic acid (0.376 g, 1.315 mmol,90% yield) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm0.92-1.01 (m, 2H) 1.05-1.12 (m, 2H) 3.51 (tt, J=7.07, 3.66 Hz, 1H) 6.89(d, J=2.53 Hz, 1H) 7.52 (d, J=3.03 Hz, 1H) 7.80 (d, J=1.77 Hz, 1H) 7.99(d, J=1.01 Hz, 1H) 13.05 (br. s., 1H). MS(ES) [M+H]⁺ 280.1.

Intermediate 29 6-Bromo-1-cyclobutyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-1-cyclobutyl-1H-indole-4-carboxylate

In an oven dried 100 ml RBF, equipped with a stir bar, septum, nitrogeninlet was added methyl 6-bromo-1H-indole-4-carboxylate (1.0 g, 3.94mmol) and (cyanomethyl)(trimethyl)phosphonium chloride (1.491 g, 9.84mmol). Added in THF (40 mL) and stirred suspension for 5 min. Thereaction was cooled with an ice bath for 10 min, then was addedcyclobutanol (0.616 mL, 7.87 mmol), followed by sodium hydride (0.346 g,8.66 mmol) portionwise. The ice bath was removed and the reactionstirred at ambient temperature for 45 min, then heated at 50° C. for 18h. LCMS showed mostly SM. Heated at 75° C. for 24 h. The reaction wasallowed to cool to RT, then poured into water (200 ml) and extractedwith EtOAc (2×). The combined organics were dried over magnesiumsulfate, filtered, and concentrated. Purification of the residue bycolumn chromatography (40 g Isco silica column; gradient B: 2-25%;A:hexane, B: EtOAc) gave methyl6-bromo-1-cyclobutyl-1H-indole-4-carboxylate (0.3 g, 25% yield, —45%pure by HPLC). MS(ES) [M+H]⁺ 308.2.

b) 6-Bromo-1-cyclobutyl-1H-indole-4-carboxylic acid

To a solution of ethyl 6-bromo-1-cyclobutyl-1H-indole-4-carboxylate (0.3g, 0.973 mmol) (crude residue from above) in MeOH (8 mL) and THF (2 mL)was added 3 M NaOH (1.298 mL, 3.89 mmol). The reaction was stirred at RTfor 16 h, at which time the volatiles were removed in vacuo. The residuewas diluted with water and slowly acidifed with 1 N HCl to pH 3-4. Thesolids were filtered and dried on hivac for 16 h to give6-bromo-1-cyclobutyl-1H-indole-4-carboxylic acid (0.21 g, 0.535 mmol,55.0% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.79-1.89 (m, 2H)2.34-2.46 (m, 2H) 3.84 (s, 1H) 5.08 (t, J=8.21 Hz, 1H) 6.99 (d, J=3.03Hz, 1H) 7.75-7.79 (m, 1H) 7.81 (d, J=3.03 Hz, 1H) 8.01-8.05 (m, 1H)13.03 (br. s., 1H). MS(ES) [M+H]⁺ 294.1.

Intermediate 301-Isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxylic acid

To a 30-mL microwave tube were added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (490 mg,1.580 mmol), methanesulfinic acid (212 mg, 2.054 mmol), DMSO (7 mL),N,N′-dimethyl-1,2-ethanediamine (18.10 mg, 0.205 mmol), and the mixturewas degassed for 5 min by bubbling N2. Copper(I)trifluoromethanesulfonate benzene complex (63.6 mg, 0.126 mmol) wasadded and the tube was sealed. The mixture was heated at 165° C.overnight with stirring. The mixture was allowed to cool, filtered andpurified using reverse-phase HPLC (Gemini 5u C18(2) 100A, AXIA; 30×100mm 5 micron; 30 mL/min, 30% ACN/H₂O, 0.1% formic acid to 60% ACN/H₂O,0.1% formic acid) to give the title compound (118 mg, 25%) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) ppm 1.47 (d, J=8.00 Hz, 6H), 2.30-2.41(m, 3H), 4.94 (quin, J=6.63 Hz, 1H), 7.80 (s, 1H), 7.88 (d, J=1.77 Hz,1H), 8.24 (d, J=1.52 Hz, 1H), 13.17 (br. s., 1H). MS: (M+H)⁺=296.3.

Intermediate 31 1-Isopropyl-6-(methylsulfonyl)-1H-indole-4-carboxylicacid

To a 10-mL microwave tube were added methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (160 mg, 0.540 mmol),sodium methanesulfinate (80 mg, 0.702 mmol), DMSO (2 mL), andN,N′-dimethyl-1,2-ethanediamine (6.19 mg, 0.070 mmol), and the mixturewas degassed for 5 min by bubbling N₂. Copper(I)trifluoromethanesulfonate benzene complex (25.6 mg, 0.043 mmol) wasadded and the mixture was heated to 165° C. for 2 h with stirring. Themixture was filtered and the DMSO solution was purified usingreverse-phase HPLC to give 14 mg of product as white solid. ¹H NMR (400MHz, DMSO-d₆) ppm 1.51 (d, J=4.00 Hz, 6H), 4.90-5.11 (m, 1H), 7.13 (d,J=3.03 Hz, 1H), 7.98-8.08 (m, 1H), 8.15-8.23 (m, 1H), 8.32-8.46 (m, 1H),13.19 (br. s., 1H). MS: (M+H)⁺=281.9.

Intermediate 326-(Cyclopropylsulfonyl)-1-(1-methylethyl)-1H-indole-4-carboxylic acid

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.03 (dd, J=7.71, 2.40 Hz, 2H), 1.17(dd, J=7.20, 3.41 Hz, 2H), 1.50 (d, 6H), 2.83-2.97 (m, 1H), 5.02 (dt,J=13.14, 6.57 Hz, 1H), 7.17 (d, J=2.27 Hz, 1H), 7.99 (d, J=3.03 Hz, 1H),8.13 (s, 1H), 8.28 (s, 1H). MS: (M+H)⁺=308.3.

Intermediate 33 1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid methylester

Freshly prepared sodium methoxide (500 mg in 5 mL methanol) was added toa stirred suspension of 6-bromo-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester (500 mg, 1.68 mmol) and CuI (480 mg, 2.53 mmol) in NMP (8mL) and then heated at 120° C. for 2 h. The reaction mixture was cooledto room temperature, diluted with water (5 mL) and acidified with 1NHCl. The reaction mixture was filtered through Celite and washed withEtOAc (5 mL). Separated the EtOAc layer from filtrate, dried overanhydrous Na₂SO₄ and concentrated under reduced pressure to furnish thecrude 1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid (700 mg), whichwas used in the next stage without further purification. ¹H NMR (400MHz, DMSO-d₆): δ 1.44 (d, J=6.4 Hz, 6H), 3.84 (s, 3H), 4.80-4.76 (m,1H), 6.87 (d, 1H), 7.33 (t, J=3.2 Hz, 2H), 7.49 (d, J=3.2 Hz, 1H), 12.65(bs, 1H). LCMS (ES+): m/z=234.11 [M+H].

To a stirred suspension of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid (700 mg, 3.00 mmol) in MeOH was added H₂SO₄ (440 mg, 4.50 mmol) andthen heated at reflux for 3 h. Methanol was distilled off completelyunder reduced pressure and the residue basified with saturated aqueousNaHCO₃ solution and extracted with ethyl acetate (2×5 mL). The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography (SiO₂,100-200) by eluting 5% ethyl acetate in petroleum ether to afford1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid methyl ester (240 mg,32.4%) as white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 1.45 (d, J=6.8 Hz,6H), 3.84 (s, 3H), 3.88 (s, 3H), 4.81-4.78 (m, 1H), 6.86 (d, J=3.2 Hz,1H), 7.34 (d, J=2.4 Hz, 1H), 7.39 (d, J=2 Hz, 1H), 7.54 (d, J=3.6 Hz,1H). LCMS (ES+): m/z=248.16[M+H].

Intermediate 34 1-Isopropyl-6-methoxy-1H-indole-4-carboxylic acid

To a stirred solution of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid methyl ester (320 mg, 1.29 mmol) in THF (2 mL) was added LiOH.H₂O(160 mg, 3.88 mmol) in water (2 mL) at room temperature and heated atreflux for 2 h. The THF was removed under reduced pressure and theresulting aqueous layer was acidified with 1 N HCl (pH˜6) and extractedwith ethyl acetate (2×5 mL). The combined organic layer was dried overanhydrous Na₂SO₄ and concentrated to afford1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid (210 mg). ¹H NMR (400MHz, DMSO-d₆): δ 1.42 (d, 6H), 3.88 (s, 3H), 4.85 (m, 1H), 6.81 (d,J=2.8 Hz, 1H), 7.26 (s, 2H), 7.45 (s, 1H), 12.68 (s, 1H).

Intermediate 35 6-Hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methylester

To a stirred solution of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid methyl ester (1.9 g, 7.69 mmol) in toluene (20 mL) was addedanhydrous aluminum chloride (5.11 g, 38.4 mmol) at room temperature andthen heated to reflux for 2 h. The reaction mixture was diluted withwater and extracted with ethyl acetate (2×20 mL). The combined organiclayer was dried over Na₂SO₄ and concentrated under reduced pressure. Theresidue was purified by column chromatography by eluting 3-15% Ethylacetate in petroleum ether to afford the title compound6-hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methyl ester (1.5 g,83%) as yellow colored gum. ¹H NMR (400 MHz, DMSO-d₆): δ 1.43 (d, J=6.8Hz, 6H), 3.86 (s, 3H), 4.65-4.61 (m, 1H), 6.81 (d, J=2.8 Hz, 1H), 7.11(s, 1H), 7.29 (s, 1H), 7.44 (d, J=2.8 Hz, 1H), 9.32 (bs, 1H). LCMS(ES+): m/z=234.09 [M+H].

Intermediate 363-Methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxylic acid

To methyl 6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(1.3 g, 4.19 mmol) and copper(I) iodide (1.0 g, 5.25 mmol) was added NMP(8 mL). To the mixture was added dropwise a solution of sodium methoxide25 wt % in methanol (4.0 mL, 17.49 mmol) with stirring. The reaction washeated to 120° C. and stirred for 1.5 hr. The reaction was allowed tocool and when the temperature reached 80° C., water (200 uL) was added.The reaction was allowed to continue to cool to RT and stirredovernight. The reaction was acidified with 1 N HCl (17 mL) and dilutedwith water and EtOAc. The mixture was filtered through Celite and washedwith EtOAc. The filtrate was poured into a separatory funnel and theorganic phase was separated, washed with brine, dried (MgSO4), filtered,and concentrated under vacuum. Purification by silica gel chromatography(Analogix, SF25-60 g, 20 to 50% EtOAc in hexanes) gave afterconcentration, trituration with hexanes, filtration and drying undervacuum 3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxylicacid (825 mg, 3.34 mmol, 80% yield) as an light yellow solid. MS(ES)+m/e248.3 [M+H]⁺.

Intermediate 37 6-Iodo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a stirred solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (1.1 g, 3.71 mmol) indioxane (50 mL) was added sodium iodide (1.2 g, 8.01 mmol),N,N′-dimethylethylenediamine (200 μL, 1.858 mmol) and copper(I) iodide(150 mg, 0.788 mmol). The reaction was purged with N₂ then refluxed(110° C. oil bath) overnight. LCMS indicated that the reaction was 90%complete with 6% remaining SM. Another 0.75 g sodium iodide and 75 mgcopper(I) iodide was added and the reaction refluxed for another 24 hr.(LCMS showed less than 4% bromide SM.) The reaction was concentratedunder vacuum, taken up in EtOAc, washed with water, brine, dried(MgSO4), filtered and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF25-60 g, 0 to 10% EtOAc in hexanes) gavethe ester product as a light yellow oil. (1.27 g, 100%). MS(ES)+m/e344.0 [M+H]⁺.

The above ester was taken up in 40 mL (3:1) MeOH, THF and treated with 1N NaOH (15 mL). The reaction was refluxed overnight, cooled to RT andconcentrated under vacuum. Neutralization with 1 N HCl (15 mL) gave awhite suspension that was filtered, washed with cold water and driedunder vacuum to give the product6-iodo-1-(1-methylethyl)-1H-indole-4-carboxylic acid (1.12 g, 3.40 mmol,92% yield) as a light yellow solid. ¹H NMR (400 MHz, DMSO-d₆) 6=12.94(br. s., 1H), 8.20 (s, 1H), 7.94 (d, J=1.5 Hz, 1H), 7.66 (d, J=3.3 Hz,1H), 6.97 (d, 1H), 4.86 (quin, J=6.6 Hz, 1H), 1.44 (d, J=6.6 Hz, 6H).MS(ES)+m/e 330.0 [M+H]⁺.

Intermediate 38 6-Cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

a) Methyl 6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

To a 10 ml microwave vial was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (500 mg,1.612 mmol), dicyanozinc (150 mg, 1.277 mmol) and DMF (5 mL). Themixture was degassed and stirred at rt under N2 for 15 min. To themixture was added palladium tetrakis (118 mg, 0.102 mmol) and thereaction was stirred at 95° C. for 1 h. The reaction was allowed to cooland poured into saturated aqueous Na₂CO₃ (50 mL) and EtOAc (50 mL) andstirred for 20 min. The mixture was extracted with ether (100 ml) andEtOAc (100 ml) (1:1), followed by filtration and evaporation to yield aresidue. The residue was purified by silica gel chromatography (AnalogixIF280, 0-8% EtOAc/hexanes, SF25-40 g, 30 minutes) to give methyl6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (130 mg,0.497 mmol, 38.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δppm 8.38 (d, J=1.52 Hz, 1H) 7.82 (s, 1H) 7.71 (d, J=1.52 Hz, 1H)4.85-4.97 (m, 1H) 3.90 (s, 3H) 2.29 (s, 3H) 1.45 (d, J=6.57 Hz, 6H).MS(ES) [M+H]⁺ 257.4.

b) 6-Cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

To a 50 ml round bottom was added methyl6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (230 mg,0.897 mmol), followed by methanol (1 mL) and THF (1 mL). To the solutionwas added 3 M NaOH (0.449 mL, 2.69 mmol). The reaction stirred at rt for20 h. The reaction was evaporated and treated with acidic water to pH 5.A brown solid crashed out and was collected by filtration. The solid wasan impurity. The pH of the liquid was adjusted to 3 and the liquid wasevaporated leaving a residue. Trituration of the residue with water,followed by filtration yielded6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (155 mg,0.576 mmol, 64.2% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-δ₆) δppm 13.16 (br. s., 1H) 8.33 (s, 1H) 7.78 (s, 1H) 7.66 (s, 1H) 4.81-4.98(m, 1H) 2.33 (s, 4H) 1.45 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺ 243.3.

Intermediate 391-Isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid

a) Methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate

To a stirred suspension of methyl6-cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.50 g, 1.951mmol) in azidotrimethylsilane (1.0 mL, 7.53 mmol) in a small vial wasadded tetrabutylammonium fluoride trihydrate (300 mg, 0.951 mmol). Thereaction was heated to 85° C. and stirred for 18 hr (attached a smallreflux condensor). (The reaction became a semi-solid mass.) The reactionwas taken up in EtOAc (75 mL), washed with 1 N HCl (75 mL) (stirred tilldissolved). The organic phase was removed, dried (Na2SO4), filtered andconcentrated under vacuum. Purification by silica gel chromatography(Analogix, SF40-80 g, 0 to 3% MeOH/CH2C₁₂ with 0.1% HOAc) gave theproduct methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate (0.28g, 0.935 mmol, 48.0% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆)δ 8.40 (d, J=1.3 Hz, 1H), 8.15 (d, J=1.5 Hz, 1H), 7.69 (s, 1H), 4.86(quin, J=6.6 Hz, 1H), 3.94 (s, 3H), 2.33 (s, 3H), 1.50 (d, J=6.6 Hz,6H). MS(ES)+m/e 300.3 [M+H]⁺.

b) 1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid

To a stirred solution of methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate (0.27g, 0.902 mmol) in MeOH (15 mL) and tetrahydrofuran (5 mL) was added 1NNaOH (5 mL, 5.00 mmol). The reaction was heated to 60° C. and stirredfor 48 hr. LCMS showed that the reaction was complete. The reaction wasconcentrated to near dryness under vacuum, acidified with 1 N HCl (5mL), triturated, filtered and washed with a small volume of water, anddried under vacuum to give the product1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid(0.26 g, 0.911 mmol, 101% yield) as a light yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 13.04 (br. s., 1H), 8.36 (d, J=1.5 Hz, 1H), 8.13 (d,J=1.3 Hz, 1H), 7.65 (s, 1H), 4.85 (quin, J=6.6 Hz, 1H), 2.36 (s, 3H),1.50 (d, J=6.6 Hz, 6H). MS(ES)+m/e 286.1 [M+H]⁺.

Intermediate 40 6-Bromo-3-chloro-1-isopropyl-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (1.100 g, 3.71 mmol)as a solution in THF and a magnetic stir bar. To the same was added1-chloro-2,5-pyrrolidinedione (0.546 g, 4.09 mmol) and the systemstirred at room temperature overnight. The solvent was removed underreduced pressure and the residue dissolved in EtOAc (60 ml) and washedwith saturated NaHCO3 (20 ml) and brine (8 ml). The organic layer wasdried over Na2SO4, filtered and concentrated. Purification of theresidue by column chromatography provided methyl6-bromo-3-chloro-1-isopropyl-1H-indole-4-carboxylate (as a thick goldoil), which was used in the next step. ¹H NMR (400 MHz, DMSO-d₆) δ 8.15(d, J=1.52 Hz, 1H), 7.93 (s, 1H), 7.50 (d, J=1.77 Hz, 1H), 4.90 (quin,J=6.63 Hz, 1H), 3.89 (s, 3H), 1.43 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺332.2.

To a solution of methyl6-bromo-3-chloro-1-(1-methylethyl)-1H-indole-4-carboxylate (1.2 g, 3.63mmol) in THF (2.368 ml) and MeOH (14.21 ml) was added 3 N NaOH (1.573ml, 4.72 mmol). The resulting mixture was heated at 55° C. for 4 h. Thereaction was removed from the heat and the solvent removed in-vacuo. Theremaining residue was dissolved with water (12 ml) and made acidicdropwise with 1 N HCl. The product precipitated and the slurry becametoo thick to stir and was diluted with water (10 ml). After theprecipitation haulted no more acid was added. The solid was collected byvacuum filtration, washed with water, and air dried under vacuumovernight to give6-bromo-3-chloro-1-(1-methylethyl)-1H-indole-4-carboxylic acid (650 mg,2.033 mmol, 56.0% yield over 2 steps) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 13.22 (s, 1H), 8.09 (d, J=1.77 Hz, 1H), 7.89 (s, 1H), 7.45(d, J=1.77 Hz, 1H), 4.88 (quin, J=6.63 Hz, 1H), 1.43 (d, J=6.57 Hz, 6H).MS(ES) [M+H]⁺ 316.0.

Intermediate 41 Methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (2.5 g, 9.41 mmol)in DMF (25 mL) was added NBS (1.7 g, 9.55 mmol). The reaction wasstirred for 18 h then evaporated to dryness under vacuum. The reactionwas purified by silica gel chromatography (Analogix, SF40-80 g, 0 to 5%EtOAc in hexanes) then (Analogix, SF25-60 g, 25% CH₂Cl₂ in hexanes) togive the product methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (1.79 g,5.19 mmol, 55.2% yield) as a clear oil. ¹H NMR (400 MHz, DMSO-d₆) 6=7.98(d, J=1.8 Hz, 1H), 7.41 (d, J=1.8 Hz, 1H), 5.05 (dt, J=6.7, 13.4 Hz,1H), 3.89 (s, 3H), 2.22 (s, 3H), 1.57 (d, J=7.1 Hz, 6H). MS(ES)+m/e344.0 [M+H]⁺.

Intermediate 421-Isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid

a) Methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate

To a 50 ml round bottom flask was added; methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (150 mg, 0.484mmol), PdCl2(dppf)-CH2C₁₂ adduct (39.5 mg, 0.048 mmol) and 1,4-Dioxane(4836 μl) followed with 4-(tributylstannyl)pyridazine (179 mg, 0.484mmol) and a magnetic stir bar. The flask was equipped with a refluxcondenser and an exhaust bubbler and heated to 105° C. The reactionsolution changed to a dark brown at 30 minutes. LCMS (105C-3 h) showedthe reaction to be complete. The reaction solvent was removed in-vacuoand the remaining residue taken up with DMSO. (1.5 ml). The DMSOsolution was purified by reverse phase HPLC using a Phenomenex Gemini100×30 mm column, neutral acetonitrile and 0.1% formic acid in water,40-70%, 10 min gradient. The desired fractions were dried in a GenovacEZ-2 evaporator and the solid residues combined. The product, methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate, wasobtained as a white solid. ¹H NMR (400 MHz, METHANOL-δ₄) 9.68 (6, J=1.26Hz, 1H), 9.19 (d, J=5.56 Hz, 1H), 8.20 (d, J=1.52 Hz, 1H), 8.13 (dd,J=2.53, 5.56 Hz, 1H), 7.98 (d, J=1.52 Hz, 1H), 7.48 (s, 1H), 4.96 (dt,J=6.60, 13.33 Hz, 1H), 4.00 (s, 3H), 2.39 (s, 3H), 1.56 (d, 6H). MS(ES)[M+H]⁺ 310.2.

b) 1-Isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate (74.0mg, 0.239 mmol), Methanol (1595 μl), Tetrahydrofuran (THF) (3189 μl) anda magnetic stir bar. To the same was added lithium hydroxide, H₂O (30.1mg, 0.718 mmol) and the mixture was stirred at 55° C. Reaction progresswas monitored by LCMS. LCMS(weekend) showed 50% conversion. To thereaction mixture was added lithium hydroxide, H₂O (20.08 mg, 0.478 mmol)The reaction was continued to stir and heated to 55° C. After completeconversion the reaction solvent was removed and the remaining residuedissolved with water (1.5 ml). The aqueous solution was made acidic dropwise with 1N HCl until precipitation was complete. The solid wascollected by vacuum filtration and washed with water (5 ml). The solidwas dried under vacuum open to the air overnight. The product,1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid (68mg, 0.228 mmol, 95% yield), was obtained as a brown solid. ¹H NMR (400MHz, DMSO-δ₆) δ 9.71-9.83 (m, 1H), 9.23 (dd, J=1.26, 5.56 Hz, 1H), 8.32(s, 1H), 8.11 (dd, J=2.65, 5.43 Hz, 1H), 7.86 (s, 1H), 7.58 (s, 1H),4.90-5.09 (m, 1H), 2.34 (s, 3H), 1.47 (d, J=6.82 Hz, 6H).MS(ES)[M+H]⁺296.2.

Intermediate 43 6-Bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate

To a 20 ml vial was added methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (50.0 mg, 0.169 mmol),(selectfluor) 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octaneditetrafluoroborate (78 mg, 0.219 mmol) followed with a magnetic stirbar and nitroethane (2 ml). The vial was capped and the reaction stirredat room temperature. Reaction progress was monitored by LCMS. Afterreaction completion the reaction solvent was removed in-vacuo. Theresidue was dissolved with DCM(1.4 ml). The DCM solution was chargedonto an analogix Si35 SF10-8 gram column. The compound was eluted withEtOAc/Hexanes, 5-15%, 20 min. The desired product and side MW629co-eluted. The mixture was dissolved with DMSO (1 ml) and purified byreverse phase HPLC using a Gemini 5μ 30×100 mm column, neutralacetonitrile/0.1% formic acid in water, 50-80%, 7 min gradient. Thedesired product eluted at 6.8 minutes and the side product MW 629 at 9.5minutes. The desired fractions were concentrated to a residue. LCMS andNMR support the desired structure and analytical HPLC showed 100%purity. The product, methyl6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate (11 mg, 0.035 mmol,20.53% yield), was obtained as a white solid. ¹H NMR (400 MHz,METHANOL-d₄) δ 7.95 (t, J=1.77 Hz, 1H), 7.78 (d, J=1.77 Hz, 1H), 7.47(d, J=2.53 Hz, 1H), 4.76-4.84 (m, J=1.64, 6.65, 6.65, 13.36 Hz, 1H),3.96 (s, 3H), 1.50 (d, 6H).

MS(ES)[M+H]⁺ 315.1.

b) 6-Bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate (33.0 mg, 0.105mmol), Methanol (700 μl), Tetrahydrofuran (THF) (1401 μl) and a magneticstir bar. To the same was added lithium hydroxide, H₂O (13.22 mg, 0.315mmol) and the mixture was stirred at room temperature. Reaction progresswas monitored by LCMS. LCMS(18 h) showed 60% conversion. The reactionwas heated to 50° C. in an aluminum heating block with stirring. Aftercomplete conversion the solvent was removed in-vacuo and the remainingresidue was dissolved with water (1 ml) and 1N HCl was added dropwise (9drops) until precipitation stopped. The fine pale-yellow solid wascollected by vacuum filtration. LCMS and HPLC showed 100% purity and NMRsupports the desired structure. The product,6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid (24 mg, 0.080mmol, 76% yield), was obtained as a yellow solid. ¹H NMR (400 MHz,DMSO-d₆) δ 13.07 (br. s., 1H), 8.12 (t, J=1.89 Hz, 1H), 7.77 (d, J=2.27Hz, 1H), 7.66 (d, J=1.77 Hz, 1H), 4.88 (qd, J=5.31, 6.65 Hz, 1H), 1.40(d, 6H). MS(ES) [M+H]⁺ 300.1.

Intermediate 44N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-4-carboxamide

Trial run: A mixture of6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(1.0 g, 2.32 mmol, 1 equiv), bis(pinacolato)diboron (0.71 g, 2.79 mmol,1.2 equiv), KOAc (0.47 g, 4.76 mmol, 2 equiv) and PdCl₂(dppf)-CH₂Cl₂adduct (104 mg, 00.13 mmol, 0.1 equiv) in 10 mL of dioxane in a 20 mLmicrowave vial was bubbled with nitrogen for 10 min, followed by cappingand heating in an oil bath at 80° C. for 3 h. LCMS showed conversioncomplete. Only 4% debromo byproduct was detected.

Production run: A mixture of6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(22.0 g, 51.1 mmol, 1 equiv), bis(pinacolato)diboron (15.58 g, 61.3mmol, 1.2 equiv), KOAc (10.29 g, 105 mmol, 2 equiv) and PdCl₂(dppf)-CH₂Cl₂ adduct (2.30 g, 2.81 mmol, 0.1 equiv) in 190 mL of dioxanewas degassed and backflushed with nitrogen (repeated 4×). The mixturewas heated in an oil bath at 90° C. for 2 h. The dark brownish mixturewas combined with the crude mixture from the trial run above, andfiltered through celite (rinsing with EtOAc). The filtrate was conc invacuo. The residue was taken up in CHCl₃ and split into 9 equalportions. One portion was absorbed onto a celite-packed dryloadcartridge. Purification was done on an SF40-80 g silica gel cartridgeusing gradient elution of 25% EtOAc in hexane to 100% EtOAc (gradient:0-5 min, 25% EtOAc, 5-20 min, linear gradient 25-100% EtOAc, 25-65 min,100% EtOAc). The desired product eluted at 100% EtOAc (with a longtail). The DASI portion was clogged during the process, and needed to beremoved to continue the chromatography, causing loss of material. Thusthe use of FCC was abandoned and switched to gravity column.

The remaining 8 portions were recombined and dissolved in CHCl₃,followed by adding to a silica gel column (500 g of coarse grade silicagel packed in 25% EtOAc in hexane), and then elution with 1 L of 25%EtOAc in hexane, 1 L of 50% EtOAc, 1 L of 75% EtOAc in hexane, 2 L of100% EtOAc, 1 L of EtOAc with 25 mL increments of MeOH. The desiredproduct eluted at 100% EtOAc, 25 mL-100 mL of MeOH in EtOAc fractions.

The EtOAc fractions were combined with the FCC purified material. Themixture was conc in vacuo. The residue was taken up in MTBE (5 mL) andhexane (100 mL) as a suspension, which was filtered. The cake was washedwith hexane (30 mL) and dried under vacuum at rt for 4 h to provideN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-4-carboxamide(14.01 g) as light beige solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31 (s,12H), 1.41 (d, J=6.8 Hz, 6H), 2.11 (s, 3H), 2.16 (s, 3H), 2.22 (s, 3H),4.33 (d, J=8 Hz, 2H), 4.79 (quin, J=6.6 Hz, 1H), 5.87 (s, 1H), 7.23 (s,1H), 7.40 (d, J=1.0 Hz, 1H), 7.75 (s, 1H), 8.04 (t, J=5.1 Hz, 1H), 11.46(s, 1H).

Assay Protocol

Compounds contained herein were evaluated for their ability to inhibitthe methyltransferase activity of EZH2 within the PRC2 complex. HumanPRC2 complex was prepared by co-expressing each of the 5 member proteins(FLAG-EZH2, EED, SUZ12, RbAp48, AEBP2) in Sf9 cells followed byco-purification. Enzyme activity was measured in a scintillationproximity assay (SPA) where a tritiated methyl group is transferred from3H-SAM to a lysine residue on Histone H3 of a mononucleosome, purifiedfrom HeLa cells. Mononucleosomes were captured on SPA beads and theresulting signal is read on a ViewLux plate reader.

Part A. Compound Preparation

-   -   1. Prepare 10 mM stock of compounds from solid in 100% DMSO.    -   2. Set up an 11-point serial dilution (1:3 dilution, top        concentration 10 mM) in 100% DMSO for each test compound in a        384 well plate leaving columns 6 and 18 for DMSO controls.    -   3. Dispense 100 nL of compound from the dilution plate into        reaction plates (Grenier Bio-One, 384-well, Cat#784075).

Part B. Reagent Preparation

Prepare the following solutions:

-   -   1. 50 mM Tris-HCl, pH 8: Per 1 L of base buffer, combine 1 M        Tris-HCl, pH 8 (50 mL) and distilled water (950 mL).    -   2. 1× Assay Buffer: Per 10 mL of 1× Assay Buffer, combine 50 mM        Tris-HCl, pH 8 (9958 uL), 1 M MgCl₂ (20 uL), 2 M DTT (20 uL),        and 10% Tween-20 (2 uL) to provide a final concentration of 50        mM Tris-HCl, pH 8, 2 mM MgCl₂, 4 mM DTT, 0.002% Tween-20.    -   3. 2× Enzyme Solution: Per 10 mL of 2× Enzyme Solution, combine        1× Assay Buffer and PRC2 complex to provide a final enzyme        concentration of 10 nM.    -   4. SPA Bead Suspension: Per 1 mL of SPA Bead Suspension, combine        PS-PEI coated LEADSeeker beads (40 mg) and ddH2O (1 mL) to        provide a final concentration of 40 mg/mL.    -   5. 2× Substrate Solution: Per 10 mL of 2× Substrate Solution,        combine 1× Assay Buffer (9728.55 uL), 800 ug/mL mononucleosomes        (125 uL), 1 mM cold SAM (4 uL), and 7.02 uM 3H-SAM (142.45 uL;        0.55 mCi/mL) to provide a final concentration of 5 ug/mL        nucleosomes, 0.2 uM cold SAM, and 0.05 uM 3H-SAM.    -   6. 2.67× Quench/Bead Mixture: Per 10 mL of 2.67× Quench/Bead        Mixture, combine ddH₂O (9358 uL), 10 mM cold SAM (267 uL), 40        mg/mL Bead Suspension (375 uL) to provide a final concentration        of 100 uM cold SAM and 0.5 mg/mL SPA beads.        Part C. Assay Reaction in 384-well Grenier Bio-One Plates

Compound Addition

-   -   1. Dispense 100 nL/well of 100× Compound to test wells (as noted        above).    -   2. Dispense 100 nL/well of 100% DMSO to columns 6 & 18 for high        and low controls, respectively.

Assay

-   -   1. Dispense 5 uL/well of 1× Assay Buffer to column 18 (low        control reactions).    -   2. Dispense 5 uL/well of 2× Enzyme Solution to columns 1-17,        19-24.    -   3. Spin assay plates for ˜1 minute at 500 rpm.    -   4. Stack the assay plates, covering the top plate.    -   5. Incubate the compound/DMSO with the enzyme for 30 minutes at        room temperature.    -   6. Dispense 5 uL/well of 2× Substrate Solution to columns 1-24.    -   7. Spin assay plates for ˜1 minute at 500 rpm.    -   8. Stack the assay plates, covering the top plate.    -   9. Incubate the assay plates at room temperature for 1 hour.

Quench/Bead Addition

-   -   1. Dispense 5 uL/well of the 3× Quench/Bead Mixture to columns        1-24.    -   2. Seal the top of each assay plate with adhesive TopSeal.    -   3. Spin assay plates for −1 minute at 500 rpm.    -   4. Equilibrate the plates for >20 min.

Read Plates

-   -   1. Read the assay plates on the Viewlux Plate Reader utilizing        the 613 nm emission filter with a 300 s read time.        Reagent addition can be done manually or with automated liquid        handler.        *The final DMSO concentration in this assay is 1%.        *The positive control is in column 6; negative control is in        column 18.        *Final starting concentration of compounds is 100 μM.

Part D. Data Analysis

Percent inhibition was calculated relative to the DMSO control for eachcompound concentration and the resulting values were fit using standardIC₅₀ fitting parameters within the ABASE data fitting software package.

Exemplified compounds of the present invention were generally testedaccording to the above or an analogous assay and were found to beinhibitors of EZH2. The IC₅₀ values ranged from about 1 nM to about 10μM; The IC₅₀ values of the more active compounds range from about 1 nMto about 500 nM; The most active compounds are under 50 nM. As tested inthe foregoing assay or an analogous assay, compounds of the variousExamples gave the pIC₅₀ data in the compound table above or the IC₅₀data in the paragraph below. Repeating the assay run(s) may result in asomewhat different.

Ex 78, 1800; Ex 174, 18; Ex 211, 14; Ex 212, 9; Ex 234, 1000; Ex 244,29; Ex 264, 13; Ex 265, 13; Ex 266, 25; Ex 267, 20; Ex 268, 40; Ex 269,4; Ex 270, 4; Ex 271, 8; Ex 272, 13; Ex 273, 10; Ex 274, 32; Ex 275, 3;Ex 339, 13.

What is claimed is:
 1. A method of treating cancer comprisingadministering to a patient with cancer a therapeutically effectiveamount of a compound of formula (I):

wherein: X and Z are selected independently from the group consisting ofhydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl,(C₆-C₁₀)bicycloalkyl, unsubstituted or substituted heterocycloalkyl,unsubstituted or substituted heterocycloalkyl-(C₁-C₈)alkyl or—(C₂-C₈)alkenyl, unsubstituted or substituted aryl, unsubstituted orsubstituted aryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, halo, cyano, —COR^(a),—CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a),—SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),—NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), and —OC(O)NR^(a)R^(b); Y is H or halo; R¹ is (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted or substituted(C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₆-C₁₀)bicycloalkyl, unsubstituted or substitutedheterocycloalkyl, unsubstituted or substitutedheterocycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted aryl, unsubstituted or substituted aryl-(C₁-C₈)alkyl or—(C₂-C₈)alkenyl, unsubstituted or substituted heteroaryl, unsubstitutedor substituted heteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, —COR^(a),—CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b); R² is hydrogen; R³ ishydrogen, (C₁-C₈)alkyl, cyano, trifluoromethyl, —NR^(a)R^(b), or halo;R⁶ is selected from the group consisting of hydrogen, halo,(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl, (C₆-C₁₀)bicycloalkyl, unsubstituted orsubstituted heterocycloalkyl, unsubstituted or substitutedheterocycloalkyl-(C₁-C₈)alkyl, unsubstituted or substituted aryl,unsubstituted or substituted aryl-(C₁-C₈)alkyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),—CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b),nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),—NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),—NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), and —OC(O)NR^(a)R^(b); wherein any (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl,heterocycloalkyl, aryl, or heteroaryl group is optionally substituted by1, 2, or 3 groups independently selected from the group consisting ofhalo, (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a),—SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b),—NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a),—NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a),—OC(O)NR^(a)R^(b), heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl,and heteroaryl(C₁-C₄)alkyl; wherein any aryl or heteroaryl moiety ofsaid aryl, heteroaryl, aryl(C₁-C₄)alkyl, or heteroaryl(C₁-C₄)alkyl isoptionally substituted by 1, 2, or 3 groups independently selected fromthe group consisting of halo, (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl,(C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a),—CONR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,—NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),—NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —OR^(a),—OC(O)R^(a), and —OC(O)NR^(a)R^(b); R⁷ is hydrogen; and R^(a) and R^(b)are each independently hydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl,(C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl, whereinsaid (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl,cycloalkenyl, bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl groupis optionally substituted by 1, 2, or 3 groups independently selectedfrom halo, hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, or —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl); orR^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2, or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring; or R^(a)and R^(b) taken together with the nitrogen to which they are attachedrepresent a 6- to 10-membered bridged bicyclic ring system optionallyfused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroarylring; or a pharmaceutically acceptable salt thereof.
 2. The method ofclaim 1 wherein X and Z are independently selected from the groupconsisting of (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl,heteroaryl, —NR^(a)R^(b), and —OR^(a).
 3. The method of claim 1 whereinR¹ is (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, or heterocycloalkyl.
 4. Themethod of claim 1 wherein: X is methyl, ethyl, n-propyl, isopropyl,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl,trifluoromethyl, tetrahydropyran, hydroxymethyl, methoxymethyl, orbenzyl; Y is H; Z is methyl, ethyl, n-propyl, isopropyl,trifluoromethyl, or benzyl; R¹ is isopropyl, tert-butyl, cyclobutyl,cyclopentyl, cyclohexyl, (1-methylethyl)cyclopropyl,1,1-dioxo-tetrahydrothiophene-3-yl, 1-Me-piperidin-4-yl,tetrahydrofuran-3-yl, tetrahydropyran-4-yl, N,N-dimethyl-1-propanaminyl,benzyl, or 4-pyridyl; R₂ is hydrogen; R³ is H, methyl, or Br; R⁶ ismethyl, cyclopropyl, propyl, dimethylamino, ethylamino,(2-hydroxyethyl)amino, 2-propen-1-ylamino, 1-piperazinyl, 1-piperidinyl,4-morpholinyl, 4-piperidinylamino, tetrahydro-2H-pyran-4-ylamino,phenylamino, (phenylmethyl)amino, (4-pyridinylmethyl)amino,[2-(2-pyridinylamino)ethyl]amino, 2-(dimethylamino)ethyl]amino,4-pyridinylamino, 4-[(aminocarbonyl)phenyl]amino,3-hydroxy-3-methyl-1-butyn-1-yl, 4-pyridinylethynyl, phenylethynyl,2-furanyl, 3-thienyl, 1H-pyrazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl,3-methyl-1H-indazol-5-yl, 1H-1,2,3-benzotriazol-5-yl,2-oxo-2,3-dihydro-1H-benzimidazol-5-yl, 2-oxo-2,3-dihydro-1H-indol-5-yl,2-oxo-2,3-dihydro-1H-indol-6-yl, 2,1,3-benzoxadiazol-5-yl,2-amino-6-quinazolinyl, 2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl,2-amino-5-pyrimidinyl, 7-oxo-1,5,6,7-tetrahydro-1,8-naphthyridin-3-yl,phenyl, 2-methylphenyl, 2-nitrophenyl, 2-phenylethyl, 3-aminophenyl,4-aminophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-(methyloxy)phenyl,3-(acetylamino)phenyl, 4-(acetylamino)phenyl, 4-(aminocarbonyl)phenyl,4-(1H-pyrazol-4-yl)phenyl, 4-(aminosulfonyl)phenyl,4-(methylsulfonyl)phenyl, 4-[(dimethylamino)sulfonyl]phenyl,4-[(methylamino)carbonyl]phenyl, 4-[(methylamino)sulfonyl]phenyl,4-[(methylsulfonyl)amino]phenyl, 3-pyridinyl, 4-pyridinyl,2-(4-morpholinyl)-4-pyridinyl, 2-amino-4-pyridinyl,5-(methyloxy)-3-pyridinyl, 5-(methylsulfonyl)-3-pyridinyl,5-[(cyclopropylsulfonyl)amino]-6-(methyloxy)-3-pyridinyl,5-[(phenylsulfonyl)amino]-3-pyridinyl,6-(4-methyl-1-piperazinyl)-3-pyridinyl, 6-(4-morpholinyl)-3-pyridinyl,6-(acetylamino)-3-pyridinyl, 6-(dimethylamino)-3-pyridinyl,6-(methyloxy)-3-pyridinyl, 6-[(methylamino)carbonyl]-3-pyridinyl,6-[(methylamino)sulfonyl]-3-pyridinyl, 6-methyl-3-pyridinyl, or4-pyridinyloxy; and R⁷ is hydrogen.
 5. The method of claim 1 wherein thecompound of formula (I) is selected from the group consisting of:N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-methoxypyridin-3-yl)-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-morpholinopyridin-3-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-methylpyrimidin-5-yl)-1H-indole-4-carboxamide;6-(2-aminopyrimidin-5-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;6-(6-aminopyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(dimethylamino)pyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluorophenyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(1H-indazol-6-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;6-bromo-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(2-methyl-5-pyrimidinyl)-1H-indole-4-carboxamide;6-(6-amino-3-pyridinyl)-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-[6-(dimethylamino)-3-pyridinyl]-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-methyl-3-pyridinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrazol-3-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrazol-4-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2-thienylmethyl)-1H-pyrazol-4-yl]-1H-indole-4-carboxamide;N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;6-(6-acetamidopyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;6-(6-acetamidopyridin-3-yl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;6-bromo-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(2-methyl-3-pyridinyl)-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[5-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(6-methyl-3-pyridinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;6-bromo-1-cyclopentyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-cyclobutyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[3-(methylsulfonyl)phenyl]-1H-indole-4-carboxamide;6-bromo-1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridin-3-yl)methyl]-1H-indole-4-carboxamide;6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide;N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1-pyrrolidinyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylamino)-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;6-[6-(acetylamino)-3-pyridinyl]-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-(4-fluorophenyl)-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-[4-(acetylamino)phenyl]-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;methyl4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoate;methyl5-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinecarboxylate;methyl3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]benzoate;6-bromo-N-((6-ethyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;N-((6-benzyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-1H-indole-4-carboxamide;6-bromo-N((6-cyclobutyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-1H-indole-4-carboxamide;1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indole-4-carboxamide;1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(4-morpholinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(piperazin-1-yl)phenyl)-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(piperazin-1-yl)pyridin-4-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(piperazin-1-yl)pyridin-4-yl)-1H-indole-4-carboxamide;1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(methylsulfonyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(methylsulfonyl)-1H-indole-4-carboxamide;3-({2-[6-(cyclopropylsulfonyl)-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;3-({2-[6-(cyclopropylsulfonyl)-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;3-methyl-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-6-(methyloxy)-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(methyloxy)-1H-indole-4-carboxamide;6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;6-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-iodo-1-(1-methylethyl)-1H-indole-4-carboxamide;6-iodo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-bromo-1-ethyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-bromo-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1-propyl-1H-indole-4-carboxamide;3-({2-[6-chloro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;3-({2-[6-chloro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;3-({2-[6-chloro-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-fluoro-1-(1-methylethyl)-1H-indole-4-carboxamide;3-({2-[6-fluoro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxamide;1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2H-tetrazol-5-yl)-1H-indole-4-carboxamide;6-cyano-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-bromo-3-chloro-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;6-bromo-3-chloro-1-(1-methylethyl)-N-(({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-1H-indole-4-carboxamide;6-bromo-3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(4-((1H-pyrazol-1-yl)methyl)phenyl)-3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(2-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;3-chloro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;3-chloro-1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;3-chloro-1-isopropyl-N-((4-(methoxymethyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(pyridin-3-yl)-1H-indole-4-carboxamide;3-chloro-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;3-chloro-N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-6-(3,5-difluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-6-(3,4-difluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoro-3-hydroxyphenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoro-3-methoxyphenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-methoxyphenyl)-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(3-methoxyphenyl)-1H-indole-4-carboxamide;3-chloro-6-(3-cyano-4-fluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-phenyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-fluoro-4-morpholinophenyl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-fluoropyridin-3-yl)-1-isopropyl-1H-indole-4-carboxamide;3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-indole-4-carboxamide;3-chloro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;6-bromo-1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;6-bromo-3-chloro-1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-fluoro-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-3-fluoro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-fluoro-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-fluoro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(4-pyridazinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-phenyl-3-pyridinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[5-(4-morpholinylcarbonyl)-3-pyridinyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-(6-formyl-3-pyridinyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;3,6-dibromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(1H-imidazol-1-ylmethyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-1,3-thiazol-5-yl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-1H-indole-4-carboxamide;6-[6-(4-ethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-6-{6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl}-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-morpholinyl)-2-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-methyl-2-pyridinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4-morpholinyl)-4-pyrimidinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(2-pyrimidinyl)-1H-indole-4-carboxamide;6-(6-amino-2-pyridinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-[2-amino-6-(4-morpholinyl)-4-pyrimidinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[2-(methylamino)-4-pyrimidinyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-pyrimidinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(ethylamino)-4-pyrimidinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(2-amino-4-pyrimidinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(1H-benzimidazol-5-yl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(3-amino-1H-indazol-6-yl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1-methyl-1H-indazol-6-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(5-methyl-1H-indazol-6-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-ethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;6-chloro-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-(6-chloro-3-pyridinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(1H-imidazol-1-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-{6-[3-(dimethylamino)-1-pyrrolidinyl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methylhexahydro-1H-1,4-diazepin-1-yl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-piperidinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-isopropyl-N-((6-methyl-2-oxo-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxamide;N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-chloro-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(3R)-tetrahydro-3-furanyl]-1H-indole-4-carboxamide;6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;6-[(aminocarbonyl)amino]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-[6-(2,6-dimethyl-4-morpholinyl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(2-methyl-4-morpholinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-fluoro-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;(R)—N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1-(tetrahydrofuran-3-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indole-4-carboxamide;6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1-(pentan-2-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2-methoxypyrimidin-4-yl)-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo[4,3-c]pyridin-6-yl)-1H-indole-4-carboxamide;6-methyl-3-({2-[3-methyl-1-(1-methylethyl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4-propyl-2(1H)-pyridinone;6-(1H-benzo[d]imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-methylpyrimidin-4-yl)-1H-indole-4-carboxamide;6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;(R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(4-(2-oxopiperazin-1-yl)phenyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;6-methyl-3-[(2-{3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indol-4-yl}-2-oxoethyl)amino]-4-propyl-2(1H)-pyridinone;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1H-pyrazol-4-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(5-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(3-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoicacid;3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]benzoicacid;5-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinecarboxylicacid;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;6-methyl-3-({2-[3-methyl-1-(1-methylethyl)-6-(4-piperidinyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4-propyl-2(1H)-pyridinone;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(2-piperidinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;1-cyclopentyl-6-(cyclopropylsulfonyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide;1-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide;1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(pyrrolidin-1-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(pyridin-3-ylamino)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(4-fluorophenyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoropiperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(3-fluorophenyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-1H-indole-4-carboxamide;6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide;6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylamino)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;N-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;N-((6-amino-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;6-bromo-1-isopropyl-3-methyl-N-((4-methyl-6-(methylamino)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(3,4-dimethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(3,3-dimethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2S)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(2S,5S)-2,5-dimethyl-1-piperazinyl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-((2R,5R)-2,5-dimethylpiperazin-1-yl)pyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylicacid;3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid;6-(2-aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(4,5-dihydro-1H-imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(3-oxetanyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{[(4-methyl-1-piperazinyl)carbonyl]amino}-1H-indole-4-carboxamide;6-{[3-(dimethylamino)propyl]thio}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;6-(cyclopropylethynyl)-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-phenyl-1H-indole-4-carboxamide;1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indole-4-carboxamide;6-bromo-1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-phenyl-1H-indole-4-carboxamide;6-bromo-N-[(4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;6-bromo-N-[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;6-bromo-1-(1-methylethyl)-N-[(4-methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;and6-bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-phenyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;or a pharmaceutically acceptable salt thereof.
 6. The method of claim 1,wherein said cancer is selected from the group consisting of: brain,glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome, Cowdendisease, Lhermitte-Duclos disease, breast, inflammatory breast cancer,Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung,liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma,osteosarcoma, giant cell tumor of bone and thyroid.
 7. The method ofclaim 2, wherein said cancer is selected from the group consisting of:brain, glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome,Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breastcancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung,liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma,osteosarcoma, giant cell tumor of bone and thyroid.
 8. The method ofclaim 3, wherein said cancer is selected from the group consisting of:brain, glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome,Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breastcancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung,liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma,osteosarcoma, giant cell tumor of bone and thyroid.
 9. The method ofclaim 4, wherein said cancer is selected from the group consisting of:brain, glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome,Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breastcancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung,liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma,osteosarcoma, giant cell tumor of bone and thyroid.
 10. The method ofclaim 5, wherein said cancer is selected from the group consisting of:brain, glioblastomas, leukemias, lymphomas, Bannayan-Zonana syndrome,Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breastcancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma,medulloblastoma, colon, gastric, bladder, head and neck, kidney, lung,liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma,osteosarcoma, giant cell tumor of bone and thyroid.